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ABSTRACT 
A. baumannii resistant to multiple antibiotics challenges the treatment of infections caused by 
this organism. Multiply-antibiotic resistant (MAR) isolates mainly belong to two major global 
clones GC1 and GC2, and emergence of MAR strains is mainly due to the global spread of these 
clones. The objective of this study was to analyze the genetic basis of antibiotic resistance in 
Australian GC1 isolates.  
Twenty six MAR GC1 isolates were recovered from different Australian hospitals in Sydney, 
Melbourne, Adelaide and Brisbane between 1997 to 2011. The isolates were examined to determine 
how closely they were related to one another. This included examining resistance to 23 antibiotics 
and the causes of the resistance phenotypes observed. All but one were resistant to ciprofloxacin 
and nalidixic acid, and all but one isolate were resistant to gentamicin, kanamycin and streptomycin 
and sulphonamides. More than half of the isolates were resistant to 3rd generation cephalosporins 
but only five isolates were resistant to carbapenems. 
Molecular typing revealed that the GC1 collection consisted of diverse isolates but two 
outbreak strains from a Sydney hospital were identified. The outbreak strains all belonged to 
ST109/231 (Oxford Scheme) but there were 2 groups based on their shared properties. These strains 
were recovered between 2006-2011 in the spinal injury unit of one of the Sydney hospitals 
indicating that they have persisted in the hospital environment. MLST analysis showed that more 
than half of the remaining 12 Australian GC1 isolates belonged to ST109/231, and the remainder 
were all SLV (ST347 and ST247) and DLV (ST126) of ST109/231 differing either in gpi or the gpi 
and gyrB alleles respectively. 
 MAR GC1 isolates include an AbaR3-type island, which usually includes several antibiotic 
and heavy metal resistance determinants, in the comM gene. An AbaR island of this type was found 
in all but one of the Australian GC1 isolates. Amongst the isolates with an AbaR3-type island, only 
four isolates from different Australian hospitals were found to contain AbaR3 and the remaining 
isolates contained distinct variants, some of which had not been seen before. The loss of the AbaR 
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segments had largely occurred by IS26-mediated deletion. Homologous recombination between two 
Tn6018 copies removing the entire multiply antibiotic resistance region was also found in one 
isolate. A deletion in the 5'-CS of the class 1 integron was also identified in some AbaR islands. 
This separated the islands into two groups, one with the deletion and the other without. The AbaR 
island in an isolate from a Sydney hospital, which was named AbaR0, lacked the deletion but was 
otherwise identical to AbaR3. AbaR0 was proposed to be the ancestral island as it includes an intact 
5'-CS and also contains an additional orfP in the integron cassette array. The structure of AbaR 
islands was also a property that could group the isolates as the ones with the same AbaR were 
closely related. 
One carbapenem resistant isolate recovered in Sydney in 2008 was found to carry oxa23 in 
the AbaR4 island in the comM gene instead of an AbaR0/AbaR3-type island. This isolate belongs to 
a separate lineage that has derived from its antibiotic susceptible ancestor, found in WGS database 
of GenBank, by incorporating AbaR4 and becoming carbapenem resistant. 
In Australian isolates, resistance to third generation cephalosporins was due to the activation 
of the ampC gene by an ISAba1 providing it with a new promoter. In three Australian ST126 
(Oxford Scheme) isolates, the ISAba1-ampC structure was found to be part of an ISAba1 bounded 
transposon, Tn6168. Several other isolates included an ampC sequence distinct from the standard 
GC1 sequence. Comparison of the draft genome of these isolates to the standard GC1 sequence 
without the IS next to ampC, revealed sequence patches of 30 kb in a single isolate and 2.4 kb in 
one group of 8 strains. In the later case, the source of sequence was found to be ST25 strains 
(Institut Pasteur). In one isolate from Greece activation of ampC was found via insertion of 
ISAba125 next to the start of ampC. 
Plasmids were found to play an important role in carbapenem and tobramycin resistance in 
Australian isolates. In two carbapenem resistant isolates AbaR4 was found in an 86 kb conjugative 
plasmid. Variants of a 6 kb plasmid named pRAY*, which carries the aadB gene were found to be 
responsible for tobramycin resistance. 
 
 
ix 
Together, the results of this study showed the variety of mobile elements, genomic islands, 
plasmids, transposons and insertion sequences, that incorporate antibiotic resistance genes in 
Australian GC1 isolates. AbaR islands were found to carry genes conferring resistance to 
kanamycin, gentamicin, streptomycin and sulphonamides. IS26-mediated deletions and homologous 
recombination between Tn6018 copies in the AbaR islands were shown to be responsible for 
generating new variants. AbaR0, the ancestor of AbaR islands was found and all of the variants 
seen so far could be derived from it. Moreover, structure of AbaR islands was found to be an 
extremely useful tool to type the strains. 
Carbapenem resistance was rare in Australian GC1 strains. Three strains carried the oxa23 
carbapenem resistance gene in an AbaR4 island, which includes a backbone related to the backbone 
of AbaR islands. In one isolate, AbaR4 was found where AbaR0/AbaR3 type islands are usually 
found. This indicates that transposon backbone of AbaR4 can target the same position as 
AbaR0/AbaR3. The other two strains carried AbaR4 in a conjugative plasmid, and the oxa23 gene 
can be potentially disseminated by this plasmid into strains of different types. The small plasmid 
pRAY* was responsible for introducing the tobramycin resistance gene aadB into GC1s. Hence, 
this study shows the significance of plasmids incorporating additional determinants in GC1s. The 
most unexpected finding was horizontal transfer of DNA segments that contain ISAba1-ampC 
generating resistance to third generation cephalosporins. 
Overall, Australian GC1 isolates included a diverse collection. However, two outbreak GC1 
strains were identified in a single ward of one of the Sydney hospitals. Outbreak strains persisted 
for a period of time and were then replaced by a GC2 strain.  
 !!! !!
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1.1 Hospital-acquired infections 
 
Hospital-acquired infections are a major challenge to patient safety. These infections are 
mainly associated with invasive medical devices or surgical procedures (165).  It is estimated that in 
2002, a total of 1.7 million hospital-acquired infections occurred (4.5 per 100 admissions), and 
almost 99,000 deaths resulted from or were associated with a hospital-acquired infection (108, 251), 
making hospital acquired infections the sixth leading cause of death in the United States; similar 
data have also been reported from Europe.  The estimated costs to the U.S. health care budget are 
$5 billion to $10 billion annually (222). These indicate the financial impact of nosocomial 
infections as well as their impact on patient safety and mortality rate. 
Recent data from the U.S. National Healthcare Safety Network indicate that Gram-negative 
bacteria are responsible for more than 30% of hospital-acquired infections (165). In intensive care 
units (ICUs) in the United States, Gram-negative bacteria account for about 70% of these types of 
infections, and similar data are reported from other parts of the world (165).  
The surface environment in rooms of colonized or infected patients is frequently 
contaminated with different pathogens and it has also been shown that this plays an important role 
in transmission of these pathogens (251).  Contact with hospital room surfaces or medical 
equipment by healthcare personnel frequently leads to contamination of hands and/or gloves and 
clonal outbreaks of pathogens contaminating the room surfaces of colonized or infected patient are 
demonstrated to be due to person-to-person transmission or shared medical equipment (251). In 
addition, the survival of nosocomial pathogens on environmental surfaces has been shown, which 
makes these pathogens a potential threat to patients in hospitals especially intensive care units 
(251). 
A range of Gram-negative organisms are responsible for hospital-acquired infections and 
multiply antibiotic resistant (MAR) organisms, including Pseudomonas aeruginosa, Acinetobacter 
baumannii, and extended-spectrum !-lactamase (ESBL) producing or carbapenemase producing 
Enterobacteriaceae, are increasingly being reported worldwide (165, 256). These pathogens often 
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cause a range of nosocomial infections such as pneumonia, blood stream infections, urinary tract 
infection (233) and wound infections (165).  
In recent years, the Infectious Diseases Society of America has coined the term ‘the ESKAPE 
pathogens’ for a fraction of antibiotic-resistant bacteria (Enterococcus faecium, Staphylococcus 
aureus, Klebsiella pneumoniae, A. baumannii, P. aeruginosa and Enterobacter spp.) that are 
capable of ‘escaping’ the biocidal action of antibiotics, posing a new challenge in treating the 
infections caused by them (18, 21, 167, 192).  Amongst these, infections caused by Gram-negative 
bacteria have features that are of particular concern as these pathogens can acquire genes that code 
for mechanisms of antibiotic resistance (165). These features of Gram-negative bacteria have led to 
a significant increase in treatment failure of the infections caused by bacteria resistant to several 
families of antibiotics (167, 225). Over the last decade, the alarming increase in antimicrobial 
resistance has raised global concerns regarding the treatment of the patients infected with multiply-
antibiotic resistant pathogens (225) as there are fewer, or even sometimes no effective antibiotic 
available for treating infections caused by these pathogens (130).  
 
1.1.1 Resistance to multiple antibiotics 
Many different definitions for multiply antibiotic-resistant (MAR), extensively antibiotic-
resistant (XAR) and pan antibiotic-resistant (PAR) bacteria are being used in the medical literature 
(130). However, a group of international experts from the European Centre for Disease Prevention 
and Control (ECDC) and the Centers for Disease Control and Prevention (CDC), proposed a 
standardized international terminology describing resistance to multiple antibiotics. Accordingly, 
MAR has been defined as acquired non-susceptibility to at least one agent in three or more 
antimicrobial categories, XAR has been defined as non-susceptibility to at least one agent in all but 
two or fewer antimicrobial categories (i.e. bacterial isolates remain susceptible to only one or two 
categories) and PAR has been defined as non-susceptibility to all agents in all antimicrobial 
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categories (130). The number of and classes of antibiotics used to define MAR, XAR and PAR are 
different in different bacterial species (130). However, according to the current classification, there 
are nine classes of clinically relevant antibiotics for treatment of A. baumannii (Table 1.1), which 
have been used to define the terms, MAR, XAR and PAR in A. baumannii (130).  
 
Table 1.1: Antimicrobial categories used to define MAR, XAR and PAR in A. baumannii 
Antibiotic category Antibiotic 
Aminoglycosides Gentamicin 
Tobramycin 
Amikacin 
Netilmicin 
Carbapenems Imipenem 
Meropenem 
Fluoroquinolones Ciprofloxacin 
Levofloxacin 
Antipseudomonal penicillins 
+!-lactamase inhibitors 
Piperacillin-tazobactam 
Ticarcillin-clavulanic acid 
Cephalosporins Cefotaxime 
Ceftriaxone 
Ceftazidime 
Cefepime 
Folate pathway inhibitors Trimethoprim-sulphamethoxazole 
Penicillins 
+!-lactamase inhibitors 
Ampicillin-sulbactam 
Polymixins Colistin 
Polymixin B 
Tetracyclines Tetracycline 
Doxycycline 
Minocycline 
 
1.2 Antibiotics and mechanisms of resistance in Gram-negative 
bacteria 
 
Discovery and production of antibiotics in the first half of the 20th century was one of the 
greatest achievements of medical sciences (244). After the discovery of antibiotics they were used 
to treat human infections starting with sulphonamide and followed by the aminoglycoside 
streptomycin and streptothricin. The use of antimicrobial agents has significantly reduced morbidity 
and mortality in humans and contributed substantially to increased lifespan in humans. Antibiotics 
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are now widely used as therapeutic or prophylactic agents (34, 128, 229). Antibiotics are classified 
based on their chemical structure and mechanisms of action (6). Antibiotics can inhibit protein 
synthesis, such as aminoglycoside, chloramphenicol, macrolide, streptothricin, and tetracycline or 
interact with the synthesis of DNA and RNA, such as quinolone and rifampicin (244). Other groups 
inhibit the synthesis of, or damage the bacterial cell wall such as !-lactam and glycopeptide. Others 
modify the energy metabolism of a microbial cell such as sulphonamide and trimethoprim (244). 
When antibiotics started to be used clinically it was thought that antibiotic resistance is 
unlikely to emerge given the negligible frequency of generation of mutations. In addition, the 
ability of bacteria to interchange genetic material that is now well known as horizontal gene transfer 
had not been discovered. Shortly after the introduction of antibiotics, bacterial isolates resistant to 
antibiotics started to appearing (46). In fact, emergence of resistance to beta-lactam antibiotics 
began even before the first beta-lactam penicillin was developed. The first beta-lactamase was 
identified in Escherichia coli prior to the release of penicillin for use in medical practice (46). In 
addition to beta-lactams, the aminoglycoside-aminocyclitol family was one of the first groups of 
antibiotics to face the challenge of resistance (46).  
Over the last decades emerging Gram-negative bacterial isolates resistant to multiple 
antibiotics have remained a great concerning issue that threaten public health by compromising 
treatment of infectious diseases (53). A number of clinically important classes of antibiotics used to 
treat infections caused by Gram-negative bacteria and their resistance mechanisms are described 
here.  
1.2.1 Aminoglycoside antibiotics 
The aminoglycoside antibiotics are over 60 years old (53). In the early 1940s the first 
aminoglycoside discovered was streptomycin in Streptomyces griseus. Several years later, 
additional aminoglycosides were characterized from other Streptomyces species; neomycin and 
kanamycin in 1949 and 1957, respectively, and later in the 1960s gentamicin was recovered from 
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the Actinomycete; Micromono sporapurpurea. These antibiotics have now been used for a long time 
for the treatment of infections in hospitalized patients (239).   
Aminoglycosides exhibit several characteristics that make them useful as antimicrobial 
agents. Among them are concentration-dependent bactericidal activity, post-antibiotic effect, 
relatively predictable pharmacokinetics, and synergism with other antibiotics (239). These 
antibiotics have potential nephrotoxicity, ototoxicity. Though there are problems associated with 
aminoglycoside-resistant organisms these antibiotics have remained valuable and sometimes 
indispensable for the treatment of various infections (239, 244). 
Aminoglycoside antibiotics kill bacterial cells since they inhibit protein synthesis by binding 
to the bacterial ribosomes and/or alter the integrity of bacterial cell membranes (126).  
Several aminoglycoside resistance mechanisms have been recognized, active efflux, decreased 
permeability, ribosome alteration and inactivation of the antibiotics by aminoglycoside-modifying 
enzymes. The main mechanism of resistance is modification. Aminoglycoside-modifying enzymes 
are classified into three major classes according to the type of modification: AAC 
(acetyltransferases), AAD (aminoglycoside adenyltransferase) and APH (phosphotransferases) 
(126, 239).  
 
1.2.2 ß-lactam antibiotics 
All ß-lactam antibiotics contain a core ß-lactam ring structure (30). These antibiotics 
generally act by inhibiting the cell wall synthesis and disrupting the structural cross-linking of 
peptidoglycan. This leads to the weakening of the bacterial cell wall and cytolysis due to osmotic 
pressure (54, 110).  
 Several mechanisms of resistance against ß-lactam antibiotics have been described such as 
changes in the permeability of the cell wall and/or hyper activity of the efflux pumps but the most 
important mechanism is the production of ß-lactamase enzymes which destroy the antibiotics by 
hydrolyzing them (29, 145, 162, 180). The current and simplest classification of the ß-lactamase 
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enzymes is by protein sequence, which divides these enzymes into 4 groups (29) whereby ß-
lactamase enzymes fall into four classes A (e.g. TEM, SHV, PER and CTX-M), B (e.g. VIM and 
IMP carbapenemases), C (AmpC cephalosporinases) and D (OXA carbapenemases) (29). Classes 
A, C and D are ß-lactamase enzymes with serine in their active sites whereas class B ß-lactamases, 
metalloenzymes, utilize zinc in their active site as cofactor for their catalytic activity (29).  
1.2.3 Tetracycline  
Tetracyclines interact with bacterial 30S ribosomes and block protein synthesis (35, 187). 
Tetracyclines have been used extensively to tread various bacterial infections such as respiratory 
infections, urogenital and periodontal diseases (36, 194). In Gram-negative bacteria tetracycline 
resistance generally occurs via extrusion of the antibiotic by efflux pumps, alteration of the 
antibiotic target (30S ribosome) or enzymatic inactivation of the antibiotic (35, 36, 187, 194).  
1.2.4 Trimethoprim and sulphonamides  
Sulphonamides were first used in 1932, while trimethoprim became available 3 decades later 
(215). Trimethoprim interacts with the dihydrofolate reductase (DHFR), whereas sulphonamides 
interact with dihydropteroate synthase (DHPS). These two enzymes are part of the folate 
biosynthetic pathway that is required for thymine production and bacterial cell growth (215). Both 
antibiotics have a wide spectrum of activity in Gram-positive and Gram-negative bacteria and are 
used to treat a range of bacterial infections such as urinary tract, respiratory, and skin infections 
(215). Trimethoprim and sulphonamides are synergetic antibiotics and have been used in 
combination (trimethoprim-sulfamethoxazole) extensively to treat various infections (194, 215).  
1.2.5 Fluoroquinolones  
These antibiotics inhibit the function of DNA gyrase and topoisomerase IV, which are 
essential for bacterial replication. This leads to the inhibition of replication and consequently 
bacterial cell death (88, 89). Bacterial DNA gyrase is composed of 2 GyrA and 2 GyrB subunits 
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encoded by gyrA and gyrB genes. The topoisomerase IV is comprised of 2A and 2B subunits 
encoded by parC and parE genes (88, 89). In Gram-negative bacteria the main mechanism of 
resistance to this class of antibiotics is via mutations of molecular targets of fluoroquinolones, DNA 
gyrase and topoisomerase (88, 89). The resulting changes lower the affinity of the quinolone for the 
enzyme-DNA complex (88, 89).  
Resistance to fluoroquinolones could also be due to different mechanisms including changes 
in the outer membrane permeability, over-expression of naturally occurring efflux pumps and 
plasmid-mediated determinants, qnr genes, which encode for proteins that protect DNA gyrase and 
type IV topoisomerase from quinolone inhibition (88, 89, 136).  
 
 
1.3 Mobile genetic elements & acquisition of antibiotic resistance 
genes 
 
The emergence of antibiotic resistance in Gram-negative bacteria occurs most often via 
acquisition of antibiotic resistance genes by transfer of gene from one bacterium to another (46). It 
has also been argued that antibiotic resistance in Gram-negative bacteria is often due to the 
acquisition of resistance determinants from a shared pool (125, 156). Gene capture usually involves 
two types of mobile genetic elements (60, 131, 156); those able to transfer DNA between molecules 
such as insertion sequences (131), integrons (72, 76) and transposons and those able to transfer 
DNA segments between cells such as conjugative and mobilisable plasmids (32). 
The exchange of bacterial genetic materials between cells can occur by different mechanisms 
including bacteriophage transduction, transformation and conjugation (81). In bacteriophage 
transduction fragments of DNA are transferred into the bacterial strains by phage and in 
transformation bacteria uptake single-stranded fragments of DNA from the external environment 
(81). In conjugation, pieces of DNA including antibiotic resistance genes, can be transferred via 
direct cell-to-cell contact (13). Plasmids are mobile genetic elements that can act as vehicles to 
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carry genetic materials. Plasmids can move between bacterial species and carry variety of mobile 
elements such as insertion sequences, transposons and/or integrons including antibiotic resistance 
gene cassettes (13, 125). 
 
1.3.1 Transposons 
Transposons are amongst the mobile genetic elements referred to as jumping gene systems 
and also as elements capable of incorporating antibiotic resistance determinants. These elements 
come in many forms and are classified in different classes, which can be distinguished by their 
structures (13, 66). Transposons have the ability to move both from one site to another within a 
DNA molecule or from one DNA molecule to another, for instance from one plasmid to another, or 
from a plasmid to a bacterial chromosome and vice versa (13). These mechanisms generally do not 
require DNA homology between the element and the sites of insertion. Although there are 
transposons known to target specific sites e.g. Tn7, Tn402 and Tn5053 (44, 103), many others show 
no obvious preference and insert into new sites almost randomly (43).  
Transposons are classified into two main classes. Composite transposons or class I 
transposons are constructed from a central DNA segment bounded by two IS elements and class II 
transposons constitute Tn3-family transposons (13, 66). There is also a third class, which includes 
transposons Tn7 (66), Tn402 (185), Tn5053 (106) and related transposons. 
 
1.3.1.1 Class I transposons and insertion sequences 
Insertion sequences (ISs) have been defined as small  (<2.5 kb) phenotypically cryptic 
segments of DNA with a simple genetic organization that are capable of independently inserting at 
multiple sites in a target molecule (131). Insertion sequences encode no functions other than those 
involved in their mobility (transposases), which catalyse transposition (131). The transposase is 
usually encoded by 1 or 2 open reading frames, which occupy almost the length of the IS (131, 
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181). ISs are bounded by two short terminal inverted repeats (IR), which range between 10 and 40 
bp (Figure 1.1) (131).  IRs are involved in transposase binding as well as in the cleavages and 
strand transfer reactions leading to transposition of the element (131). On insertion at new site, most 
IS elements generate a short direct repeats (DRs) of the target DNA (131). The length of the DR, 
which is usually between 2 and 14 bp, is also characteristic for a given element (131, 214).  
Many IS elements have been shown to enhance the expression of neighbouring genes by 
providing the genes with new promoters when inserted in an appropriate orientation (131). IS 
elements are able to insert into the bacterial genomes and expand into multiple locations, which can 
lead to a tremendous impact on the genomes in different ways including enhancement of the 
expression of the neighbouring genes, gene inactivation, chromosomal rearrangement and gene loss 
by deletion (14).  
 
Figure 1.1: General structure of insertion sequences (ISs). Green open box indicates the IS and the arrow inside the box 
represent the transposase gene. The red line represent a segment of DNA that the IS is inserted in. The portions inside 
the green box coloured yellow indicate inverted repeats and the green flags above the green box show direct repeats 
created after the insertion of an IS.     
 
 
 
1.3.1.0.1 IS26 
One of the ISs of greatest significance in Gram-negative bacteria, including A. baumannii, is 
IS26. IS26 belongs to the IS6 family and was first sequenced in 1983 (142). IS26 is 820 bp long, is 
bounded by perfect 14 bp terminal inverted repeats (IR) and it carries an open reading frame (orf) 
that encodes a 234 aa transposase (142). Transposition of IS26 has been experimentally shown and 
IS26 creates an 8 bp duplication of the target sequence (141, 142, 159). IS26 is a flanking element 
in a number of transposons and also has been associated with several antibiotic resistance genes 
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(94, 107, 117, 159, 248, 254). It has been also argued that IS26 plays an important role in 
assembling resistance regions by gene mobilization (139, 140, 248). 
 
1.3.1.0.2 ISAba1 
Another IS element of interest in this study is ISAba1, which is 1,180 bp and belongs to the 
IS4 family. ISAba1 includes 15 bp inverted repeats and duplicates 9 bp of the target DNA upon 
insertion (144, 206). ISAba1 has only been found in A. baumannii and in association with several 
antibiotic resistance genes such as ampC, oxa23 and sul2 (144, 206). It has been shown that ISAba1 
is responsible for the mobility of oxa23, with the help of two ISAba1 copies bracketing this gene 
(Figure 1.2) (143, 144). The role of ISAba1 in the expression of the antibiotic resistance genes of A. 
baumannii has been shown for the ampC, and oxa23 genes and it has been proposed that it might 
have the same role with other resistance genes (144).  
 
1.3.1.0.3 Class I transposons 
Class I transposons consist of a central DNA segment that is bounded by two copies of an IS 
and contains a phenotypic determinant such as antibiotic resistance gene (66). The movement 
ability of the composite transposons is due to the transposases provided by the IS elements, which 
are necessary for transposition (131). The IS elements can be either in direct orientation e.g. IS26 in 
Tn6020 (183, 184), or in inverted orientation such as IS10 in Tn10 (33, 116) and ISAba1 in Tn2006 
(143) (Figure 1.2). So far, a wide range of antibiotic resistance genes are known to be carried on the 
class I transposons, such as the tetracycline resistance tetA(B) gene in Tn10 (33, 116), the 
chloramphenicol resistance catA1 gene in Tn9 (Figure 1.2) (3), the kanamycin and neomycin 
resistance aphA1 gene in Tn4352 (159) or Tn6020 (183, 184). The oxa23 carbapenem resistance 
gene in Tn2006 (143) has also been frequently found in A. baumannii (Figure 1.2). 
CHAPTER ONE                                                                                                      General Introduction 
 
 
12 
Figure 1.2: Structures of the class I transposons. Thick horizontal lines indicate the central segments of the class I 
transposons. The extent of the antibiotic resistance genes are indicated by coloured arrows and the antibiotic(s) they 
confer resistance to are indicated above.  Coloured boxes represent the insertion sequences (ISs) with their name below 
and the arrows inside the boxes indicate the direction of the tnp genes. 
 
 
 
1.3.1.1 Class II transposons  
Class II transposons are often referred to as Tn3 family transposons (66, 67). The members of 
this family have common features including: i) a two-step transposition mechanism called 
replicative transposition that requires two gene products, the transposase and the resolvase, encoded 
by the tnpA gene and the tnpR gene, respectively (66), ii) all carry a small inverted repeated 
sequence (IR) of 38 bp at each end, which are related, and iii) their transposition duplicates a 5 bp 
sequence at the insertion point on the target DNA (119).  
Although class II transposons are called Tn3 family there are two main groups represented by 
Tn3 and Tn501 which differ by the orientation of tnpA and tnpR genes (Figure 1.3) (66, 67). 
Tn5393 is widely distributed and carries the tnpA and tnpR genes in the same orientation as in Tn3. 
Tn5393 has an unusual 80 bp IR, the outer ends of which share 21/38 bp of the 38 bp IR of Tn3. 
This transposon carries strA and strB that confers resistance to streptomycin (223). 
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Figure 1.3: Structure of the class II transposons, Tn3 and Tn501. Coloured arrows represent the tnpA and tnpR genes 
and the vertical lines indicate inverted repeats. 
 
1.3.1.2 Class III transposons  
Many transposons do not belong to class I and class II transposons and in particular 
transposons related to Tn7, which share characteristic features that are distinct from the other 
transposons. Here, for simplicity transposons related to Tn7 are called class III transposons.  
Tn7 is a 14 kb transposon that moves via both replicative and conservative mechanisms (44). 
Transposition can occur in a targeted or non-specific manner. The transposition module in Tn7 
consists of five genes namely tnsA, tnsB, tnsC, tnsD, and tnsE (44). The essential tnsA and tnsB 
genes encode a transposition protein, the TnsA resembles a restriction enzyme and TnsB a 
transposase (44, 171). Tn7 includes 25 bp IRs, which include a shorter binding site for TnsB that is 
repeated multiple times at both ends of Tn7 (44, 171). 
Another transposon that falls into this potential transposon class is Tn402. Transposon Tn402, 
is both a transposon and class 1 integron (185). Tn402 contains a transposition module that consists 
of four genes, tniA, tniB, tniQ and tniR that are necessary for its transposition but lacks the 3'-CS 
and the sul1 gene (106, 185).  Both transposons are bounded by 25 bp IRs. Within the transposition 
module the tniA gene encodes a transposase, TniA, which is 25% identical to TnsB of Tn7. TniB, 
encoded by tniB, shares 21% identity to TnsC in Tn7 (185).   
1.3.2 Gene cassettes and integrons 
Gene cassettes are small mobile elements, which usually contain only a single gene and a 
specific recombination site, known as attC (59-base element) that is necessary for their mobility 
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(75-77, 188). Cassettes vary in length from 262 to 1549 bp depending on the size of the genes they 
carry (188). Many genes found in gene cassettes are antibiotic resistance genes but any gene could 
be part of a cassette (77). Cassettes are identified by the gene name they encode or in the case of 
cassettes including open reading frames of unknown functions letters have been assigned to them 
(188). Gene cassettes, unlike other mobile elements, do not include all functions required for their 
mobility (73, 76). They can be found free in a circularized form or integrated at the attI site of an 
integron (76, 77). Multiple cassette insertions can also occur and integrons containing several 
cassettes have been found (76). 
Integrons are defined by the ability to incorporate gene cassettes by site-specific gene 
integration system (39, 72, 73, 220). Integrons carry a gene, intI, encoding a DNA integrase (Int) 
and an adjacent site, attI site, which is recognised by the integrase at which gene cassettes are 
incorporated (Figure 1.4) (160, 161). In fact, a site-specific recombination between attI and attC in 
a free circular cassette, catalysed by IntI, leads to the incorporation of the cassette into the integron 
(72, 75, 188). Several cassettes may also be integrated into the same integron to create a cassette 
array (75, 188). The excision of gene cassettes from integrons, which leads to free circularised gene 
cassettes, is also mediated by integrase (Int) (188). 
 
Figure 1.4: Gene cassette capture mechanism in a class 1 integron. The gene cassette is shown as a purple box and attC 
site as a box coloured black. The attI site is shown as an open box on the thick pink box. The extent of the genes is 
shown by a horizontal arrow with the gene name below. The direction and position of the Pc promoter is indicated by 
arrow labelled Pc.  
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Amongst different classes of integrons known so far, class 1, class 2 and class 3 are most 
commonly associated with antibiotic resistance (161). Class 1 integrons are generally recognized by 
the 5'-conserved segment (5'-CS) (73, 76, 160), which consists of the intI1 gene and the attI1 site 
(72, 76, 160). Most class 1 integrons also have a region known as the 3'-conserved segment (3'-CS), 
which carries a truncated qacE!1 gene that confers only marginal resistance to quaternary 
ammonium compounds, the sul1 (sulphonamide resistance) gene and two open reading frames, orf5 
and orf6, of unknown function (75, 102). This indicates that the presence of sulphonamide 
resistance could be an indicative of the presence of integrons (74). In addition, antibiotic resistance 
gene cassettes are expressed from the integron promoter Pc located 214 bp from the inner boundary 
of the 5'-CS as most gene cassettes do not include a promoter signal (38).  
Class 1 integrons can often be found in clinical isolates resistant to multiple antibiotics as they 
often carry gene cassettes encoding resistance determinants (161). Class 1 integrons with the 
cassette array aacC1-orfP-orfP-orfQ-aadA1, with aacC1 encoding gentamicin resistance and aadA1 
conferring resistance to streptomycin and spectinomycin, are amongst the ones that have been 
found in clinical strains of A. baumannii from different countries (65, 147, 237). 
1.3.3 Complex transposons 
Transposons can have complex structures if other mobile elements such as insertion 
sequences, integrons and other transposons insert within them (125, 255). These elements can jump 
within a transposon with or without disrupting the transposition functions of the original 
transposon.  
Tn21 is one of the well studied transposons with complex structure and is one of the best 
examples of the insertion of an integron inside a transposon (125). Tn21 is a class II transposon, 
which includes 38 bp imperfect repeats and generates 5 bp duplication of the target DNA on 
insertion (125).  The transposition system in Tn21 includes the tnpA and tnpR, which are in the 
same orientation as in Tn501 (125). Both Tn501 and Tn21 carry a mercuric ion (mer) operon 
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conferring resistance to mercuric ion but the mer region in Tn21 (GenBank accession no. 
AF071413) carries an additional mer gene, merC (175), located between merP and merA (Figure 
1.5) (68, 125).  
Figure 1.5: Structure of the different mer (mercuric ion) regions Tn21 (GenBank accession no. AF071413). Horizontal 
arrows indicate the extent of the genes and reading frames. Inverted repeats are vertical lines with identifying notation 
IRtnp and IRmer for the IR at the tnp and mer end, respectively.  
 
 
Tn21 carries a class 1 integron, designated In2. In2 includes one integrated gene cassette, the 
aadA1 cassette (Figure 1.5) (125). In2 is flanked by imperfect inverted repeats of 25 bp (IRi and 
IRt) and bounded by a 5-bp direct duplication of the target sequence indicating that it has 
transposed into an ancestral tnp-mer transposon to create Tn21 (125). In2 is a composite element 
that contains a single cassette and two insertion sequences, IS1326 and IS1353 (125). 
Tn21 is one of the most widely distributed transposons and many transposons carrying 
antibiotic resistance determinants belong to the Tn21 subgroup and many of its close relatives also 
carry a class 1 integron (72, 125). 
Tn1696 is also another example of complex transposon with an integron inserted within it 
(157). Tn1696 is a 13.6 kb mercury resistance transposon, which includes the class 1 integron, In4. 
In4 is 8.33 kb long and includes four integrated cassettes and its 3'-CS region is followed by one 
full copy and an adjacent partial copy of the insertion sequence IS6100 flanked, in inverse 
orientation (157).  Although Tn21 and Tn1696 are both classified as members of the Tn21 
subfamily of the class II transposons, the backbone mercury resistance transposons are only 79 to 
96% identical. Tn1403 and Tn1412 are also other examples of complex transposons carrying a class 
1 integron (157).   
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Tn2670 has a complex structure and is an example of transposon inside another transposon 
(158). Tn2670 has arisen via a series of transpositional and other events and it is composed of a 
transposon closely related to Tn9, with the Tn21 (19) within it (158). 
1.3.4 Genomic antibiotic resistance islands  
Genomic islands are large chromosomal regions that have been previously transferred in and 
are present in certain bacteria but are absent in their closest relatives (28, 51, 242). Hence, they are 
part of the flexible gene pool and often carry several genes that can increase the adaptability and 
versatility of bacteria (28, 210).  
Antibiotic resistance islands are a group of genomic islands that include several genes 
conferring resistance to antibiotics (28, 242). The presence of these elements can enhance 
adaptability and competitiveness of bacteria within a niche (51). Several of these antibiotic 
resistance islands have been described in Gram-negative bacteria. SGI1 and SGI2 in Salmonella 
enterica are the best examples that have had a major contribution in antibiotic resistance in this 
organism (122).  
Many of the genomic antibiotic resistance islands are in fact complex transposons composed 
of several antibiotic resistance determinants (or sometimes heavy metal resistance genes) derived 
from bacterial chromosomes and/or plasmids, insertion sequences, integrons and different types of 
transposons. Some of the genomic resistance islands found in Pseudomonas aeruginosa are 
amongst this type (79, 196). The antibiotic resistance island found in the genome of MAR A. 
baumannii AYE is also another example. This island is composed of a transposon backbone and 
several insertion sequences, integrons, and transposons carrying segments of DNA from other 
Gram-negative bacteria, mainly from Salmonella sp., Pseudomonas sp. and E. coli, inserted within 
it (58, 241). This island has greatly contributed to development of antibiotic resistance in this 
organism (58, 241).  
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1.3.5 Plasmids 
Plasmids are double stranded, extra-chromosomal DNA capable of replicating autonomously. 
Plasmids are able to move genes from one bacterial cell to another (42, 61). Most plasmids include 
3 essential features including (i) the origin(s) of replication (ori), which is characteristic of each 
replicon (ii) a rep gene, which encodes a replication initiation protein, Rep protein, and (iii) genes 
involved in the control of replication (42, 47).  Amongst these, the sequence of Rep proteins has 
been extensively used to classify plasmids, which includes the comparison of the amino acid 
sequences of Rep proteins (47). Rep proteins recognize specific sequences at the origin of 
replication and they generate a nucleoprotein initiation complex, in which essential macromolecular 
interactions take place (42, 47).   
Bacterial plasmids can be conjugative (self-transmissible) or mobilizable (60). Conjugative 
plasmids encode the functions necessary to promote cell-to-cell DNA transfer, via formation of a 
conjugal bridge called a sex pilus, which acts to join donor and recipient cells and is then retracted 
into the donor to effect envelope-to-envelope contact (13, 61). Mobilizable plasmids are 
transmissible only in the presence of additional conjugative functions because they carry the 
mobilization region (mob genes) encoding specific relaxosome components and the origin of 
transfer (217), but lack the functions required for mating pair formation (60, 217). Mobilizable 
plasmids are generally small, less than 10 kb, whereas conjugative plasmids tend to be relatively 
larger, greater than 30 kb, as they need to carry genes encoding their conjugation functions, tra 
genes (13). Conjugative plasmids can have broad or narrow host range (115). Some broad host 
range plasmids from Gram-negative bacteria can transfer between a wide range of bacterial species. 
For instance, RP1, which was first identified in a clinical isolate of Pseudomonas aeruginosa is able 
to transfer to most, if not all Gram-negative bacteria (13).   
Plasmids do not carry genes necessary for basic cellular functions but they often include 
genes that enable the cell to survive under potentially lethal circumstances e.g. antibiotic exposure 
(13). Plasmid-encoded antibiotic resistance includes most, if not all classes of antibiotics currently 
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in clinical use and includes resistance to many that are the forefront of antibiotic therapy such as 
cephalosporins and aminoglycoside (13). Plasmids carrying antibiotic resistance genes in complex 
structures such as transposons and integrons have also been implicated as the main vehicles for 
DNA transport between different strains facilitating the movement and circulating these 
determinants amongst bacterial species (13, 61).  
1.4 Genus Acinetobacter 
 
The taxonomy of the genus Acinetobacter has a long and convoluted history (230, 249). 
According to the most recent taxonomic studies, the genus Acinetobacter belongs to subclass !-
Proteobacteria, family Moraxellaceae (249). This genus includes a heterogeneous group of non-
fermentative Gram-negative cocobacilli that are strictly aerobic, catalase positive and oxidase 
negative with a DNA G+C content of 39% to 47% (15, 166). In 1911 Beijerinck, a Dutch 
microbiologist, isolated and described the first example of an organism that is now recognised as 
Acinetobacter (230). The genus Acinetobacter includes 23 species for which a formal name has 
been assigned as well as at least 11 recognized additional genomic species without a name, 
although names have recently been proposed for some but are not yet formally assigned (249). The 
Acinetobacter species for which official names are assigned are A. baumannii, A. baylyi, A. 
beijerinckii, A. bereziniae, A. bouvetii, A. calcoaceticus, A. gerneri, A. grimontii, A. guillouiae, A. 
gyllenbergii, A. haemolyticus, A. johnsonii, A. junii, A. lwoffii, A. parvus, A. radioresistens, A. 
schindleri, A. soli, A. tandoii, A. tjernbergiae, A. towneri, A. ursingii, A. venetianus (249). 
In the clinical environment, Acinetobacter baumannii is of great importance, as it accounts for 
the vast majority of nosocomial infections and hospital outbreaks involving Acinetobacter spp. (15, 
169, 230, 231). A. baumannii, genomic species 3 and 13TU are closely related and, in fact, very 
difficult to be distinguished from each other by phenotypic methods (149). Recently, Acinetobacter 
genomic species 3 and Acinetobacter genomic species 13TU have been renamed as Acinetobacter 
pittii and Acinetobacter nosocomialis, respectively (149).  
CHAPTER ONE                                                                                                      General Introduction 
 
 
20 
1.5 Acinetobacter baumannii  
 
A. baumannii  is an opportunistic pathogen and is frequently isolated from different hospital 
infections especially in ICUs (15, 169, 230, 231, 249). Despite the other members of the 
Acinetobacter genus, which are ubiquitous, being recovered easily from water, soil and animals, A. 
baumannii is not ubiquitous and has no known natural habitat outside the hospital (230). However, 
it has rarely been isolated from soil and water (230).  
A. baumannii causes mainly nosocomial infections and relatively rarely community acquired 
infections (166). Nosocomial infections caused by this organism mainly involves critically ill 
patients such as immunocompromised patients, and patients in ICU and burn units with hospital 
acquired pneumonia, associated with ventilators, being the most encountered disease (166). 
Catheter associated bloodstream infections, post-neurosurgical meningitis, wound and urinary tract 
infections have also been observed (15, 166, 168, 169, 230, 231, 249). Overall, mortality rates 
between 30-75% have been observed for nosocomial infections caused by A. baumannii (15).  
Major surgery, major trauma, burns, premature birth, previous hospitalization, stay in an ICU, 
length of hospital or ICU stay, mechanical ventilation, indwelling foreign devices, the number of 
invasive procedures performed, and previous antimicrobial therapy have all been identified as risk 
factors predisposing to the acquisition of and infection with A. baumannii (249). 
A. baumannii has proven to be a successful nosocomial pathogen due to its (i) natural 
resilience, especially on dry surfaces, (ii) resistance to disinfectants, and (iii) a wide range of 
antibiotic resistance (101, 166, 169, 249). Jawad et al. compared the survival times of sporadic and 
outbreak strains of A. baumannii on dry glass coverslips and determined an overall mean survival 
time of 27 days with no difference between sporadic and outbreak strains (101). This indicates the 
ability of A. baumannii to survive for a long time on dry surfaces and therefore an increased 
potential for epidemic spread (101). 
There are reports of A. baumannii resistant to multiple antibiotics from different continents 
and even from remote areas such as Tahiti in the South Pacific (169) indicating the global 
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distribution of MAR A. baumannii. Resistance to antibiotics often provide certain A. baumannii 
strains with selective advantage in an environment such as ICU where microorganisms are 
confronted with extensive exposure to antibiotics (166). This is also supported by several studies 
showing that resistance rates in epidemic strains, which cause outbreaks, are significantly higher 
than the sporadic strains (49, 80, 101). Over the last decades, A. baumannii outbreaks in hospitals 
have been increasingly reported globally, leading to great challenges in controlling its spread as it is 
often impossible to trace the source of infection (168). There is an opinion that A. baumannii has 
coevolved with our healthcare systems such that it is able to overcome and even exploit measures 
taken to prevent infection and spread, leading to a ‘highly successful human pathogen’ (168). 
Unfortunately, very little is known about the virulence and persistence strategies of A. 
baumannii. Smith et al. with the help of new technology to determine and analyse the whole 
genome, identified a remarkable number of putative alien islands, 28 islands, 16 of which contained 
genes implicated in virulence, indicating that the organism devotes a considerable portion of its 
genes to pathogenesis (218). It also highlights the presence of a large amount of foreign DNA 
(218). However, overall the ability to survive on dry surfaces for a long time, antibiotic resistance, 
hydrolytic enzymes and cell surface components, such as adhesins, are thought to be the major 
contributors to the importance of A. baumannii in clinical settings (241).  
An oxacillinase gene, oxa-Ab (hereafter referred to oxa-51-like as for simplicity; Ab for A. 
baumannii), has been found to be present in all A. baumannii (82) and absent from other 
Acinetobacter species. The oxa-Ab gene has been rapidly characterised in recent years and proven 
effective in differentiating A. baumanni from other species of the Acinetobacter genus (238). For 
the first time this gene was identified in A. baumannii strains in Argentina in 2004 (26). Subsequent 
studies also showed that variants of the oxa-Ab gene are present in A. baumannii (82, 83) but not in 
the other species of the Acinetobacter genus such as A. haemolyticus, A. lwoffi and genomic species 
(138).  
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1.6 A. baumannii European Clones 
Since the early 1980s, different hospital outbreaks of infections due to multiply antibiotic 
resistant (MAR) A. baumannii in Europe mainly in England, France, Germany, Italy, Spain and the 
Netherlands have been investigated using different molecular techniques (50, 166, 249). Initially, 
the typing methods, which were used to study A. baumannii mainly included plasmid profiles, 
ribotyping, AFLP (Amplified Fragment Length Polymorphism) and PFGE (Pulsed Field Gel-
Electrophoresis). In AFLP, DNA is digested with restriction enzymes, followed by selective 
amplification, electrophoretic separation of fragments, and visualization (100). Ribotyping works 
by restriction digesting of chromosomal DNA followed by electrophoresis and hybridizing with 
labelled cDNA probes (166, 249). However, each of these old methods had limitations. AFLP was a 
sensitive method but it was very cumbersome and expensive (166). Ribotyping also had a limited 
discriminatory power (166, 249). Pulsed Field Gel-Electrophoresis (PFGE) is based on restriction 
digestion and separation of large fragments of DNA by electrophoresis (166, 249). However, PFGE 
is laborious and takes several days to generate the typing results and its discriminatory power for 
large-scale population studies is too high, which makes it more suitable for local epidemiological 
studies (166, 249). Plasmid profiles were easy to generate but given that plasmids can move they 
could change the plasmid profiles (166). Using these typing methods, the spread of strains between 
hospitals was noticed and in a majority of cases transmission of one or two epidemic strains were 
detected in a given outbreak (50, 166).  
Dijkshoorn et al. in 1996 investigated the relatedness of 31 MAR A. baumannii strains 
comprising 14 strains from 14 outbreaks in different north-western European cities and 17 sporadic 
strains by various phenotypic (biotyping and antibiotic resistance profile) and molecular methods 
(cell envelope protein electrophoretic profile, ribotype pattern and AFLP) (49). They found that 12 
strains from unrelated outbreaks were linked together in two AFLP clusters whereas sporadic 
strains were more heterogeneous (49). They showed that strains in each group were highly similar. 
The 2 distinct groups, which were designated clone I and II, mainly comprised strains from 
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outbreaks at different locations in north-western Europe (49).  
Later studies, in 1999 and 2004, from the Czech Republic using ribotyping, plasmid profiles 
and AFLP showed that MAR outbreak strains were mainly members of the clones I and II (146, 
148), though the Czech epidemic strains exhibited intra-clonal diversities (146). In 2001, in another 
study two groups of strains which had been identified as European clone I and II from northwest 
Europe and Czech Republic were examined using additional typing methods including biotyping, 
ribotyping and an O-serotyping scheme (155). These strains remained in 2 groups that were shown 
to be genetically and phenotypically similar (155).  
European epidemic MAR strains of clone I and II were also identified by Brisse et al. in 2000 
(23) and by van Dessel et al. in 2004 (243) using AFLP and PFGE among outbreak strains 
throughout the Europe. They identified members of clone I in Spain, Poland and Italy, and clone II 
in Spain, Portugal, France, Greece and Turkey (23, 243). In 2004, van Dessel et al. identified a third 
clonal group in France, the Netherlands, Spain and Italy. However, clone III was found to be more 
homogenous while clones I and II showed a similar level of intra-clonal diversity (243) as in the 
Czech study (146).  
Over the last decade with the advances in DNA sequence technologies several sequence based 
typing methods have emerged (249). In 2007, Turton et al. developed a multiplex PCR based on the 
allelic differences of the three housekeeping genes ompA  (outer-membrane protein A), csuE  (part 
of a pilus assembly system required for biofilm formation) and oxa-Ab (Figure 1.6) (235). Using 
this method they examined representatives (31 strains) of outbreak strains from five countries 
(Spain, France, Netherlands, UK and Israel) (235). This study showed that these strains fall into 3 
groups, which were designated Sequence Group or SG1- 3 (235). They also showed that Sequence 
Group 1 and 2 (SG1 and SG2) actually correspond to the previously identified European clone II 
and I respectively (235). This method has been used in several studies and has been shown to be a 
reliable tool to separate strains belonging to the major clones (151-153, 184). Sequencing of the 
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oxa-Ab gene has proved to be useful as the alleles encoding OXA-69 and OXA-66 have been 
shown to be associated with European clone I and II respectively (57, 184).    
Development of Multi-Locus Sequence Typing (MLST) provided the opportunity to look at 
the broader picture of the A. baumannii population and study the relatedness of the strains 
recovered from different countries (249). MLST works based on PCR and sequencing of 
housekeeping genes followed by comparison of allelic variations (132, 133, 249). This method has 
allowed inter-laboratory comparisons and large scale monitoring at local and international levels 
(132, 133, 249). Currently, there are two MLST schemes available for A. baumannii. The first 
scheme was developed by Bartual et al. (12) in 2005 and is hosted at Oxford University and known 
as Oxford MLST Scheme. This scheme uses seven housekeeping genes (Figure 1.6) gltA (citrate 
synthase), gyrB (DNA gyrase subunit B), gdhB (glucose dehydrogenase B), recA (Homologous 
recombination), cpn60 (60-kDa chaperonin), gpi (glucose-6-phosphate isomerase) and rpoD (RNA 
polymerase sigma) to determine the sequence type (12).  
Figure 1.6: Map of the genome of A. baumannii that shows the chromosomal location of the genes used in the allele 
specific PCR and also in the Oxford and Institut Pasteur MLST schemes. 0 represents the origin of replication.  
 
In 2010, Hamouda et al. used the Oxford MLST Scheme and sequencing of the oxa-Ab gene 
to examine the relatedness of 44 MAR isolates A. baumannii from 22 countries (78). This collection 
included representatives of European clonal lineages I, II and III.  Using these methods they showed 
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that almost half of the strains examined belonged to the clone I and II as 10 strains belonged to the 
European clone I and 11 strains belonged to the clone II (78). 
In 2010, Diancourt et al.  developed an additional MLST scheme, known as Institut Pasteur 
Scheme, which shares 3 genes (cpn60, gltA and recA) with the Oxford scheme (Figure 1.6) (48). 
This Scheme uses fusA (elongation factor EF-G), pyrG (CTP synthase), rplB (50S ribosomal protein 
L2) and rpoB (RNA polymerase subunit B) in addition to cpn60, gltA and recA (Figure 1.6) (48). 
They used this scheme to examine the phylogenetic relatedness of 154 A. baumannii strains (48) 
including representatives of previously recognized clone I and II strains. However, most strains (n= 
150) had been isolated in European countries (48). This study showed that the previously 
recognized clone I and II correspond to two distinct clonal groups, ST1 and ST2 respectively (48). 
Overall, these two schemes have been used in several studies and proved to be useful to distinguish 
members of clone I and II as well as isolates of different types and their sub-lineages (48, 78). 
However, MLST is expensive and laborious.  
All of the studies discussed above examined a large number of European strains as they 
mainly focused on outbreaks in European hospitals. However, the presence of a few strains isolated 
from non-European countries raised the possibility that these clones might be present in other 
continents. 
1.7 A. baumannii Global Clones 
 
 
In 2004, van Dessel et al. identified a single isolate from South Africa belonging to the clone 
I (243). They argued that the identification of a single isolate belonging to the European clones in 
South Africa might suggest that these clones have the potential to spread to other regions (243). 
In 2007, it was noticed that returning military personnel who have fought in Iraq or 
Afghanistan to the United States have had an extremely significant contribution to the spread of 
infections caused by MAR A. baumannii in the US (166, 203). Soldiers injured in the conflicts in 
Iraq and Afghanistan have shown increased levels of A. baumannii infections since the 
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commencement of operations in 2003 (166). These soldiers are primarily treated in field hospitals 
and then transported to Landstuhl Regional Medical Centre (Germany) or the Walter Reed Army 
Medical Centre (WRAMC) in the US, and the acquisition and dissemination of MAR isolates has 
occurred in a variety of environments (166). In 2006 Hujer et al. examined a selection of MAR 
strains isolated from both civilian and military patients at WRAMC using PCR-ESI-MS (92). This 
method is based on the amplification of six housekeeping genes, followed by purification of the 
product and determining their mass spectra (55). The results generated by this method are 
potentially comparable with PFGE and AFLP but they need to be further validated (166). They 
found a broader range of resistances than those which were typical of A. baumannii usually found in 
civilian US hospitals, and found that 60% of the isolates were related to the European clones I or II 
(92). In 2006, a parallel study showed that Acinetobacter isolates from the United States associated 
with casualties from the Iraq conflict were indistinguishable from ones from the United Kingdom 
using different molecular typing techniques (236).  
Development of whole genome sequencing methods provided a unique approach to study 
clones and their relatedness (249). Adams et al., in two studies in 2008 and 2010 determined the 
whole genome sequence of 7 MAR strains isolated from large outbreaks in WRAMC (in the US) 
and showed that they belong to the European clone 1 (1, 2). 
In 2009, Post and Hall for the first time showed the existence of a MAR strain belonging to 
the European clone I in Australia (183). They used the allele specific PCR, the sequence of oxa-Ab 
and the recA gene, which is one of the alleles in both MLST schemes and is characteristic in both A. 
baumannii clones (183). The strain 3208 was isolated from a blood sample in 1997 in a Sydney 
hospital and was resistant to gentamicin, kanamycin, sulphonamides, and streptomycin (183). Some 
of the MAR strains examined in the Mak et al. study (134) were also further characterized in a later 
study isolates were found to belong to the European Clone I and II respectively (182). 
Consequently, Post and Hall used the term “Global Clone (GC)” to replace “ European Clone (EC)” 
as they have been associated with infection and epidemic spread in hospitals globally (184). Hence, 
CHAPTER ONE                                                                                                      General Introduction 
 
 
27 
these clones are referred to as GC1 and GC2 hereafter in this study. They showed that GC1 strains 
contain a class 1 integron with the gene cassette array aacC1-orfP-orfP-orfQ-aadA1 or aacC1-orfP-
orfQ-aadA1 (184). The context of the resistance genes and class 1 integron were also determined in 
the GC1 strains and found to be clustered in a large genomic island in the chromosome (Section 
1.11) (184). They showed that GC1 strains carry the gene encoding OXA-69 and GC2 strains make 
OXA-66 (184). Nucleotide differences in the 425 bp internal segment of the recA gene were also 
characteristic for GC1 and GC2 strains (184).   
In addition, amongst the MAR strains that, Hamouda et al.  characterized in 2010, there were 
2 GC1 strains that had been recovered outside the Europe (A63 from Argentina and A479 from 
Pakistan) (78) indicating that European hospitals are not the only source of these clones. 
In 2010, Higgins at al. examined 515 MAR A. baumannii strains collected from 139 
worldwide centres representing 32 countries (85). Of these, 479 were resistant to carbapenems. 
They showed that 44 isolates belonged to the GC1 clone and 241were grouped in the GC2 clone 
(85). They also showed that isolates belonging to GC1 and GC2 groups were from different places 
including USA, pan-Europe, Israel, Asia, Australia and South Africa (85). 
In 2010, Mugnier et al. examined the relatedness of 20 carbapenem resistant A. baumannii 
from different countries (France, Tahiti, Vietnam, New Caledonia, Thailand, Reunion, Australia, 
South Africa, Libya, UAE, Bahrain, Algeria, Egypt, Belgium and Brazil) using PFGE and MLST 
(143).  Amongst the strains examined they identified 8 GC1 and 10 GC2 and the remaining 2 
strains did not belong to the global clones (143).  The results of this study was consistent with the 
previous studies and yet again confirming the global dissemination of MAR GC1 and GC2 strains 
(143). 
In 2010, another study of the molecular epidemiology of MAR strains mainly from ICU and 
burn units from a single Australian hospital (Royal Brisbane Women Hospital; RBWH) that had 
been isolated over a 10 year period, 1998-2008, was reported (197). This study determined 
resistance profiles and sequence types of 33 isolates, representative of 483 present in their 
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collection. The sequence types they found were ST126, ST92 and ST69, which belonged to the 
major global clones 1 and 2 (197). They determined the resistance profiles to gentamicin, amikacin, 
tobramycin, ciprofloxacin and meropenem. They showed that 27 strains were resistant to 
meropenem and contained the oxa23 gene. They also presented evidence for the spread of a few 
sequence types in the outbreaks they studied, which again indicates the significance of the spread of 
MAR strains belonging to the global clones causing outbreaks (197).  
In 2012, Higgins et al. examined 178 MAR A. baumannii isolates that had been isolated from 
blood stream infections in the United States between 1995 to 2004 (86). Using MLST (both 
schemes) they showed that 5 strains belonged to GC1 and 47 to GC2 (86). They also argued that the 
presence of GC1 and GC2 strains as early as 1995 in the US could indicate that global 
dissemination of these clones was an early event (86).   
Furthermore, during recent years other studies also identified MAR A. baumannii isolates belonging 
to the GC1 and GC2 in different countries including the Middle East, Europe, Asia and the United 
States which were mainly resistant to carbapenem antibiotics (48, 86, 143, 257). It has been argued 
that it is possible that clinical isolates of A. baumannii do not fully represent the diversity of the 
species, and simply constitute a restricted subset of the population that has acquired the ability to 
colonize and infect humans (249, 257). These clones appear to be genetically stable strains that are 
particularly successful in the hospital environment and evolve slowly during their spread (50, 257). 
1.8 A. baumannii in Australia 
 
The first reports of infections caused by A. baumannii came from the Northern Territory (5, 
6). These reports involved community-acquired infections and A. baumannii strains causing these 
were highly susceptible to antibiotics (5, 6). The first outbreak reported due to MAR strains 
occurred in a Western Australian hospital during 1993-94 (193). This outbreak included strains 
resistant to gentamicin, cephalosporins and ticarcillin (193). Outbreaks of MAR organisms have 
also been reported from major cities including Sydney, Melbourne and Brisbane (164, 172, 240). 
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In 2007, Valenzuela et al. described a sample collection that consists of 177 Acinetobacter 
spp. collected from patients, mostly from outbreaks that occurred in the ICU at Westmead Hospital 
(Sydney) between 1995 and 2000 and compared them to ones from Prince of Wales Hospital 
(Sydney) and Royal Brisbane Women Hospital (Brisbane) (240). They showed that carbapenem 
resistant A. baumannii isolates (n = 13) harboured oxa23, accounting for the resistance phenotype 
observed (240). A number of resistance genes responsible for the MAR phenotype were also 
identified (240). A selection of 20 MAR strains, representative of each group, were further 
characterized in their study by examining their relatedness using PFGE and RAPD (Random 
Amplification Polymorphism DNA, which is a PCR based method that works by random prime 
amplification) analysis as well as identifying their antibiotic resistance genes and the cassette arrays 
related to the class 1 integron (240). 
Mak et al. 2009 examined 32 MAR strains which had been mainly isolated during ICU 
outbreaks in 4 different hospitals in Sydney and determined their resistance profiles to 25 
antibiotics. They identified various resistance determinants accounting for the phenotype observed 
including the carbapenem resistance gene oxa23, ampC with the upstream ISAba1 activating the 
ampC (Section 1.9.1.1) and subsequent resistance to cephalosporins (134). They also identified 
tet(B), a tetracycline resistance determinant, blaTEM-1, which contributes to ß-lactam resistance, and 
strB, which confers resistance to streptomycin, an aminoglycoside antibiotic (134). They identified 
the kanamycin resistance gene, aphA1 and the class 1 integron in 10 isolates and all the integron 
containing isolates included the aacC1-orfP-orfQ-aadA1 cassette array. They also observed that 
isolates from both outbreak and sporadic cases included at least eight resistance determinants that 
give rise to the MAR phenotype. Using REP-PCR (Repetitive Extragenic Palindromic PCR) and 
genotyping they identified three main types in their collection (134).  
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1.9 Antibiotic resistance in A. baumannii 
 
Acinetobacter strains were generally susceptible to available antibiotics such as ampicillin, 
gentamicin and tetracycline when these organisms were initially recognized as a nosocomial 
pathogen in the 1970s (15, 230). However, after 1975 reports of the increasing occurrence of 
resistance in Acinetobacter started to appear (15, 230). Now the challenge with A. baumannii is that 
it has developed high levels of resistance to several antibiotics (168). Today many older antibiotics 
e.g. penicillins, cephamycins and tetracyclines (15, 230) and even new broad-spectrum antibiotics 
e.g. expanded-spectrum cephalosporins and carbapenems have become ineffective and clinicians 
are left with very few, if any, effective therapeutic options (169, 174). A. baumannii also includes a 
range of intrinsic resistance determinants, but recent data indicate the significance of acquired 
resistance determinants,  identified in other clinically significant Gram-negative species such as 
Enterobacteriaceae and Pseudomonas aeruginosa (174).  
1.9.1 Resistance to ß-lactams 
The most important mechanism is the production of ß-lactamase enzymes (145, 162, 168, 
169, 174, 180). Genes encoding Extended-spectrum ß-lactamases (ESBLs) from the Ambler class A 
have been described in A. baumannii (166, 169). However, the main cause of resistance to extended 
spectrum ß-lactams such as third generation cephalosporins is the activation of a chromosomal ß-
lactam gene, which belongs to the Ambler class C (Section 1.9.1.1). Narrow-spectrum ß-lactamases 
e.g. TEM-1 and TEM-2 are also prevalent in A. baumannii, but their current clinical significance is 
limited given the potency of other resistance determinants (166). Metallo-beta-lactamases (MBLs), 
which belong to the class B ß-lactamases have been described in A. baumannii but again they are 
not often seen (169). The ß-lactamases most frequently detected are class D carbapenemases (178, 
179, 250), and resistance to 3rd generation cephalosporins is caused by activation of an intrinsic 
chromosomal gene (84, 99, 195). 
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1.9.1.1 Class C ß-lactamases  
A. baumannii includes a chromosomally-encoded class C ß-lactamase, AmpC (169, 174). The 
ampC gene in A. baumannii is 1,152 bp long and located between the folE gene and an open 
reading frame of unknown function (Figure 1.7; Figure 1.8a).  
Figure 1.7: Map of the genome of A. baumannii that shows the chromosomal location of the ampC gene, genes used in 
Oxford and Institut Pasteur MLST schemes. 0 represents the origin of replication. AbaR is the antibiotic resistance 
island usually found in the genome of MAR GC1 isolates. 
 
Most AmpC-type beta-lactamases naturally produced by Gram-negative bacteria hydrolyze 
amino- and ureidopenicillins, cephamycins (cefoxitin and cefotetan), and, at a low level, 
oxyiminocephalosporins such as ceftazidime, cefotaxime, and ceftriaxone, as well as monobactams, 
such as aztreonam (30, 195). The presence of a chromosomal ß-lactamase gene in the genus 
Acinetobacter was first suggested by Matthew and Harris in 1976 (137) and in 2000 Bou and  
Figure 1.8: The context of the chromosomal ampC gene in A. baumannii. The thick central line represents the 
chromosome and the arrows below represent the genes and their direction. (a): represents the ampC gene without 
ISAba1 and (b) shows the position of ISAba1 relative to ampC.  
 
 
 
Martinez-Beltran cloned and sequenced the ampC gene from the A. baumannii strain RYC, 
which was isolated during an outbreak in 1997 (20). They observed no transfer of resistance 
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phenotype reinforcing the chromosomal nature of the ampC gene in strain RYC (20), and found that 
in this strain ampC was not inducible by cefoxitin (20). Following that, Corvec et al. in 2003 
showed that A. baumannii strains resistant to 3rd generation cephalosporins include an IS upstream 
of the ampC gene (40). The IS belongs to the IS4 family and was later named ISAba1. They also 
suggested that the IS they found next to the ampC gene might increase the expression of ampC (40). 
Activation of the chromosomal ampC gene in A. baumannii is now known to arise mainly as a 
consequence of acquisition of ISAba1 upstream of the chromosomal ampC gene as it is frequently 
found before the ampC gene in isolates that are resistant to third-generation cephalosporins (84, 
134, 152, 195, 206, 208, 228). 
It has been shown that the presence of a copy of ISAba1 in the appropriate orientation (Figure 
1.8) upstream of ampC provides the gene with a promoter that appears to be stronger than the 
intrinsic promoter as it enhances the transcription of ampC (40, 84, 206, 208). Segal and Elisha 
identified the transcription initiation site of the ampC gene in an A. baumannii strain (207, 208) and 
it was located 35 and 38 bp upstream of the ampC start codon (the bold black G and T with an 
asterisk above; Figure 1.9). They also identified the two hexamers, TTATTT, and TTAGAA 
upstream of the transcription start site that show similarity to the consensus -10 sequence 
(TATAAT) and -35 hexamer (TTGACA) recognized by Sigma70 (208). However, taking into 
account the transcription start site found in a different study (207), an alternative promoter seems 
more likely (Figure 1.9). 
CACTTTAAATGTGACTTGTTCCATTTTAGATATTTGTTTAAGATAAGATATAACTCATTG  
           M          -35                   -10        *  * 
AGATGTGTCATAGTATTCGTCGTTAGAAAACAATTATTATGACATTATTTCAATGAGTTA  
                    RBS         M                 
TCTATTTTTGTCGTGTACAGAGGAGCTAATCATGCGATTTAAAAAAATTTCTTGTCTACT  
                                               ! 
Figure 1.9: The nucleotide sequence of the 5'-end of ampC and its position relative to the ISAba1. The transcription 
initiation sites (G) and (T) are bold black with an asterisk above. The -35 and -10 hexamers found in (208) are shown in 
orange and the ones found here are indicated on black. The latter also includes an extended -10 sequence. The ISAba1 
sequence is coloured green and the bases coloured blue represent the start of the transposase gene. The ampC sequences 
are bold and the “M” above stands for Methionine. The ribosome binding sequence, RBS, is underlined. The vertical 
arrow indicates the first base of ISAba1 and the adjacent italic letters indicate the sequences belong to the chromosome. 
The transcription start points determined experimentally in references (207, 208) are indicated bold with an asterisk 
above.  
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Other insertion sequences have also been detected upstream of ampC. ISAba125 is present 
upstream of ampC in ACICU, a GC 2 isolate from Italy (GenBank accession no. CP000863) (93). 
However, whether ISAba125 enhances the expression of ampC in ACICU was not examined. 
It has previously been shown that incorporation of an ampC gene derived from an A. 
baumannii strain with an ISOur1 upstream into the genome of Oligella urethralis leads to 
cephalosporin resistance (135) but such an exchange has not been seen in GC1. 
1.9.1.2 Class D carbapenemases 
Class D ß-lactamases, also known as oxacillinases or OXA type ß-lactamases (OXAs), have 
serine in their active sites (176). These ß-lactamases have been named oxacillinases because they 
include mostly enzymes with higher hydrolysis rates for cloxacillin and oxacillin than for 
benzylpenicillin (176).  
Several groups of carbapenem-hydrolyzing oxacillinases have been identified in A. 
baumannii, most notably OXA-23, OXA-24, OXA-58 and an intrinsic OXA (178, 179) called 
OXA-Ab in this study. In addition to the naturally occurring oxa-Ab gene, the other carbapenem 
hydrolyzing oxacillinases, the oxa23, oxa58 and oxa24 genes have been shown to contribute 
significantly to carbapenem resistance in A. baumannii (16). The role of several oxacillinase 
enzymes in carbapenem resistance has been investigated by transformation of susceptible strains 
with oxa genes and its subsequent deletion, which restores carbapenem susceptibility (83). 
1.9.1.2.1 Naturally occurring carbapenemases  
The oxa-Ab gene occurs naturally in A. baumannii. Variants of OXA-Ab have been frequently 
found in A. baumannii strains such that so far over 30 variants have been identified (24, 25, 57). 
However, OXA-66 and OXA-69 are the most encountered variants (233). It has been observed that 
the OXA-66 and OXA-69 variants are generally associated with GC1 and GC2 strains respectively 
(57). This has also been shown to be one of the discriminatory features of these global clones (235, 
253). The oxa-Ab gene is usually weakly expressed unless it is activated via the insertion of 
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ISAba1, which will lead to carbapenem resistance (83). It has been shown that strains with ISAba1 
upstream of their oxa-Ab are resistant to carbapenems (238). 
1.9.1.2.2 OXA-23  
The oxa23 gene is the most widespread carbapenemase gene in A. baumannii (174). This was 
the first reported gene encoding a class D ß-lactamase isolated from A. baumannii 6B92 in Scotland 
in 1985 before carbapenems were in frequent clinical use (163, 202). This gene was originally 
named ari1 and found to be on a plasmid after its transfer to Acinetobacter junii (163, 202). The 
ability of OXA-23 to hydrolyse carbapenems was weak but it was significant compared to the other 
class D ß-lactamases (179). OXA-23 is not closely related to other class D ß-lactamases with only 
36% amino acid identity to OXA-5 and OXA-10 (178, 179). OXA-23 includes a unique amino acid 
motif of F-G-N, which differs from other OXAs by phenylalanine replacing a tyrosine, which was 
thought to be a factor in the evolution of carbapenem resistance (52).  
Figure 1.10: Structure of Tn2006. Open boxes indicate ISAba1 copies flanking the central segment of Tn2006 and the 
arrows inside the boxes represent the direction of transposases. Arrows below also indicate the extent of the oxa23 gene 
and orfs. 
 
The oxa23 gene is widespread in Acinetobacter spp. and has been found throughout the world 
in different countries including France, Bulgaria, Iran, the United Arab Emirates, Tunisia, Brazil, 
and Australia (178).  
The oxa23 gene has been found in various structures, namely Tn2006, Tn2007, Tn2008 and 
Tn2009 (143, 174, 259). Tn2006 is the most encountered structure (41) and also is the only one that 
has the typical properties of a transposon. Tn2006, is a 4.8 kb class I transposon that consists of a 
central segment of 2,445 bp bounded by two copies of ISAba1 (Figure 1.10)(41).   
Tn2006 can move independently and is found in several different locations and contexts 
belonging to distantly related A. baumannii strains (143). It has been shown that the presence of 
Tn2006
oxa23ISAba1 orf orforf ISAba1
1 kb
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ISAba1 upstream of oxa23 provides a strong promoter that activates the oxa23 gene most likely 
enhances the expression (207). The oxa23 gene has been identified in both A. baumannii and A. 
radioresistens, which is a commensal present on skin of both healthy and hospitalised patients 
(178). This could indicate that A. radioresistens may act as a reservoir for common resistance genes 
present in A. baumannii (178).  
1.9.1.2.3 OXA-58  
The OXA-58 oxacillinase shares 35%, 33%, and 18% amino acid identity with OXA-5, OXA-
10, and OXA-1 and hydrolyses penicillins and carbapenems at low levels. It hydrolyses imipenem 
and meropenem 10-fold and 100-fold less efficiently than benzylpenicillin (178). OXA-58 was first 
identified in a MAR A. baumannii isolate from France (177). It was found to be on a plasmid in 
both A. baumannii MAD, when it was first found (177), and in most of the OXA-58 producing A. 
baumannii isolates reported from different countries, including those in Europe, Argentina, and the 
United States (178). OXA-58 has been associated with hospital outbreaks in different countries 
such as France, Belgium, Italy, Turkey, Greece, and the United States (178). OXA-58 has also been 
identified in other Acinetobacter species, in Romania, Australia and Spain (178).  
1.9.1.2.4    OXA-24 and OXA-143  
This OXA-24 group is made up of OXA-25, OXA-26, OXA-40/OXA-24 (an original 
sequencing error makes OXA-40 OXA-24), and OXA-72, which differ by a few amino acid 
substitutions only. OXA-24 was originally identified as chromosomally encoded in a carbapenem-
resistant A. baumannii isolate recovered in Spain (178). However, plasmid borne oxa24 has also 
been found in A. baumannii (178). The oxa24 gene has been seen in different countries including 
Portugal, Spain and the Untied States (178). 
OXA-143 is a novel oxacillinases that was first identified in a clinical A. baumannii isolate in 
Brazil (87). It shares 88%, 63% and 52% amino acid identity with OXA-24, OXA-23, and OXA-58 
respectively. The substrate profile of OXA-143 is similar to class D carbapenemases (178). 
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1.9.2 Aminoglycoside resistance in A. baumannii 
All three classes of aminoglycoside modifying enzymes have been found in A. baumannii 
(174). The genes encoding aminoglycoside-modifying enzymes have been identified in A. 
baumannii in plasmids, transposons and in class 1 integrons (205, 211, 213).  
It has been shown that similar aminoglycoside-modifying enzymes are found in unrelated 
isolates of Acinetobacter spp. and they are not restricted to specific areas of the world (211). Indeed 
aminoglycoside resistance genes have been disseminated in Acinetobacter spp. by a range of 
genetic mechanisms, including transfer on plasmids, transposons and integron (211). In 2004, 
Nemec et al., analysed aminoglycoside-resistant isolates from 13 countries and showed that there is 
variation in the aminoglycoside gene pools of the geographically unrelated A. baumannii strains 
(147). They also showed the presence of the aminoglycoside resistance genes, aphA1 (confers 
resistance to kanamycin and neomycin), aphA6 (confers resistance to amikacin, kanamycin and 
neomycin), aacC1 (confers resistance to gentamicin), aacC2 (confers resistance to gentamicin and 
neomycin), aacA4 (confers resistance to amikacin), aadA1 (confers resistance to streptomycin and 
spectinomycin), and aadB (confers resistance to gentamicin, kanamycin and tobramycin) in strains 
from different countries (Table 1.2) (147).  
Among the aminoglycoside genes they found the aphA1, aacC1, aadA1, aphA6 and aadB 
genes were the most prevalent in strains from different geographical areas (147). They also found a 
combination of two to five different resistance genes observed in 84% of the strains examined, with 
a total of 12 different combinations. They found that aphA1, aacC1, aadA1 and aacA4 and aadB 
were each associated with a class 1 integron (147). A majority of the integron containing strains, 
74%, included the gene cassettes aacC1-orfP-orfQ-aadA1 and aacC1-orfP-orfP-orfQ-aadA1 
respectively (147). Both orfP and orfQ are part of the gene cassettes and encode proteins of 
unknown function (65, 147, 237). A class 1 integron with this cassette array was first found in a 
Serratia marcescens isolate in 1995 (121). Following that, it has been found only in clinical isolates 
of A. baumannii e.g. 2002 in Italy (65), 2004 in the Czech Republic (147), and 2005 in the UK 
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(237). Furthermore, aphA1 occurred in the majority of kanamycin resistant isolates, in the Nemec et 
al. study, but in more than half of these strains there was more than one gene with overlap in their 
resistance profiles (147).  
 
Table 1.2: Aminoglycoside resistance genes found in A. baumannii. 
 
Gene Phynotype a 
aacC1 Gm 
aacC2 Gm, Ne, Tm 
aacC3 Gm, Ne, Tm 
aadA1 Sm, Sp 
aphA1 Km, Nm 
aphA6 Ak, Km, Nm  
aadB Tm, Gm, Km 
aacA4 Ak, Km, Ne, Tm 
strA-strB Sm 
armA All aminoglycosides 
a Km, kanamycin; Gm, gentamicin; Tm, tobramycin; Net, Netilmicin; Sm, streptomycin; Sp, Spectinomycin; Ak, amikacin; Tm, 
tobramycin; Nm, neomycin. 
  
 
Other studies from Australia, the US and the UK have found similar aminoglycoside genes in 
clinical isolates of A. baumannii (92, 152, 153, 236). The aphA1 gene has also been found part of an 
IS26 bounded transposon, which was in an antibiotic resistance island in the GC1 strain AYE (58). 
aphA1 was later found in another GC1 strain from Australia in a similar genomic island, and was 
named Tn6020 (183). 
Amikacin and gentamicin resistance is also concerning as these antibiotics are used for 
treatment of carbapenem resistant infections. The aphA6 gene, which encodes a phosphotransferase 
enzyme and confers resistance to amikacin and kanamycin, was first identified in an Acinetobacter 
strain in 1988 on a plasmid (114, 213).  The aphA6 gene is mainly associated with Acinetobacter 
and has rarely been found in other Gram-negative organisms (213). This gene has been shown to be 
part of a 3 kb composite transposon with a 915 bp central segment flanked by two copies of 
ISAba125 in a group of Australian A. baumannii isolates (152). 
Among many aminoglycoside resistance genes only a few confer resistance to tobramycin and 
among these, aadB is one of the most encountered genes (213). Resistance to gentamicin, 
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kanamycin and tobramycin at the same time is usually indicative of the presence of the aadB gene 
(31, 188, 213). Gentamicin and kanamycin resistance can be accounted for by the presence of other 
aminoglycoside resistance genes e.g. aacC1 and aphA1, which confer resistance to gentamicin and 
kanamycin respectively (213). The aadB gene encodes an aminoglycoside adenyltransferase 
(AAD(2")) which inactivates gentamicin, kanamycin and tobramycin by adenylylating the 2"-
hydroxyl group (98, 213, 239).  
The aadB gene is part of a 591 bp gene cassette and has usually been found associated with 
class 1 integrons (31, 188). However, in 1997 an aadB gene cassette was found in a secondary 
location on a plasmid, named pRAY, from an isolate of Acinetobacter (204, 205). This strain, SUN, 
was isolated from a patient in a hospital in Cape Town but the species was not determined (204, 
205). pRAY is 6,076 bp (GenBank accession no. AF091755) and was predicted to include 10 open 
reading frames (including aadB) ranging in size from 240 to 1,095 bp (204).  
Recently, a PCR developed to detect the aadB gene in the location it occupies in pRAY (152) 
was used to show that aadB is in pRAY in 18 A. baumannii isolates from four Australian hospitals 
that were resistant to gentamicin, kanamycin and tobramycin, but did not contain a class 1 integron 
(152). The aadB cassette has also been found in the same context in A. baumannii A297 (RUH875), 
the GC1 reference strain isolated in 1984 in the Netherlands (153). pRAY has recently been 
reported to be in A. baumannii AB058 from the US (1).  
Recently, a 16S rRNA methylation has been described for A. baumannii (243) in strains from 
Japan, Korea, and the United States. The product of the armA gene impairs aminoglycoside binding 
to its target site and confers high-level resistance to all clinically useful aminoglycosides. 
Interestingly, it has been found in similar plasmids in a transposon called Tn1548, which is a large 
composite transposon formed by two copies of IS26 (62), across Gram-negative species (166, 174). 
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1.9.3 Other antibiotics 
In Gram-negative bacteria, including A. baumannii, tetracycline resistance generally occurs 
via extruding of the antibiotic by efflux pumps, alteration of the antibiotic target (30S ribosome) or 
enzymatic inactivation of the antibiotic (tet genes) (35, 36, 187, 194). However, so far, only tet(A) 
and tet(B) determinants have been described for A. baumannii (71, 190, 191). TetA and TetB are 
both specific transposon-mediated efflux pumps (169, 190). The product of the tet(A) gene extrudes 
tetracyclines but not to minocyclines whereas the tet(B) gene encodes an efflux protein, which  
pumps both tetracyclines and minocyclines (190).  
Fluoroquinolone resistance in A. baumannii is due to mutations of the molecular targets of 
fluoroquinolones, DNA gyrase and topoisomerase (88, 89, 246, 247). These changes result in a 
lower affinity for the binding of the quinolone to the enzyme-DNA complex (246, 247). Resistance 
to fluoroquinolones could also be due to different mechanisms including changes in the outer 
membrane permeability, over-expression of naturally occurring efflux pumps and plasmid-mediated 
determinants, qnr genes, which encode for proteins that protect DNA gyrase and type IV 
topoisomerase from quinolone inhibition (136). However, plasmid-mediated quinolone resistance 
(due to the qnr genes) has not yet been reported in A. baumannii (166, 174). 
In A. baumannii dfrA and dfrB gene cassettes namely dfrA1, dfrA7, dfrA10, dfrA12, dfrA17 and 
dfrB1 have been identified, which confer resistance to trimethoprim (58, 70, 173, 209) and 
resistance to sulphonamides is often encoded by the sul1 gene (215) in the 3'-CS of class 1 
integrons. 
 
1.10 A. baumannii genomes 
 
Genome sequences of a number of A. baumannii strains including representatives of GC1 and 
GC2 have now been determined and have provided useful information regarding adaptation, 
virulence, antibiotic resistance, interspecies diversity and genome evolution (95). The first A. 
baumannii genome to be sequenced was ATCC 17978, which did not belong to either GC1 or 2 
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(218). Comparison of the genome of ATCC 17978 with that of Acinetobacter baylyi ADP1 (10), a 
non pathogenic soil-living organism, led to identifying a number of alien islands, virulence genes 
and a large number of genes involved in antibiotic resistance, motility, protein secretion, quorum 
sensing and iron uptake (218). 
Five more A. baumannii genomes were sequenced in subsequent years including three GC1s 
(AYE, AB0057, and AB307-0294), one GC2 (ACICU) and the fully antibiotic susceptible isolate 
(SDF) recovered from a human body louse (2, 58, 93).  Analysis of the A. baumannii genomes also 
allowed the core genome (the genes that are present in all strains) and a pan genome (the whole 
gene repertoire; the sum of the core and disposable genomes) to be determined (2, 95, 189). 
Analysis of single nucleotide polymorphisms (SNPs) of the core genome has confirmed that 
the strains that belong to the major global clones, GC1 and 2, are indeed closely related strains at 
the genome level since they usually cluster together (95).  
 
Table 1.3: Properties of completed genomes of A. baumannii. 
Organism Country Year GCa Size 
(Mb) 
GC%b Genes Plasmids Accession 
no. 
AYE France 2001 1 4.05 39.3 3,890 4 CU459141 
AB0057 US 2004 1 4.06 39.2 3,923 1 CP001182 
AB307-0294 US 1994 1 3.76 39 3,542 - CP001172 
ACICU Italy 2005 2 4 38.9 3,845 2 CP000863 
TCDC-AB0715 Taiwan 2007-9 2 4.22 38.9 4,010 2 CP002522 
1656-2 South Korea 2010 c 2 4.02 39.1 3,913 2 CP001921 
TYTH-1 Taiwan 2008 2 3.96 39 3,770 - CP003856 
BJAB07104 China 2007 2 4.04 39 3,953 2 CP003846 
BJAB0715 China 2007 2 4.05 38.9 3,999 1 CP003847 
BJAB0868 China 2008 2 4.01 38.9 3,912 3 CP003849 
MDR-TJ China 2012 c 2 4.15 39.1 4,047 2 CP003500 
MDR-ZJ06 China 2006 2 4.01 39 3,975 1 CP001937 
D1279779 Australia 2009 - 3.71 39 3,487 1 CP003967 
SDF nk  nk  - 3.48 39.1 3,664 3 CU468230 
ATCC 17978 nk  1951 - 4 38.9 3,469 2 CP000521 
 
a Global clone. 
b GC content %. 
c the dates indicate the submission date to GenBank as the actual isolation dates are not known in the original publications. 
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Moreover, by comparing the genome of AYE to the non-human strains, A. baylyi ADP1 and 
A. baumannii SDF, several alien islands were found, one of which, an 86 kb antibiotic resistance 
island contained several genes involved in antibiotic or heavy metal resistance (next Section) (58).  
Furthermore, by comparison of MAR strains (AYE, AB0057 and ACICU) and antibiotic 
susceptible strains (ATCC 17978 and AB307-0294) it has been concluded that antibiotic 
inactivating enzymes play a more important role in antibiotic resistance than that of efflux pumps 
(2). According to the last search, 15/11/2013, there are 15 completed genomes available in the 
GenBank non-redundant database (http://www.ncbi.nlm.nih.gov/genome/genomes/403) (Table 1.3). 
There are also 234 sequenced genomes in the whole genome sequence database (WGS), which are 
not yet complete highlighting the large number of genomes that have been sequenced.  
 
1.10.1 Plasmids in complete genomes 
A majority of A. baumannii strains contain indigenous plasmids (166). Comparative analysis 
of the A. baumannii genomes has allowed several plasmids some of which carry antibiotic 
resistance genes, to be identified (95). However, none of the plasmids found in the complete GC1 
genomes AYE and AB0057 carry any antibiotic resistance determinants (2, 58). Amongst the GC1 
strains with a complete genome available, the antibiotic susceptible strain AB307-0294 does not 
include any plasmid whereas AB0057 and AYE contain 1 and 4 plasmids respectively (Table 1.4) 
(2, 58).  
 Table 1.4: Plasmids in complete A. baumannii genomes.  
 
Plasmids Strain Size (kb) Accession no. 
p1ABAYE AYE 5.6 CU459137 
p2ABAYE a AYE 9.7 CU459138 
p2ABAYE AYE 94.4 CU459140 
p4ABAYE AYE 2.7 CU459139 
pAB0057 AB0057 8.7 CP001183 
pACICU1 ACICUb 28.2 CP000864 
pACICU2 ACICU 64.3 CP000865 
 
a related to pAB0057. 
b belongs to GC2. 
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ACICU was isolated in Italy in 2005 and was the first GC2 genome to be sequenced 
(GenBank accession no. CP000863). ACICU, which is a GC2 strain and one of the early genomes 
to be sequenced, includes two plasmids of 28.2 kb and 64.3 kb, called pACICU1 and pACICU2 
respectively (93). pACICU1 carries two copies of the oxa58 carbapenem resistance gene while no 
antibiotic resistance determinant is carried on pACICU2 (93). pACICU2 carries a copy of 
ISAba125 and contains a large region of ~ 20 kb that is occupied by genes involved in transfer, tra 
genes, indicating that this plasmid might be a conjugative plasmid (GenBank accession no. 
CP000865) (93). 
Amongst the plasmids identified in A. baumannii genomes pACICU2 and pAB0057 appear to 
be widespread in the members of Global Clones as variants of these two plasmids have been found 
in most strains. For instance, TCDC-AB0715 contains two plasmids p1ABTCDC0715 (GenBank 
accession no. CP002523) and p2ABTCDC0715 (GenBank accession no. CP002524), and 1656-2 
carries pABKp1 (GenBank accession no. CP001922) and pABKp2 (GenBank accession no. 
CP001923), which are variants of pAB0057 and pACICU2 respectively (Table 1.4) though these 
strains are from geographically unrelated areas.  TCDC-AB0715 and 1656-2 are members of GC2. 
A replicon typing scheme has also been developed for A. baumannii plasmids based on the 
plasmid replication systems (17). In this scheme replicons are classified into homology groups on 
the basis of the nucleotide identity of the replicase genes (rep) and accordingly 27 replicon types 
have been identified classifying A. baumannii plasmids into different groups (17).  
 
1.11 AbaR genomic resistance island 
 
The first GC1 genome to be sequenced was from the strain AYE (GenBank accession no. 
CU459141), a MAR clinical isolate, which was responsible for a nationwide outbreak in France in 
2001 (241). AYE was representative of the epidemic strains in 54 healthcare facilities in eight 
French administrative regions and was also associated with a mortality of 26% of infected patients 
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(58). AYE was resistant to ß-lactams (except imipenem, piperacillin-tazobactam, and ticarcillin-
clavulanate), aminoglycosides, fluoroquinolones, chloramphenicol, tetracycline, and rifampicin 
(58). Comparative genome analysis revealed that most resistance determinants are concentrated in 
an 86 kb genomic island that was named AbaR1, which stands for Acinetobacter baumannii 
resistance island 1 (58). AbaR1 was defined as the region that has inserted into a putative 
chromosomal ATPase-encoding gene, now usually called comM, creating a 5 bp duplication 
(ACCGC) (58). AbaR1 is a composite transposon that is bounded by imperfect IR of 26 bp (19/26 
matches). AbaR1 includes 18 antibiotic resistance genes, some of which are present in multiple 
copies, conferring resistance to most of the known classes of antibiotics (58). The large segment, 
which includes antibiotic resistance genes located in the middle of AbaR1, is flanked by two copies 
of a 3.3 kb segment that includes cadmium/zinc resistance genes (58). AbaR1 contains a class 1 
integron with the cassette array aacC1-orfP-orfP-orfQ-aadA1. This island includes the antibiotic 
resistance genes, veb1, oxa10, arr2, aadB, an unnumbered aacA gene, aadA1, strA and strB, cmlA1, 
cmlA5, cmlA9, tetA(G), dfrA1, and dfrA10 in a 29 kb segment (58). AbaR1 also carries catA1b and 
aphA1, which confer resistance to chloramphenicol and kanamycin respectively and the aphA1 gene 
was flanked by two IS26 (58). It has been shown that, by sequence and phylogenetic analyses, 
fragments of AbaR1 have been acquired from different Gram-negative bacteria such as Escherichia 
coli, Pseudomonas spp. and Salmonella spp.  (58). 
 The second antibiotic resistance island, AbaR2, found was in the GC2 strain ACICU (93). 
AbaR2 consists of only a small remnant of the AbaR1 region. Only the region on the right of aphA1 
is present (Figure 1.11), modified by the substitution of an aacA4-orf-oxa1 cassette array for the 
aacC1-orfP-orfP-orfQ-aadA1 array found in AbaR1 (93).  
A related island called AbaR3 was later found in strain AB0057, a GC1 strain isolated in US 
in 2004, with a similar backbone but it was 29 kb smaller than AbaR1(2). In both AbaR3 and 
AbaR1, MARR (Multiple Antibiotic Resistance Region) had interrupted the uspA gene in the 
backbone transposon, the same as AbaR1 (Figure 1.11). However, none of the resistance genes 
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found on the left part of the MARR segment of AbaR1, between the cadmium/zinc operon and sul1, 
was found in AbaR3 (58). In AbaR3 this segment is replaced by a 4.4 kb fragment, marked X in 
Figure 1.11, which contains a topoisomerase gene (Figure 1.11). AbaR3 also includes the cassette 
array aacC1-orfP -orfQ-aadA1 (Figure 1.11) while AbaR1 contained an additional orfP in the class 
1 integron. The aphA1 gene was also flanked by two copies of IS26 the same as that in AbaR1 (2, 
58). 
 
Figure 1.11: Structure of AbaR3 island. In the central line, the dashed lines represent chromosomal DNA flanking 
AbaR. Lines of different thicknesses distinguish the various segments: the backbone transposon Tn6019 (thickest line); 
Tn6018 (purple line); and the MARR (thin line). Vertical lines indicate the inverted repeats (IRi and IRt) of class 1 
integron ends, and IR1696, IR21 and IR1000 for IRs from Tn1696, Tn21 and Tn1000-like, respectively. Numbered 
green open boxes represent the insertion sequences. Gene cassettes are represented by open boxes with a bar at the attC 
end. Vertical lines in the line above the MARR mark the extent of the regions derived from known transposons. The 
mer region of Tn1696, encoding merE, D, A, C, T, P and R genes, is represented by mer1696. The extent of other genes 
is shown by a horizontal arrow with the gene name below. Antibiotic resistance genes are shown red. The vertical arrow 
colored orange represent the position of the 29 kb extra segment present in AbaR1. The X segment (highlighted red) is 
missing in AbaR1. Orange box indicate the segment deleted in AbaR5.  
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In 2008, the genome of the antibiotic-susceptible isolate AB307-0294 (GenBank accession 
no. CP001172) was also sequenced (2). The comM gene is intact in AB307-0294 and does not 
include an AbaR island (2). The AbaR island is not also present in the genome of the antibiotic-
susceptible A. baumannii isolate ATCC 17978 indicating its significance to incorporate antibiotic 
resistance genes into the A. baumannii genomes (218). The comM gene is also intact in two 
antibiotic susceptible isolates recovered in 2007 in the United Kingdom (234).  
Figure 1.12: Map of the genome of A. baumannii that shows the chromosomal location of the AbaR resistance island. 
Genes used in Oxford and Institut Pasteur MLST schemes and the genes used in the multiplex PCR for characterization 
of Global Clones are also shown. 
 
 
 
In 2009, an island related to AbaR3 called AbaR5 was described in a MAR strain 3208 
isolated in 1997 in a Sydney hospital (183). AbaR5 is related to AbaR3 but it contains an IS26 
mediated deletion of 7,326 bp removing the entire Tn1, catA1 and a portion of Tn1721 (the orange 
box in Figure 1.11). In the same study (183), the structure of the AbaR islands were re-analyzed and 
shown that it is composed of a backbone transposon, designated Tn6019, which includes two copies 
of a zinc/cadmium transposon, named Tn6018, and a Multiple Antibiotic Resistance Region (64)  
located in the middle of Tn6018 copies (Figure 1.11; Figure 1.13) (183). MARR and the two 
flanking copies of Tn6018 together constitute a compound transposon that creates a duplication of 8 
bp when inserted into the uspA gene in the backbone transposon, Tn6019 (182, 183). It was also 
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shown that the aphA1 kanamycin resistance gene flanked by two IS26 copies constitutes a 
composite transposon, which was named Tn6020 (183).  In 2010, they also described further AbaR 
islands, AbaR6 and AbaR7, in which the left hand IS26 of Tn6020 has removed 36,245 bp and 
43,430 bp of the islands, respectively, to the left of Tn6020 to the transposon backbone (184). 
Exchange of the cassettes in the class 1 integron of A297(RHU875), the GC1 reference strain 
isolated in 1984 in the Netherland (78),  was also observed. An island related to AbaR3 was 
identified in A297, which includes only a dfrA5 in the class 1 integron (153). 
Following that, 50 MAR A. baumannii isolates from different countries were examined to 
determine whether they include islands related to AbaR1 (212). Majority of these isolates were 
assigned to SG1 and SG2 (212). They further examined 10 isolates, which were representative of 
the isolates they studied. Nine of these isolates included an interrupted comM, eight of which 
included insertions related to AbaR1 as they shared boundaries found in the AbaR1 island (212). 
They showed that the comM genes of diverse A. baumannii isolates are frequently disrupted by 
insertions matching the AbaR1 flanking sequences indicating the presence of an island related to 
this island (212). Another island similar to AbaR3 was later found in the MAR strain HK302, 
isolated in Switzerland in 1977 (113). This island was located in the comM gene and suggested to 
be similar to AbaR3 as it shared the properties found in AbaR3 (113). A further study also 
examined the presence of features related to the AbaR islands in a collection of 41 isolates from 
different countries including France, Brazil, Egypt, Belgium, Argentina, Algeria, United Arabic 
Emirates, Bahrain, Turkey, Poland, Tahiti, Saudi Arabia, The Netherlands, Libya, USA and Spain 
recovered between 1999-2009 (19). They showed that clinical isolates belonging to GC1 often 
possessed AbaR elements with a variable portion between the two copies of cadmium/zinc 
transposon, Tn6018 (19). 
It is now known that most MAR strains belonging to GC1 carry an AbaR island, related to 
AbaR3, in the comM gene, (1, 2, 58, 112, 183, 184, 212, 241). So far, several variants of the AbaR 
islands have been described in GC1 isolates from different countries. Most of these islands have 
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lost a fragment of different length that includes one or more antibiotic resistance genes (1, 2, 183, 
184). The AbaR islands described so far have the same general structure.  All contain the backbone 
transposon, Tn6019 and a MARR surrounded by two copies of Tn6018 (Figure 1.13) unless parts of 
the island have been lost due to a deletion (1, 2, 112, 182, 184). 
Figure 1.13: General structure of the AbaR-type islands. The central thick lines represent the backbone of the AbaR 
island and the dashed lines represent the chromosome (the comM gene) flanking the AbaR island. The multiply 
antibiotic resistance region is indicated schematically (MARR is not to scale). Two copies of Tn6018 flanking the 
MARR are highlighted blue. 
 
 
AbaR1 remains a unique island in that it lacks the X segment and contains an additional 29 kb 
segment compared to AbaR3 and includes genes that are not seen in the other AbaR islands 
reported so far (1, 2, 112, 184). Consequently, it is now widely accepted that AbaR3 is the ancestor 
of the islands found in the GC1 clone (183, 184). Detailed analysis of the AbaR island has shown 
that the additional segment in AbaR1 appears to be derived from the SGI islands found in 
Salmonella enterica (122). 
 
1.12 AbaR4  
 
Isolate AB0057 (GenBank accession no. CP001182), which carries AbaR3 in the comM gene, 
also includes a second island that was called AbaR4 (2). The location of AbaR4 is shown in Figure 
1.12. AbaR4 is a 16.8 kb transposon that carries only one resistance gene, the oxa23 carbapenem 
resistance gene (Figure 1.14) accounting for the carbapenem resistance of AB0057 (2). In AbaR4, 
the oxa23 gene is in the transposon Tn2006, which is inserted just inside the 5'-end of the sup gene 
(encoding a sulphate permease) (Figure 1.14). The AbaR4 island is flanked by 26 bp imperfect 
inverted repeats and has created a five base duplication (ACTGA) of the target site upon insertion in 
AB0057. In AB0057, AbaR4 is inserted between two open reading frames of unknown functions 
labelled as AB57_0546 and AB57_0566 (GenBank accession no. CP001182).   
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Figure 1.14: Structure of the AbaR4 island in AB0057.  The thick central line represents the backbone of AbaR4. The 
vertical genes represent the IRs of AbaR4 and the extent of the genes are shown by arrows below. Green open boxes 
indicate ISAba1 copies and the extent of AbaR4 and Tn2006 is indicated above. 
 
The transposon backbone of AbaR4 is related to the Tn6019 backbone of the AbaR3-type 
islands but is more closely related to a transposon, recently named Tn6021 that interrupts comM in 
ATCC 17978 (184). In AbaR4, the uspA gene is intact (Figure 1.14 & Figure 1.15) while this gene 
is interrupted at the corresponding position in AbaR3 as it has been interrupted by the Tn6018-
flanked MARR (2). The region occupied by the arsenic region in Tn6019 (the backbone of AbaR3) 
is replaced by an open reading frame of unknown function in AbaR4. The backbone of AbaR4 
differs from Tn6021 in that it lacks the insertion sequence, ISAba11, in orf1 of Tn6021 (Figure 
1.15), and the sequence of the orf1-tniA region. 
 
 
 
Figure 1.15:  Structures of Tn6019, Tn6021 and AbaR4. Inverted repeats are shown as vertical lines and thickened 
lines indicate patches of sequence divergence. Labelled arrows below show the genes and open reading frames and their 
extent. The vertical arrows above uspA, in Tn6019, and sup in AbaR4 show the location of MARR flanked by two 
copies of Tn6018 and Tn2006 in AbaR3 and AbaR4 respectively. ISAba11 is shown as an open box the arrow below 
indicates the orientation of the transposition gene.  
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CHAPTER ONE                                                                                                      General Introduction 
 
 
49 
1.13 Aims 
 
Spread of A. baumannii belonging to different clonal types is particularly important in the 
evolution and emergence of MAR strains. These clones may be constantly evolving by gaining 
antibiotic resistance determinants through various mechanisms from their close and distant 
relatives. Hence, studying the evolution of antibiotic resistance in such clones is also crucial to 
gaining a better understanding of the genes involved as well as the mechanisms through which these 
strains have become resistant to many different antibiotics.  
The overall aim of this project was to study antibiotic resistance in one of the two major 
global clones of A. baumannii, namely GC1. This initially required assembling a collection of 
Australian multiply antibiotic resistant GC1 isolates and examining the relationship of these isolates 
using different molecular techniques. Analysis of antibiotic resistance included characterization of 
the genetic content of the AbaR island, which contains several antibiotic resistance determinants. A 
further aim was to investigate the role of plasmids and chromosomal alterations in determining 
resistance phenotypes which could not be explained by the genes in the main resistance island.  
The specific aims were: 
1. To examine the relationships of Australian GC1 isolates using different typing methods.  
2. To characterize genetic content of the AbaR genomic resistance islands in MAR GC1. 
3. To investigate how GC1 isolates have become resistant to the 3rd generation cephalosporins. 
4. To investigate how GC1 isolates have become resistant to carbapenems.  
5. To investigate the role of plasmids in antibiotic resistance in GC1.  
 
   
 
 
 
 
 
 
 
 
Chapter 2  
 
 
 
 
 
  
Materials and Methods 
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2.1 Materials used in this study 
2.1.1 Chemicals and reagents  
All chemicals and reagents used in this study were molecular biology grade and were 
purchased from the following companies: Bio-Rad (Hercules, CA, USA), Becton Dickinson 
(Cockeysville, MD, USA), Promega (Madison, MI, USA), Oxoid (Basingstoke, Hampshire, 
England) and Sigma-Aldrich (St. Louis, MO, USA). Restriction endonucleases and Taq DNA 
polymerase, were purchased from New England BioLabs (Beverly, MA, USA). All primers were 
obtained from Integrated DNA Technology (IDT, Coralville, USA). Lysosome and Proteinase K 
were obtained from Sigma-Aldrich (St. Louis, MO, USA) and RNase A was purchased from 
Promega (Madison, MI, USA). Bacto Yeast extract was obtained from Becton Dickinson 
(Cockeysville, MD, USA). Mueller Hinton II agar, Bacto tryptone, Sensitest agar and antibiotic 
discs were purchased from Oxoid (Basingstoke, Hampshire, England). Mueller Hinton Broth and all 
antibiotic powders were purchased from Sigma-Aldrich (St. Louis, MO, USA). Easy Hybridization 
Granules, DIG-labeled DNA ladders, and DIG-labeled dNTP mix were all purchased from Roche 
(Roche Diagnostics Corporation-Roche Applied Science, Indianapolis, USA). TOPO cloning kit 
was obtained from Invitrogen (Carlsbad, CA, USA) and RNA extraction kit was purchased from 
Bio-Line (Bio-line, Humber Road, London, UK). Phase Lock GelTM tubes were obtained from 5-
Prime, Inc (Gaithersburg, USA). 
  
2.2 Bacterial strains  
 
This study was commenced on a set of A. baumannii isolates collected from 2006-2009 that 
was available in Hall lab. These strains were from Royal North Shore Hospital in Sydney and had 
kindly been supplied by Dr. Clarence Fernandez (Royal North Shore Hospital Sydney) via Prof. 
Peter White (UNSW) (Table 2.1 and 2.4). More GC1 isolates were also isolated from two further 
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sets of isolates received from the same hospital in 2010 and 2011 (Table 2.1, 2.3, 2.4). These strains 
were kindly supplied by Mr. Peter Huntington and Dr. Clarence Fernandez (Table 2.1).  
 
 
Table 2.1: MAR GC 1 isolates from hospital Da in Sydney. 
 
Isolate Date of 
Isolation 
 
Ward 
Site Source Reference 
3208 1997 - Blood C. Fernandez (183) 
      
D2 3.7.2006 10A Wound P. White  (134) 
D3 4.7.2006 7D Catheter ” (134) 
D6 8.8.2006 7D Wound ” (134) 
D7 24.8.2006 7D Urine ” (134) 
      
D27 23.3.2008 9A Wound  C. Fernandez This study 
D30 14.4.2008 7D Wound  ” This study 
D36 08.7.2008 4_NSP Wound  ” This study 
      
D15 16.5.2009 RRC Urine ” This study 
D14 30.5.2009 7D Urine ” This study 
D13 03.6.2009 7D Urine C. Fernandez This study 
D20 18.6.2009 RRC Urine ” This study 
D18 04.7.2009 7D Wound  ” This study 
      
D45 2010 7D B/C-TSAB P. Huntington This study 
D48 2010 7D MSU ” This study 
D62 2010 7D MSU ” This study 
D78 2010 COFH Isolate ” This study 
D81 2010 6NI Wound ” This study 
      
D108 2011 7D MSU P. Huntington This study 
 
a Royal North Shore Hospital. 
 
 
Further batches of A. baumannii received from Westmead Hospital (Hospital J), Prince of Wales 
(Hospital A), St. George Hospital (Hospital B) and Concord Hospital (Hospital C) were supplied by 
Prof. Jon Iredell, Dr. Ian Carter, and Prof. Peter White respectively (Table 2.4). 
The remaining A. baumannii isolates from the Royal Brisbane Hospital (RBH), the Alfred hospital 
in Melbourne and the Royal Adelaide Hospital were kindly supplied by Dr. Mohammad Katouli 
(University of Sunshine Coast, Sunshine Coast, Australia), Dr. Anton Peleg (Monash University, 
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Clayton, Australia) and Prof. Mellissa Brown (Flinders University). All these strains were screened, 
and the ones with particular resistance phenotype (e.g. cefotaxime and tobramycin resistant isolates 
belong to different clonal types) and all the isolates belonging to the GC1 lineage included in this 
study for further characterisation (Table 2.2, Table 2.3 and Table 2.4).  
 
Table 2.2: MAR GC 1 A. baumannii from Australian hospitals. 
 
Isolate Date of 
Isolation 
City Site Source Reference 
WM98a 1998 Sydney Wound J. Iredell (240) 
A85 (PW01c) b 2003 Sydney Sputum I. Carter (240) 
A83 2002 Sydney - ” This study 
A92 2005 Sydney Catheter urine  ” This study 
RBH3c 2002 Brisbane BA M. Katouli (127) 
6772166 2002 Adelaide  Pus M. Brown (56) 
G7 2002 Melbourne - A. Peleg (164) 
 
a WM: Westmead Hospital Sydney  
b A: Prince of Wales Hospital (PW);  
c RBH: Royal Brisbane Hospital. 
 
 
Overseas isolates A1, A297, A320 and A388 were supplied by Dr. Kevin Towner (Health 
Protection Agency, UK) and were used as controls. Strain AB0057 was used as a control in most 
experiments and was kindly supplied by Dr. Robert Bonomo (Department of Veterans Affairs 
Medical Center, Cleveland, Ohio) (Table 2.3).  
 
 
Table 2.3: Overseas A. baumannii strains and controls. 
 
Isolate GC Date  Country Site Source Reference 
A297 1 1984 Netherlands - K. Towner  (78) 
A1 1 1982 UK - ” (78) 
A388 1 2001-4 Greece - ” (78) 
AB0057 1 2004 USA Blood R. Bonomo (2) 
A320 2 1982 UK - K. Towner (78) 
ACICU 2 2005 Italy CSF A. Carattoli (93) 
ATCC19606 - 1967 USA Urine - (90) 
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Table 2.4: Tobramycin and/or cefotaxime resistant A. baumannii. 
 
Isolates Date of 
isolation 
GC City 
  
Site Tmb CTXb Source Reference 
A72a 2001 2 Sydney - Rb Sb I. Carter This study 
A87 2004 2 Sydney MSU R S " This study 
A91 2005 2 Sydney Catheter urine S R " (134) 
         
B1 a 2007 2 Sydney Groin swab S R P. White (134) 
         
C2 a 2007 2 Sydney Catheter  R R P. White  (134) 
C3 2007 2 Sydney Bed railing R R " (134) 
C4 2007 2 Sydney Environmental R R " (134) 
C5 2007 2 Sydney Catheter R R " (134) 
C8 2007 2 Sydney Wound drain R R " (134) 
C13 2006 2 Sydney Catheter S R " (134) 
C15 2006 2 Sydney Blister wound R R " (134) 
C18 2002 2 Sydney Wound R S " (134) 
C20 2002 2 Sydney Wound S R " (134) 
D8 a 2006 2 Sydney CVC tip R S C. Fernandez This study 
D9 2006 2 Sydney Perianal ulcer R S " This study 
D12 2007 2 Sydney Urine R S " This study 
D37 2008 2 Sydney - R S " This study 
RBH1c 2002 2 Brisbane CVL tip R S M. Katouli (127) 
RBH18 2002 2 Brisbane RS R S " (127) 
RBH38 2000 2 Brisbane EA R S " (127) 
RBH44 2002 2 Brisbane Burns S R " (127) 
RBH45 2002 2 Brisbane RS R S " (127) 
E1d 2006 2 Canberra CSU R S P. Collignon This study 
E16 2009 2 Canberra MSU R S " This study 
WM99c e 1999 2 Sydney Sputum S R J. Iredell  (240) 
         
RBH2 1999 - Brisbane - R R M. Katouli (127) 
D4 2006 - Sydney Wound R R P. White  This study 
D46 2010 - Sydney MSU R R C. Fernandez This study 
RCH51 - - Brisbane - R S M. Katouli (127) 
RCH52f - - Brisbane - S S " (127) 
PCH49 - - Brisbane - R S " (127) 
J9 1999 - Sydney - R R J. Iredell  (240) 
J11 1996 - Sydney - R R " (240) 
J12 1996 - Sydney - R R " (240) 
J13 1997 - Sydney - R R " (240) 
J14 1998 - Sydney - R R " (240) 
J15 1999 - Sydney - R R " (240) 
WM97a 1997 - Sydney  R R " (240) 
 
a Hospital A, C and D are different Sydney hospitals, A: Prince of Wales Hospital, B: St. George Hospital, C: Concord    
  Hospital and D: Royal North Shore Hospital.  
b R: resistant, S: susceptible; antibiotic abbreviations Tm: tobramycin. CTX: cefotaxime. 
c RBH: Royal Brisbane Hospital. 
d E: Woden Valley Hospital. 
e WM: Westmead Hospital.  
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Table 2.5:  Plasmids used in this study. 
 
Plasmid Description Relevant antibiotic 
resistance phenotypea 
Source 
Control plasmids   
pUC19 Cloning vector  Ap Promega 
pCR®2.1-TOPO®  TOPO cloning vector  Ap, Km Invitrogen 
 
Plasmids generated in this study 
 
pRMH970 ampC: pCR2.1-TOPO  Ap, Km This study 
pRMH971 ISAba125-ampC:: pCR2.1-TOPO Ap, CTX, CAZ This study 
pRMH972 aadB Gm, Tm, Km This study 
 
a Ap: ampicillin, CAZ: ceftazidime, CTX: cefotaxime, Tm: tobramycin, Km: kanamycin. 
 
2.3 General methods 
2.3.1 Growth media 
 
A. baumannii strains were routinely cultured overnight in Luria broth (LB; 10 g/L tryptone; 5 
g/L yeast extract; 10 g/L NaCl) or on Luria agar (LA with 15 g/L agar) supplemented with 
appropriate antibiotics at the final concentrations listed in Table 2.6. Sensitest agar (32 g/L) was 
used for antibiotic susceptibility testing according to the instruction of CDS (Calibrated 
Dichotomous Sensitivity) method (Section 2.3.2.1). For long-term storage of the isolates, 750 "L of 
an overnight LB culture was added to 750 "L of 50% (v/v) glycerol and stored at -80°C. 
 
Table 2.6: Antibiotic powders used in this study and the final concentrations. 
 
Antibiotic Abbreviation Diluent Stock conc. 
(mg/ml) 
Final conc. 
 ("g/ml) 
Cefotaxime CAZ MQ water 10 1 
Ceftazidime CTX MQ water 10 1 
Kanamycin  Km MQ water 50 50 
Ticarcillin TIC MQ water 100 100 
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2.3.2 Antimicrobial susceptibility  
2.3.2.1 Calibrated Dichotomous Sensitivity disc diffusion assay (CDS) 
Calibrated Dichotomous Sensitivity disc diffusion assay (CDS)  
(http://web.med.unsw.edu.au/cdstest) was used to determine antibiotic resistance profiles. The 
antibiotic discs (Oxoid, New Hampshire, UK) contained amikacin (30 µg), ampicillin (25 µg), 
cefotaxime (30 µg), ceftazidime (30 µg), chloramphenicol (30 µg), ciprofloxacin (5 µg), florfenicol 
(30 µg), gentamicin (10 µg), imipenem (10 µg), rifampicin (30 µg), timentin (ticarcillin clavulanic 
acid) (85 µg), ampicillin/sulbactam (20 µg), kanamycin (50 µg), meropenem (10 µg), nalidixic acid 
(30 µg), neomycin (30 µg), netilmicin (30 µg), streptomycin (25 µg), spectinomycin (25 µg), 
sulphamethoxazole (300 µg), tetracycline (30 µg), tobramycin (10 µg) and trimethoprim (5 µg). A 
single colony was picked from a fresh overnight LB agar culture and was suspended in 4 ml of 
sterile 0.9% (w/v) saline. The suspension was spread onto Sensitest agar plates to form a bacterial 
lawn and then six antibiotic discs were stamped onto each plate. After overnight incubation at 37°C, 
the annular radius of the inhibition zone surrounding each antibiotic disc was measured and 
recorded. According to the CDS instructions a zone equal to or greater than 6 mm was considered 
as sensitive, a zone size between 4 to 5 as intermediate and a zone size less than 4 mm as resistant. 
2.3.2.2 Minimal Inhibitory Concentrations (MICs) 
Minimal inhibitory concentrations were determined for ceftazidime and cefotaxime according 
to the standard broth micro-dilution method (4, 252).  Individual antibiotic solutions were prepared 
by dissolving the antibiotic powders in appropriate solvents and diluents as previously described 
(4). In Micro Broth Dilution format, bacteria are inoculated into Muller Hinton broth growth 
medium in the presence of different concentrations of an antimicrobial agent. The concentration 
ranges used for ceftazidime and cefotaxime were 0-128 "g/ml as previously described (4, 252). 
Antibiotic stock solutions were prepared using the formula 1000/P * V * C = W, where P is potency 
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and is given by the manufacturer ("g/mg), V is volume required, C is the final concentration of 
solution (mg/ml) and W is weight of antibiotic (mg) to be dissolved in volume V (4, 252).  
Bacterial isolates to be tested were streaked onto Luria agar without inhibitor and the plates were 
incubated overnight at 37°C. For each isolate 3 to 5 morphologically similar colonies from the 
overnight agar plate were selected and re-suspended in LB and mixed completely. The broth 
cultures were incubated at 37°C until they reached the turbidity of the 0.5 McFarland standards (~ 3 
to 4 hours), containing approximately 1-2 x 10
8 
cfu/ml.  
The density of the inoculum was determined by comparison with a 0.5 McFarland standard 
prepared by adding 0.5 ml of 0.048 M BaCl2 (1.17% w/v BaCl2. 2H2O) to 95.5 ml of 0.018 M 
H2SO4 (1% v/v) with constant stirring. A small volume of the turbid solution was transferred to a 
glass tube and stored at room temperature in the dark (4, 252).  
One row of a 96-well micro-titer plate was used for each test with different antibiotic dilutions and 
the last 2 wells of each row were used for sterility and growth controls. For each bacterial isolate to 
be tested, 50 "l of each antibiotic dilution was added into the respective wells. The Bacterial 
suspension was adjusted to 1-2 x 108 cfu ml-1 (0.5 McFarland turbidity), and then diluted 1:100 and 
mixed thoroughly. 50 "l of this bacterial suspension was inoculated to each well containing the 
antibiotic solutions and growth control well. This resulted in the desired final inoculum of 5 x 105 
cfu/ml. Inoculated micro-titer plates were then incubated at 37°C for 16-20 h (4, 252).  
After overnight incubation, growth was assessed and the MICs were defined as the lowest 
concentration of ceftazidime and cefotaxime that inhibited the visible growth of the A. baumannii 
strains after overnight incubation. Results were recorded as mg/L.  
2.3.2.3 Determination of IC50  
Isolates were grown overnight at 37ºC in liquid LB media. The bacterial cultures were diluted 
ten fold in saline (0.9%, w/v) to 10-7 and 100 "l was spread, in duplicate, on LB agar plates 
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containing different concentrations of ceftazidime (0 to 10 and 100 to 400 µg/ml). The plates were 
incubated overnight at 37ºC and the colonies on each plate were counted. 
For each individual isolate the percentage survival was calculated by dividing the average number 
of colonies on the ceftazidime containing plate by the average numbers of colonies on the antibiotic 
free plates. This experiment was performed in triplicate for each isolate. The percentage of survival 
was plotted against the ceftazidime concentration. The graph was then used to deduce the 
concentration at which 50% (IC50) of cells form viable colonies.  
 
2.4 Molecular techniques  
2.4.1 Isolation of chromosomal DNA  
Chromosomal DNA was extracted from an overnight culture using the CTAB (Cetyltrimethyl 
ammonium bromide) genomic DNA Purification Method. 1–1.5 ml of overnight culture was 
harvested by centrifugation, and the pellet was resuspended in 630 "l of TE containing 20 "l of 10 
mg/ml lysozyme, 20 "l RNase (10 mg/ml), 5 "l Proteinase K (10 mg/ml) and 40 "l of 10% SDS 
(Sodium Dodecyl Sulfate). The samples were incubated for 1 hr at 37°C, and then 1 hr at 50°C. 
After incubation, 200 "l of 5M NaCl and 100 "l 10% CTAB were added to the samples and then 
incubated at 65°C for 10 min. 500 "l of chloroform/isoamyl alcohol (24:1) was added and the 
samples were mixed thoroughly by shaking so that the aqueous and organic phases combined. The 
mixture was incubated on ice for 30 mins (important to separate cell debris from DNA) and then 
samples were centrifuged at max speed (20,000 # g) for 10 min.  The aqueous  phase was 
transferred to a fresh 1.5 ml tube before adding 500 "l phenol/chloroform/isoamyl alcohol  
(25:24:1) and then mixing thoroughly (130). After centrifuging at max speed (20,000 # g) for 10 
min, the aqueous (130) phase was transferred again to a fresh 1.5 ml tube. DNA was precipitated by 
addition of 1 volume isopropanol followed by 2 washes with 70% ethanol. The isolated DNA was 
reconstituted in 50 µl TE (10 mM Tris-HCl, 1 mM EDTA, pH 8) and stored at 4ºC. DNA was then 
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diluted 1 in 100 in sterile Milli-Q (MQ) water before use for PCR. The quality and concentration of 
the extracted DNA was determined by agarose gel electrophoresis and spectrophotometry on a 
Nanodrop ND-1000 spectrophotometer.  
2.4.2 Extraction of plasmid DNA  
Plasmid isolations were either carried out using the Wizard®Plus SV Miniprep DNA 
Purification Kit (Promega, Madison, WI, USA) and performed according to the instructions of the 
manufacturer or by using a standard alkaline lysis purification method (201). To remove any 
remaining protein contamination plasmid DNA Purified using Wizard®Plus SV Miniprep Kit was 
phenol extracted followed by an ethanol precipitation step.  
Using the alkaline lysis purification method cells from a 1.5 ml overnight culture were 
harvested by centrifugation and resuspended in 200 µl ice-cold re-suspension solution (25 mM Tris-
HCl, 50 mM glucose and 10 mM EDTA, pH8). Cells were then lysed by addition of 200 µl freshly 
prepared lysis buffer (0.2 M NaOH, 1% w/v SDS), mixed gently by inversion (5 times) and 
incubated on ice for 5 min. 150 "l of ice-cold precipitation solution (potassium acetate; the solution 
contains 5 M potassium and 3 M acetate; PH 8) was added and incubated on ice for 5 min. The cell 
lysate was centrifuged for 10 min at high speed to precipitate cell debris and the supernatant 
transferred to a fresh 1.5 ml tube. 0.6 volumes of isopropanol was added and then centrifuged for 10 
min at high speed. The pellet then was washed with 70% ethanol, drained thoroughly and 
resuspended in a TE buffer containing 100 "g/ml RNase followed by incubation at 37ºC for 30 min. 
An equal volume of phenol/chloroform/isoamyl alcohol (25:24:1) was added and the solution was 
mixed by gentle agitation then centrifuged for 2 min. The supernatant transferred to a fresh tube, 
and the plasmid DNA was precipitated from the aqueous phase by addition of 1/10 volume of 
sodium acetate (3M, pH 5.2) and 2 volumes of ethanol (100%) and incubated on ice for 30 min. 
Purified plasmid DNA was recovered from the solution by centrifugation, the pellet washed with 
70% (v/v) ethanol and resuspended in 50 "l TE (1 mM EDTA, 10 mM Tris-HCl, pH 8). 
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2.4.3 Polymerase Chain Reaction (PCR) 
All PCR amplifications were carried out in an Eppendorf Thermocycler (Eppendorf) in a 
reaction with total volume of 12.5-50 µl (12.5 µl reaction for general PCR amplifications and 25-50 
µl reaction where needed e.g. amplicons that needed to be sequenced) containing 1x PCR reaction 
buffer (supplied with Taq polymerase, New England BioLabs), 200 µM dNTP Mix (New England 
BioLabs), 1 U of Taq DNA Polymerase (New England BioLabs), 50 pmol of each forward and 
reverse primers and 10-50 ng template DNA.  
Generally, thermal cycling conditions consisted of an initial denaturation step at 95°C for 5 
min, followed by 35 cycles of denaturation at 95°C for 30 sec, annealing at 57-62°C for 30 sec, and 
extension at 72°C for 60 sec per 1 kb amplicon, followed by a final extension step at 72°C for 
10 min.  For larger amplicons ($ 3 kb), a high fidelity polymerase, Phusion DNA polymerase 
(Finnzyme OY) and Phusion HF buffer replaced Taq polymerase and PCR buffer. When Using 
Phusion DNA polymerase cycling conditions were an initial denaturation cycle at 98°C for 30 s, 
followed by 35 cycles of denaturation at 98°C for 10 s, annealing at 60°C for 30 s, and extension at 
72°C for 30 s per 1 kb of expected PCR product. The final extension was at 72°C for 10 min.  
Strains known to carry individual genes, gene cassettes, insertion sequences, and structures were 
used as positive controls in all PCR reactions when screening for those particular elements. The 
results were then confirmed by either DNA sequencing or restriction digestion of the PCR 
amplicons. A negative control reaction consisting of all PCR reagents but replacing the DNA 
template with sterile MQ water was also run for each set of PCR reactions. 
Characterization and screening for integrons, integron associated gene cassettes, common antibiotic 
resistance genes and insertion sequences (IS) were performed with the primers listed in Appendix II 
in Table II-1 and Table II-4 or in the text where appropriate. Where possible primers were designed 
with an annealing temperature of approximately 60°C. This allowed primers to be easily combined 
to detect different amplicons.  
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Overlapping PCR strategy was also applied to link flanking resistance genes and regions (e.g. 
AbaR islands, plasmids and ampC transposon) and key mapping primer pairs are listed in Appendix 
II unless specified in the text where appropriate. 
Primers were produced by Integrated DNA Technology, USA and were received in lyophilized 
form. The primers were re-suspended in 1x TE (10 mM Tris-HCl, 1 mM disodium EDTA, pH 8) to 
a concentration of 500 "M and stored at -20°C. These primers were diluted in MQ to a working 
concentration of 50 "M for general PCR use.  
2.4.4 Agarose gel electrophoresis  
DNA size fractioning of PCR products restriction digests and isolated plasmids was done by 
electrophoresis using agarose gels (0.8-1.5% (w/v)) containing 0.5 µg/ml Ethidium Bromide. DNA 
samples (5 µl of PCR products and 20 µl of restriction digest) and 3 µl of loading buffer (10% (w/v) 
bromophenol blue; 15% (w/v) Ficoll; 0.2% (w/v) xylene) were loaded into the gels and gels were 
run at 150 V for 35 to 45 min in 0.5x TBE (45 mM Tris-borate, 1 mM disodium EDTA). 1 kb, 100 
bp and 50 bp molecular weight markers (New England BioLabs, Ipswich, USA) were included 
where appropriate. DNA bands were visualised under UV transillumination and imaged using a 
Molecular Imager Gel Doc XR System (BioRad, Hercules, USA). 
2.4.5 Restriction endonuclease digestion 
PCR products, plasmid DNA and genomic DNA were digested with 10 units of appropriate 
restriction endonuclease, 1x restriction buffer and sterile MQ water in a total volume of 20 "l. 
Digestion reactions were incubated for at least 2-3 h at the appropriate temperature and then 
reactions were heat inactivated at 65°C for 20 min. PCR digests were separated via gel 
electrophoresis analysis on 1 % (w/v) agarose. Restriction enzyme fragments of genomic and 
plasmid DNA were separated on a 0.8-1.2  % (w/v) agarose gel either in 0.5 x TBE or 1X TAE 
buffer where appropriate.  
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2.4.6 PCR purification and gel extraction 
PCR amplicons to be sequenced were routinely purified by ethanol precipitation. PCR 
product was mixed with 2 volume 100% ethanol and 1/10 volume 3M sodium acetate and then 
incubated on ice for 30 min followed by centrifugation at max speed for 10 min. The pellet then 
washed with 70% ethanol and resuspended in sterile MQ water. When multiple bands of different 
sizes were in a sample, a QIAquick Gel Extraction-Kit (QIAGEN Inc, Valencia, CA, USA) was 
used to purify the band of interest excised from an agarose gel according to the instructions of the 
manufacturer.  
2.4.7 DNA sequencing and sequence analysis 
Sequencing reactions were prepared in a total volume of 12.5 "L using 12-75 ng of PCR 
templates, dependent on the amplicon size, and 9.6 pmol of the appropriate primer. Automated 
sequencing was performed at the Australian Genome Research Facility (AGRF; www.agrf.org) on 
an Applied Biosystem 3730xl Capillary platform. DNA sequences were assembled using 
Sequencher version 5.1 (Gene Codes Corporation, Ann Arbor, Michigan). Sequenced regions were 
identified using the National Centre for Biotechnology Information (NCBI) BLAST 
(http://blast.ncbi/nlm.nih.gov/BLAST.cgi) (258) and pair wise comparisons using the BLAST 
paired alignment facility. Multiple sequence alignments were generated with ClustalW available at 
the EMBL-EBI website (www.ebi.ac.uk/Tools/clustralw2) (227). Gene Construction Kit (GCK) 
version 4.0 (Textco, West Lebanon, NH, USA) was used to create figures to scale.  Artemis 
Comparison Tool was also used for sequence comparisons of genomic regions generated by 
assembling multiple sequence reads done by manual sequencing (53). SnapGene® Viewer, Version 
1.5.3 (www.snapgene.com), was also used to analyse the sequences and draw figures to scale.  
Standalone Blast software (ftp://ftp.ncbi.nlm.nih.gov/blast/executables/blast+/LATEST/) was also 
used to create a database of whole genome sequencing data and enabled searching through the 
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sequences and analyse them locally. The local database was created using the command 
“makeblastdb” and searches were done using the “blastn” command. 
2.4.8 Preparation of genomic DNA for whole genome sequencing 
Whole genome sequencing was performed using paired-end Illumina sequencing method at 
the Welcome Trust Sanger Institute. The following steps were carried out to prepare genomic DNA 
(gDNA) for whole genome sequencing. 
Genomic DNA was isolated as described in section 2.4.1 with a slight modification. During 
the Phenol:Chloroform extraction, Phase Lock GelTM (PLG) tubes were used (instead of regular 1.5 
mL eppendorf tubes) to increase DNA yield and minimize protein contamination in order to make 
high quality genomic DNA. PLG acts as a barrier between the organic and aqueous phases, 
allowing the nucleic-acid-containing phase to be free of contaminants.  
To determine the quality and purity of genomic DNA, 1 "L (20-50 ng/"L) of diluted gDNA 
was loaded on a 1% agarose gel. RNA or protein contaminants would appear on the gel as a low 
molecular weight band or high molecular weight band respectively. A HindIII digested % DNA 
marker (with known fragment concentrations) was also loaded in the gels. This allowed us to 
compare the concentrations of the gDNA samples on the gels with that obtained from a Nanodrop 
Spectrophotometer ND-1000.  The 260/280 ratio was also determined using the Nanodrop 
Spectrophotometer. According to the Welcome Trust Sanger Institute instruction for whole genome 
sequencing, a 260/280 ratio of between 1.8-1.9 was considered to be optimal. Final genomic DNA 
dilutions for sequencing were prepared in a total volume of 100 "L in TE (1 mM EDTA, 10 mM 
Tris-HCl, pH 8) and a concentration of 20-50 ng/"L. 
2.4.9 Cloning  
A TOPO TA Cloning® system was used to clone segments of ampC and ISAba125-ampC. 
This system uses a one-step cloning strategy for the direct insertion of Taq polymerase-amplified 
PCR products into a plasmid vector. Taq polymerase has a nontemplate-dependent terminal 
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transferase activity that adds a single deoxyadenosine (A) to the 3’ ends of PCR products. The 
TOPO vector (pCR2.1TOPO) has single, overhanging 3’ deoxythymidine (T) residue, allowing 
PCR inserts to ligate with the vector. 
For ligation, inserts were prepared by conventional PCR using Taq DNA polymerase. A final 
extension time of 20 min at 72°C was performed to ensure the majority of the DNA molecules 
included the single deoxyadenosine (A) overhangs at the 3’ ends. Five "l of PCR product was 
analysed by electrophoresis on a 1% (w/v) agarose gel to check for non-specific amplification and 
the remaining product was used for ligation into a pCR2.1TOPO vector. 
Ligation was performed using 2 "l of PCR product, 2 "l of vector (pCR2.1TOPO) and 1 "l of 
Salt Solution in a total volume of 20 "l. The ligation mix was incubated at room temperature for 15 
min, quickly chilled on ice and transformed into TOP10 competent cells (Invitrogen, Carlsbad, CA, 
USA) as described in the following section. 
Chemical transformation was performed by adding 2 "l of TOPO ligation mix to 100 "l 
chemically competent TOP10 cells (Invitrogen, Carlsbad, CA, USA) and incubating on ice for 
20 minutes. The transformation mix was heat-shocked for 40 seconds by transferring to a 42°C 
water bath and then immediately chilled on ice for 2 min. 950 "l of pre-warmed LB media was 
added and incubated for 1 h at 37°C with shaking at 200 rpm. 100 "l of transformation reaction was 
plated on LB agar plates supplemented with 40 mg/ml X-Gal, 50 "g/ml kanamycin and 10 "g/ml 
ceftazidime and incubated at 37°C to select for transformants.  
 
2.4.9.1 Analysis of Transformants 
Obtaining white colonies is often due to the disruption of the Lac Z& reading frame by the insert 
and no longer the substrate, X-Gal, can be used leading to the production of white colonies. 
After picking and patching of the white colonies, recombinant plasmids were isolated (as 
described in Section 2.4.2) and were examined by EcoRI digestion to determine whether they carry 
the correct insert. Also, PCR assay using a combination of M13F and M13R primers with pw51 and 
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pw52 (Table 2.7) was used to determine the orientation of inserts. Plasmid digestions were carried 
out as described in section 2.4.5. 
2.4.10 Electro-transformation of A. baumannii 
The following protocol is a slightly modified version of those previously described (7, 34). 10 
mL of overnight culture was grown at 37°C, diluted 1:100 into a fresh LB and grown at 37°C to 
exponential phase (OD600nm: 0.5-0.7). The cells were pelleted by centrifugation at 4500 rpm for 10 
minutes at 4°C. The pellet was re-suspend in 1 mL ice-cold 10% glycerol and centrifuged at 12,000 
rpm for 2 minutes at 4°C. This washing step was repeated (3 times) and then the pellet was re-
suspend in 200 "L, ice-cold 10% glycerol (v/v). The cells were stored at -70°C or kept on ice for 
use. 80 "L of competent cells was mixed with ~ 50 ng of plasmid DNA and then transferred into a 
pre-chilled electroporation cuvette. Electroporation was performed using a BioRad gene pulser unit 
with the following parameters, 0.2 cm cuvettes, 2.5kV, 25 "F, 200'.  
1 mL of fresh LB was transferred to the electroporation cuvette immediately after electroporation. 
The culture was transferred to a McCartney bottle containing 2 mL pre-warmed LB media and 
incubated at 37°C for ~2 hrs with shaking at 200 rpm to recover the cells. 100 "l of transformation 
reaction was plated on LB agar plates containing the appropriate antibiotics and incubated at 37°C 
to select for transformants. Transformation efficiency is defined as the number of transformed cells 
(transformants) generated by 1 "g of supercoiled plasmid DNA in a transformation reaction. 
Transformation efficiency (transformants/"g) was calculated as follows: (Number of colonies on 
plate/ng of DNA plated) X 1000. 
Ligations were carried out in MQ water in total volume of 20 µL using approximately 50 ng 
of digested plasmid, 1 µl of T4 DNA ligase (New England BioLabs, Ipswich, USA) and 2x 
Ligation buffer. The reactions were then thoroughly mixed by pipetting up and down 3-4 times. The 
ligation mix was incubated at room temperature for 20 min, quickly chilled on ice and then used for 
electro-transformation of competent A. baumannii cells as described before. 
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2.4.11 Total RNA isolation  
Total RNA was isolated using an Isolate RNA Mini Kit (Bioline, Australia) according to the 
manufacturer’s instruction. To check the integrity of extracted RNA, 2-3 "L of the RNA samples 
(300-500ng) were mixed with 2.2 M formaldehyde, 50% formamide and 1X MOPS (4-
morpholinepropanesulfonic acid) and heated for 5 min at 60 ºC and chilled was immediately on ice 
and then mixed with 1"L of 1"g/ml Ethidium bromide and 1"L of 10X loading dye. Then RNA 
samples were separated by electrophoresis for 45 minutes at 80 V on a 1% agarose gel containing 
2.2 M formaldehyde, 50% formamide and 1X MOPS buffer (118). A eukaryotic RNA sample 
(kindly supplied by Dale Hancock, School of Molecular Bioscience, University of Sydney) was also 
used as a marker in each gel. Concentration and 260/280 and 260/230 ratios of extracted RNA were 
determined using a Nanodrop ND-1000 spectrophotometer. 
 
2.4.11.1 DNase treatment of RNA samples 
RNA samples were treated with Amplification Grade DNAse I (Sigma-Aldrich, St. Louis, 
MO, USA) to remove any genomic DNA contaminants remaining after RNA isolation. The DNase 
I reaction was set up in a total volume of 10"L in 1X Reaction Buffer, 1U/"L Amplification Grade 
DNAse I and 8 "L of extracted RNA. The reactions were incubated at room temperature for 15 
minutes. 1"L Stop Reaction Solution was added to the reactions to inactivate DNAse I and the 
samples were heat treated for 10 min at 70°C to denature both DNase I and RNA. RNA samples 
were frozen at -80 for future use or immediately for cDNA synthesis. 
 
2.4.12 cDNA Synthesis 
500 ng of DNAse I treated RNA was reverse transcribed into cDNA using a SuperScript® 
VILO™ cDNA Synthesis Kit (Invitrogen, Carlsbad, CA, USA). The reaction was set up in DEPC-
treated water in a total volume of 20 "L containing 1X VILO Reaction Mix and 1X SuperScript 
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Enzyme Mix. The reaction conditions were an initial incubation at 25ºC for 10 min, the main 
incubation at 42ºC for 60 min and a final termination of 10 min at 85ºC according to the 
manufacturers instruction (Invitrogen, Carlsbad, CA, USA).  
 
2.4.13 Plate layouts 
The qPCR experiments were carried out in 96 well plates in a total volume of 20"L for each 
reaction. In each 96 well plate one row was assigned to one sample including 4 consecutive wells 
for 16S rRNA detection and the four wells for ampC. For each primer reaction (16S rRNA or 
ampC) the first two wells contained 10 ng/20"L RNA (duplicate of the same reaction) and the next 
two wells contained 1 ng/20"L (duplicate of the same reaction). For each primer pair used in the 
experiment two non-template wells were included as negative controls. 
 
2.4.14 Quantitative Real-Time PCR 
To examine the relative expression level of the ampC gene quantitative real-time PCR (qRT-
PCR) assay was performed. Each qPCR reaction was performed in a total volume of 20"L 
containing 10 "L SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA), 1.5 "L of 
each forward and reverse primer and either 10 or 1 ng of cDNA in 7 "L of DEPC-treated water. 
The cDNAs were quantified on an ABI7500 Real-Time PCR System (Applied Biosystems) using 
the following cycling conditions; an initial enzyme activation step at 95°C for 20 sec followed by 
40 cycles of 3 sec denaturation at 95°C and 30 sec annealing/extension at 60°C. The primers listed 
in Table 2.7 (RH1388-RH1389 and RH1384-RH1385), were specifically designed for ampC and 
16SrRNA genes in qRT-PCR experiments.  
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Table 2.7: Primers used for hybridization and qRT-PCR experiments. 
 
PCR 
/Region 
Primer Sequence 5’-3’ Amplicon 
length (bp) 
Reference 
ampC a  RH1357 
RH1358 
TCACCGATTGGGTTTTTAGG 
TGGCTGTGGGTGTTATTCAA 
355 This study 
This study 
ISAba1a ISAba1A 
ISAba1B 
GTGCTTTGCGCTCATCATGC 
CATGTAAACCAATGCTCACC 
435 (41) 
(41) 
ampC b RH1388 
RH1389 
TGGCTGTGGGTGTTATTCAA 
ACCTGCTGTCGCGGTAAATA 
140 This study 
This study 
16SrRNA b RH1384 
RH1385 
GGAGAAAGCAGGGGATCTTC 
ATCCTCTCAGACCCGCTACA 
114 This study 
This study 
 
a RH1357-RH1358 and ISAba1A-ISAba1B were used to produce ampC  and ISAba1 probe respectively.   
b These primers were designed for Real-Time PCR experiments.  
 
 
2.4.14.1 Data normalization & expression level changes 
To compensate for the analytical variability produced by the multiple steps of the method and 
to correct for sample-to-sample variations, relative quantification of the measured cDNA was 
performed based on normalization to endogenous 16SrRNA gene as an internal control.   
This measure relies on the principle that the expression ratio of the internal control gene is identical 
in all samples, regardless of the experimental condition or cell type (11). After normalization of 
expression of ampC genes to the endogenous 16SrRNA, ceftazidime and cefotaxime susceptible A. 
baumannii strain 3208 was used as a control and the differences in relative ampC expression levels 
were converted to fold changed compared to this strain.  
2.4.15 Southern hybridisation 
The followings are the buffers and their concentrations used in Southern Hybridization 
experiments. 
! Depurination solution 0.2% HCL. 
! Denaturation Solution (0.5N Sodium Hydroxide, 1.5M Sodium Chloride). 
! Neutralization Buffer (0.1M Tris, 1.5M Sodium Chloride). 
! 20x & 2x SSC (Sodium Chloride, Sodium Citrate solution). 
! 10% SDS (w/v). 
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! 2x SSC, 0.1% SDS (w/v). 
! 10x Maleic Acid (0.1M Maleic acid, 0.15M NaCl) pH 7.5. 
! Detection buffer (0.1M Tris HCl (pH9.5), 0.1M NaCl). 
! Probe Stripping Solution (0.2M NaOH, 0.1% (w/v) SDS). 
! Washing buffer (0.1M maleic acid, 0.15M NaCl, 0.3% (v/v) Tween 20) pH 7.5). 
 
2.4.15.1 Preparation of Digoxygenin-labelled DNA probe  
The DNA probes used in hybridization were prepared using the PCR DIG-labelling Mix 
(Roche Applied Science) as described in the manufacturer’s instructions. Primer pairs used for PCR 
amplification of ISAba1 and ampC with DIG-labelled dNTPs are listed in Table 2.7.  
Prior to the addition of DIG-labelled PCR probes to the Easy Hyb solution for hybridization, 
the DIG-labelled PCR products were cleaned up using a PCR purification kit as described in 
Section 2.4.6. 
DIG-labelled PCR products were purified and then heated at 100ºC for ~10 min to denature 
the probe. After heating, DIG-labelled probes were placed on ice immediately to remain denatured. 
Hybridisation solutions were prepared by adding denatured (by boiling for 5 min) DIG-labelled 
probe (~25 ng/ml DIG easy Hyb) to fresh pre heated DIG easy Hyb solution (~3.5 ml/100 cm2 
membrane) and mixed well. Diluted probes were stored at -20°C and reused 4-5 times when freshly 
denatured at 68°C for 10 min before use.   
2.4.15.2 Genomic DNA digestion 
Approximately 2-3 "g of genomic DNA was digested using 2U of appropriate restriction 
enzyme in the supplied buffer for ~2 h at 37ºC in a total volume of 20 "l. The digested genomic 
DNA samples were then separated on a 0.8% (w/v) agarose gel. DIG-labelled ladders II and VII 
(Roche Applied Science) were used as DNA molecular weight standards and the gels visualised 
under UV illumination.  
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2.4.15.3 Transfer of DNA and Nitrocellulose membrane preparation 
Separated DNA was nicked by soaking the gel in Depurination Solution (0.2N HCl) with 
gentle agitation for ~ 15 min. The gel was then immersed in denaturation solution (0.5M NaOH, 
1.5M NaCl) with gentle agitation (three washes for 15 min) followed by two washes in 
neutralisation solution (1M Tris, 1.5M NaCl) for 7.5 min each. The digested DNA fragments from 
the gel were then transferred to a N+ nylon membrane (Amersham, Buckinghamshire, UK) 
overnight by capillary action as described previously (201).  Following transfer the DNA fragments 
were cross-linked to the membrane using the Stratalinker®1800 (Stratagene, CA, USA) using Auto 
cross-linking settings (1200 "Joules x100). A washing step was performed with sterile MQ H2O 
and the membrane allowed to air dry.  The membranes were either immediately used for 
hybridization or stored at 2-8°C. 
2.4.15.4 Determining hybridisation temperature 
The appropriate hybridisation temperature was calculated according to GC content and 
percent homology of probe to target according to the following equation: 
Tm = 49.82 + 0.41 (% G+C) – (600 / length of the probe in base pairs) 
Topt = Tm – 20 to 25°C 
Topt for ISAba1 hybridization experiments was calculated as follows:  
ISAba1 Tm = 49.82 + 0.41 (37.9) – (600/435) = 63.989 
The actual hybridisation temperature Topt for hybridisation with DIG Easy Hyb is ~20°C below the 
calculated Tm value. Topt can be regarded as a stringent hybridisation temperature, allowing up to 
18% mismatches between probe and target. 
Topt (ISAba1) = Tm -20°C= 63.989-20 = 44 
(The given numbers of the equation were calculated according to a standard equation for 
hybridisation solutions containing 50% formamide) (200). 
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2.4.15.5 Hybridization Steps 
The membrane was pre-hybridized by immersing the membrane in 25 ml of fresh Easy Hyb 
solution (granules) and incubated at 44ºC (hybridization temperature) for 2 h. The pre-hybridization 
solution was replaced by 25 ml of hybridization solution containing the DIG-labelled probe and 
incubated at 58°C for 30 min followed by 64°C for 45 min and then overnight at 44ºC which is the 
Topt. All Hybridization steps were applied to N+ nylon membranes in sterile hybridization bottles 
(Pyrex tubes, Amersham, Buckinghamshire, UK) in a hybridization oven with rotisserie (Hybaid) 
for constant agitation and temperature control.  
2.4.15.6 Post-Hybridization washings, immunological detection and imaging 
After overnight incubation the hybridization solution was replaced by 2X SSC/0.1% SDS and 
the membrane was washed 2 x 15 min (at room temperature) to remove unbound probe.  The 
washing step was repeated twice at 68°C (stringency washes) and followed by a washing step with 
Roche Wash buffer (Roche Applied Science). The membrane was blocked using 50 ml of Roche 
Blocking buffer for ~ 1 hour (Roche Applied Science) under constant rotation. The membrane was 
then immersed in anti-DIG antibody (Roche Applied Science) solution (5 "l of anti-DIG antibody 
in 50 ml Roche Blocking buffer) and then incubated under constant rotation for 30 min at 25ºC, 
followed by 2x 15 min washes with Roche Wash Buffer. The membrane was developed by 
applying 1 ml detection buffer that containing 50 "l of CSPD chemiluminescence substrate (Roche 
Applied Science) and incubated for ~10 min. The membrane was then exposed to an X-ray film 
(Amersham, Buckinghamshire, UK) for 30 sec - 5 min at 15-25°C. The X-ray film was developed 
using a CP100 film processor (AGFA, Mortsel, Belgium). The membranes were washed briefly in 
sterile double distilled or sterile MQ H2O then two washing steps were applied (for 15 min each) in 
0.2N NaOH, 0.1% (w/v) SDS at 37°C under constant agitation. The membranes were then 
equilibrated briefly in 2X SSC and stored in Maleic acid buffer or 2X SSC until used again.   
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2.5 Conjugation 
 
A spontaneous rifampicin resistant mutant of A. baumannii ATCC17978, which is resistant only to 
sulfonamides, was isolated for use as a recipient. Equal amounts of overnight cultures of the donor 
and recipient cells were mixed and incubated on an L agar plate overnight. Cells were resuspended, 
diluted in 0.9% saline and transconjugants selected by plating on L-agar plates containing 
rifampicin (100 mg/L-1) and ticarcillin (100 mg/L-1 ). To ensure that rare transconjugants were not 
spontaneous rifampicin resistant derivatives of the donor, potential transconjugants were purified 
and screened for growth on L agar containing antibiotics to which the donor was resistant, 
ceftazidime (25 mg/L-1113 ), and the recipient susceptible, nalidixic acid (100 mg/L-1114 ). 
 
2.6 Methods for Characterization of Acinetobacter spp. 
 
2.6.1 PCR based species typing  
A PCR assay targeting highly conserved region in the recA gene of Acinetobacter was carried 
out to distinguish between different genomic types and characterize the isolates at genus level. The 
primers rA1: 5’-CCTGAATCTTCTGGTAAAAC-3’ and rA2: 5’-
GTTTCTGGGCTGCCAAACATTAC-3’ were used to screen the strains for the recA gene and the 
PCR was carried out as previously described (111, 154). In order to simplify sequencing, the 
primers used to amplify the recA gene were replaced by RH748 5’- 
TACGGTTATGCGTCTTGGTG-3’ and RH749 5’- CCAACAATTTCATCGCCTTC-3’ that 
generate a 645 bp product. Sequencing of the recA amplicon was performed as described in Section 
2.4.7. The recA sequences were compared with the recA sequences in MLST website 
(www.pubmlst.org/abaumannii/) to assign an allele number. 
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2.6.2 Identifying major clones of A. baumannii  
Two multiplex PCR assays amplifying alleles of ompA, csuE and intrinsic oxa-Ab (blaOXA-51-
like) were used to detect group 1 (SG 1 or GC 2) or group 2 (SG 2 or GC 1).  Primers for ompA, 
csuE and oxa-Ab (blaOXA-51-like) and reaction conditions were those previously described (235). 
All three alleles of the multiplex PCR are required to be amplified for group 1 (GC2) and 2 (GC1) 
isolates whereas group 3 isolates only generate the ompA allele amplification from group 2 PCR, 
and the csuE and oxa-Ab alleles from group 1 PCR. The expected products for group 1 PCR are 355 
bp, 702 bp and 559 bp for ompA, csuE and blaOXA-66 respectively. For group 2 PCR ompA, csuE and 
blaOXA-69 generate 343 bp, 580 bp and 162 bp products respectively (235).  
2.6.3 Detection of the oxa-Ab gene 
The oxa gene which is characteristic for A. baumannii was amplified using the primers OXA-
69A, 5(-CTAATAATTGATCTACTCAAG-3(, and OXA-69B, 5(-
CCAGTGGATGGATGGATAGATTATC-3(, and reaction conditions as previously described (82). 
The 975 bp PCR product of oxa-Ab that includes the complete oxa-Ab gene was sequenced and 
compared to the reference sequences of GC 1 (oxa69; GenBank accession number CP001182) and 
GC 2 (oxa-66; GenBank accession number CP000863). The oxa-Ab sequence for GC 1 (oxa-69) 
and GC 2 (oxa66), differs at 15 positions. 
2.7 Molecular Typing Methods 
 
The following typing techniques were applied to investigate the relationships of A. baumannii 
and to identify closely related isolates studied over the course of this project. 
2.7.1 Random amplification of polymorphic DNA (RAPD)  
Random amplification of polymorphic DNA (RAPD) PCR was carried out with two different 
primers M13: 5’-GAGGGTGGCGGTTCT-3’ and DAF4: 5’-CGGCAGCGCC-3’(69). 
Amplification and cycling conditions were as described previously (69). PCR products were 
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separated by gel electrophoresis and visualized as described in Section 2.4.4. Profiles were then 
analysed and interpreted by visual inspection for the presence or absence of bands as well as 
comparison of RAPD profiles of different strains and profiles were considered identical only when 
two strains shared all of the same bands.  
2.7.2 rep-PCR 
As a second PCR based typing method, rep-PCR (repetitive sequence-based PCR using 
repetitive extragenic palindromic primers) was carried out using the primer set  (REP1: 5'-
GCGCCGICATCAGGC-3' and REP2: 5'-ACGTCTTATCAGGCCTAC-3') and the cycling 
conditions previously described (69). rep-PCR products were separated by gel electrophoresis and 
visualized as described in Section 2.4.4. The strain profiles were then analysed and interpreted by 
the same strategy as performed for RAPD PCR. 
2.7.3 Multi-locus sequence typing (MLST)  
As part of the molecular investigation of the genetic relationship amongst the A. baumannii 
isolates a multi-locus sequence typing (MLST) was performed as previously described (12). 
 The Oxford A. baumannii MLST scheme (hosted at the University of Oxford; 
www.pubmlst.org/abaumannii/) and is based on PCR amplification of seven housekeeping genes 
gltA (Citrate synthase), gyrB (DNA gyrase subunit B), gdhB (Glucose dehydrogenase B), recA 
(Homologous recombination factor), cpn60 (60-kDa chaperonin), gpi (Glucose-6-phosphate 
isomerase) and rpoD (RNA polymerase sigma factor). PCR amplification was performed using the 
primers and reaction conditions as described in the scheme with some modifications in order to 
simplify sequencing and amplification. Allele sequences and the distinct sequence type (ST) were 
obtained using the A. baumannii MLST web site. STs were also determined using whole genome 
sequence data and using Short read sequence typing (SRST) and standalone blast 
(http://www.ncbi.nlm.nih.gov/books/NBK52640/) as previously described (96). 
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2.8 Resistance profiles of controls and overseas isolates  
Four strains, which had already been characterized as GC1, were added to the collection as 
controls (Table 2.8). A297 (RUH875) is the GC1 reference strain isolated in 1984 in the 
Netherlands (78). The resistance genes, of A297, and their context has been previously 
characterized (153). A388 was isolated in Greece and shown that it belongs to SG6 (sequence group 
6) by generating the csuE band in the group 1 (GC2) PCR (78, 232). AB0057 has been isolated 
from the US in 2004 (2). It was also used as control in most experiments e.g. finding the context of 
the resistance genes, AbaR mapping and sequence analyses as its whole genome sequence was 
available in the GenBank database (accession no. CP001182) when this study began. A1 has been 
isolated in 1982 in the UK and is one of the oldest GC1 strains available (78). The strains used as 
control exhibited different resistance profile patterns. All were resistant to ampicillin, 
chloramphenicol, florfenicol, sulphonamide and tetracycline. A297 and AB0057 were resistant to 
kanamycin, gentamicin and neomycin however A1 was not resistant to kanamycin and neomycin. 
A297 was also resistant to tobramycin. AB0057 exhibited resistance to imipenem and meropenem. 
A388 also exhibited resistance to amikacin and carbapenems.  
 
 
Table 2.8: Antibiotic resistance profiles of the controls and overseas isolates. 
 
Isolate Year Origin  Resistant to: 
A297 (RUH875)  1984 Netherlands Km Nm Gm Tm Su Tc  
A1 1982 UK Gm Sp Su Tc  
A388 a 2001 Greece  Km Nm Sp Su Tc Gm Ne CTX IPM  
AB0057 2004 USA Km Nm Sp Su Tc Gm Cip Nx CTX IPM  
 
a SG6; the exact isolation date is also not known; 2001-2004. 
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3.1 Introduction  
 
The first Australian GC1 isolate, 3208, was reported in 2009 (183).  3208 was multiply 
antibiotic resistant and had been isolated in 1997 from a blood sample (183). In 2009, Mak et al. 
(134) described the resistance profiles for 25 antibiotics of 32 MAR strains and identified the 
antibiotic resistance determinants. These strains had been isolated mainly during ICU outbreaks in 4 
different hospitals in Sydney (134). These MAR isolates were subsequently found to belong to the 
global clones, GC1 and GC2 (184). The GC1 set included 4 MAR isolates from the Royal North 
Shore Hospital (RNSH; Hospital D) and a single strain from Prince of Wales Hospital (Hospital A) 
that were resistant to ampicillin, sulphonamides, kanamycin and gentamicin (Table 3.1) (134, 184).  
 
 
Table 3.1: Previously identified GC1 strains from Sydney hospitals. 
 
Isolate Year Hospital a/ 
ward 
Isolation 
location 
Resistant to: b Reference 
A92 2005 A Urine catheter  Km Gm Sp Su Cip Nx Ap (184) 
3208 1997 D Blood Km Gm Sp Su Cip Nx Ap (183) 
D2 2006 D/10A Wound Km Gm Sp Su Cip Nx Ap (184) 
D3 2006 D/7D Catheter Km Gm Sp Su Cip Nx Ap (184) 
D6 2006 D/7D Wound Km Gm Sp Su Cip Nx Ap (184) 
D7 2006 D/7D Urine Km Gm Sp Su Cip Nx Ap (184) 
D27 2008 D/9A Wound swab Km Gm Sp Su Cip Nx Ap (182) 
D30 2008 D/7D Wound swab Km Gm Sp Su Cip Nx Ap (182) 
D36 2008 NSP Wound swab Km Gm Tm Su Cip Nx Ap CTX CAZ 
IPM MEM 
(182) 
SG6 Isolates     
     
D13  2009 D/7D MSU c Km Gm Sp Su Cip Nx Ap CTX CAZ (182) 
D14  2009 D/7D MSU Km Gm Sp Su Cip Nx Ap CTX CAZ (182) 
D15  2009 RRC MSU Km Gm Sp Su Cip Nx Ap CTX CAZ (182) 
D18  2009 D/7D Wound swab Km Gm Sp Su Cip Nx Ap CTX CAZ (182) 
D20  2009 RRC MSU Km Gm Sp Su Cip Nx Ap CTX CAZ (182) 
 
a A: The Prince of Wales hospital, D: Royal North Shore hospital (RNSH), RRC: Ryde Rehabilitation Centre, NSP: 
North Shore Private hospital. 
b Ap, ampicillin; CTX, cefotaxime; CAZ, ceftazidime; Km, kanamycin; Gm, gentamicin; Tm, tobramycin; Su, 
sulphonamide; Cip, ciprofloxacin; Nx, nalidixic acid; IPM, imipenem; MEM, meropenem. 
c Midstream urine. 
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Further isolates from RNSH were previously identified as GC1 (182) but had not been 
characterized (Table 3.1). Five strains had been shown to be members of GC1 clonal complex but 
belonged to sequence group 6 or SG6 (Table 3.1) (182). SG6 isolates are identified based on a 
specific pattern they generate in the allele-specific PCR (235). 
The aim of the work presented in this chapter was to increase the number of isolates in the 
Australian GC1 collection by screening further sets of clinical isolates obtained from Sydney, 
Melbourne, Brisbane and Adelaide hospitals, and to examine resistance phenotypes and 
relationships of the isolates using different molecular methods.   
 
3.2 Isolates from Royal North Shore hospital 
 
A total of 71 Acinetobacter isolates, recovered between 2010-2011 from clinical samples, 
obtained from the RNSH (Hospital D), were screened for the oxa-Ab intrinsic gene (undertaken 
with Steven Nigro). 51 isolates generated the predicted band of 975 bp using the primers OXA-69A 
and OXA-69B (Chapter 2; section 2.5.3) amplifying the intrinsic oxa-Ab gene and classifying them 
as A. baumannii.  
The global clones, GC1 and GC2, were identified by the allele-specific multiplex PCRs, 
which amplify the three housekeeping genes oxa-Ab, csuE and ompA (Chapter 2; section 2.5.2) 
(235). Reference strains, A297 and A320, were used as controls for GC1 and GC2 clones, 
respectively (78). Isolates belonging to the Sequence Group 1 (SG1), which corresponds to GC2 
generate all three fragments in the Group 1 PCR, and none in the Group 2 PCR. Isolates belonging 
to the Sequence Group 2 (SG2), which correspond to GC1, produce the converse results (235) 
(Figure 3.1). Three isolates were identified as GC1 (Figure 3.1 and Table 3.2) and 23 isolates were 
GC2. Three further isolates, D45, D48 and D108, generated a typical SG6 pattern (Figure 3.1), with 
the oxa-Ab and ompA bands in the group 2 PCR and the csuE band in the group 1 PCR (Figure 3.1). 
The SG6 strains, D45, D48 and D108, together with the ones from 2009 (Table 3.1) were all 
isolated from either the spinal injury ward 7D of RNSH (Hospital D) or at the Ryde Rehabilitation 
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Center (RRC)  (Table 3.2). RRC is a separate hospital located ~10 km away from the hospital D and 
spinal injury patients 
 
Table 3.2: GC1 isolates from Royal North Shore Hospital (Hospital D). 
 
Isolate Isolation date Isolation location Ward Sequence  
group 
D45  2010 B/C-TSAB 7D 6 
D48  2010 MSU 7D 6 
D62  2010 MSU RRC 2 
D78 2010 ISOLATE COFH  2 
D81 2010 Wound swab 6NI  2 
D108  2011 MSU 7D 6 
 
 from the 7D ward are usually sent to RRC. To confirm that the SG6 isolates are GC1, an internal 
fragment of the recA gene and the entire oxa-Ab gene were sequenced from D45, D48, and D108. 
All contained recA11 (Oxford MLST scheme), which is usually found in GC1s, and an identical 
oxa-Ab gene, which predicts the OXA-69 protein also is usually found in GC1. The oxa-Ab and 
recA genes from additional isolates, D30, D36, D62, D78 and D81, were also sequenced and all 
contained recA11 and an oxa-Ab gene, which predicts the OXA-69 confirming that these isolates 
belong to GC1. 
Figure 3.1: Allele-specific PCR patterns. The arrows indicate the bands corresponding to the csuE, ompA, and oxa-Ab 
genes used in the multiplex PCR. Lane 2, A297, lane 3, D15, and lane 9, A320, show typical pattern produced by GC1, 
SG6 and GC2 isolates respectively. 
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3.3 Isolates from other Australian hospitals 
 
Among a total of 18 MAR Acinetobacter strains isolated from clinical samples (between 
1999-2010) obtained from the Prince of Wales Hospital (Hospital A), two isolates, A83 and A85, 
were found to be GC1 (Table 3.3) and 14 isolates belonged to GC2. The strain WM98, which had 
been identified as GC1 (56) was also added to the collection. WM98 was one of the 177 isolates of 
Acinetobacter spp., which had caused ICU outbreaks between 1995-2000 in the Westmead 
Hospital, Sydney. WM98 is representative of the 52 strains, which generated pulsotype I (240).  
Among 15 isolates received from the Royal Brisbane Hospital and identified as A. baumannii, 
only one, RBH3, isolated in 2002, generated the GC1 pattern by the allele-specific PCR and 11 
isolates were identified as GC2 (Table 3.3). Seventeen A. baumannii isolates were identified 
amongst 21 clinical MAR Acinetobacter spp. obtained from the Alfred Hospital in Melbourne 
(164). Amongst these only one isolate, G7, was identified as GC1 and 11 were found to be GC2. 
6772166 was isolated in 2002 in the Royal Adelaide Hospital and was previously identified as GC1 
(56). 6772166 was representative of 4 strains, which were part of the 52 Acinetobacter spp. isolates 
examined in a previous study (56).   
 
Table 3.3: GC1 strains isolated from different Australian hospitals. 
 
Isolate City Date 
A83 Sydney 2002 
A85 Sydney 2003 
WM98 Sydney 1998 
G7 Melbourne 2002 
RBH3 Brisbane 2002 
6772166 Adelaide 2002 
 
The oxa-Ab gene was also sequenced from each of these isolates, A83, RBH3, 6772166, 
WM98, G7 and A85, using the product of the oxa-Ab PCR (Chapter 2; section 2.5.3), and all 
predicted the OXA-69 protein sequence confirming their assignment to the global clone 1.  
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3.4 Antibiotic resistance profile 
 
The GC1 strains identified were screened for resistance to 23 antibiotics: ampicillin, 
cefotaxime, ceftazidime, imipenem, meropenem, timentin (ticarcillin-clavulanic acid), 
ampicillin/sulbactam, chloramphenicol, florfenicol, gentamicin, kanamycin, neomycin, 
streptomycin, spectinomycin, amikacin, netilmicin, tobramycin, ciprofloxacin, nalidixic acid, 
sulphamethoxazole, tetracycline, rifampicin, and trimethoprim.   
All the GC1 isolates were resistant to ampicillin, chloramphenicol and florfenicol and only 
G7 was susceptible to nalidixic acid and ciprofloxacin (Table 3.4). However, the isolates exhibited 
different aminoglycoside, cephalosporin and carbapenem resistance patterns, which allowed the 26 
Australian isolates to be divided into 9 groups (Table 3.4).  
Two main groups were identified, group 2 and 4. The oldest Australian isolates, 3208 and 
WM98, exhibited the same resistance profile (group 1) and differed from group 2 by resistance to 
tetracycline.  Group 2 included eight isolates from two Sydney hospitals, which exhibited resistance 
to kanamycin, neomycin, gentamicin, sulphonamide, nalidixic acid and ciprofloxacin. Group 4 
included 7 strains, all identified as SG6, which were distinguished from group 2 by resistance to 
ceftazidime and cefotaxime (CTX and CAZ). The last SG6 strain, D108, exhibited a different 
resistance profile compared to the other SG6 isolates. D108 was susceptible to aminoglycosides and 
sulphonamide and was resistant to imipenem, meropenem and timentin and was placed in group 5.  
D36, group 3, was resistant to third generation cephalosporins, CTX and CAZ and 
carbapenems (imipenem and meropenem). The aminoglycoside resistance profile of D36 differed 
from the other GC1 strains, as it was resistant to tobramycin in addition to gentamicin and 
kanamycin.  The strains in the group 6, D78 and D81, and (group 9), G7, also had a distinct 
aminoglycoside resistance pattern, as they were resistant to amikacin in addition to gentamicin and 
kanamycin. These were also resistant to third generation cephalosporins. RBH3 and 6772166, from 
Brisbane and Adelaide, exhibited similar resistance pattern and were distinguished from SG6 
isolates by resistance to tetracycline and from the isolates in group 1 by resistance to third 
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generation cephalosporins (Table 3.4).  A85, which was placed in group 8, also differed from group 
7 by resistance to carbapenems (Table 3.4). CDS results can be found in Appendix I, Table I-1. 
 
Table 3.4: Antibiotic resistance profiles of the Australian GC1 strains. 
 
Isolate Year Origin  Resistant to: a 
Group 1    
3208 1997 Sydney Gm Km Nm Sm Sp Su Tc Cip Nx  
WM98 1998 Sydney Gm Km Nm Sm Sp Su Tc Cip Nx  
Group 2    
A83 2002 Sydney Gm Km Nm Sm Sp Su Cip Nx  
A92  2005 Sydney Gm Km Nm Sm Sp Su Cip Nx  
D2, D3, D6, D7 2006 Sydney Gm Km Nm Sm Sp Su Cip Nx  
D27, D30 2008 Sydney Gm Km Nm Sm Sp Su Cip Nx  
D62 2010 Sydney Gm Km Nm Sm Sp Su Cip Nx  
Group 3    
D36 2008 Sydney Gm Km Tm Sm Su Cip Nx CTX IPM  
Group 4 b    
D13, D14, D15, 
D18, D20  
2009 
 
Sydney 
 
Gm Km Nm Sm Sp Su Cip Nx CTX  
 
D45, D48  2010 Sydney Gm Km Nm Sm Sp Su Cip Nx CTX  
Group 5 b    
D108  2011 Sydney  Sp Cip Nx CTX IPM  
Group 6    
D78, D81 2010 Sydney Ak Gm Km Nm Sm Sp Su Tc Cip Nx CTX IPM  
Group 7    
RBH3 2002 Brisbane Gm Km Nm Sm Sp Su Tc Cip Nx CTX  
6772166 2002 Adelaide Gm Km Nm Sm Sp Su Tc Cip Nx CTX  
Group 8    
A85 2003 Sydney Gm Km Nm Sm Sp Su Tc Cip Nx CTX IPM 
Group 9    
G7 2002 Melbourne Ak Gm Km Nm Sm Sp Su Tc CTX  
 
a Ap, ampicillin; CTX, cefotaxime; CAZ, ceftazidime; Sp, spectinomycin; Sm, streptomycin; Tc, tetracycline; Km, 
kanamycin; Gm, gentamicin; Nm, neomycin; Ne, netilmicin; Tm, tobramycin; Su, sulphonamide; Cip, ciprofloxacin; Nx, 
nalidixic acid; IPM, imipenem; MEM, meropenem and TIM timentin (ticarcillin clavulanic acid). All the isolates were 
resistant to ampicillin, florfenicol and chloramphenicol. All the IPM resistant isolates also exhibited resistance to MEM and 
TIM and CTX resistant isolates were also exhibited resistance to CAZ. All the strains but G7 were also resistant to nalidixic 
acid and ciprofloxacin.  
b SG6 strains.  
 
3.5 Carbapenem resistance genes 
 
Only five isolates were resistant to carbapenems, D36, D108, D78, D81 and A85 (Table 3.4 
groups 3, 5, 6 and 8 respectively). All the isolates were screened for the acquired oxa 
carbapenemase genes oxa23, oxa58 and oxa24 by a multiplex PCR previously described (253). An 
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oxa gene was detected in the five carbapenem resistant strains. D78 and D81 contained oxa58 and 
the oxa23 gene was found in D36, D108 and A85 (Table 3.5).  
 
Table 3.5: Distribution of carbapenem resistance oxa genes in Australian GC1. 
 
Isolates a Year oxa23/58/40 Carbapenem 
resistance profile 
A92 2005 - - 
A83 2002 - - 
3208 1997 - - 
WM98 1998 - - 
D2, D3, D6, D7 2006 - - 
D27, D30 2008 - - 
D62 2010 - - 
D36 2008 23 IPM MEM TIM 
D13, D14, D15, 
D18, D20 c 
2009 - - 
D45, D48 c 2010 - - 
D108 c 2011 23 IPM MEM TIM 
D78, D81 2010 58 IPM MEM TIM 
G7 2002 - - 
RBH3  2002 - - 
A85 2003 23 IPM MEM TIM 
6772166 2002 - - 
a  resistance genes and their context have been determined in 3208, D2, D3, D6 and D7 (182). 
b IPM, imipenem; MEM, meropenem; TIM, timentin (ticarcillin clavulanic acid). 
c SG6 strains. 
 
 
The presence of an AbaR island, an important antibiotic resistance element in MAR GC1, was 
explored in the isolates by a diagnostic PCR using the primers RH791 and RH913 that amplify a 
982 bp internal fragment of the comM gene (184). Generation of this amplicon indicates that this 
gene is intact and failure to generate the amplicon suggests the presence of an AbaR island, which 
usually interrupts the comM gene.  The comM PCR failed to generate product in any GC1 isolates 
suggesting the presence of an AbaR island in comM (Chapter 4). 
3.6  Molecular typing 
Randomly amplified polymorphic DNA (RAPD), repetitive element palindromic PCR (rep-
PCR), ISAba1 profiles using Southern hybridization, and Multi-locus Sequence Typing (MLST) 
were used to further examine the relationships of the GC1 strains in the collection.  
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3.6.1 RAPD and rep-PCR analyses  
Two RAPD PCR primers, DAF4 and M13, and a rep-PCR primer were used as previously 
described (69). Using rep-PCR it was not possible to distinguish between the isolates as most 
strains generated almost the same pattern (data not shown). RAPD using the DAF4 primer also 
resulted in a common pattern (data not shown). However, two main RAPD patterns were identified 
using the M13 primer. Though patterns for the two main RAPD profiles were slightly different 
when experiments were repeated, it was still possible to distinguish two groups. Non-GC1 isolates 
used as controls generated profiles that were completely different from those of GC1 isolates 
(Figure 3.2) indicating that the M13 primer is generally more useful to separate GC1 isolates from 
other clones. 
Figure 3.2: RAPD-PCR profiles generated by M13 for representatives of the main groups. The isolate C1 is a GC2 and 
D4 is a non-GC1 non-GC2 isolate used as controls. A388 is a Greek GC1 isolate. Panels a, b and c different experiment 
under the same conditions.   
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Majority of the isolates including the ones in the group 2 of Table 3.4, which exhibited the 
same resistance profile, the old Australian isolates 3208 and WM98, isolates from other Australian 
cities e.g. G7 and RBH3, generated RAPD pattern 1 (Figure 3.2). SG6 strains, isolated in different 
years, all produced the same pattern, RAPD pattern 2, though the bottom band of D108, isolated in 
2011, was slightly faint compared to other SG6 isolates (Figure 3.2 b). D36 also generated a pattern 
that differed from both group 1 and 2 by 1 band suggesting that this isolate could be from a 
different lineage. 
 
3.6.2 ISAba1 profiles of the strains 
ISAba1 is an IS often associated with A. baumannii (206), and examining the distribution of 
the ISAba1 copies in the genomes has been shown to be a useful method to discriminate A. 
baumannii isolates (84).  
Genomic DNA was digested with either EcoRI or PstI, which do not cut ISAba1, separated on 
agarose gel and hybridized to a probe internal to ISAba1. Four isolates, 3208, D30, A83 (Figure 
3.3; Lane 8) and WM98 did not hybridize with the ISAb1 probe indicating that these isolates do not 
carry an ISAba1 in their genomes. This was also confirmed by PCR using ISAba1A and ISAba1B 
primers (Chapter 2 section 2.4.14) to amplify an internal fragment of ISAba1 and these isolates 
were the only ones that did not generate an amplicon. Hence these isolates predate the entry of 
ISAba1 into GC1 genomes. 
On the whole, representatives of the isolates from different RAPD and antibiotic resistance 
groups generated distinct ISAb1 profiles indicating that they include a different number of the IS 
copies in different genomic locations. A85 and PW01c are the same isolate received under different 
names and they generated the same ISAba1 profile (Figure 3.3). Isolates A92 and D81 generated 
only one band indicating the presence of a single ISAba1 copy in their genome (Figure 3.3). D78 
and A297 generated a few additional faint bands, in addition to the main signal. Analysis of the 
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draft genomes of these isolates revealed that they include only one copy of ISAba1 indicating that 
the additional faint bands are due to partial digestion of the DNA. This also indicates that D78 and 
D81, which produced the same antibiotic resistance profiles, are related. The remaining isolates 
generated different profiles and could not be grouped indicating that these isolates are different in 
respect to the number and locations of ISAba1 copies in their genomes. 
 
 
Figure 3.3: ISAba1 profiles using Southern hybridization. Genomic DNA is digested with EcoRI and probed with an 
internal portion of ISAba1. 
 
Six strains, D2, D3, D6, D7, D27 and D62, isolated between 2006-2010 generated almost the 
same ISAba1 profiles in EcoRI and PstI digests (Figure 3.4). These strains also exhibited the same 
antibiotic resistance profiles. However, D62, isolated in 2010, included two additional copies 
(Figure 3.4 a; Lane 8). This suggests a recent incorporation of these two ISAba1s. Hence, these 
strains are closely related and are probably derived from a common ancestor. 
The SG6 isolates, which had the same RAPD pattern, did not generate the same ISAba1 
profile. They shared only a 9 kb band. All except D15 and D108 shared two additional bands of ~15 
kb and > 23 kb (Figure 3.4 b). D108 is not shown in Figure 3.4 as it was isolated later and examined 
in a separate experiment. D18, D20, D45 and D48 also shared 4 bands indicating the presence of 
ISAba1 in 4 identical locations in their genomes. This suggests that ISAba1 has been actively 
moving in these genomes, since the latest strains include a further number of ISAba1. This finding 
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indicates that ISAba1 profiles alone could not be relied on to differentiate closely related strains 
amongst a large number of isolates and should be combined with other typing methods.  
Figure 3.4: ISAba1 profiles using Southern hybridization. Genomic DNA from GC1 isolates digested with EcoRI and 
probed with an internal portion of ISAba1. (a) represents ISAba1 profiles of D2 group using PstI and EcoRI restriction 
enzymes. (b) shows ISAba1 profiles generated by SG6 strains using EcoRI to digest their genomes. Gel conditions: (a) 
is run using PFGE and (b) using standard conditions. 
 
 
3.6.3 Multi-locus sequence typing 
MLST analysis was performed, using the Oxford scheme (www.pubmlst.org/abaumannii/), 
for at least one representative of each group and all the sporadic strains. ST109 (gltA10, gyrB12, 
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gdhB4, recA11, cpn60-4, gpi9 and rpoD5) was found to be the most common ST type in the 
collection as all but 6 of the Australian strains tested belonged to this ST type (Table 3.6). All 
isolates belonged to the GC1 clonal complex, CC109, with most differences in gpi. D36, which was 
carbapenem resistant, was a single locus variant (SLV) of ST109 differing in the gpi gene by 23 bp. 
Both D78 and D81, which were carbapenem and amikacin resistant, were also an SLV of ST109, 
again with a different gpi gene (gpi80 differs from gpi9 by 6 bp; Table 3.6).  
Three isolates recovered in different cities, A85 (2003, Sydney), RBH3 (2002, Brisbane) and 
6772166 (2002, Adelaide) had the same ST type, ST126 (10-53-4-11-4-64-5), which was double 
locus variant (DLV) of ST109 (10-12-4-11-4-9-5) (Table 3.6). ST126 differed from ST109 by gyrB 
(gyrB53 differs from gyrB12 by 2 bp) and gpi (gpi64 differs from gpi9 by 21 bp).  
 
 
Table 3.6:  RAPD-PCR profiles and Oxford MLST types of the GC1 isolates. 
 
Isolate a Year RAPD 
group 
ST Allelic profiles 
 gltA-gyrB-gdhB-recA-cpn60-gpi-rpoD 
Clonal complex 
3208 1997 1 109  (10-12-4-11-4-9-5) 109 
WM98 1998 1 109  (10-12-4-11-4-9-5) 109 
G7 2002 1 109  (10-12-4-11-4-9-5) 109 
A83 2002 1a 109  (10-12-4-11-4-9-5) 109 
A92 2005 1 109  (10-12-4-11-4-9-5) 109 
D2 2006 1 109  (10-12-4-11-4-9-5) 109 
D30 2008 1 109  (10-12-4-11-4-9-5) 109 
D36 2008 3 247  (10-12-4-11-4-58-5) 109 (SLV) 
D13 b  2009 2 109  (10-12-4-11-4-9-5) 109 
D108 b 2011 2 109  (10-12-4-11-4-9-5) 109 
D78 2010 1 347  (10-12-4-11-4-80-5) 109 (SLV) 
D81 2010 1 347  (10-12-4-11-4-80-5) 109 (SLV) 
RBH3  2002 1 126  (10-53-4-11-4-64-5) 109 (DLV) 
A85  2003 1 126  (10-53-4-11-4-64-5) 109 (DLV) 
6772166 2002 1 126  (10-53-4-11-4-64-5) 109 (DLV) 
A1 1982 1 109  (10-12-4-11-4-9-5) 109 
A297 1984 1a 109  (10-12-4-11-4-9-5) 109 
 
a colour coding shows the groups that do not belong to ST109.  
b SG6.  
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Both A1 from the UK and A297 from the Netherlands have previously been shown to belong 
to ST109 (78). Since the gpi gene was the most variable locus in this scheme it was re-sequenced 
for A297, the GC1 reference strain, and generated the same results as previously described (78). 
In addition, when whole genome sequence data became available at the end of this project, it 
was used to determine ST types using short read sequence typing (SRST) (96) and standalone blast 
(http://www.ncbi.nlm.nih.gov/books/NBK52640/) software. This revealed that in all cases the ST 
type determined using the standard method was an SLV of the SRST output using the genome 
sequence data. This was traced to a single base difference in the gpi allele caused by a single base 
difference between the GC1 sequence and primer gpi-F, and inclusion of the primer in the region 
analysed. The difference is revealed in genome sequences, making ST109, 247, 347 the same as 
231, 458 and 441 respectively. The ST type equivalent to ST126 could not be determined from 
genomes, as the gpi allele was not defined in the Oxford MLST database (Table 3.7).  
 
 
Table 3.7: Discrepancies between Oxford MLST typing and SRST. 
 
ST (gltA-gyrB-gdhB-recA-cpn60-gpi-rpoD) a 
Standard method in-silico from genomes 
109 (10-12-4-11-4-9-5) 231 (10-12-4-11-4-98-5) 
247 (10-12-4-11-4-58-5) 458 (10-12-4-11-4-142-5) 
347 (10-12-4-11-4-80-5) 441 (10-12-4-11-4-100-5) 
126 (10-53-4-11-4-64-5) *** (10-53-4-11-4-* a -5) 
 
a New allele. 
 
3.7 csuE region in SG6 strains 
SG6 strains generate the csuE band in the group 1 (GC2) PCR (Figure 3.1). In order to 
determine the extent of the csuE region presumably acquired from another A. baumannii strain, the 
draft genome of the SG6 strains was compared to that of 3208 as a standard GC1 strain. The contig 
containing csuE from 3208, contig_84 was 656,588 bp and was identical to the sequences in GC1 
genomes from AB307-294 (GenBank accession no. CP001172) and AYE (GenBank accession no. 
CU459141), which indicates that 3208 contains a standard sequence in the csuE region. 
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Comparison of the contigs containing the csuE region from D13, as representative of the Australian 
SG6 strains, to that of 3208 revealed that a 32,161 bp segment of 3208, containing the csuE gene, 
has been replaced with a 19,718 bp segment in D13 (Figure 3.5). Three gaps of 12,675, 1,186 and 
154 bp in the replaced segment account for the difference in the size of this segment (Figure 3.5). 
The 19,718 bp segment, indicated by the red lines in Figure 3.5, is flanked by sequences identical to 
the corresponding region in 3208 (black lines in Figure 3.5). The red segment in Figure 3.5 differs 
from the corresponding region in 3208 by 467 bp (2.3 %).  
 
 
 
Figure 3.5: Schematic representation of the contigs containing the csuE region in 3208 and the SG6 strain D13.  The 
red lines represent the regions that contain a different sequence compared to the corresponding region in 3208. The 
segments indicated 1-4, red portions, differ from the corresponding region in 3208 by 77, 228, 55 and 107 bp over the 
lengths of 5575, 6340, 2523 and 5280 bp respectively. The numbers above the top line indicate the base positions in 
contig 84 of isolate 3208. Gaps between the red lines represent the missing portions of the csuE region in D13 
compared to that in 3208.  
 
The contig containing the csuE gene was retrieved from the other Australian SG6 isolates, 
D14, D15, D18, D20, D45, D48 and D108, and all contained identical sequences. This reinforces 
that these strains belong to the same lineage as D13.  
 
 
 
3.8 Discussion 
Resistance to multiple antimicrobials in A. baumannii species has been associated with 
several global lineages, most notably global clone 1 and 2 (1, 2, 112, 182, 183). 10 GC1 and 60 
GC2 isolates were identified in this study among 131 Acinetobacter isolates screened (Table 3.8). 
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Though GC2 isolates seem to dominate in the population of MAR A. baumannii, GC1s still 
constitute a considerable portion (14.2%) of Australian MAR isolates. However, the data presented 
in this Chapter indicated that the isolates in the Australian GC1 collection are diverse.  It is notable 
that this data is biased by the larger number of the isolates screened from RNSH, in which GC1s 
appeared to be more common.  
 
Table 3.8: Acinetobacter isolates obtained from different Australian Hospitals. 
Hospital City  oxa-Ab+ GC1 GC2 Total 
Royal North Shore  Sydney 51 6 23 71 
Prince of Wales  Sydney 16 2 14 18 
St. George Sydney 3 0 1 6 
Royal Brisbane Brisbane 15 1 11 15 
Melbourne Alfred Melbourne 17 1 11 21 
Total - 102 10 60 131 
 
 
Royal North Shore Hospital is the main hospital in the Sydney area that admits spinal injury 
patients, and most GC1 isolates come from 7D, the spinal injury ward, or Ryde Rehabilitation 
Center (RRC), which is located ~10 km away and admits spinal injury patients from 7D. Therefore, 
a shared patient population, who are mainly immobilized and catheterized, directly connects these 
locations.  
Two outbreaks were identified among isolates coming from 7D ward at RNSH indicating that 
these patients maybe more susceptible to GC1s. The first outbreak included 7 isolates, recovered 
between 2006-2010 (Table 3.1 & 3.2), which belonged to ST109 and exhibited the same resistance 
profile, RAPD pattern and almost identical ISAba1 profiles. The second outbreak consisted of 8 
SG6 isolates (recovered between 2009-2011). These strains belonged to ST109 and exhibited the 
same RAPD pattern but the latest one, from 2011, exhibited a different resistance profile (Table 
3.4). However, they exhibited different ISAba1 profiles indicating that they contain different 
number of ISAba1 in their genomes. This finding also indicates that this method should not be used 
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as the sole way to identify related strains. SG6 strains belong to a lineage within the GC1 clonal 
complex that includes a csuE allele that does not match either to the GC1 or GC2 sequence (235). 
Analysis of the csuE region revealed that a 32,461 bp region in other GC1 strains is replaced by a 
19,718 bp from another A. baumannii strain, which differs from the original sequence by 2.3%. The 
csuE region was identical in all the SG6 strains providing very strong evidence that these isolates 
are closely related. This demonstrates the value of using a combination of different typing 
techniques to identify closely related isolates. This also indicates that no set of methods can 
unambiguously distinguish Australian GC1s.  
RAPD analysis could not differentiate the remainder of GC1 collection as most isolates 
generated similar patterns and, on the whole, RAPD was more useful to distinguish GC1s from non-
GC1 isolates. However, using other properties such as antibiotic resistance, ISAba1 profile and 
MLST type, it was found that that the remainder of GC1 collection consists of diverse isolates. 
MLST analysis revealed that only half of these isolates belonged to ST109/ST231. Three further ST 
were seen. Three isolates were ST126, two isolates were ST347 and a single isolate belonged to 
ST247. ST347 and ST247 are an SLV of ST109/ST231 and include different gpi alleles. ST126 is a 
DLV of ST109/ST231 and includes different gyrB and again a different gpi allele. Hamouda et al. 
(78), reported a similar finding. Amongst seven oxa69 containing isolates they tested, only four 
ST109/ST231 (published as ST33) were found. The remaining three isolates were SLV of 
ST109/ST231 that differed in the gpi allele (78). One isolate from Pakistan was ST247 (published 
as ST47) (78), the same as D36. The other two isolates contained two further gpi alleles not seen in 
the Australian collection, thus increasing the diversity of the gpi alleles observed in GC1 so far. The 
authors concluded that gpi and gyrB were the most variable alleles of the Oxford MLST scheme 
indicating recombination in the regions these genes are located (78). This conclusion is also 
consistent with the results of the present study. Further more, MLST type of the three completed 
GC1 genomes were determined, in silico, in this study and was found that AYE (GenBank 
accession no. CU459141) and AB307-0294 (GenBank accession no. CP0001172) belong to ST231 
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(ST109) and AB0057 (GenBank accession no. CP001182) belonged to ST207 differing from 
ST109, by three alleles, two of which were gpi and gyrB. 
Recently, it has been shown that the gpi gene is located in the capsule cluster (105) and this 
region is clearly being substituted repeatedly in MAR A. baumannii isolates belonging to members 
of global clones. The chromosomal location of gyrB is relatively close to gpi (Figure 1.6), making it 
possible that recombination events that involve exchange of the capsule cluster might affect the 
gyrB gene. It appears that this variation has led to the separation of members of the GC1 clone into 
different lineages.  
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4.1  Introduction  
Multiply antibiotic resistant GC1 strains often include a large genomic island, called an 
AbaR, which carries a number of antibiotic and heavy metal resistance genes found in a specific 
position in the chromosomal gene comM (Figure 1.6) (1, 2, 58, 183, 184). The AbaR island is not 
present in the genome of the antibiotic-susceptible A. baumannii GC1 isolate AB307-0294 (2). The 
first AbaR island, AbaR1, was found in the GC1 strain AYE (58). Following that, a GC1 strain, 
AB0057 (from the US), which contained a related island, AbaR3, with a Tn6019 backbone (Figure 
1.8) in the same position as AbaR1, was reported (2). Then in 2009, an Australian MAR isolate, 
3208, was found to include an island, AbaR5, with Tn6019 backbone in the same chromosomal 
position as in AbaR1 and 3 (183). AbaR5 was 7,326 bp smaller than AbaR3 lacking the blaTEM and 
catA1 resistance genes (183). In AbaR1, AbaR3 and AbaR5, the uspA gene in the backbone 
transposon, Tn6019, is interrupted by a compound transposon carrying the MARR, which is flanked 
by copies of Tn6018 (Figure 1.8).  However, AbaR1 contained an additional 29 kb segment, located 
between the sul1 gene and Tn6018-L, which was not present either in AbaR3 or AbaR5 (Figure 1.8) 
(2, 58, 183).  
In 2010, additional variants of AbaR islands were found in further Australian MAR GC1 
strains and named AbaR6 and AbaR7 (184). AbaR6 and AbaR7 had been created via two distinct 
deletions caused by the left hand IS26 in Tn6020, which had removed 36,245 bp and 43,430 bp, 
respectively, of the island left to the Tn6020 and extending into the transposon backbone (184). 
Two additional AbaR island variants, AbaR9 and AbaR10, were also described in GC1 strains from 
the US (1). AbaR9 had been created as the result of an IS26 deletion, the right hand IS26 of Tn6020 
removing 23,721 bp of the MARR (1). However, AbaR10 had lost a 31,859 bp segment in the 
middle of MARR via homologous recombination between two sul1 copies (1). Each of the several 
variants of the AbaR islands described so far has lost a fragment of different length from AbaR3. 
None of them contains the additional 29 kb observed in AbaR1 (1, 112, 183, 184). Hence AbaR3 
seems to be the ancestor as it is the longest island seen so far (1, 2, 112, 184). 
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The aim of the work presented in this chapter was to characterize resistance islands present in 
the comM gene of the Australian GC1 strains.  
4.2  The transposon backbone 
Tn6019, the backbone of AbaR3-type islands, and related transposons, Tn6021 (184, 218) and 
the backbone of AbaR4 (2, 184), which all carry orf1, tniA, tniB, orf1, orf3, uspA, sup and orf4 
were further examined.  
AbaR4 differs from Tn6021 only in that it lacks ISAba11 in orf1 (Figure 4.1), includes a short patch 
of only 90.8% identity (49 differences in 531 bp) in the orf1- tniA gene region (shown as a thicker 
line in Figure 4.1), and includes the transposon Tn2006 carrying oxa23 inserted just inside the 5'-
end of the sup gene (encoding a sulphate permease) (Figure 4.1). For simplicity, the AbaR4 
backbone was designated as Tn6022. Tn6022 differs from the corresponding region in Tn6019 
(orf1, tniA, tniB, orf2, orf3 and orf4) by 3.25% (282 differences in 8,426 bp). There was also a 
patch of 2053 bp in Tn6019, starting 380 bp before the 5'-end of the uspA gene and extending to 30 
bases before the start of sup, which differs from the corresponding region in AbaR4 by 23% (474 
differences in 2053 bp) (Figure 4.1).  
 Figure 4.1: Structures of Tn6019, Tn6021 and AbaR4. Inverted repeats are shown as vertical lines and thickened lines 
indicate patches of sequence divergence. Labelled arrows below show the genes and open reading frames and their 
extent. A minus 1 frame-shift error in the tniA gene of Tn6021 disrupts the reading frame. The vertical arrows above 
uspA, in Tn6019, and sup in AbaR4 show the location of MARR flanked by two copies of Tn6018 and Tn2006 in 
AbaR3 and AbaR4 respectively. ISAba11 is shown as an open box and the extent of Tn6022 is indicated below.  
AbaR4
orf1 tniA tniB orf2 orf3 orf uspA sup orf4
Tn2006
oxa23
Aba1 Aba1
Tn602
1 kb0
Aba11
Tn6021
orf1 tniA tniB orf2 orf3 orf uspA sup orf4
MARR
Tn6019
orf1 tniA tniB orf2 orf3 trkA trxB arsH arsB arsC R C uspA sup orf4
AbaR4
orf1 tniA tniB orf2 orf3 orf uspA sup orf4
Tn6022
1 kb0
Aba11
Tn6021
orf1 tniA tniB orf2 orf3 orf uspA sup orf4
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Tn6019
orf1 tniA tniB orf2 orf3 trkA trxB arsH arsB arsC R C uspA sup orf4
Tn2006
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The fact that Tn6019 and Tn6021 are located at precisely the same position in comM indicates 
that transposons belonging to the Tn6021/Tn6022/Tn6019 family can target this site (184, 212, 
241). Other transposons known to target specific sites are Tn7 (44), Tn402 and Tn5053 (106). It has 
previously been noted (184) that two of the predicted polypeptides are related to the TniA and TniB 
proteins of Tn5053 and Tn402, which are known to be required for transposition (106). 
Transposons of the Tn402/Tn5053 family resemble Tn7 in that they are bounded by 5'-TGT at the 
left end and ACA-3' at the right end as the terminal bases of inverted repeats (IR) of approximately 
25-28 bp, and they generate a duplication of 5 bp. The Acinetobacter transposons generate a 5 bp 
duplication (58) and have 26 bp imperfect IR at their termini with 5'-TGT or ACA-3' at their outer 
end (183). Further copies of the inner portion of the IR that are binding sites for the transposase 
TniA of Tn402/Tn5053 (104) or TnsB of Tn7 (8) are found within 150 bp of the transposon 
boundaries. A similar arrangement was found in Tn6022 (Figure 4.2).  
 
 
Figure 4.2: Structure of the ends of Tn6022. The sequence of (a) the left end and (b) the right end of AbaR4 (Tn6022) 
is shown. The bases derived from the comM gene are lower case with the bases duplicated by insertion of the 
transposon underlined. The inverted repeats are white on black and the potential transposase binding sites are marked 
with numbered arrows above indicating their extent and orientation. In (c) the sequences of the transposase binding sites 
are aligned and identical bases in 4 or more of the sequences are shown as white on black.  
(a) Left end 
  L1 
 
tgaaccgcTGTCA TTTACAGCAATAGAATAGAGTGGCATTATAGAT AATCAATAGGTTGT 
acttggcg ACAGTAAATGTCGTTATCTTATCTCACCGTAATATCT A TT  AGTTATCCAACA 
   IRl 
        L2                     L3 
CACTCTAATT TCACACAATTAAATTAGA TTATTTACATAAATAGATAAGAGTGACTTGCA 
GTGAGATTAAAGTGTGTTAATTTAATCTAATAAATGTATTTATCT ATTCTCACTGAACGT 
 
L4                                 
                                 
AAATTACATTAATAGGCACGAGTGCCTGAATGGTGACTTTTTTATGAAAAAATTGAGTGA 
TTTAATGTAATTATCCGTGCTCACGGACTTACCACTGAAAAAATACTTTTTTAACTCACT 
 
(b) Right end 
 
TTAACAGGCATATATTTTTACAAAATGAAAAATTAAGCATATAGATAATATACTTTTTAT 
AATTGTCCGTATATAAAAATGTTTTACTTTTTAATTCGTATATCTATTATATGAAAAATA 
                  
                       R2     R1 
 
TCTTGCTCTAGTTTATTTGTGTAAACTCTGATTTATTTGTGGAACTGACAaccgccccca 
AGAACGAGATCAAATAAACACATTTGAGACTAAATAAACACCTTGACTGTtggcgggggt       IRr 
 
(c) Alignment of transposon binding sites  
 
 TTTACAGCAATAGAATAGAGT    L1 
T TCACACAATTAAATTAGA TT    L2 
TTTACATAAATAGATAAGAGT    L3 
ATTACATTAATAGGCACGAGT    L4 
TTTACACAAATAAACTAGAGC    R2 
GTTCCACAAATAAATCAGAGT    R1 
 
 
 
 
 
 
(a) Left end 
  L1 
 
tgaaccgcTGTCA TTTACAGCAATAGAATAGAGTGGCATTATAGAT AATCAATAGGTTGT 
acttggcg ACAGTAAATGTCGTTATCTTATCTCACCGTAATATCT A TT  AGTTATCCAACA 
   IRl 
       L2                   L3 
CACTCTAATT TCACACAATTAAATTAGA TTATTTACATAAATAGATAAGAGTGACTTGCA 
GTGAGATTAAAGTGTGTTAATTTAATCTAATAAATGTATTTATCT ATTCTCACTGAACGT 
 
L4                                 
                                 
AAATTACATTAATAGGCACGAGTGCCTGAATGGTGACTTTTTTATGAAAAAATTGAGTGA 
TTTAATGTAATTATCCGTGCTCACGGACTTACCACTGAAAAAATACTTTTTTAACTCACT 
 
(b) Right end 
 
TTAACAGGCATATATTTTTACAAAATGAAAAATTAAGCATATAGATAATATACTTTTTAT 
AATTGTCCGTATATAAAAATGTTTTACTTTTTAATTCGTATATCTATTATATGAAAAATA 
                  
                       R2     R1 
 
TCTTGCTCTAGTTTATTTGTGTAAACTCTGATTTATTTGTGGAACTGACAaccgccccca 
AGAACGAGATCAAATAAACACATTTGAGACTAAATAAACACCTTGACTGTtggcgggggt       IRr 
 
(c) Alignment of transposon binding sites  
 
 TTTACAGCAATAGAATAGAGT    L1 
T TCACACAATTAAATTAGA TT    L2 
TTTACATAAATAGATAAGAGT    L3 
ATTACATTAATAGGCACGAGT    L4 
TTTACACAAATAAACTAGAGC    R2 
GTTCCACAAATAAATCAGAGT    R1 
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Bioinformatic analysis revealed that none of the proteins predicted from the four open reading 
frames, orfs1-4, that are present in Tn6021, Tn6022 and Tn6019, resemble the remaining protein, 
TniQ, that is required for Tn5053 movement (106). TnsA, TnsD, TnsE that are involved in Tn7 
transposition (44) could not also be aligned with the orfs1-4, present in Tn6021, Tn6022 and 
Tn6019.  
The non-redundant protein sequence database was searched, using the TniA and TniB 
sequence as query, in order to find potential transposons that carry genes that encode these proteins. 
For a selected set that carried both genes adjacent to one another (listed in Table 4.1), the presence 
of genes encoding proteins related to Orf1, Orf2 Orf3 and Orf4 was investigated. 
A series of potential transposons that all encode homologues of orf1, orf2 and orf3 with the 
genes in the same order (orf1-tniA-tniB-orf2-orf3) were found. Relatedness to the orfs of Tn6022 is 
shown in Table 4.1. These observations are consistent with a role for these 5 genes in transposition 
of the A. baumannii transposons and they were designated tniC (orf1), tniD (orf2) and tniE (orf3). A 
closer examination of the contigs for the two Acinetobacter genomes (listed in Table 4.1) revealed 
that in both cases the tni gene cluster was part of a transposon that is bounded by inverted repeats, 
had 5'-TGT...ACA-3' at their outer ends, were flanked by a duplication of 5 bp and interrupted the 
comM gene in precisely the same position as Tn6019 (and AbaR3 type islands) and Tn6021.  
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Table 4.1: Transposition modules related to that of Tn6019, Tn6021 and Tn6022 (AbaR4).  
 
Strain 
                          Identity (%)  
Genes for TniC-TniA-TniB-TniD-TniEa 
Accession number 
ORF1 
TniC 
 
TniA 
 
TniB 
ORF2 
TniD 
ORF3 
TniE 
AbaR4 100 100 100 100 100 tniC-tniA-tniB-tniD-tniE-sup-uspA-orf4 JN107991 
Tn402b - 33 35 - - tniA-tniB X72585 
Acinetobacter sp.  
ATCC 27244 
40 44 40 34 41 P0023_(1170- 1171-1172-1173-1175)c ABYN01000000 
Acinetobacter haemolyticus  
ATCC 19194 
38 43 40 29 43 HMP_0015_(0592- 0593- 0594 and 
0595- 0596)d 
ADMT01000000 
Ralstonia pickettii 12D 29 34 32 27 28 Rpic12D_(0201-0202-0203-0204-0205) NC_012856 
Mannheimia  
succiniciproducens  
MBEL55E     
33 41 50 30 28 MS(2017-2016-2015-2014-2013) NC_006300 
 
Acidithiobacillus 
ferrooxidans ATCC 23270 
34 41 48 30 38 AFE_(2506-2505-2504-2503-2502) NC_011761 
 
Pseudomonas syringae pv. 
aceris str.  DC3000 
35 38 45 26 27 PSPTO_(0059-0058-0057- 0054-0053) e NC_004578 
 
Actinobacillus 
pleuropneumoniae serovar 
7 str. AP76 
32 40 50 30 29 APP7_(0376-0375-0374-0373-0372) NC_010939 
 
Eikenella corrodens  
ATCC 23834 
30 64 51 26 31 EIKCOROL_(00356-00355-00354-
00353-00352) 
NZ_ACEA00000000 
 
 
a gene designations in the listed accession number for the putative transposition proteins are listed. 
b Tn402 and related transposons carry tniA-tniB with tniQ-tniR 
c P0023_1174 encodes a 69 aa protein. 
d genes are in two contigs, 144 and 145. 
e the region is interrupted by an IS containing PSPTO_0056 and PSPTO_0055 which encode 269 aa and 340 aa proteins respectively.  
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4.3  General structure of AbaR islands  
In the previous chapter, it was shown that all the MAR GC1 isolates contain an interrupted 
comM gene, which suggests the presence of an AbaR island inserted in this gene. This was confirmed 
by screening the strains for the junctions of the AbaRs with the comM gene, J1 (RH927-RH792) and 
J2 (RH916-RH928) PCRs (Figure 4.3). All the isolates tested generated the expected amplicon for J2 
junction and all but D30 included the J1 junction (Table 4.2). The internal junctions of the island, J3-
J6, were also examined using the PCR strategy developed previously (182) and shown in Figure 4.3. 
Primers for J1-J6 and PCR conditions can be found in Appendix II, Table II-8. 
Figure 4.3: PCRs used to identify the presence of an AbaR3-type island and to identify its internal junctions. The dashed 
lines represent the chromosome (the comM gene). 
 
 
The isolates were also screened for arsB, Tn6018, and whether uspA is interrupted by Tn6018 
(Figure 4.3). Tn6018 was found to be present in all the isolates except D36. D36 did not include arsB 
or J3-J6 junctions and it contained an intact uspA. Together, this suggests that D36 carries a different 
island with a related backbone that contains an uninterrupted uspA in the comM gene. This is 
described in Chapter 5.  
An intact uspA gene was present in A85 and D108 but they also contained J3 and J4 indicating 
the presence of an additional island that includes an intact uspA. The remaining isolates did not 
generate amplicon for uspA and they all included the J4 junction. However, 4 isolates, A83, D27, 
D30 and D62, did not include J3 (Table 4.2) or arsB, and this is the same as A92 and D2, which 
contained AbaR7 and AbaR6 respectively (184). Screening for the J5 and J6 junctions of MARR and 
MARR
IR6019IR6019
Tn6018-L Tn6018-R
J1 J2J3 J5 J6 J4
IR6019 IR6019
J1 J2
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1500 bp
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Tn6018arsB Tn6018
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Table 4.2: Distribution of the selected features of transposon backbone of the AbaR islands, Tn6019. 
 
Isolates Origin  Year uspA arsB Tn6018 J1 b J3 J5 J6 J4 J2 PCR1b PCR2b PCR3b PCR4b PCR5b PCR6b 
AB0057 USA 2004 + + + + + + + + + + + + + + + 
3208 a Sydney 1997 - + + + + + + + + + + + + + + 
A92 Sydney 2005 - - + + - - + + + - - - - + + 
D2  Sydney 2006 - - + + - - + + + + + - - + + 
A83 Sydney 2002 - - + + - - + + + - - - - + + 
D27 Sydney 2008 - - + + - - + + + + + - - + + 
D62 Sydney 2010 - - + + - - + + + + + - - + + 
D30 Sydney 2008 - - + - - - + + + - - - - + + 
D13c, D14, 
D15, D18, D20  
Sydney 2009 - + + + + + + + + + + + + + + 
D45, D48 c Sydney 2010 - + + + + + + + + + + + + + + 
D108 c Sydney 2010 + + + + + - - + + + + + + + + 
D78, D81 Sydney 2010 - + + + + + + + + + + + + + + 
WM98 Sydney 1998 - + + + + + + + + + + + + + + 
G7  Melbourne 2002 - + + + + + + + + + + + + + + 
RBH3  Brisbane 2002 - + + + + + + + + + + + + + + 
A85 Sydney 2003 + + + + + + + + + + + + + + + 
6772166 Adelaide 2002 - + + + + + + + + + + + + + + 
D36  Sydney 2008 + - - + - - - - + + - - - - - 
 
a Isolates highlighted yellow are the controls. 
b The spans amplified by junction PCRs and backbone PCRs are shown in Figure 4.3 and 4.5 respectively. 
c SG6.  
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Tn6018 revealed that the isolates that did not include J3 (A83, D27, D30 and D62) did not contain J5 
(Table 4.2). This was observed previously (184) in isolates D2 and D92 that contain AbaR6 and 
AbaR7 respectively (Table 4.2). 
D108 was the only isolate that did not include the J5 and J6 junctions, which suggested that 
MARR is missing in D108 even though Tn6018 (J3 and J4) is present. In order to examine whether 
MARR is missing and only 1 copy of Tn6018 is present in D108, a PCR spanning from the left hand 
side to the right hand side of Tn6018 was used (Figure 4.4). This PCR generated the predicted 
amplicon of 6,130 bp. NaeI restriction digest of this amplicon also yielded fragments of 3,921, 1,694 
and 515 bp indicating that the entire MARR has been removed. This could occur via homologous 
recombination between two copies of Tn6018. This configuration has been reported previously in the 
strain NIPH470 (GenBank accession no. JF262167) and designated AbaR11 (112). However, this 
name seems inappropriate, as this transposon is no longer an antibiotic resistance island since the 
entire MARR has been deleted. 
Figure 4.4: PCR used for characterizing the transposon in the comM gene in D108. Primer sets are listed in Appendix II, 
Table II-6. 
 
4.3.1 Tn6019 backbone 
In addition to the junction PCRs, a previously described PCR mapping strategy (182) utilizing 
6 large PCRs (Figure 4.5) was used to map the backbone of the AbaR islands. The products of the 
PCR1-b, 2-b, 3-b, 4-b, and 5-b were also digested with an appropriate restriction enzyme (Table 4.2) 
and generation of predicted fragments was used to confirm their identity (Table 4.3). 
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Table 4.3: Predicted fragment sizes for restriction digest of the backbone PCRs. 
 
PCR  Primer a  Amplicon 
size 
Restriction fragments sizes (bp) 
DdeI HindIII  NheI  
1-b  RH791 
RH909 
3120 1599, 654, 603,  
264 
- - 
2-b  RH910 
RH911 
3607 - 2897, 709 - 
3-b  RH912 
RH800 
3919 - 1535, 1264, 
1120 
- 
4-b  RH799 
RH767 
4350 1300, 767, 753, 574, 
365, 337, 240, 14, 
- - 
5-b 
  
RH772 
RH913 
3949 - 
 
- 2782, 694, 
473 
6-b RH768 
RH771 
3128 - - - 
 
a Primer sequences and PCR cycling conditions can be found in Appendix II, Table II-7. 
 
PCR1-b and 5-b link the left and right hand sides of the Tn6019 to the chromosome. For D36 
only PCR1-b generated an amplicon of the predicted size consistent with the results generated by 
junction PCRs suggesting the presence of a related island in the comM gene. The remaining isolates 
included PCR5-b. However, amongst these isolates A83 and D30 were the only isolates that did not 
include PCR1-b. 
 
Figure 4.5: PCR strategy used for investigating the presence of an AbaR island and characterizing the general structure 
of the AbaR islands. The letter “b” in front of the PCRs stands for backbone. 
 
PCR6-b, which links the right copy of Tn6018 to Tn6019 (Figure 4.5), generated an amplicon 
of 3.1 kb using the primers RH768 and RH771 for all the isolates tested (Table 4.2).  
PCRs 2-b, 3-b and 4-b map the segment that includes the transposase genes and the arsenic 
operon and link them to Tn6018-L (Figure 4.5). PCR2-b, 3-b and 4-b did not produce amplicon for 
A83. These results are the same as the results previously seen, and generated here for A92 which 
includes AbaR7. Two isolates, D27 and D62, did not produce the PCR3-b and PCR4-b amplicons 
2 kb
Tn6019
comM
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while they included PCR2-b. These results were also the same as that in D2, which contains AbaR6 
(Table 4.2). In D30, the absence of PCR1-b, 2-b, 3-b and 4-b together with J1 (Table 4.2) suggested 
the presence of a deletion, which has extended further into the chromosome. The remaining isolates 
included an intact Tn6019 backbone, as they gave amplicons of the predicted size with PCR1-b - 6-b.  
 
4.4  MARR features  
In order to infer which segments of the MARR are present, the isolates were further screened 
for the antibiotic resistance genes, transposons and ISs that are usually found in the AbaR3-type 
islands (2, 58, 183). These included IS6100, mer, tetA(A), catA1, blaTEM, aphA1b, sul1, aadA1 as 
well as the class 1 integron and its associated gene cassette array. The complete list of primers used 
for screening for MARR features can be found in Appendix II, Table II-1, II-2. As expected D36 and 
D108 did not include any of the MARR features consistent with the results of the backbone and 
junction screenings. 
4.4.1 Class 1 integron and associated cassette array 
The class 1 integron is found in the AbaR3 genomic island and carries the aacC1-orfP-orfQ-
aadA1 cassette array (2), while AbaR1 and AbaR5 carry an additional orfP in the cassette array (58, 
183). All isolates were found to carry intI1 (using the primers HS463a and HS464; Appendix II, 
Table II-2) indicating the presence of a class 1 integron. Associated cassette arrays were also 
determined by the L1-R1 PCR that amplifies the cassettes present (Figure 4.6). The L1-R1 PCR, 
yields a 3 kb amplicon when the aacC1-orfP-orfP-orfQ-aadA1 cassette array is present and 2.5 kb 
product when only one orfP is present (182). This was confirmed by RsaI digestion of the product 
generating fragments of 584, 498, 483, 320, 257, 223, 218, 218, 138, 63, 63, 8 and 7 bp for the PPQ 
cassette array and 584, 498, 483, 320, 223, 218, 138, 63, 8 and 7 bp when one orfP is missing. 
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Figure 4.6: Schematic representation of L1R1 PCR amplifying the cassette array in the class 1 integron. 
 
 
 
Amongst the isolates examined, only WM98 and D27 included aacC1-orfP-orfP-orfQ-aadA1 
and the remaining isolates contained the aacC1-orfP-orfQ-aadA1 cassette array (Table 4.4). In 
Chapter 3, it was shown that D27 and D62 generated almost the same ISAba1 profile indicating they 
are closely related. However, D62, which is the latest isolate in this group, has lost an orfP while the 
others in this group, including D27, contain two orfP in the cassette array.  
 
4.4.2 Other MARR features 
D78 and D81 were the only isolates that did not contain aphA1 and they also lacked blaTEM 
(Table 4.4). Four isolates, D27, D30, D62 and A83 did not include IS6100, mer, tetA(A), catA1 and 
blaTEM (Table 4.4) suggesting the presence of a deletion on the left hand side of the MARR, which 
was consistent with the results of the backbone screening (Table 4.2). In the cases of D62 and D27, it 
was suggested that they might contain AbaR6 as they generated the same result as the control strain 
D2, and also generated similar ISAba1 profiles (Chapter 3; section 3.6.2). The absence of tetA(A), 
catA1 and blaTEM  in SG6 isolates also suggested a  deletion of the segment where these genes are 
located. The remaining isolates WM98, G7, A85, RBH3 and 6772166 included all the MARR 
features suggesting that they might carry an AbaR3.  
intI1 sul1 orf5QaacC1 aadA1P
5'-CS 3'-CScassettes
2.5 kbL1> <R1
(a)
intI1 sul1 orf5QaacC1 P aadA1P
5'-CS 3'-CScassettes
L1> <R13 kb
(b)
1 kb
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Table 4.4: Distribution of the MARR features in the isolates containing Tn6018. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a isolates highlighted yellow are the controls. 
b SG6. 
c D78, D81 and G7 contained aphA6 amikacin resistance gene accounting for the amikacin resistance phenotype observed. 
 
 
Isolates a arsB IS6100 mer tetA(A) catA1 blaTEM Tn6020 aphA1b intI1 sul Gene cassette array 
3208 + + + + - - + + + 1 aacC1-orfP-orfQ aadA1 
A92 - - - - - - + + + 1 aacC1-orfP-orfQ aadA1 
D2 - - - - - - + + + 1 aacC1-orfP-orfP-orfQ aadA1 
A83 - - - - - - + + + 1 aacC1-orfP-orfQ aadA1 
D27 - - - - - - + + + 1 aacC1-orfP-orfP-orfQ aadA1 
D62 - - - - - - + + + 1 aacC1-orfP-orfQ aadA1 
D30 - - - - - - + + + 1 aacC1-orfP-orfQ aadA1 
D13 b, D14, 
D15, D18, 
D20 
+ + + - - - + + + 1 aacC1-orfP-orfQ aadA1 
D45, D48 b + + + - - - + + + 1 aacC1-orfP-orfQ aadA1 
D108 b - - - - - - - - - - - 
D78, D81 c + + + + + - - - + 1 aacC1-orfP-orfQ aadA1 
WM98 + + + + + + + + + 1 aacC1-orfP-orfP-orfQ aadA1 
G7 c + + + + + + + + + 1 aacC1-orfP-orfQ aadA1 
RBH3  + + + + + + + + + 1 aacC1-orfP-orfQ aadA1 
A85 + + + + + + + + + 1 aacC1-orfP-orfQ aadA1 
6772166 + + + + + + + + + 1 aacC1-orfP-orfQ aadA1 
D36 - - - - - - - - - 2 - 
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4.4.3 Tn6020 and linkage to the class 1 integron 
It has been shown that Tn6020 and the class 1 integron are characteristic features of the AbaR 
islands (182). In order to identify if the aphA1b gene is present in Tn6020, as it usually is in the 
AbaR islands, two linkage PCRs (Figure 4.7) were used as previously described (184). These PCRs 
generated amplicons of the predicted sizes for all the strains that contained the aphA1b gene 
indicating that this gene is in Tn6020. 
Figure 4.7: Structure of Tn6020 and the PCRs used to identify this transposon. Open green boxes represent the 
insertion sequence IS26 and the arrows below indicate the direction of their transposase gene. The thin lines below 
represent the PCRs used to identify Tn6020. The primer names and the product sizes are also indicated. 
 
In all the isolates containing Tn6020 and a class 1 integron two linkage PCRs were used to 
link the aphA1b gene to intI1 and then to aacC1 in the class 1 integron (Figure 4.8).  Using these 
PCRs it was possible to link aphA1b to intI1 and aacC1 indicating that Tn6020 is next to the class 1 
integron, in the isolates carrying aphA1b, as previously identified in AbaR1, 3 and 5 (2, 58, 183).  
 
Figure 4.8: Linking Tn6020 to the intI1 gene and to the class 1 integron. PCRs were performed using a forward primer 
in aphA1b and the reverse primers in intI1 and aacC1.  
 
4.5 A deletion in the 5'-CS; a new epidemiological marker 
In the course of screening for linking Tn6020 to the class 1 integron, it was noticed that some 
isolates e.g. D13 and A85 (Figure 4.10) as well as one of the controls, AB0057, produced slightly 
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smaller PCR products than did the other control isolate, 3208. This was further investigated by 
comparing the sequence of this region from 3208 (GenBank accession no. FJ172370) to the 
corresponding region in AbaR1 (in AYE; GenBank accession no CU459141) and AbaR3 (in 
AB0057; GenBank accession no. CP001182). It was found that the sequences of AbaR5 (3208) and 
AbaR1 (AYE) were identical while 108 bp of the 5'-CS in AbaR3 was missing. The deleted 
sequence includes 52 bp of the 3'-end of the intI1 gene together with 56 bp directly adjacent to the 
end of intI1 (Figure 4.9). This deletion appears to have arisen via an event involving a very short, 8 
bp duplication.  
(a)                                                                                                                     5'-CS> 
                                                                                                                <Tn21  IRi 
3208      GCAACCACGCAAGGCAGTCGGGTGTTTCCACACCCTCGGCTACCACCTCCATTGTCGTTT 
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
AB0057    GCAACCACGCAAGGCAGTCGGGTGTTTCCACACCCTCGGCTACCACCTCCATTGTCGTTT  
 
3208      TCAGAAGACGGCTGCACTGAACGTCAGAAGCCGACTGCACTATAGCAGCGGAGGGGTTGG 
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
AB0057    TCAGAAGACGGCTGCACTGAACGTCAGAAGCCGACTGCACTATAGCAGCGGAGGGGTTGG  
 
3208      ATCCATCAGGCAACGACGGGCTGCTGCCGGCCATCAGCGGACGCAGGGAGGACTTTCCGC 
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
AB0057    ATCCATCAGGCAACGACGGGCTGCTGCCGGCCATCAGCGGACGCAGGGAGGACTTTCCGC  
 
3208      AACCGGCCGTTCGATGCGGCACCGATGGCCTTCGCGCAGGGGTAGTGAATCCGCCAGGAT 
          |||||||||||||||||||||||| 
AB0057    AACCGGCCGTTCGATGCGGCACCG------------------------------------  
 
                         * 
3208      TGACTTGCGCTGCCCTACCTCTCACTAGTGAGGGGCGGCAGCGCATCAAGCGGTGAGCGC  
AB0057    ------------------------------------------------------------ 
                                                                             
 
3208      ACTCCGGCACCGCCAACTTTCAGCACATGCGTGTAAATCATCGTCGTAGAGACGTCGGAA 
                      ||||||||||||||||||||||||||||||||||||||||||||||||        
AB0057    ------------CCAACTTTCAGCACATGCGTGTAAATCATCGTCGTAGAGACGTCGGAA  
                                                                 <intI1 
3208      TGGCCGAGCAGATCCTGCACGGTTCGAATGTCGTAACCGCTGCGGAGCAAGGCCGTCGCG 
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||        
AB0057    TGGCCGAGCAGATCCTGCACGGTTCGAATGTCGTAACCGCTGCGGAGCAAGGCCGTCGCG  
 
(b)                                                                                                                     
3208      ACTTTCCGCAACCGGCCGTTCGATGCGGCACCGATGGCCTTCGCGCAGGGGTAGTGAATC 
          |||||||||||||||||||||||||||||||||      |||       |   || |||| 
AB0057    ACTTTCCGCAACCGGCCGTTCGATGCGGCACCGCCAACTTTCAGCACATGCGTGTAAATC 
          |        | | |   |  |  | ||||||||||||||||||||||||||||||||||| 
3208      AGCGCATCAAGCGGTGAGCGCACTCCGGCACCGCCAACTTTCAGCACATGCGTGTAAATC 
 
Figure 4.9: Sequence alignment of the 5'-end of the class 1 integron in (in strain 3208) AbaR5 and AbaR3 (in strain 
AB0057). In (a) IRi of the class 1 integron is shown white on black and the stop codon of the intI1 gene is indicated 
yellow on black. (b) indicates how the deletion arose via the recombination between a repeated 8 bp sequence. 
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Therefore a PCR, followed by BamHI digestion of the product, amplifying 146 bp of IS26, 
the segment derived from Tn21 and 630 bp of the 5'-CS was developed to screen the collection in 
order to determine if the same deletion is present in the 5'-CS of the isolates. This PCR generates a 
1,222 bp product when this region is intact and an 1,114 bp product when the 108 bp deletion is 
present. 
Old strains, including A297, 3208 and WM98, contained an intact 5'-CS. A92 and A83, also 
contained an intact 5'-CS. D27, D62 together with the previous strains that included AbaR6 all 
generated a 1,222 bp product, and predicted BamHI fragments of 659 and 563 bp, indicating that 5'-
CS does not include the 108 bp deletion in these strains (Table 4.5). 
Figure 4.10: PCR and BamHI restriction digest used to identify the 5’-CS deletion. (a) shows the PCR and the 
positions of the primers used and the red arrow indicated the position of 108 bp deletion in AB0057 (b) shows the PCR 
products generated and their BamHI digests.  
 
 
The remaining isolates, including the SG6 strains and the other isolates from Sydney, 
Brisbane and Adelaide, all produced 1,114 bp product followed by the BamHI digestion fragments 
of 455 bp for A85 indicating the presence of the 108 bp deletion in 5'-CS (Table 4.5). It should be 
noted that, though D78 and D81 did not contain aphA1b and Tn6020, it was possible to link the 
IS26 to the class 1 integron. The PCR and subsequent BamHI digest showed the presence of the 
deletion in the 5'-CS. The presence of this deletion in the intI1 gene is an interesting feature of 
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MARR and can be potentially used as an epidemiological marker to trace the integron containing 
strains. Interestingly, the isolates, which generated the same screening results for Tn6019 and 
MARR features had the same result for the presence of the intI1 deletion.  
 
Table 4.5: Distribution of 108 bp deletion in 5'-CS of class 1 integron. 
 
Isolate intI1 ! intI1 a Cassette array 
A297 + - dfrA5 
3208 + - aacC1-orfP-orfP-orfQ-aadA1 
WM98 + - aacC1-orfP-orfP-orfQ-aadA1 
A92 + - aacC1-orfP -orfQ-aadA1 
A83 + - aacC1-orfP -orfQ-aadA1 
D2, D3, D6, D7 + - aacC1-orfP-orfP-orfQ-aadA1 
D27 + - aacC1-orfP-orfP-orfQ-aadA1 
D62 + - aacC1-orfP -orfQ-aadA1 
D30 + - aacC1-orfP -orfQ-aadA1 
D13, D14, D15, D18, D20 b + + aacC1-orfP -orfQ-aadA1 
D45, D48 b  + + aacC1-orfP -orfQ-aadA1 
D78, D81 + + aacC1-orfP -orfQ-aadA1 
G7 + + aacC1-orfP -orfQ-aadA1 
RBH3  + + aacC1-orfP -orfQ-aadA1 
A85 + + aacC1-orfP -orfQ-aadA1 
6772166 + + aacC1-orfP -orfQ-aadA1 
 
a  “+” indicates the presence of the 108 bp deletion. 
b SG6. 
 
4.6 A83 carries AbaR7 
A83 included the same features as AbaR7 in A92 (Table 4.2 and 4.4). This suggested that 
these two isolates carry the same AbaR variant. In order to examine this the PCR that had been 
developed to identify the novel junction in AbaR7 was used (184). This PCR uses the left-hand 
primer in comM (RH791) with the RH880 (aphA1-F) primer in the aphA1b gene of Tn6020 (Figure 
4.11). A 3.36 kb amplicon was obtained for A83 and A92 and a DdeI restriction digest generated 
the predicted bands of 1243, 854, 654, 440 and 175 bp. This indicated that the same IS26 mediated 
deletion as in AbaR7 that removed 43,245 bp of the AbaR3 island is in A83. 
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Figure 4.11: Schematic representation of the AbaR7 PCR linkage. This PCR links Tn6020 to the left hand segment of 
the interrupted comM gene.  
 
 
In order to examine if the segment on the right hand side of Tn6020 in A83 is the same as 
A92, PCR mapping was used as previously described (182). This included a set of overlapping 
PCRs that link the gene cassettes to the segment marked Y in Figure 4.12 and then to the Tn6018-R 
(RH522-RH783, RH763-RH764 and RH766-RH767; Figure 4.12). All of these PCRs generated an 
amplicon of the predicted size indicating that A83 includes AbaR7 in the comM gene.  
 
 
Figure 4.12: PCR strategy used to map the AbaR7 island. Resistance genes are in red. The extent of the mapping PCRs, 
their sizes and primers used are indicted.   
 
 
4.7 Isolates carrying AbaR6 
D27 and D62 generated the same screening results for Tn6019 and MARR features as D2 
(GenBank accession no. GQ406245), which contains AbaR6. Therefore, D62 and D27 were 
examined with the PCR that distinguishes the AbaR6 island linking aphA1b to the backbone 
transposon (182). This linkage PCR generates a 4,018 bp product if AbaR6 is present (Figure 4.13). 
The predicted amplicon was obtained for both D27 and D62 and HindIII restriction digest also 
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generated the predicted fragments of 2,363, 1,120 and 535 bp the same as for the control strain D2.  
Following that, the regions on the right hand side of Tn6020 in D27 and D62 were shown to be the 
same as that in AbaR6 and AbaR7 using the set of overlapping PCRs shown in Figure 4.12. Hence 
D27 and D62 isolated in 2008 and 2010, respectively, include AbaR6 in the comM gene the same as 
strains from 2006. This was also consistent with the results of the ISAba1 profiles as D27 exhibited 
almost identical pattern compared to the isolates from 2006, and D62 exhibited the same profile 
with two additional ISAba1 copies. Another feature that distinguished D62 from the others is the 
presence of one orfP in the cassette array of the class 1 integron. 
 
Figure 4.13: Linkage PCR that detect the AbaR6 island spanning the aphA1b to trkA located on the backbone. The 
thick horizontal line represents Tn6019 and the dashed line on the left indicates the comM gene. The extent of the 
linkage PCR, its size and the primers used are indicated below.  
 
 
 
4.7.1 AbaR26 island in D30 
The J1, J3, J5 junctions together with the Tn6019 backbone regions detected by PCRs 1-b, 2-
b, 3-b and 4-b were all absent in D30 while all the right hand junctions, J2, J4 and J6, were present. 
In addition, as in AbaR6 and AbaR7, only Tn6020 and the class 1 integron were present. This 
suggested that the left hand IS26 of Tn6020 has removed the entire left hand side of MARR and 
Tn6019 and the deletion has extended to the chromosome.    
In order to assemble the island and determine the extent of the deleted segment, the draft 
genome of D30 was searched to find the contigs that end with sequence derived from IS26. Only 
three contigs, which contained 50-60 bp of IS26 sequence at their end (contigs 14, 55 and 16) were 
found. One of them contig_55, contained aphA1b and 60 bp of IS26 sequence at both ends. 
Contig_16 contained the sequence belonging to the segment right to the Tn6020 extending into and 
Tn6020
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beyond the comM gene (Table 4.6). Comparison of contig_14 to the AB0057 genome revealed that 
the sequence directly adjacent to the IS26, in contig 14, is located ~ 5 kb away from where the 
comM gene is usually located in the chromosome.  
 
Table 4.6: Contigs ending with IS26 sequence. 
 
Contig 
number 
Length 
(bp) 
Content 
14 26,923 Chromosome (orf-ppa-oprE3) - IS26 
55 2,193 IS26 - aphA1b - IS26 
16 72,640 IS26 - integron - Tn6018 - Chromosome (comM) 
 
 
 
A new primer, RH1390 5'-TCCTTTTGCCTCACTTTGCT-3', was made in order to join 
contig_14 to contig_55 that contains the Tn6020 sequence. Using RH1390 with RH880, which is in 
aphA1b, an amplicon with the predicted size of 2,428 bp was generated. This PCR product was also 
sequenced to confirm its identity. This indicates that the left IS26 of in Tn6020 has removed 49,942 
bp including the left hand side of MARR, the adjacent backbone transposon and 5,505 bp of the 
chromosome. Hence this is a new AbaR variant found in D30 and it was named AbaR26. The 
sequence of the oprE3 gene, AbaR26 and comM!-R was deposited in the GenBank database under 
accession number KC665626.  
Figure 4.14: PCRs used to map AbaR26. The top central lines represent the contigs containing the sequence of IS26 
and the green boxes at the end of horizontal lines indicate 50-60 bp of the IS26 sequence. The PCRs used to join the 
contigs are shown on the top and the rest of overlapping PCRs are on the bottom. Primers are listed in Appendix II 
Table II-5. 
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4.7.2 AbaR8 in SG6 isolates 
Five SG6 strains identified previously, D13, D14, D15, D18 and D20 (182), together with the three 
identified here, D45, D48 and D108, were shown to include a complete Tn6019 backbone 
transposon but they did not include tetA(A), catA1 and blaTEM (Table 4.2 and 4.4). This suggested 
that a deletion had occurred and removed the central portion of the MARR that usually contains 
these elements. The extent of the deletion was examined using PCR to link aphA1b in Tn6020 to 
the mer module (Figure 4.15). This PCR generated an amplicon of ~ 2.5 kb (2,493 bp) for all seven 
isolates. Restriction digestion of the PCR product yielded DdeI fragments of 1,031, 854, 433 and 
175 bp in all isolates indicating that Tn6020 is directly adjacent to the mer module (Figure 4.15).   
The sequence of the mer-Tn6020 amplicon from D13 revealed that the deletion has extended from 
adjacent to the IS26 on the left side of Tn6020 to within the mer module derived from Tn1696 
removing 17,852 bp of the MARR of AbaR3 including the tetA(A), catA1 and blaTEM resistance 
genes. The deletion has extended 850 bp into the mer module. 
 
Figure 4.15: Schematic representation of the Tn6020 to mer PCR identifying the AbaR8 island.  
 
 
The region on the right hand side of Tn6020 was also mapped using the mapping strategy 
shown in Figure 4.12, and shown to be the same as all the other AbaRs. The mer module was linked 
to IS6100 using four PCRs, shown in Figure 4.16 generating 1,163, 1,590, 1,841 and 1,436 bp 
amplicon. IS6100 was linked to sul1 using sul1-F and IS6100-Rv2 and generated the predicted 
amplicon of 2,719 bp (Figure 4.16). The mer module was also directly linked to the sul1 gene using 
sul1-F and RH521 primers and generated predicted amplicon of 3,799 bp (Figure 4.16).  
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Figure 4.16: PCR mapping used to link the mer module to IS6100, 3'-CS, segment X and Tn6018-L.  
 
The remaining PCRs shown in Figure 4.16 generated predicted amplicons and linking 3'-CS to the 
segment X and Tn6018-L respectively. This new AbaR island variant was named AbaR8 (Figure 
4.17). 6,579 bp of AbaR8 (total length of 45.7 kb, which was fully mapped by PCR) was sequenced 
and deposited in the GenBank under accession number HM590877. This sequence includes the 
novel mer-Tn6020 junction from the strain D13. 
Figure 4.17: Structure of the AbaR8 island. Dashed lines on either side represent the chromosome (comM). Antibiotic 
resistance genes are indicated red and the two copies of Tn6018 are colored purple. The red vertical arrow on the right 
end of the mer module indicates the presence of IS26 mediated deletion and therefore a new boundary in the island.  
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4.7.3 D78 and D81 contain AbaR23 
D78 and D81 included an intact backbone and all the MARR features except blaTEM and 
aphA1b. This suggested that a deletion has occurred in the middle of the MARR where blaTEM and 
aphA1b are located.  In order to examine this a PCR using the catA1 reverse primer and intI1-RV 
(Figure 4.18) was used and yielded an amplicon of ~2.7 kb.  
Figure 4.18: PCR that links catA1 to the class 1 integron. Primer sequences are listed in Appendix II, Table II-6. 
 
This amplicon, from D81, was sequenced and the sequence revealed that the IS26 on the right 
hand side of Tn6020, in AbaR3, has caused a deletion removing 12,174 bp including the aphA1b 
gene, Tn1000-like and Tn1 such that only 15 bp of the IR of IS1 remained (Figure 4.20). DdeI 
digestion of the catA1-intI1 PCR product from D78 and D81 produced fragments of 1,194, 930, 448 
and 195 bp for both isolates, confirming their identity. The catA1-intI1 amplicon from D81 was 
sequenced and deposited in GenBank under accession number JN409449. Following that the catA1 
gene was linked to Tn1721 and mer module using the PCRs shown in Figure 4.19. The mer module 
was also linked to IS6100 and Tn6018-L using the PCRs described for the corresponding region in 
AbaR8 and generated the same results. 
Figure 4.19: Overlapping PCRs that links catA1 to Tn1721 and to the mer module. Primer sets are listed in Appendix 
II, Table II-5. 
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Furthermore, the regions right and left of the IS26 were mapped using the strategy that was 
described for AbaR6 and 7 and shown to be intact. This AbaR variant was named AbaR23 (Figure 
4.20).  
 
Figure 4.20: Structure of the AbaR23 island and the linkage PCR used to identify flanking regions of IS26. The vertical 
arrow coloured blue indicates the presence of the 108 bp deletion in the intI1 gene. The vertical arrow coloured red 
indicates the 15 bp from IRi of the IS1, which has remained after the IS26-mediated deletion creating AbaR23. Primer 
sets are listed in Appendix II, Table II-6. 
 
4.8  Isolates containing AbaR3 
Five isolates from different Australian hospitals, A85, RBH3, G7, WM98 and 6772166 
included an intact Tn6019 backbone and all the MARR features (Table 4.2 and 4.4). These five 
isolates were further mapped to examine whether they carry an AbaR3 and in all experiments 
AB0057 was used as control for AbaR3. It was shown, section 4.4.1, that Tn6020 is located next to 
the class 1 integron in isolates carrying aphA1. Following that, the same overlapping PCRs used to 
characterize the segment to the right of Tn6020 of AbaR6 and 7 was used and PCRs generated 
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amplicons of the predicted sizes for all five isolates, indicating that this segment of the island has 
the same structure as AbaR3 (Figure 4.21).  
A PCR amplifying a 1.7 kb internal fragment of Tn1000-like was used to test the presence of 
this element and generated the predicted amplicon of 1,773 bp for all of them. Using a PCR, which 
generated a 3.2 kb product, Tn6020 was linked to Tn1000-like on the left (Figure 4.21) indicating 
that these two are next to each another as in AbaR3. 
Figure 4.21: PCR strategy used to link Tn6020 to the class 1 integron and Tn1000like. The vertical lines at the end of 
the thick central line indicate the inverted repeats. PCRs and the primers used are shown below. The amplicon sizes are 
indicated. 
 
 
AbaR3 in the strain AB0057 contains a copy of Tn1, which is missing 129 bp at the blaTEM 
end. It is flanked by IS1! on the left and an IS26 on the right (2).  The five isolates that contained 
blaTEM were examined to determine if blaTEM is in the Tn1 structure using a PCR strategy developed 
previously (9). This includes 5 overlapping PCRs, which amplify the complete extent of Tn1-3 
(Figure 4.22). Primer sequences can be found in Appendix II, Table II-9. Amplicons of the 
predicted sizes were generated for all five isolates indicating the presence of a Tn1.  
Figure 4.22: PCR strategy used to map Tn1. The vertical lines at the end of the thick central line indicate the inverted 
repeats. PCRs, the primers and the amplicon sizes are indicated. 
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Following that, the isolates were further mapped to link Tn1 to Tn1000-like on the right and 
Tn2670 and Tn1721 on the left. IS26 was shown to be present directly on the left hand side of 
Tn1000-like using the IS26F-RH759 PCR (Figure 4.23). Tn1000-like was also linked to Tn1 using 
the RH605 and RH759, which produced the predicted amplicon of 2,651 bp indicating (Figure 4.23) 
that IS26 is flanked by Tn1000-like on the right and Tn1 on the left, as in AbaR3 in all five isolates. 
The PCR using the RH405 and RH410 also amplified the 3,592 bp internal fragment of Tn1 (Figure 
4.23), which was then linked to catA1 in Tn2670 using the catA1 reverse primer, RH513, and 
RH356 in Tn1 and generated the predicted product of 2,586 bp (Figure 4.23) indicating that IS1! 
separates catA1 and Tn1. 
Figure 4.23: PCR mapping strategy used to map the central portion of the AbaR island in A85. These PCRs indicate 
that Tn1721, Tn2670, Tn1 and Tn1000-like are in the same order as in AbaR3 (in AB0057).  
 
 
The PCR using primers in catA1, RH514, and pecM, RH761 in Tn1721, generated a 3,865 bp 
product the same as the AB0057 control (Figure 4.23). A 3,371 bp of central fragment of Tn1721 
was also amplified using RH1001 and RH762 (Figure 4.23). Primers in Tn1696 and Tn1721, 
RH383 and tetA-R generated the predicted product of 2,536 bp indicating that Tn1696 and Tn1721 
are next to each other (PCR11; Figure 4.24). Tn1721 was also linked to the mer module, IS6100, 
segment X and to Tn6018 using the same PCRs used for mapping of AbaR23 and AbaR8 and 
generated predicted amplicons for all five isolates. Hence, the isolates, A85, RBH3, G7, and 
6772166, contain AbaR3.  
However, the AbaR island found in the isolate WM98 does not contain the 5'-CS deletion. 
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orfP-orfQ-aadA1 while there is only one orf P in AbaR3. Therefore, the AbaR variant found in 
WM98 was named AbaR0 as it appears to be the ancestor of AbaR3, which is currently thought to 
be the precursor. 
The complete mapping strategy used for mapping of AbaR3 in Australian isolates is shown in 
Figure 4.24 and primer sequences together with the PCR cycling conditions of the AbaR3 mapping 
PCRs, 1-25, can be found in Appendix II; Table II-5. 
Figure 4.24: PCR mapping strategy used to map the entire AbaR3 island in A85. The PCRs 1-b to 5-b are the backbone 
transposon PCRs. Primer sequences are listed in Appendix II Table II-5.   
 
4.9 AbaR24 in A1 from UK 
Strain A1, isolated in 1982, is one of the oldest GC1 isolates in available collections in the 
UK. This strain has been shown to belong to ST109 (10-12-4-11-4-9-5), Oxford MLST Scheme 
(78). The comM and uspA genes were interrupted, and screening for the AbaR backbone and 
MARR revealed that it contains a complete Tn6019 backbone, the J1-J6 junctions, and all the 
MARR features, but blaTEM, aphA1b and Tn1000-like suggesting the absence of the central segment 
of MARR. It included a class 1 integron with the gene cassette aacC1-orfP-orfP-orfQ-aadA1 and an 
intact 5'-CS. 
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Since the screening results were similar to that of D78 and D81 it was suggests that a similar 
deletion is likely to have occurred in A1.  The PCR used to identify AbaR23 was used to examine 
the extent of deletion in A1. However, the PCR generated a ~ 4 kb product while it generated a 2.7 
kb product for AbaR23, indicating that a smaller segment of MARR is deleted in A1 (Figure 4.25). 
The 4 kb product of the catA1-intI1 PCR was sequenced (GenBank accession no. JN968482) and 
revealed that the right hand IS26, in Tn6020, has removed 10,876 bp including aphA1b, Tn1000-
like together with a big portion of Tn1 such that only 582 bp of Tn1 remained. Hence this is a novel 
junction and the island in A1 was named AbaR24 (Figure 4.25). 
Figure 4.25: Structure of the AbaR24 island. Green open box indicates IS26, which has made a deletion and the 
remaining segment of Tn1 is indicates in blue, 582 bp. 
 
4.10 Discussion  
The work presented in this chapter focused on characterizing the AbaR island in Australian 
GC1 isolates. All Australian MAR GC1 isolates include an AbaR island in the comM gene precisely 
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duplication was found in all cases by analysing the draft genomes, indicating that they are all 
located precisely in the same chromosomal location, which has also been reported by other studies 
(1, 2, 112, 113, 183, 184, 212).  
AbaR islands are an important feature of GC1 strains as they carry several antibiotic and 
heavy metal resistance genes and are present in all MAR strains (2, 58, 183).  
Using the structure of the islands, two main groups were identified. The first group included 6 
strains, which showed similar antibiotic resistance, RAPD and ISAba1 profiles, Chapter 3. These 
strains had been isolated from hospital D and RRC and all had AbaR6, which indicates that they are 
closely related and descendants of a common ancestor. The second SG6 group included 8 isolates 
and all but D108 included AbaR8. These strains contained the same csuE allele and exhibited the 
same RAPD and antibiotic resistance profile but different ISAba1 profiles. However, the presence 
of AbaR8 again indicates that these strains have diverged from a common ancestor. The island in 
D108 could be derived from AbaR8 by recombination between the two Tn6018 copies. This 
indicates that the structure of AbaR variants can serve a useful epidemiological marker as IS26-
mediated deletions are, in fact, footprints left behind, and can be traced to group strains.  
Several variants of AbaR were found in this study some of which had not been seen before, 
namely AbaR0, AbaR8, AbaR23, AbaR24 and AbaR26. Krizova et al. 2011, also described 8 
variants of AbaR islands, AbaR12-AbaR19, each had lost a segment in the middle via an IS26-
mediated deletion (112). All these variants, except AbaR6, AbaR7, AbaR14 and AbaR26, include 
an intact Tn6019 backbone. All of the AbaR variants found so far appear to have been derived from 
AbaR0 or AbaR3 though some variants such as AbaR6, AbaR7, AbaR14 and AbaR26, which have 
lost the entire left hand side of MARR, could theoretically have been derived from AbaR1. None of 
the AbaR types characterized here and/or published so far contained the additional 29 kb found in 
AbaR1, therefore AbaR1 remains as a unique island, representing the epidemic strains causing 
outbreaks in France hospitals (58). 
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Figure 4.26: Comparison of the AbaR3-type islands found in the comM gene. The thickest lines represent the backbone 
transposon and black open boxes at both sides show the Tn6018 copies. Green open boxes also represent the IS26 
copies. The dashed lines indicate the deleted segment. The “*” above the gene cassettes indicate the presence of aacC1-
orfP-orfQ-aadA1 and the vertical arrows before the gene cassettes indicate the 108 bp deletion.  GenBank accession 
numbers: AbaR0 KF483599, AbaR3 CP001182, AbaR5 FJ172370, AbaR6 GQ406245, AbaR7 GQ406246, AbaR8 
HM590877, AbaR9 ADGZ00000000, AbaR10 ADHA00000000, AbaR23 JN409499, AbaR24 JN968482, AbaR26 
KC665626.  
 
The results presented indicated that IS26 is playing a major role in creating new variants of the 
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a copy of different IS26 elements. The first, IS26-1, of the three IS26 found in AbaR1 and AbaR5 
was responsible for the loss of one antibiotic resistance gene in AbaR1 and two antibiotic resistance 
genes in AbaR5. In AbaR6, AbaR7, AbaR8, and AbaR26 the second copy of IS26 (IS26-2) caused 
the deletion of several antibiotic resistance genes (Figure 4.26). In AbaR23, AbaR24 and AbaR27 
(TnAbaR23 in the original publication (109); GenBank accession no. JN676148) the third copy of 
IS26 (IS26-3) caused the deletion of several antibiotic resistance genes. Homologous recombination 
between the two Tn6018 copies, as was found in this study in D108 (Figure 4.26) and NIPH470 
(GenBank accession no. JF262167) (112), and the two sul1 copies, in AbaR10 (1) are also 
important as they cause the deletion of the entire MARR in D108 and NIPS470, and the segments 
between the two sul1 genes respectively. Comparison of the AbaR islands found in this study is 
shown in the Figure 4.26 (AbaR 9 and 10 are from the reference (1)). 
A deletion in the 5'-CS in the class 1 integron was found to have occurred via a rare event 
involving 8 bp duplication. Isolates containing AbaR0, AbaR5, AbaR6, AbaR7, and AbaR24 also 
did not include the deletion. This deletion is an interesting finding, which can be used to trace 
different lineages of integron containing GC1 isolates (Table 4.7). 
Analysis of the proteins encoded by the set of A. baumannii transposons that target the comM 
gene also revealed a large family of related transposons and provided evidence that 5 genes are 
involved in coding for proteins with a role in transposition. Though the level of identity between 
corresponding proteins was not high (generally 25-50%), at least two of these transposons were 
found to be also located in comM, suggesting that the ability to recognise this site as a preferred 
target may be a shared property of all members of the family. The analyses also revealed that these 
transposons are not confined to Acinetobacter species and appear to represent a novel family of 
transposons that have not previously been recognised. 
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5.1 Introduction 
 
The oxa23 gene is one of the most widespread acquired carbapenemase genes in A. 
baumannii and has been found worldwide (174). This gene has been identified as part of various 
transposon structures, namely Tn2006, Tn2007, and Tn2008 (143, 174). Tn2006, which is one of 
the most encountered structures containing oxa23, is a 4.8 kb class I transposon that consists of a 
central segment of 2,445 bp bounded by two copies of ISAba1 (Figure 1.4) (41). Tn2006 can move 
independently and is found in several different locations and contexts in isolates belonging to both 
GC1 and GC2 (143).  
Isolate AB0057, which carries AbaR3 in comM, also harbours Tn2006 in a second island in 
the chromosome called AbaR4 (Figure 5.1) (1). The transposon backbone of AbaR4 is Tn6022 
(Chapter 4; section 4.2).  
 
Figure 5.1: Structure of the AbaR4 island. The thick central line represents the backbone of AbaR4 (Tn6022). And the 
vertical lines indicate the IRs of AbaR4. The extent of Tn2006 is shown above. Open boxes represent ISAba1 copies 
and oxa23 is shown in red. 
 
 
In chapter 3, it was shown that three strains D36, D108 and A85 (Table 5.1) were carbapenem 
resistant due to the presence of oxa23. ISAba1 was not detected upstream of the chromosomal oxa-
Ab gene in any of these isolates indicating that the oxa23 identified accounts for the carbapenem 
resistance observed. In chapter 4, it was shown that A85 and D108 carry AbaR3 and 
Tn6019::Tn6018 in comM, respectively, whereas D36 carried a related island that was not of the 
AbaR0/AbaR3 type. 
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The work presented in this chapter focused on examining the genetic environment of oxa23 in 
the three GC1 isolates. 
 
Table 5.1: Carbapenem resistant GC1 isolates carrying oxa23. 
Isolate Year City/Country ST a AbaR0-type 
D36 2008 Sydney 247 - 
D108 b  2011 Sydney 109 Tn6019-Tn6018 
A85  2002 Sydney 126 AbaR3 
 
a Oxford MLST scheme, which includes gltA, gyrB, gdhB, recA, cpn60, gpi, rpoD genes. ST247 (10-12-4-11-4-58-5), 
ST109 (10-12-4-11-4-9-5), ST126 (10-53-4-11-4-64-5). 
b SG6. 
 
 
5.2 oxa23 is carried on Tn2006 
 
The three isolates, D36, D108 and A85, were screened for Tn2006 using two overlapping 
PCRs linking the oxa23 gene to the left and right copies of ISAba1 (Figure 5.2; Table 5.2) and it 
was detected in all three strains (see Table 5.2 for primers). 
 
 
 
Figure 5.2: Structure of Tn2006 and the overlapping PCRs used to detect Tn2006. Open boxes indicate the ISAba1 
copies. The PCRs, their amplicon sizes and primers are shown below. 
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In Chapter 3, it was shown that the comM gene is interrupted in D36, and as the J1 and J2 
junctions produced an amplicon, the insert is related to Tn6019, Tn6021 or Tn6022. The J1 and J2 
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and the chromosomally-derived comM region was identical to that found flanking AbaR3 and 
relatives in sequenced GC1 genomes. However, the portion derived from the inserted transposon 
differed from Tn6019 by 6/401 bp in J1 (Figures 5.3) and 4/286 bp in J2. The allelic variations were 
shared by the corresponding portions of AbaR4 in AB0057 (GenBank accession no. CP001182). 
This, and the presence of Tn2006 and an intact uspA gene suggested that AbaR4 might be present in 
comM in D36.  
 
J1_D36     TGTCGCACAGTTGTAGAATCTTCTGCAGGTGTTGGGTCTTGCAGTTCTTGAGCTTTTAAT  
J1_AB0057  ------------------------------------------------------------ 
 
J1_D36     GGCGGTACATCAATATGTAAATCGATGCGGTCGAGTAACGGTCCCGATATGCGGTTTTGA  
J1_AB0057  ------------------------------------------------------------  
 
J1_D36     TAGCGTTTAATGCTTTCTGGTGAACACTGACAACGGCTATCTTGATTAAATGCATACCCA  
J1_AB0057  ------------------------------------------------------------ 
 
J1_D36     CATGGACAAGGATTCATTGCTGCAATGAGCTGAAAGTTCGCCGGATAAGTAATTTGCCGA  
J1_AB0057  ------------------------------------------------------------  
 
J1_D36     GCTGCACGTGAAATAATGATTTCTTTTGACTCAAGCGGTTGGCGTAAGACTTCTAGAACC  
J1_AB0057  ------------------------------------------------------------  
 
J1_D36     TTTCTGTCAAACTCGGGAAGTTCATCTAAAAATAGAACACCTAAATGAGATAAAGTAATT  
J1_AB0057  ------------------------------------------------------------ 
                               <comM            IRl 
J1_D36     TCACCCGGTTTGGGGTGTGAACCGCTGTCATTTACAGCAATAGAATAGAGTGGCATTATA  
J1_AB0057  ------------------------------------------------------------ 
  
J1_D36     GATAATCAATAGGTTGTCACTCTAATTTCACACAATTAAATTAGATTATTTACATAAATA  
J1_AB0057  ------------------------------------------------------------  
 
J1_D36     GATAAGAGTGACTTGCAAAATTACATTAATAGGCACGAGTGCCTGAATGGTGACTTTTTT  
J1_AB0057  ----------G------------------------------------------A------  
 
J1_D36     ATGAAAAAATTGAGTGACGAATACTTACCTGTTAGAAAAGCTCAAACTGTTTATGGGAGT  
J1_AB0057  -------------------------C----------------------------------  
 
J1_D36     ATTTCGGGAAATTATGCCTTTAGAGGTGAGAAAACCATTTGGTTTGAATCGACCCTTGAG  
J1_AB0057  --------------------------C---------------------------------  
 
J1_D36     CGTGATTTCATACTTAAGCAAGAATTTAATAACAATGTGATTGATGTTATCGGTCAACCT  
J1_AB0057  ------------------------------------------------G-----------  
 
J1_D36     GTAGTTATCCCCTACATCACTGAATTGGGTAACCAATCAACCTACACTCCTGACTTTTTA  
J1_AB0057  --------------------------------T--------------------------- 
 
Figure 5.3: Alignment of the sequences of the boundaries between comM and the genomic island in the J1 amplicon 
from D36 (GenBank accession no. JN107991) and AB0057 (GenBank accession no. CP001182). Bold and italic 
sequences show the comM and the sequences highlighted red are differences of the genomic island in D36 compared to 
AbaR3 islands in AB0057. The IRl is white on black and the 5 bp duplication is shown blue.   
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Tn2006 in D36 was shown to be located in the position it occupies in AbaR4 using primers 
shown in Figure 5.1. These primers were used to demonstrate that a complete copy of AbaR4 was 
present in D36. Following that, AbaR4 in D36 was shown to be located in comM by linking oxa23 
to comM with primers oxa23-R and RH913 (Figure 5.4; Table 5.2). 
 
 
 
Figure 5.4: PCR mapping strategy used to characterize AbaR4 in D36. The chromosomal region (comM) flanking 
AbaR4 is a dashed line. IR are vertical lines and the extent of AbaR4 and Tn2006 are indicated above. Insertion 
sequences are shown as open boxes with their designation inside and an arrow below indicating the orientation of the 
transposition genes. The arrows below the central line indicate extent of the genes and the open reading frames. The 
extents of PCRs used for mapping are shown below as lines with the position of the primers indicated by vertical lines 
and primer names adjacent.  
 
 
The complete sequence of AbaR4 in D36 (16,811 bp) was determined using the amplicons 
shown in Figure 5.4. The AbaR4 sequence determined differed from the available sequence 
(GenBank accession no. CP001182) (2) by only single base substitutions at 3 positions and 5 single 
base additions or deletions. The 17,632 bp sequence from D36 consisting of AbaR4 (16,811 bp) 
flanked by part of comM was submitted to GenBank under accession number JN107991. 
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Table 5.2: Primer pairs used for characterization of AbaR4 in comM.  
Region Primer 
name 
Primer sequence (5'-3') Amplicon 
length (bp) 
Primer  
Reference 
comM RH791 
RH913 
TGCTGCAATGAGCTGAAAGT 
GCCTCTCATTGAGGTTGAGG 
982 (183) 
(184) 
comM-Tn (J1) RH927 
RH792 
CAACCCTGTCTTTGCATTTG 
TTCGAGCTTGAAAACTGCAC 
846 (184) 
(184) 
Tn-comM (J2) RH916 
RH928 
CCCAAATACTGCCATGTTGA 
GCCAGCAAGCTCAGCATAA 
796 (184) 
(184) 
uspA RH919 
RH793 
TGTCAAAAATTATTGCATGT 
CCCAAGAGAGCTGATTTTGC 
632 (184) 
(184) 
Tn6018 
 
RH768 
RH769 
GAATCGCTGGTGATGATGGC 
GGTCTGAGACTTCGTGAGCGC 
1630 (184) 
(184) 
comM-Tn 
(PCR1) 
RH791 
RH909 
TGCTGCAATGAGCTGAAAGT 
GCGATTCAAAATATCGGTCAA 
3120 (183) 
(183) 
tniB-orf3 RH910 
RH587 
GCGATAGTGAACGGATTGAGA 
TTGCCCATTAAGCACAACAG 
3410 (183) 
This study  
orf3-ISAba1 RH586 
ISAba1A 
TGGGCTTAGGTATTTTCATCAAC 
GTGCTTTGCGCTCATCATGC 
4675 This study 
(41) 
sup-oxa23 oxa23-F 
RH772 
GATCGGATTGGAGAACCAGA 
GCAGCCATAGGAATGACTTTTA 
4260 (253) 
(183) 
ISAba1-oxa23 ISAba1B  
oxa23-F 
CATGTAAACCAATGCTCACC 
GATCGGATTGGAGAACCAGA 
2725 (41) 
(253) 
oxa23-ISAba1 oxa23-R 
ISAba1B 
ATTTCTGACCGCATTTCCAT 
CATGTAAACCAATGCTCACC 
1369 (253) 
oxa23-orf4 oxa23-R 
RH773 
ATTTCTGACCGCATTTCCAT 
GGGCGAAAATTATTGTTCTTA 
2629 (253) 
(184) 
oxa23-comM oxa23-R 
RH913 
ATTTCTGACCGCATTTCCAT 
GCCTCTCATTGAGGTTGAGG 
5004 (253) 
(184) 
 
5.4 A85 and D108 carry AbaR4 in a plasmid 
The PCR mapping strategy developed to identify AbaR4 in D36 (Figure 5.4) was used to 
show if Tn2006 is located in AbaR4 in both A85 and D108. Since A85 and D108 contained an 
insert in the comM gene with a Tn6019 backbone, the primers RH587 and RH586 (Table 5.2; 
Figure 5.4) were particularly important. These primers had been designed to detect the central 
portion of Tn6022 transposons (Figure 5.4) using the sequence differences between Tn6019 and 
Tn6022 and they could only amplify Tn6022, but not Tn6019. Using this carefully designed PCR 
strategy it was possible to show that AbaR4 is also present in A85 and D108. In addition, oxa23 
 
CHAPTER FIVE                                                                       Carbapenem resistant isolates carrying oxa23 
 
 
 
131 
could not be linked to the comM gene confirming that AbaR4 is located somewhere else in these 
genomes.  
 Using the primers RH907 5'-GCAGTCGACGAGGTAAATGG-3' and RH908 5'-
TTGGGATGAAGGAAGGTCTG-3' previously designed (182) to detect the region interrupted by 
AbaR4 in AB0057, a 972 bp product was generated indicating that AbaR4 is not present in this 
location in D108 and A85. This PCR did not generate an amplicon for AB0057, which was used as 
control. 
When a genome sequence for A85 was determined, the location of AbaR4 was examined. A 
500 bp sequence at the left end of AbaR4 was used to retrieve matching contigs. Two blast hits 
were obtained one of which (contig 27) contained an identical sequence to the AbaR4 end and the 
second contig contained a sequence that was ~ 98% identical to the query and belonged to Tn6019. 
The sequence flanking AbaR4, in contig 27, was used to query the GenBank non-redundant 
database in order to identify the location of AbaR4. The three matches obtained were related 
plasmids of 64-75 kb from GC2 strains. These were p2ABTCDC0715 (70,894 bp; GenBank 
accession no. CP002524), pACICU2 (64,366 bp; GenBank accession no. CP000865) and pABKp1 
(74451 bp; GenBank accession no. CP001922). The sequence flanking the right hand end of AbaR4 
matched the same three plasmids indicating that AbaR4 is inserted in a similar plasmid in A85. This 
plasmid was named pA85. AbaR4 is surrounded by a 5 bp duplicated sequence (CCATT) that is 
present only once in the related plasmids, pACICU2, pABKp1 and p2ABTCDC0715. 
Using a combination of the primers used for mapping AbaR4 in D36 and two additional 
primers (RH1392 and RH1391; Figure 5.5) that were designed to detect the backbone of the 
plasmid in A85, it was possible to link the oxa23 gene and tniB of AbaR4 to the region 
corresponding to the backbone of pA85 indicating that AbaR4 is carried on this plasmid in A85 
(Figure 5.5). The products of these PCRs and the PCRs used to map AbaR4 were also sequenced to 
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join the contigs belonging to AbaR as the backbone of AbaR4 was in multiple contigs because A85 
also includes AbaR3. 
 
Figure 5.5: Schematic representation of the PCRs developed to assemble pA85. Black lines schematically represent the 
contigs belong to the plasmid backbone and blue lines represent the backbone of AbaR4. Short red lines represent the 
sequences determined by sequencing of the PCR amplicons shown in the picture. Green vertical arrows indicate the 
repeated sequence and the numbers above the black lines indicate the contig numbers. 
 
 
Complete sequences of pACICU2, pAB2TCDC-AB0715 and ABKp1 were used to search the 
draft genome of A85 in order to find the remaining segments of pA85. Eight contigs were found 
ranging in size from 198 bp to 41 kb (Table 5.3).   
 
 
Table 5.3: Contigs containing backbone sequence of plasmid in pA85. 
 
Contig no. Size (bp) Comment 
27 41517 AbaR4-plasmid backbone 
231 13575 Plasmid backbone 
65 4577 Plasmid backbone 
233 1171 Plasmid backbone 
129 418 Repeated sequence 
232 111 Repeated sequence 
239 198 Repeated sequence 
35 8986 Plasmid backbone-AbaR4 
 
The sequence of the known plasmids was used as guide to determine the order of the multiple 
contigs belonging to the plasmid backbone. A repeated region, identical 423 bp sequence at two 
positions and a truncated 225 bp version at third position, was found in pAB2TCDC-AB0715 and 
ABKp1. Analysis of the contigs of A85, containing pA85 sequence, revealed ~ 60 bp identical to 
one end of this repeated sequence at one end of contig 27 and 233 and at both ends of the contigs 23 
and 65 (Figure 5.5). In order to confirm the order of contigs found in A85 several primers were 
23
65
233
35
RH1398 RH1399 RH1395 RH1394 RH1391 RH909991 1372 3053
RH1396 RH13971011
RH1396 RH15052671
AbaR4AbaR4
RH1392RH1208 4852
27
1 kb
Plasmid backbone
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designed and contigs were paired using PCR and their products sequenced (Figure 5.5; Table 5.4). 
This allowed the sequence of an 86,355 bp plasmid that contains AbaR4 to be assembled.  
pA85 includes a rep gene, which predicts a 390 aa Rep protein, the same as p2ABTCDC0715 
and pABKp1. The Rep protein, in pA85, is identical to that of p2ABTCDC0715 and differs from 
pABKp1 by only a single aa, T-189(pA85)!P(pABKp1). The rep gene, in pA85, differs from that 
of pACICU2 at 9 positions including 7 nucleotide substitutions and two additional A residues 
(GenBank accession no. CP000865) at positions 1106 and 1139 of rep in pACICU2. The additional 
A residues create a frameshift in the Rep sequence of pACICU2, which replaces the C-terminal 21 
aa with 2 new aa creating a 368 aa Rep sequence. The protein sequence predicted by the rep gene of 
pACICU2 has been named Aci6 in the PCR-based typing scheme developed for A. baumannii 
plasmids (17). Aci6 in pACICU2 differs from that found in pA85 by 2 aa in a total 368 aa (P-
189(pACICU2)!T(pA85) and I-344(pACICU2)!L(pA85)). The Rep sequence of pABKp1 also 
contains P at position 189, the same as pACICU2 and pABTCDC0715 includes a T, the same as 
pA85. At position 344, pACICU2 is the only one that includes I as the others all contain an L. 
 
 
Table 5.4: Primers used for mapping pA85. 
 
Primer 
names 
Primer sequence (5'-3') Amplicon 
size (bp) 
Annealing 
temperature 
Amplicon 
RH1391 
RH909 
ATGCGAGGCTTCTTGGTCTA 
GCGATTCAAAATATCGGTCAA 
3053 60 pA85-tniB 
RH1398 
RH1399 
TTTGACGTTGCTCTTGTTGC 
TTCTCCCAAGTGGTCAGGTC 
991 60 Repeated sequence 1 
RH1394 
RH1395 
TGGTTGGCAGAACAAGATGA 
TCAAACGATGCAATGGAAGA 
1372 60 Repeated sequence 2  
RH1396 
RH1397 
AGTTCTTTCGGCACATTGGT 
CCATGTTCTTTTCCACATGC 
1011 60 Repeated sequence 3 
RH1396 
RH1505 
AGTTCTTTCGGCACATTGGT 
TTTCTGGTGCAGCTTTTTCA 
2671 60 Contigs 65, 233 and 
35 
RH1208a 
RH1392 
ATTTCTGACCGCATTTCCAT 
CCTTAACGCTCAGTCTTTTGG 
4852 60 oxa23-pA85 
 
a oxa23-R 
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Furthermore, comparison of the pA85 sequence to the related plasmids also revealed a large 
number of open reading frames of unknown function together with regions containing 16 genes 
predicted to be involved in plasmid transfer (Figure 5.6).  
Figure 5.6: Circular map of pA85 carrying AbaR4. Arrows shown inside the circle indicate the extent of the transfer 
genes. The red arrow indicates rep and arrows shown on the black lines, representing the plasmid, indicate genes and 
orfs belong to AbaR4. Genes involved in the transfer of the plasmid, tra genes, are coloured blue. Red boxes on the 
circle, representing the plasmid, show the repeated sequences found in pA85. Transposition genes of AbaR4 are 
coloured orange and the oxa23 gene blue. The green boxes also indicate the ISAba1 copies and the arrows inside the 
boxes show the direction of the transposase genes. Open reading frames of unknown functions are not shown in this 
map. The numbers inside the circle are the base positions in kb. 
 
 
The presence of transfer genes suggested that pA85 is a conjugative plasmid. To examine 
whether pA85 was conjugative, A85 was mated with a rifampicin resistant mutant of A. baumannii 
pA85
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ATCC17978. Transconjugants were selected on L agar supplemented with rifampicin and ticarcillin 
to detect oxa23 as previously described (17). To ensure that transconjugants were not spontaneous 
rifampicin resistant derivatives of the donor, potential transconjugants were purified and screened 
for growth on L agar containing antibiotics to which the donor was resistant and the recipient 
susceptible.  All the transconjugants tested were rifampicin, imipenem, meropenem and ticarcillin 
resistant. They were also susceptible to kanamycin, neomycin and gentamicin, which distinguished 
them from the donor (Table 5.5). This demonstrated that pA85 is conjugative.  This indicates that 
moving AbaR4, which includes the oxa23 carbapenem resistance gene, in A. baumannii populations 
can be potentially facilitated as is carried on a conjugative plasmid. 
 
Table 5.5: CDS results of the donor (A85), recipient and transconjugants containing pA85.  
 
Isolate  Annular radius of inhibition zone (mm)   
IPM MEM TIM Ap Km Nm Gm Ne Cip Nx Rif 
A85 4 3 0 0 0 3 2 6.5 0 0 8 
ATCC17978 rifR 11 9 8.5 3.5 7.5 7 7 9 9 7.5 0 
Transconjugant 1 3 3.5 0 0 8 8 8 10 9 6 0 
Transconjugant 2 4 3.5 0 0 8 7.5 7.5 10 8 6.5 0 
Transconjugant 3 4 3.5 0 0 8 7.5 8 9.5 9 6 0 
 
 
 
5.5 Location of AbaR4 in D108 
Searching through the draft genome of D108 also revealed two contigs (contigs 7 and 14) that 
contained sequences from the ends of AbaR4. The flanking sequences were found to be identical to 
those found in pA85, which raised the possibility that AbaR4 is in a similar plasmid. To confirm 
this the two PCRs linking the backbone of pA85 to AbaR4 (RH1391 with RH909 linking plasmid 
backbone to tniB and RH1208 with RH1392 linking oxa23 to the plasmid backbone) were used 
(Table 5.4) and they generated the predicted amplicons of 3,053 and 4,852 bp (Table 5.4) 
respectively indicating that AbaR4 is on a similar plasmid in D108.  
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Table 5.6: Contigs containing the sequence of pD108. 
 
Contig no. Size (bp) Comment 
7 29356 AbaR4-plasmid backbone 
57 12949 Plasmid backbone 
40 13589 Plasmid backbone 
162 4591 Plasmid backbone 
17 5566 Plasmid backbone 
238 155 Repeated sequence 
186 198 Repeated sequence 
75 149 Repeated sequence 
14 5712 Plasmid backbone-AbaR4 
37 393 AbaR4 (tniC) 
38 423 AbaR4 (tniA) 
40 678 AbaR4 (tniB) 
15 7459 AbaR4 (orf3-sup-ISAba1) 
78 2507 AbaR4 (ISAba1-oxa23-ISAba1) 
21 508 AbaR4 (ISAba1-orf4) 
43 260 AbaR4 (orf4) 
46 315 AbaR4 (orf4) 
 
The complete sequence of pA85 was used to retrieve the contigs making up the complete 
plasmid in D108. Nine contigs were found, ranging in size from 149 bp to 29 kb (Table 5.6). Two 
of these contigs, contig 7 and 14 (Table 5.6), contained the sequence of the ends of AbaR4 and 
flanking plasmid sequence. Seven contigs contained the plasmid backbone, including the repeats 
(Table 5.6). Seven contigs also included sequences belonging to the internal segments of AbaR4. 
The same PCR strategy developed to pair the contigs broken up by the repeat regions of pA85 were 
performed and generated predicted amplicons indicating that the order of contigs related to the 
plasmid in D108 is the same as that in A85. Hence, D108 includes a plasmid that carries AbaR4 and 
was named pD108. Comparison of the pA85 and pD108 sequences revealed that they differ only by 
5 single base substitutions.  
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5.6 Discussion  
 
The three carbapenem resistant strains carrying oxa23 had been isolated from different 
hospitals and belonged to different ST types within the GC1 clonal complex (Table 5.1). Isolate 
D36 was an unusual multiply antibiotic resistant isolate that carried oxa23 in AbaR4 in the 
chromosomal comM gene, replacing the AbaR3-type island usually associated with multiply 
antibiotic resistant GC1 isolates. This is the first report of AbaR4 replacing the AbaR0-type island 
in A. baumannii GC1. D36 belongs to a rare GC1 lineage, ST247, which has only one other 
representative in the MLST database (http://pubmlst.org/abaumannii/), isolate A479 from Pakistan 
(78). Potential ancestors of D36 were found in the whole genome shotgun database (strains 
6013113 and 6013150; Table 5.7). These strains were closely related to D36 as they belonged to 
ST247 and clustered with D36 in SNP analysis (Kat Holt, University of Melbourne- personal 
communication).  However, they did not include AbaR3 or AbaR4 and instead contained an intact 
comM gene. D36 has probably arisen from such a strain by acquisition of AbaR4.  
 
Table 5.7: Properties of ST247 strains. 
 
Strain Country Source comM AbaR4 ST (gltA-gyrB-gdhB-recA-
cpn60-gpi-rpoD) 
Accession no. 
D36 Australia Wound - + ST247 (10-12-4-11-4-58-5) JN107991 
6013113 USA Skin + a - ST**  (10-12-*b-11-4-58-5) ACYR02000002 
6013150 USA Skin + a - ST247 (10-12-4-11-4-58-5) ACYQ02000000 
 
a the comM gene is not interrupted in 6013113 and 6013150. 
b the sequence could not be found in MLST database but it differs from gdhB-4 by 1 bp. 
 
Six UK isolates, 46 and 52-56, that like D36 have an insertion in comM but do not have any 
of the features expected for AbaR3-type islands (234) may carry AbaR4 or a related transposon in 
comM. However, none of the PCRs used in that study determined whether oxa23 was in Tn2006 or 
whether Tn2006 was in AbaR4. The MLST type is also unknown. Further work will be needed to 
determine the relationships of these UK isolates to D36. 
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AbaR4 was also found in an 86 kb conjugative plasmid in two unrelated strains, D108 and 
A85. D108, which was a SG6 strain, belonged to ST109 (10-12-4-11-4-9-5) (Oxford MLST 
scheme), while A85 was ST126 (10-53-4-11-4-64-5), which is a DLV of ST109. Previously, a 130 
kb conjugative plasmid carrying oxa23 in Tn2006 has been shown to contribute to carbapenem 
resistance in A. baumannii (143). However, this is the first time that AbaR4 carrying Tn2006 has 
been detected in a conjugative plasmid in A. baumannii. 
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6.1 Introduction  
In A. baumannii, resistance to third-generation cephalosporins such as ceftazidime (CAZ) and 
cefotaxime (CTX) is known to occur mainly due to the activation of the chromosomally located 
ampC gene (84, 99, 195, 206, 208). The presence of a chromosomal ß-lactamase gene in the genus 
Acinetobacter was first suggested by Matthew and Harris in 1976 (137) and in 2000 Bou and 
Martinez-Beltran determined the nucleotide sequence of the ampC gene from the A. baumannii 
strain RYC, which was isolated during an outbreak in 1997 (20). They also reported the 
biochemical properties and resistance profile of the A. baumannii AmpC ß-lactamase and showed 
that, in strain RYC, it was not inducible (20). Later study then showed that A. baumannii strains 
resistant to 3rd generation cephalosporins include an insertion sequence upstream of the ampC gene 
(40).  
The ampC gene in A. baumannii is 1152 bp long and located between the folE gene and an 
open reading frame of unknown function (Figure 6.1). Most AmpC-type beta-lactamases naturally 
produced by Gram-negative bacteria hydrolyze amino- and ureidopenicillins, cephamycins 
(cefoxitin and cefotetan), and, at a low level, oxyiminocephalosporins, such as ceftazidime, 
cefotaxime, and ceftriaxone, as well as monobactams, such as aztreonam (30, 195). The MICs of 
other ß-lactams such as carbapenems are not affected by AmpC ß-lactamases (20).  
Cephalosporin resistance in now known to arise via activation of the chromosomal ampC 
gene in A. baumannii as a consequence of acquisition of an insertion sequence, ISAba1, upstream 
of the chromosomal ampC gene (40, 84, 195, 206, 208).    
Figure 6.1: The context of the chromosomal ampC gene in A. baumannii. The thick central line represents the 
chromosome and the arrows below represent the genes and their direction. (a): represents the ampC gene without 
ISAba1 and (b) shows the position of ISAba1 relative to ampC.  
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ISAba1 is frequently found upstream of the ampC gene in isolates that are resistant to third-
generation cephalosporins (1, 2, 84). The presence of a copy of ISAba1 in the appropriate 
orientation (Figure 6.1) upstream of ampC provides the gene with a promoter that appears to be 
stronger than the intrinsic promoter as it enhances transcription of ampC (40, 84, 206, 208) (Figure 
6.1). Segal and Elisha identified the transcription initiation site of the ampC gene in an A. 
baumannii strain (207, 208) and it was located 35 bp upstream of the ampC start codon (the bold 
black G with an asterisk above; Figure 6.2). They also identified the two hexamers, TTATTT, and 
TTAGAA within ISAba1 and upstream of the transcription start site that shows similarity to the 
consensus -10 sequence (TATAAT) and -35 hexamer (TTGACA) recognized by Sigma70 (208) 
(see discussion for alternative promoter).  
 
CACTTTAAATGTGACTTGTTCCATTTTAGATATTTGTTTAAGATAAGATATAACTCATTG 
 
      M             -35                   -10     *  * 
AGATGTGTCATAGTATTCGTCGTTAGAAAACAATTATTATGACATTATTTCAATGAGTTA 
 
                          RBS         M 
TCTATTTTTGTCGTGTACAGAGGAGCTAATCATGCGATTTAAAAAAATTTCTTGTCTACT 
                                                                             " 
 
Figure 6.2: The nucleotide sequence of the 5'-end of ampC and its position relative to the ISAba1. The transcription 
initiation sites (G) and (T) are bold black with an asterisk above. The “T” with asterisk above indicates the transcription 
initiation site when ISAba1 is upstream of oxa23. The -35 and -10 hexamers are shown white on black. The ampC 
sequences are bold and the “M” above stands for Methionine. The ribosome binding sequence, RBS, is underlined. The 
vertical arrow indicates the first base of ISAba1 and the adjacent italic letters indicate the sequences belong to the 
chromosome. The bases coloured blue represent the start of the transposase gene. The transcription start points 
determined experimentally in references (207, 208) are indicated bold with an asterisk above. 
 
 
The chromosomal position of the ampC gene in the genome of A. baumannii is shown in 
Figure 6.3 relative to the genes used in the MLST schemes. The ampC gene is in this location in all 
the complete A. baumannii genome sequences available in the non-redundant GenBank database. 
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Figure 6.3: Map of the genome of A. baumannii that shows the chromosomal location of the ampC gene, genes used in 
Oxford and Institut Pasteur MLST schemes and the genes used in the multiplex PCR for characterization of Global 
Clones. 
 
Other insertion sequences have also been detected upstream of ampC. ISAba125 is present 
upstream of ampC in ACICU, a GC 2 isolate from Italy (GenBank accession no. CP000863), and it 
has been suggested that it may also increase the ampC expression, leading to cephalosporin 
resistance (93). However, whether ACICU is ceftazidime and cefotaxime resistant and whether 
ISAba125 activates ampC has not been examined. 
In the literature the AmpC proteins predicted by the ampC genes, are sometimes named ADC, 
which stands for Acinetobacter-derived cephalosporinases and are numbered (40, 91). This 
numbering has also been applied to the blaADC genes. However, as more than one DNA sequence 
can predict an identical amino acid sequence; therefore, throughout this chapter ampC sequences 
were named according to the DNA sequence and in regards to the clones e.g. allele 1 for GC1s, 
allele 2 for GC2s and etc. 
The aim of the work in this chapter was to investigate the molecular basis of resistance to 
third generation cephalosporins in the GC1 collection. In addition, a few GC 2 strains were also 
included in this part of the study for comparison. Ceftazidime and cefotaxime were chosen as 
representatives of third generation cephalosporins for antimicrobial susceptibility testing.   
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6.2 Cephalosporin resistance in the GC1 collection  
The GC1 strains in the collection were examined for resistance to third generation 
cephalosporins cefotaxime (CTX) and ceftazidime (CAZ) using the CDS method (Chapter 2). 
According to the CDS method instructions a zone equal or greater than 6 mm annular radius is 
considered as sensitive, a zone size between 4 to 5 as intermediate and a zone size less than 4 mm 
as resistant (see Chapter 2). In addition, to validate the interpretation of the CDS results, MICs of 
the strains were determined (Table 6.1) using the standard Micro Broth Dilution method (4, 252). 
According to the CLSI recommendations for antimicrobial susceptibility testing, in A. baumannii 
the MICs of "64 mg/L for cefotaxime and "32 mg/L for ceftazidime are considered resistant (37).  
Analysis of the annular radius of the inhibition zones of CTX and CAZ (Table 6.1) revealed 
two distinct groups of isolates in the collection, the isolates with marginal inhibition zones (annular 
radius 4-7 mm) and the second group that were resistant (0-3 mm). The isolate D62 showed a high 
level of susceptibility (12 mm) (Table 6.1), and had the lowest MICs of 4 and 2 mg/L for 
cefotaxime and ceftazidime respectively. On the whole, there was a correlation between the CDS 
inhibition zones and the MICs as most strains with the inhibition zone of 0-3 mm had MIC "128 
mg/L and the strains with the CDS inhibition zones of 4-6 mm all had MICs 4-16 mg/L. However, 
there were a few variations in the MICs of CAZ. Three strains G7, D78 and D81, even though they 
were CAZ resistant according to the CLSI guidelines (37), exhibited a low MIC of 32 mg/l (Table 
6.1), which was at least 4 fold less than that of the other resistant strains. D108 also showed the 
MIC 64 mg/l, which was at least 2 fold less than the other CAZ resistant strains (see discussion). 
Together, the CDS and MIC data identified 16 cefotaxime and ceftazidime resistant strains in 
different groups of the collection. Most notably, the strains that were grouped based on the AbaR 
type shared the same cefotaxime and ceftazidime resistance profile (Table 6.1).  
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Table 6.1: Cefotaxime and ceftazidime resistance in the GC1 collection. 
 
Isolate Origin  Year RI type Annular 
radius (mm) 
MIC (mg/L) R/ Sa ISAba1
-ampC 
CTX CAZ CTX  CAZ  
AB0057 USA 2004 AbaR3 0 0 >128 >128 R + 
A1 UK 1982 AbaR24 4.5 6 8 4 S - 
A297 Netherlands 1984 AbaR21 5 5.5 8 4 S - 
A388 Greece  2001 AbaR3-like 0 0 >128 >128 R - 
A92 Sydney 2005 AbaR7 4 5 8 4 S - 
A83 Sydney 2002 AbaR7 5 5.5 16 4 S - 
3208 Sydney 1997 AbaR5 6 7 16 8 S - 
WM98 Sydney 1998 AbaR3 4 5 16 8 S - 
D2 Sydney 2006 AbaR6 4 5 8 4 S - 
D3 Sydney 2006 AbaR6 6 4 8 4 S - 
D6 Sydney 2006 AbaR6 4 4 8 4 S - 
D7 Sydney 2006 AbaR6 4 5 8 4 S - 
D27 Sydney 2008 AbaR6 4 5 16 8 S - 
D62 Sydney 2010 AbaR6 12 12 4 2 S - 
D30 Sydney 2008 AbaR26 4 5 16 16 S - 
D36 Sydney 2008 AbaR4 0 2 >128 >128 R + 
D13 b  Sydney 2009 AbaR8 0 1 >128 >128 R + 
D14  Sydney 2009 AbaR8 0 1 >128 >128 R + 
D15  Sydney 2009 AbaR8 0 1 >128 >128 R + 
D18  Sydney 2009 AbaR8 0 1 >128 >128 R + 
D20  Sydney 2009 AbaR8 0 1 >128 >128 R + 
D45  Sydney 2010 AbaR8 0 0 >128 >128 R + 
D48  Sydney 2010 AbaR8 0 0 >128 >128 R + 
D108 Sydney 2011 Tn6019/Tn6018 0 1 >128 64 R + 
D78 Sydney 2010 AbaR23 0 3 >128 32 R + 
D81 Sydney 2010 AbaR23 0 3 >128 32 R + 
G7 Melbourne 2002 AbaR3 0 4.5 128 32 R + 
RBH3  Brisbane 2002 AbaR3 0 0 >128 >128 R + 
A85  Sydney 2003 AbaR3 0 0 >128 >128 R + 
6772166 Adelaide 2002 AbaR3 0 0 >128 >128 R + 
 
a Resistant/ Susceptible. Related isolates with the same resistance  profile and AbaR islands are highlighted. 
b D13,D14, D18, D18, D20, D45, D48 and D108 belong to the sequence group 6 (SG6). 
 
 
To examine whether there is a copy of ISAba1 between folE and ampC genes in CTX and 
CAZ resistant isolates, a PCR using previously published primers was carried out (134). To link 
ISAba1 to ampC this PCR uses a combination of the ampC reverse primer (pw52) and the ISAba1 
reverse primer (ISAba1B) and generates a 1700 bp product only when ISAba1 is present (Figure 
6.4).  
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Figure 6.4: The PCR used to identify ISAba1 upstream of ampC. The thick central line represents the chromosome and 
the arrows below represent the extent of the genes and their direction. The extent of the PCR amplicon is shown below 
with the amplicon size in the middle.   
 
All of the Australian ceftazidime and cefotaxime resistant strains generated the expected 1700 
bp. This shows a strong correlation between CTX and CAZ resistance and the presence of ISAba1 
before the ampC gene. A388, an isolate from Greece, which was highly resistant to CTX and CAZ, 
did not generate an amplicon indicating that this strain does not include ISAba1 upstream of the 
ampC gene, and its resistance must be explained by another mechanism. 
 
6.3 Transcription of ampC in cephalosporin resistant isolates 
To examine the relative transcript level of the ampC gene in the strains with and without 
ISAba1 upstream of ampC, a quantitative reverse transcription PCR (qRT–PCR) was designed 
(Chapter 2 section 1.4.14) and performed for a representative of each group. In these experiments 
the CTX and CAZ sensitive strain 3208 that did not include ISAba1 upstream of ampC was used as 
control. Four further isolates, A297, WM98, D2 and D3 were also examined (Table 6.2). 
The relative transcript levels of ampC in the isolates without ISAba1 were found to be the same 
as 3208 (Table 6.2). In most the isolates that contained ISAba1-ampC, the relative transcript level 
was almost 8-fold higher than that of 3208. The relative transcript level in D14 and D81 was 
slightly higher (14.3 and 11.6 fold, respectively) (Table 6.2). This confirms that presence of an 
upstream ISAba1 increased transcription of the ampC gene.  
A388, which was resistant to CTX and CAZ but did not carry ISAba1 next to the ampC gene, 
exhibited 21.4 fold increase in the transcript level relative to the control. This is 2-3 fold higher than 
for the strains with ISAba1-ampC structure. This may indicate the presence of another IS upstream 
of ampC. ACICU, which contains an ISAba125 before the start of ampC, was found to be resistant 
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to CTX and CAZ (CTX and CAZ >128 mg/L). ACICU exhibited 20.2 fold increase in the ampC 
transcript level relative to the control (3208), which was almost the same as that in A388 (Table 
6.2).  
 
 
Table 6.2: Relative ampC transcript level. 
 
Isolate MIC (mg/L) R/ Sa ISAba1
-ampC 
The relative transcript level b 
CTX  CAZ  1 2 3 Average 
3208 16 8 S - 1.0 1.0 1.0 1.0 
A297 8 4 S - -1.31 -1.4 -1.22 -1.3 
WM98 16 8 S - -1.21 -1.3 -1.4 -1.3 
D2 8 4 S - 1 -1.4 -1.2 1.2 
D3 8 4 S - 1.01 1.04 1.03 1.02 
D36 >128 >128 R + 8 7.6 9.2 8.2 
D13  >128 >128 R + 11.3 7.82 9.8 8.53 c 
D14  >128 >128 R + 16 16 10.9 14.3 
D81 >128 32 R + 16 9.5 9.9 11.6 
A85 (PW01c) >128 >128 R + 7.76 7.8 7.7 7.75 
6772166 >128 >128 R + 9.1 7.69 6.5 7.76 
A388 >128 >128 R - 24 20 19.5 21.4 
ACICU >128 >128 R - 20 17.2 22.9 20.2 
 
b R: resistant, S: Susceptible. 
b the 3 experiments shown for each isolate used different extracted RNA and each value is an average of 4 different 
replicate.  
c 8.53 is the average of 4 biological replicates (11.3, 7.82, 9.8 and 5.2). 
 
 
6.4 IC50  
The IC50, which is the antibiotic concentration that allows 50% of the bacterial cells to form 
colonies (216), of ceftazidime was measured for 3208, D36 and A388 to examine whether there is a 
significant difference between the isolates.  
The IC50 value for ceftazidime was found to be 7 mg/L for the susceptible isolate 3208,. There 
was a higher IC50 in A388 (300 mg/L) compared to D36 (150 mg/L) (Figure 6.5).  
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Figure 6.5: Comparison of the IC50 values of ceftazidime in strains with ISAba1, ISAba125 and no IS before the 
ampC gene. The x-axis indicates the ceftazidime concentrations mg/L and the y-axis represents the number of colonies 
%. The error bars indicate the standard deviation (SD) of the 3 colony counts. 
 
 
Hence, there was a good correlation between IC50 values and the relative transcript levels 
obtained from qRT-PCR experiments (Table 6.3).  
 
Table 6.3:  CTX, CAZ resistance profile and relative transcript level. 
 
Isolate Annular radius  MIC (mg/L) Transcript 
level 
IC50 (mg/L) 
CTX CAZ CTX  CAZ 
3208 6 7 16 8 1 7 
D36 0 2 >128 >128 8.2 150 
A388 0 0 >128 >128 21.4 300 
ACICU 0 0 >128 >128 20.02 300 
 
6.5 A388 
A388 is a GC1 isolate from Greece. In order to determine if an IS is present before the ampC 
gene in A388, PCR was used to amplify the ampC region (Figure 6.6; Table 6.4). The amplicon 
includes the complete ampC gene as well as 122 bp of the 3'-end of the folE gene and 165 bp of the 
3'-end of the orf downstream of ampC (Figure 6.6). This PCR would detect any insertion sequence 
upstream of ampC. This PCR generates a 1667 bp product (short) when there is no ISAba1 and a 
longer one when an IS is present. The size of the long product is variable depending on the IS 
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present (Figure 6.6) (Table 6.4). For simplicity, this PCR is called folE-orf PCR throughout this 
chapter. 
 
 
Figure 6.6: PCR strategy to detect ISs upstream of the ampC gene. The thick central line represents the chromosome 
and the arrows below represent the extent of the genes and their direction. The extents of the PCR amplicons are shown 
below with the primer names next to the vertical lines. The vertical arrow represents the insertion point of ISAba1.  
 
Table 6.4: Primer pairs used to characterize the ampC region. 
 
PCR /Region Primer Sequence 5’-3’ Amplicon 
length (bp) 
Reference 
ampC pw51 
pw52 
CGGGCAATACACCAAAAGAC 
CCTTAATGCGCTCTTCATTTGG 
1050 (134) 
(134)  
ISAba1 ISAba1-A 
ISAba1-B 
GTGCTTTGCGCTCATCATGC 
CATGTAAACCAATGCTCACC 
435 (41) 
(41) 
ISAba1-ampC pw52 
ISAba1B 
CCTTAATGCGCTCTTCATTTGG 
CATGTAAACCAATGCTCACC 
1700 (134) 
(41) 
folE-ampC-orf RH581 
RH582 
TGATGATGCGTGGTGTAGGT 
GAGCTGCCATATTGGGAAGA 
1667a This study 
This study 
 
a RH581 and RH582 generate variable products depending on the IS present upstream of ampC.  
 
A large, 2.7 kb, product was obtained for A388 indicating the presence of an IS. To identify the 
IS, the 2,753 bp product was sequenced. The sequence revealed a copy of ISAba125 located 57 bp 
upstream of the initiation codon of the ampC gene (Figure 6.7) suggesting that ISAba125 has 
contributed to cephalosporin resistance in this strain. ISAba125 has previously been seen in the 
same position before the start of ampC in ACICU (GenBank accession no. CP000863) (93). 
 
 
Figure 6.7: The ampC region in the strain A388, which include ISAba125 upstream.  The folE-orf PCR 
generates a 2753 bp PCR when ISAba125 is present upstream of the ampC gene.  
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Insertion sequences are known to activate neighbouring genes by providing outwardly 
directed -35 and -10 promoters, which enhance expression (131, 214), and ampC transcript level in 
A388 was higher than in the control that did not contain any IS. However, analysis of the sequence 
at the boundaries of ISAba125 and ampC in A388 did not reveal a promoter consensus (Figure 6.8). 
Therefore, further work such as transcription initiation experiments will be needed to determine the 
start of the ampC transcript and hence potential promoters.  
 
                       < M            -10 
ATGACAATTTTATATACTCCATAAACCCTTTAAATTAATT AGGTGGTTTA 
                -35                 M > 
TGTCGCACTTCAAGCTTTACTCTGCCGGTGATTTTTGTTATAAAAGTAGG 
 
 *      RBS       M 
CATCTTTCTTTTTAAATAATTTATGAGCTAATCATGCGATTTAAAAAAAT 
 
Figure 6.8: The nucleotide sequence of the 5'-end of ampC and its position relative to the ISAba125. The potential -35 
and -10 hexamers for the transcription of transposase are underlined. The ampC sequences are red and the “M” above 
stands for Methionine. The ribosome binding sequence, RBS, is underlined. The letters coloured green represent 
ISAba125 the “M” above the green letters indicates Methionine, which belongs to the start of transposase. 
 
The folE-ampC amplicons from A297, 3208 and D2, as representatives of CTX and CAZ 
susceptible GC1 strains, were also sequenced to examine if A388 has the same ampC sequence. The 
sequence of the ampC gene in A388 was found to be identical to that found in A297, D2 and 3208, 
except that A388 included a 15 bp duplication of positions 727 to 742.  This has caused the 
duplication of the last 5 amino acid of the # loop, which has been shown to be one of the motifs 
critical for ß lactamase activity (195). In addition, the sequence of the region from A297, D2 and 
3208 was identical to that found in the published genome of the antibiotic-susceptible GC1 isolate 
AB307-0294 (GenBank accession number CP001172). Hence, it appears that ISAba125 in A388 
has inserted into the standard GC1 genome. 
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6.5.1 Cloning of the ISAba125-ampC segment 
To confirm that the ISAba125 contributes to activating the ampC gene, the product of the RH581–
RH582 PCR (Figure 6.6 and 6.7) from 3208 and from A388 was purified and cloned into pCR2.1TOPO. 
The MICs of ceftazidime and cefotaxime conferred by pRMH970, the plasmid containing the fragment 
from 3208, (8 mg/L and 16 mg/L) were 16-fold and 32-fold higher, respectively, than for the vector 
control (0.5 mg/L). When the cloned fragment contained ISAba125 (pRMH971), the MICs were even 
further elevated to at least 256 mg/L. Relative to the vector backbone the ampC gene was in the same 
orientation in pRMH70 as pRMH971. TOP10 cells containing the vector were susceptible to CAZ and 
CTX (Table 6.5). Together the data indicated that the CTX and CAZ resistance observed in pRMH971 
accounts for the presence of ISAba125 as this was the only difference between pRMH971 and 
pRMH970. Together, cloning, qRT-PCR and IC50 data indicated that ISAba125 increases the level of 
CTX and CAZ resistance by increasing the ampC transcript levels.  
 
 
Table 6.5:  MICs of recombinant TOPO plasmids containing ampC and ISAba125-ampC. 
 
Plasmid/ Cell MIC (mg/L)  
CAZ  CTX  Comments 
TOP10a <0. 25 <0. 25 - 
TOP10/pCR®2.1-TOPO® 0.5 0.5 Vector 
pRMH970 b 8  16 Vector/ampC 
pRMH971 c >256 >256 Vector/ISAba125-ampC 
 
aTOP10 cells used for transforming the recombinant plasmids. 
bTOP10 containing pCR®2.1-TOPO®/ ampC; the cloned fragment is derived from 3208. 
cTOP10 containing pCR®2.1-TOPO®/ ISAba125-ampC; the cloned fragment obtained from A388. 
 
 
6.6 ACICU has incorporated the ampC gene from a GC1 strain 
The A. baumannii ACICU, which is a GC2 isolate from Italy and contains ISAba125 upstream 
of the ampC gene was found here to be CTX and CAZ resistant (93). Examination of the sequence 
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at the junction between ISAba125 and ampC revealed that the IS is at the precisely same position 
(GenBank accession no. CP000863) as it was found in A388.  
Analysis of the ampC sequence from ACICU (GenBank accession number CP000863) revealed 
that it differs by only 3 bp, in 1152 bp, from the one found in A388, which is the standard GC1 
ampC allele. The 3 differences in ACICU were 2 base changes and 1 missing base, which cause 
frameshift at the 5'-end of ampC. The sequence of ampC in the region of those differences was re-
determined and the missing base, a T in a run of Ts, was found to be present (Figure 6.9) revealing 
a sequencing error in CP000863. Hence the ampC gene in ACICU differs only by 2 point 
mutations, G547 in 3208 to A in ACICU and A932 in 3208 to G in ACICU, from the standard GC1 
sequences. The 2 base changes cause two amino acid changes of Gly183 in 3208 to Arg in ACICU 
and Asn311 in 2308 to Ser in ACICU, that are not located in the motifs important for ß-lactam 
activity (195). 
                                       L 
CP000863    ATGCGATTTAAAAAAATTTCTTGTCTACTTTTATCCCCGCTTTTTATTTT  
            |||||||||||||||||||||||||||||||||||||||||||||||||| 
corrected   ATGCGATTTAAAAAAATTTCTTGTCTACTTTTATCCCCGCTTTTTATTTT  
             M 
 
CP000863    -AGTACCTCAATTTATGCGGGCAATACACCAAAAGACCAAGAAATTAAAA  
             ||||||||||||||||||||||||||||||||||||||||||||||||| 
corrected   TAGTACCTCAATTTATGCGGGCAATACACCAAAAGACCAAGAAATTAAAA  
 
 
Figure 6.9: Sequence alignment of ampC in the available sequence of ACICU (GenBank accession number CP000863) 
compared to the corrected sequence determined here. The Red “T” indicates the missing base that has caused frameshift 
in the original sequence. The “ATG” coloured green indicates the corrected start codon for ampC in ACICU and the 
“TTG” coloured blue represents the start codon for the available sequence containing the frameshift. 
 
 
This raised the possibility that ACICU might have incorporated the ampC gene together with 
the IS from a GC1 strains such as A388. To determine the size of the segment potentially derived 
from a GC1 genome, the sequence of ACICU in this region was compared with the corresponding 
region from AB307-0294 and AYE, representing GC1, and MDR-ZJ06 (GenBank accession 
number CP001937), representing GC2. The distance between the first and last SNPs shared with 
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AYE is 9677 bp (Figure 6.10 b). The same segment of about 9.6 kb surrounding ISAba125 in 
ACICU differs from that of other GC2 isolates by about 2%, but is nearly identical, (differs by 2 
bp) to the standard GC1 sequence. Surrounding this segment, the sequences of ACICU and other 
GC2 strains were the same, but diverged from the GC1 sequence, due to multiple single-nucleotide 
polymorphisms (Figure 6.10). On average, GC1 and GC2 sequences differed by 3%.   
   (a) 
   (b) 
 
  MDR-ZJ06   GTTGTTTCGATGAAATCCCTTCTATCCCGATCGGGCAAACCAAACGTTGTAATGTTTCCG  
  ACICU      -------C-----------T--------------G-------------------------  
  AYE        -------T-----------G--------------A-------------------------  
 
 
  MDR-ZJ06   AAGTATAACCTCGCACCTGCATACGTTTTTCAAAAATGGCCCTTTTACTCTTTGAGCCAA  
  ACICU      ----------------------------------------T--------T----------  
  AYE        ----------------------------------------T--------T----------  
 
Figure 6.10:  Schematic representation of the diverged region in ACICU compared to a GC1 (AYE) and GC2 (MDR-
ZJ06) strain. (a) comparison of ~ 6 kb on either side of the ampC gene in ACICU, AYE and MDR-ZJ06. The central 
lines represent chromosomes. The continuous lines indicate standard GC1 sequence and the dashed lines represent 
standard GC2 sequence. The numbers in (a) indicate the sequence span, in which a crossover has occurred. (b) shows 
the sequence alignment at the left side boundary of the diverged sequence in ACICU compared to the corresponding 
region in AYE and MDR-ZJ06. Yellow shows the SNPs shared with MDR-ZJ06 (GC2) and red indicates the SNPs 
shared with AYE (GC1). Bold italic sequences indicate the region, in which crossover has occurred between GC1 and 
GC2 sequences.  A similar picture was also observed at the right side boundary of the diverged sequence.  
 
 
 To confirm that MDR-ZJ06 contains the standard GC2 sequence, the ampC gene of A 
baumannii A320 (RUH134), the GC2 reference strain, which is one of the oldest strains available 
and was isolated in 1982, was sequenced. A320 is cephalosporin susceptible and ISAba1 was not 
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found upstream of ampC. The ampC sequence of A320 was designated allele 2. MDR-ZJ06, which 
differed only by a single base that changes the amino acid Asn 340 in A320 to Thr in MDR-ZJ06.  
Together this data indicated that the 9.6 kb DNA segment surrounding the ampC gene in 
ACICU is different to the standards GC2 sequence and the same as that in the GC1 isolate A388. 
This suggests that ACICU has incorporated the ampC gene together with the IS from a GC1 strains, 
such as A388 via homologous recombination. 
 
6.7 Location of ISAba1-ampC  
In order confirm that ISAba1 is between folE and ampC the folE-orf PCR was used to screen 
the remaining strains. This PCR generates a 2853 bp product if ISAba1 is present and a 1667 bp 
product if no ISAba1 is between folE and ampC (Figure 6.11).  
 
Figure 6.11: The PCR strategy used for amplifying the ampC region. The thick central line represents the chromosome 
and the arrows below represent the extent of the genes and their direction. The extents of the PCR amplicons are shown 
below with the primer names next to the vertical lines.   
 
 
 
An amplicon of 1667 bp was obtained for the isolates that were negative for ISAba1-ampC. 
Most of the ceftazidime and cefotaxime resistant strains generated a large PCR product suggesting 
that ISAba1 is located between folE and ampC in these strains (Table 6.6). However, the shorter 
amplicon was generated for 3 ceftazidime and cefotaxime resistant strains, A85, RBH3 and 
6772166 that carry ISAba1 upstream of the ampC gene. This shows that the ISAba1 is not present 
between folE and ampC and also indicates that there is a second ampC in these strains (Table 6.6). 
The control strain AB0057 also generated a short folE-orf product. The three strains, A85, RBH3 
and 6772166, were shown belonging to the ST126.  
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Table 6.6: Properties of the GC1 strains. 
 
GC1 isolates Origin  STa R/Sb ISAba1
-ampC 
folE-
ampC c 
A1 UK 109 S - S 
A297 The Netherlands 109 S - S 
A92, A83 Sydney 109 S - S 
3208 Sydney 109 S - S 
WM98 Sydney 109 S - S 
D2, D3, D6, D7, D27, D62 Sydney 109 S - S 
D30 Sydney 109 S - S 
D36 Sydney 247 R + L 
D13d, D13, D14, D15, D18, 
D18, D20, D45, D48, D108  
Sydney 109 R + L 
D81, D78 Sydney 347 R + L 
G7 Melbourne 109 R + L 
RBH3  Brisbane 126 R + S 
A85  Sydney 126 R + S 
6772166 Adelaide 126 R + S 
AB0057 USA 207 R + S 
 
a Oxford MLST scheme, which includes gltA, gyrB, gdhB, recA, cpn60, gpi, rpoD genes. ST109 (10-12-4-11-4-9-5), 
ST247 (10-12-4-11-4-58-5), ST347 (10-12-4-11-4-80-5), ST126 (10-53-4-11-4-64-5) and ST207 (10-53-74-11-4-100-
5). 
b S= Susceptible; R= Resistant. 
c S= short; L= long. 
d the strains in this group belong to the sequence group 6 (SG6). 
 
 
6.7.1 AB0057 includes two ampC copies 
A. baumannii AB0057, a GC1 strain from the United States (GenBank Accession number 
CP001182), is cefotaxime and ceftazidime resistant and includes two copies of the ampC gene (2). 
ISAba1 is not found upstream of the ampC gene in its normal chromosomal location. Instead, in 
this genome ISAba1 is next to a second copy of the ampC gene found near the origin of replication.  
Here, the region surrounding of the second ampC gene of AB0057 was analysed. This 
revealed an orf immediately downstream that differs by only 20 bp compared to the corresponding 
orf downstream of the ampC in the main location. There is also another ISAba1 immediately 
downstream of the orf in the second ampC region (Figure 6.12 b). ISAba1 is known to generate a 9 
bp duplication after insertion (40), and a 9 bp direct duplication, TTATTTATT, of the chromosome 
was found immediately before the left hand ISAba1 and after the right hand ISAba1 (Figure 6.12 
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b). Moreover, this region is not interrupted in AYE (accession no. CU459141) and AB307-0294 
(accession no. CP001172) genomes.  
(a) 
(b)  
Figure 6.12: The position and structure of Tn6168 in A. baumannii AB0057. (a) circular map of AB0057 and showing 
the positions of ampC, Tn6168 and the genes used in MLST schemes. (b) shows the structure of Tn6168 and a 
comparison of its central segment with the folE-ampC region. Open boxes represent ISAba1 and 9 bp duplications are 
shown next to the left and right ISAba1 copies. Horizontal arrows represent the extent and direction of the genes. 
 
 
This shows that the second copy of the ampC gene is part of a 5516 bp transposon bounded by two 
copies of ISAba1, which includes a central segment of 3155 bp. This structure, the central segment 
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and 2 ISAba1 copies, was named Tn6168 (5516 bp) because it exhibits the typical properties of 
class 1 transposons. This transposon was not noticed previously (2).  
The sequences of the central portion of Tn6168 and the resident copy differ at 72 positions. 
15 bases of the ampC gene (bp 729-743) were also duplicated causing a duplication of the last 5 
amino acids of the # loop. This duplication is also present in A388. 68 differences were single base 
substitutions, 22 in ampC causing 5 amino acid substitutions, and 20 in the orf. The remaining base 
substitutions and three 1-3 bp additions/deletions were in the 65/68 bp between the termination 
codons of ampC and the orf. In addition, a stem-loop structure was found 22 bp downstream of the 
ampC stop codon in 3208 similar to the stem-loop structures involved in $-independent termination 
(Figure 6.13).  
                                 A A  
 (a)                                         T   T 
                            A   C 
                             G-C 
                             G-C 
                             T-A 
                             A-T 
                             A-T 
                             A-T 
                             G-C       
                             A-T     
ampC >*                      G-C                  * < orf 
     TAACCGTTTTAGCCAAAAACAAAAA TTTTTTATGCACTTATTCTTTA 
 
                              T 
 (b)                         A   C 
                           C     A 
                            T   T 
                             G-C 
                             A-T 
                             T-A 
                             A-T 
                             A-T 
                             A-T 
                             G-C 
                             A-T 
                             G-C 
                             A-T 
   ampC> *                   G-C                    * <orf 
        TAATTTTTCCCTAAAATAAAAA TTTTTTTATAGGTACATGGTTTA 
 
Figure 6.13: Stem-loop structures found downstream of the ampC stop codon in (a) 3208 and (b) in Tn6168 from A85. 
Though complementary, the underlined bases are not folded, as these bases define the site of termination and do not 
contribute to the stem loop structure.    
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A similar stem-loop structure was found 19 bp downstream of the ampC in Tn6168 as the 
stem loop was not disrupted by differences within it.  
Examination of the sequence between ISAba1 and ampC, in the strains containing the IS next 
to the ampC e.g. AYE (GenBank Accession no. CU459141), revealed that 9 bp lie between the IS 
and the ATG of ampC while in Tn6168 there are only 7 bp between the IS and start of the ampC 
gene (Figure 6.14).   
 (a)                     
                      9 bp                                                                   9 bp 
          TTTATGAGCTAATCCTCTGT…CTATTTTTGTCGTGTACAGAGGAGCTAATCATGCGATTTA  
 
 (b) 
                                                        7 bp  
          TTAAATTATTTATTCTCTGT…ATCTATTTTTATCGTGTACAGAGGCTAATCATGCAATTTA  
 
Figure 6.14: Boundaries of the ISAba1 insertion sites upstream of ampC at the main position  (a) and the second 
position (b) relative to the start of the ampC gene. (a) represents the boundaries of the ISAba1 insertion sites 
upstream of ampC in the main position of strain AYE and (b) Tn6168 in AB0057. The ampC sequences are bold. 
23 bp from the beginning and 5 bp from the end of ISAba1 are shown white on black.  In (a) the 9 bp duplication 
generated by the insertion of ISAba1 in the main position is underlined.  
 
6.8 Tn6168 in Australian ST126 strains 
To examine if ISAba1-ampC is in Tn6168 in the three Australian ST126 isolates, a PCR was 
developed to link the ampC gene to the right hand ISAba1 (Figure 6.15). All three strains generated 
4036 bp products, which suggest that there is a complete copy of Tn6168 in A85, RBH3 and 
6772166.  
Figure 6.15: PCR mapping strategy developed to identify Tn6168. Open boxes indicate ISAba1 copies and the arrows 
indicate the direction of the transposase genes. PCRs and their amplicon sizes are also shown below. 
 
The products of the PCRs linking ampC to the left and right ISAba1 (Figure 6.15) were 
sequenced from A85. The sequence was identical to that of Tn6168, in AB0057, confirming that 
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A85 includes a copy of Tn6168. The PCR amplicon linking ampC to the left ISAba1 copy was also 
sequenced from RBH3 and 6772166 and was identical to the corresponding region in Tn6168.  
 
6.8.1 Location of Tn6168 
To examine if the three ST126 strains include Tn6168 in the same position as in AB0057, a 
further PCR was designed to identify the Tn6168 at this chromosomal location (Figure 6.16).  This 
PCR links the ampC gene in Tn6168 to orf AB57_0006 and generates a 2900 bp PCR product if 
Tn6168 is at this position (Figure 6.16). This amplicon includes 174 bp of 5'- end of the orf 
(AB57_0006), ISAba1, ampC, and 162 bp of the 3' end of the orf downstream of ampC.  
 
Figure 6.16: The PCR strategy to identify the ISAba1-ampC structure in the location present in AB0057. 
 
A85, RBH3 and 6772166 all generated the 2.9 kb predicted PCR product indicating Tn6168 is 
in the same chromosomal position as in AB0057. The 2900 bp product of RH741-RH582 PCR was 
sequenced using the RH741 primer, to complete the ISAba1-ampC sequence previously performed, 
from A85, RBH3 and 6772166, and the sequence was identical to that of AB0057.  
Figure 6.17: PCR mapping strategy developed to identify Tn6168 and its chromosomal location. Open boxes indicate 
ISAba1 copies and the arrows indicate the direction of the transposase genes. PCRs and their amplicon sizes are also 
shown below. 
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Another PCR that links the ampC gene to the orf AB57_0013 on the right hand side of the 
Tn6168 (Figure 6.17) also generated the predicted product 3.4 kb for A85, RBH3 and 6772166 
(Table 6.7) confirming the position of Tn6168. The ampC sequence found in Tn6168 was also 
named allele 3.   
 
Table 6.7: Primers used for mapping of Tn6168. 
 
PCR /Region Primer Sequence 5’-3’ Amplicon 
length (bp) 
AB57_0006-ampC RH741 
RH582 
TTCAGTACCCCAGCCTTTTG 
GAGCTGCCATATTGGGAAGA 
2900 
ISAba1 (L)-ampC pw52a 
ISAba1Ba 
CCTTAATGCGCTCTTCATTTGG 
CATGTAAACCAATGCTCACC 
1700 
ampC-ISAba1(R) RH1358 
ISAba1Aa 
TGGCTGTGGGTGTTATTCAA 
GTGCTTTGCGCTCATCATGC 
4036 
ampC-AB57_0013 RH1379 
RH1380 
GCAGCTTATGCTGTGCTGAA 
TCGCCTTGGCTTAACAAAAC 
3429 
 
a See table 6.3 for reference. 
 
 
The product of the PCR RH1379-RH1380 (Figure 6.17) from A85 was also sequenced, using 
the RH1380 primer, to complete the sequence of Tn6168 and its flanking region. The sequence 
differed from that in AB0057 only by 1 bp. The difference was due to an additional G in position 
574 of the right hand ISAba1 copy in AB0057. This difference is likely to be a sequencing error in 
AB0057 as ISAba1 is usually 1180 bp whereas this ISAba1 copy was the only record in the 
database that includes 1181 bp with the additional G. The extra G, in fact creates a frameshift in the 
first transposase gene and renders its product 19 aa shorter.  
The ISAba1 copies, in Tn6168, were not identical. The differences were (left copy ! right 
copy) G13A, A476G, C727T and G993A, which the latter changes the amino acid A82 to V(right) 
in the second transposase protein. The sequence of Tn6168 as well as ~200 bp flanking sequence on 
either sides from A85 has been deposited in GenBank under the accession number KC118540.  
For the other two isolates, RBH3 and 6772166, the RH1379-RH1380 product was digested 
with HindIII and generated fragments of the predicted sizes (1176 bp, 1004 bp, 750 bp, 372 bp and 
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172 bp). Together the results of the PCR mapping, sequencing and HindIII digestion indicate that 
A85, RBH3 and 6772166 contain a copy of Tn6168 in the same location as AB0057. This suggests 
that AB0057 (isolated in the US) and the three strains from different Australian cities are related.  
In addition, for all three ST126 strains, the ampC gene in the normal location was sequenced 
and was identical to the standard GC1 sequence found in 3208, D2, A297, AYE and AB307-0294. 
In AB0057, the ampC copy in the main chromosomal location differed from the standard GC1 
sequence, found in 3208, and AYE, over a short span of 214 bp. The sequence of this region was re-
determined and found to be identical to the standard GC1 sequence (Figure 6.18). This seems to 
have arisen from confusion over the assembly of the two ampC copies. Because the wrong 
sequence is identical to the corresponding sequence in the second copy, which therefore suggested 
that a few reads from the second copy had been misassembled into the first one. 
 
AYE    (allele1)      AAAACTGGCTCAACCAACGGTTTCGGAACATATGTAGTGTTTATTCCTAA   
Corrected             --------------------------------------------------   
CP001182              --------------T-----------------------------------   
CP001182(Tn6168)      --------------T-----------------------------------   
 
AYE    (allele1)      AGAAAATATTGGCTTAGTCATGTTAACCAATAAACGTATTCCAAATGAAG   
Corrected             --------------------------------------------------   
CP001182              ------------T-------------------------------------    
CP001182(Tn6168)      ------------T-------------------------------------    
 
AYE    (allele1)      AGCGCATTAAGGCAGCTTATGCTGTGCTGGATGCAATAAAGAAATAACCG   
Corrected             --------------------------------------------------   
CP001182              -----------------------------A-----------------***   
CP001182(Tn6168)      -----------------------------A-----------------***   
 
AYE    (allele1)      TTTTAGCCAAAAACAAAAAGAGAAATGGA*TAATC**CCATTTCTCT***   
Corrected             -----------------------------*-----**----------***   
CP001182              ----TC--T----T---------G-----G-C---AT-T--------CTT   
CP001182(Tn6168)      ----TC--T----T---------G-----G-C---AT-T--------CTT   
 
AYE    (allele1)      TTTTTATGCACTTATTCTTT  
Corrected             --------------------  
CP001182              -------AGGTAC--GG---  
CP001182(Tn6168)      -------AGGTAC--GG---  
 
Figure 6.18: Sequence alignment of 3’-end of the ampC gene in AYE, both copies in AB0057, bases 2874305-2874521 
of the GenBank accession number CP001182 and the corresponding region in Tn6168, and corrected sequence of ampC 
in the main chromosomal location of AB0057. Dashed lines indicate identical sequences and mismatches are shown 
white on black. Bold underlined TAA indicates the ampC stop codon and “*” indicates a missing base. 
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6.9 Evidence for movement of Tn6168 
To examine the basis of cephalosporin resistance in non-GC1 non-GC2 strains, strains from 
different clonal types were examined. One isolate, J9, that is representative of a group of 64 strains 
(240) that had caused an outbreak between 1996-1999 in Westmead hospital in Sydney (hospital J) 
(240), was found to be ceftazidime and cefotaxime resistant. The ISAba1-ampC PCR generated the 
expected band size (1700 bp) (Figure 6.11) indicating that ISAba1 is present upstream of ampC but 
the folE-orf PCR generated a short product (Figure 6.11) indicating that ISAba1 is not between 
ampC and folE. The PCR linking the ampC to the second ISAba1 in Tn6168 (RH1358-ISAba1-A) 
generated the predicted 4036 bp PCR product and HindIII digestion generated the predicted 
fragments if a complete copy of Tn6168 is present in J9 (1104 bp, 1004 bp, 806 bp, 750 bp and 372 
bp). The product of ISAba1-ampC PCR was sequenced and was identical to the sequence of the 
corresponding region in Tn6168.  Thus J9 contains Tn6168. However, the RH741-RH582 PCR that 
identifies the position of the Tn6168 in AB0057 failed to generate a product indicating that Tn6168 
is in a different location (Figure 6.17). The two primers that surround Tn6168 in AB0057, RH741-
RH1380 (Figure 6.17), generated a 535 bp product indicating that this position is not interrupted in 
J9. Hence Tn6168 must be located elsewhere. This finding represents evidence for movement of 
Tn6018 into A. baumannii strains of different clonal types and to different positions leading to their 
cephalosporin resistance.   
 
6.10 Source of Tn6168 
In order to find the source for the ampC found in Tn6168, the GenBank non-redundant and 
WGS databases were explored using the sequence of the 3155 bp central segment of Tn6168 as 
query. Several draft genomes were found to contain ampC sequence identical or almost identical, 1-
2 bp difference to the ampC in Tn6168, allele 3. The whole 3,155 bp central segment of Tn6168 
also differed only by 1-2 bp in all isolates but two, which differed by 11 bp (Table 6.8).  
 
CHAPTER SIX                                                               Ceftazidime and cefotaxime resistance in A. baumannii 
Table 6.8: Properties of strains with sequences closely related to the central portion of Tn6168. 
 
Strain Year Country ampC 
allele 
differences a 15 bp 
duplication 
  
ISAba1-
ampC 
ISAba1-
ampC b 
Tn6168 MLST Accession number 
Institut 
Pasteur  
Oxford 
scheme 
Canada BC-5 2007 Canada 3c 2 + + 7  + ST1 - d AFDN01000002 
OIFC099 2003 USA 3  1 - - - - ST32 ST463 AMFT01000059 
OIFC032 2003 Germany 3  2e - - - - ST32 ST463 AFCZ02000002 
OIFC087 2003 USA 3  2 - - - - ST32 ST472 AMFS01000087 
OIFC137 2003 USA 3  1 - + 9 - ST3 ST465 AFDK01000002 
OIFC109 2003 USA 3  1 - + 9 - ST3 ST465 ALAL01000006 
Naval-13 2006 USA 3  1 - + 9 - ST3 - d AMDR01000064 
AB-4857 2009 USA 3  2 e - + 9 - ST3 - d AHAG01000033 
Naval-81  2006 USA 3  2 e - + 9 - ST3 - d AFDB02000002 
IS-123 2009 Iraq 3  1 - + 9 - ST3 - d ALII01000007 
WC-A-694 2008 USA 3  1 - + 9 - ST3 - d AMTA01000043 
IS-143 2008 Iraq 3  1 - + 9 - - d ST265 AMGE01000039 
Naval-21 2006 USA 3  11 - + 9 - ST19 - d AMSY01000029 
OIFC074 2003 Germany 3  11 - + 9 - ST19 ST231 AMDE01000034 
CGAB09 2008 Taiwan 3f NAg - + 9 - NKh NK EU604835 
 
a this column indicates the differences of the ampC-orf region compared to the 3155 bp central segment of Tn6168. 
b numbers indicate the number of bases between ISAba1 and ampC. 
c contains an additional T at position 914 of ampC; Tn6168 is present in the position as in AB0057. 
d MLST could not be determined due to the absence of the allelic profile and/or some of the alleles in the MLST database.  
e  this sequence includes 1 base change and 1 missing base in a run of 8 Ts in Tn6168. 
f the sequence differs from the ampC in Tn6168 by 1 bp. 
g not applicable; the entry only includes partial sequence of ISAba1 and ampC. 
h not known. 
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MLST of these isolates was determined in silico. An isolate, Canada BC-5 from Canada isolated in 
2007, was found to belong to the GC1 clonal complex, ST1 (Institut Pasteur), and to contain 
Tn6168 (Table 6.8). It includes Tn6168 in the precisely same position as in AB0057 and the 
Australian ST126 strains, which indicates that these strains could be related.  
A possible origin for the central segment of Tn6168 was found in 3 draft genomes, OIFC099, 
OIFC032 and OIFC087, with sequences differing from that in Tn6168 by 1-2 bp in the 3,155 bp 
central segment. None of these isolates included ISAba1 upstream of ampC (Table 6.8). These 
strains belong to ST32 (Institut Pasteur) or ST463/ST472 (Oxford) and are mainly from the USA or 
Iraq (Table 6.8). This suggests ISAba1 might have picked up the central segment of Tn6168 from 
ST32. Even further isolates contained allele 3 with ISAba1 9 bp upstream of the ampC gene (Table 
6.8). However, the orf downstream of the ampC gene differed by 11 bp in all of them. These strains 
belonged to the ST3 or ST19 (Institut Pasteur) (Table 6.8).  
 
6.11 Discussion  
The work presented in this chapter examined the genetic basis of resistance to 3rd generation 
cephalosporins. In a collection of 26 GC1 strains resistance to 3rd generation cephalosporins was 
associated with the presence of ISAba1 upstream of the ampC gene and this is also consistent with 
the findings of previous studies (1, 2, 84, 134, 195, 206, 208). 
The -10 sequence identified here, is an extended -10 (TGnCATTAT), which would increase 
the promoter’s strength even further (11, 27). This promoter overlaps with the promoter identified 
previously (Figure 6.18) (208). In addition, in the strains contained ISAba1 upstream, the ampC 
gene was preceded by RBS sequence, which was provided by ISAbA1 (Figure 6.19). This could 
indicate that activation of the ampC gene occurs due to the strong promoters as well as the RBS 
provided by ISAba1. Though variation in the RBS could potentially affect the expression of ampC 
and subsequently the level of CTX and CAZ resistance, it has been shown that the change in the 
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RBS sequence resulting from the insertion of ISAba1 does not influence the expression of ampC as 
there were no increase in the activity (84). 
There is a long distance between the folE and ampC gene, 160 bp, which is rather unusual for 
bacterial genes and also contained a few short open reading frames, 10-20 aa. In addition, a bi-
directional rho-independent terminator was found in the region between the 3'-end of ampC and the 
3'-end of orf. Together, these finding suggested the presence of additional regulatory features that 
impact transcription and/or translation of ampC in A. baumannii. It has been previously shown that 
the ampC gene is not inducible in A, baumannii, when Bou et al. in 2000 reported the presence of a 
chromosomal ampC gene in A. baumannii for the first time (20). However, the strain they 
examined, RYC, included a copy of ISAba1 upstream of ampC, which could have potentially 
disrupted the additional regulatory features and enhanced the expression of the gene permanently 
rendering it non-inducible. Therefore, whether the ampC gene is inducible in A. baumannii needs to 
be further examined. 
In one GC1 strain, A388 isolated in Greece, ceftazidime and cefotaxime resistance was found 
to be due to the presence of ISAba125 upstream of the ampC gene. This had only been seen 
previously once in ACICU, a GC2 strain from Italy (93). However, there was no experimental work 
indicating whether ISAba125 was able to activate the ampC gene. This was shown by cloning of the 
segment that contained ISAba125-ampC as it increased the MICs for CAZ 8-fold and for CTX 16-
fold compared to the cloned fragment that included only the ampC gene.  In addition, qRT-PCR 
indicated ~20 fold higher expression level of the ampC gene driven by ISAba125 compared to the 
strains with no IS upstream. ISAba125 was located 57 bp upstream of ampC in both ACICU and 
A388. However consensus promoter sequences were not found that could direct ampC 
transcription. One of the impacts of the ISAba125 could also be disrupting additional regulatory 
features and influencing the expression of ampC. After this part of the work was finished another 
cephalosporin resistant A. baumannii strain that contain a copy of ISAba125 next to the ampC gene 
was reported but a sequence is not available (129). Comparison of 50 kb surrounding the ampC 
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gene in ACICU to GC1 and GC2 genomes provided evidence for the transfer of 9.6 kb of the 
chromosome, including ISAba125-ampC, from a GC1 isolate to a GC2 strain.  
A transposon, which contains ISAba1-ampC and was named Tn6168, was found in three 
Australian ST126 strains from different cities (from Sydney, Melbourne and Brisbane) and its 
chromosomal location was the same as that in AB0057 (ST207; Oxford scheme) from the US. 
Besides, the central portion of Tn6168 was traced to strains belong to ST32 (Institut Pasteur 
Scheme) indicating that these strains might be the source. Tn6168 was also identified in a recent 
draft genome of a GC1 strain Canada BC-5 again in the same location, which suggests that these 
strains could have been derived from a common ancestor. Tn6168 was also found in a non-GC1 
non-GC2 strain, J9, from Sydney. However, its location was not the same as that in the Australian 
ST126 strains and remains to be determined. To the best of our knowledge, this study for the first 
time proposes the movement of an ISAba1-activated ampC gene in the form of a transposon as a 
new mechanism of acquiring an activated ampC gene and becoming cephalosporin resistant. 
In summary, the Australian A. baumannii strains have become cephalosporin resistant via 
either direct insertion of ISAba1 upstream of ampC or acquisition of the activated ampC gene in 
Tn6168. Recombination events have played a role in the evolution of cephalosporin resistance in A. 
baumannii belonging to different clonal types as an ISAba125-activated ampC gene is shared 
between GC1 and GC2 strains. This study highlights homologous recombination and acquiring 
ampC in a transposon as new mechanisms that have led to cephalosporin resistance in A. 
baumannii.
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7.1 Introduction  
In the previous chapter it was shown that cephalosporin resistance in Australian GC1 strains 
is due to the presence of ISAba1 upstream of the ampC gene.  It was found that a GC2 strain, 
ACICU, had acquired an ISAba125 activated ampC gene by incorporating a 9 kb DNA segment 
from a GC1 strain via homologous recombination. Tn6168 was also found in a group of 
geographically unrelated cephalosporin resistant strains. This is the first study that has shown the 
role of horizontal transfer of the ampC gene in cephalosporin resistance, via either acquisition of a 
transposon or replacement of a chromosomal segment that includes an IS activated ampC gene.    
The work presented in this chapter was designed to examine the variability of the ampC gene 
in the remainder of the GC1 collection.  
 
7.2 Do cephalosporin sensitive isolates include the same ampC allele?  
 
 
To determine if the cephalosporin susceptible GC1 strains usually include the same ampC 
allele, the folE-orf PCR, which amplifies the whole ampC gene, was sequenced from additional 
cephalosporin sensitive strains A92 (GenBank accession no. GQ406246) and WM98 as well as 
strain A1, which was isolated in the UK. The ampC sequence in A1 is particularly important as this 
strain was isolated in 1982 and is one of the oldest strains available today.  It was found that these 
isolates all contain an ampC identical to that found in 3208 (GenBank accession no FJ172370), D2 
(GenBank accession no GQ406245), A297, AYE (GenBank accession no. CU459141) and AB307-
0294 (GenBank accession no. CP001172). This allele was named allele 1 in Chapter 6 and here it is 
considered as the original or standard GC1 ampC allele.  
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7.3 What ampC alleles do cephalosporin resistant isolates include? 
Variants of allele 1 were also found in the cephalosporin resistant strains, D36, D78 and D81. 
The ampC sequence in D36 differed from allele 1 by only 1 bp, which was the A at position 1,022 
in 3208 and C in D36 and the aa at position 341 N in 3208 and T in D36. D78 and D81 included A, 
C and A at positions 78, 117 and 150 respectively while 3208 contained C, T and G at these 
positions. Although D78 and D81 exhibited a lower MIC, 32 mg/L of CAZ, none of the differences 
altered the AmpC sequence that could potentially explain this difference. The variants of allele 1 
found in D36 and D78/D81were named alleles 1a and 1b respectively (Table 7.1). The ISAba1 
sequence next to the ampC in D36 was the same as in AYE but differed from that found in D78 and 
D81 at 5 positions indicating that different ISAba1 copies are inserted next to the ampC.  
 
Table 7.1: The sequence variations of ampC in the GC1 collection. 
 
GC1 isolates RI type MIC mg/L ampC 
allele 
ISAba1variant a 
13..44..65..112..224..980..1131..1138 CTX CAZ 
AB307-0294 - - - 1 - 
A1 AbaR24 8 4 1 - 
A297 AbaR21 8 4 1 - 
A92 AbaR7 8 4 1 - 
3208 AbaR5 16 8 1 - 
WM98 AbaR0 16 8 1 - 
D2 AbaR6 8 4 1 - 
AYE AbaR1 - - 1 G .. A .. C .. T .. G .. C  ..  C  ..  G 
D36 AbaR4 >128 >128 1a b G .. A .. C .. T .. G .. C  ..  C  ..  G 
D78 AbaR23 >128 32 1b c G .. G .. C .. G .. A .. T  ..  T  ..  A 
D81 AbaR23 >128 32 1b G .. G .. C .. G .. A .. T  ..  T  ..  A 
D13 d AbaR8 >128 >128 4 G .. A .. T .. T .. G .. C  ..  C  ..  G 
D15 d AbaR8 >128 >128 4 G .. A .. T .. T .. G .. C  ..  C  ..  G 
D45 d AbaR8 >128 >128 4 G .. A .. T .. T .. G .. C  ..  C  ..  G 
D108 d  Tn6019-6018 >128 >128 4 G .. A .. T .. T .. G .. C  ..  C  ..  G 
G7 AbaR3 128 32 5 A .. A .. C .. T .. G .. C  ..  C  ..  G 
 
a  numbers indicate the positions of sequence variations found in ISAba1. 
b  1a differs from 1 by 1 bp. 
c  1b differs from 1 by 3 bp. 
d  SG6. 
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In Chapter 3, it was noted that two ceftazidime resistant isolates, D78 and D81, contained only 1 
copy of ISAba1 in their genomes. Analysis of their genome data confirmed this and it is located before 
the start of the ampC gene. This suggests that it is also possible that the IS has picked up the ampC 
from a strain that contain an ampC close to allele1 and incorporated to these isolates. 
D13 contained a distinct ampC sequence (GenBank accession no. HM590877) differing from 
the allele 1 by 29 bp (2.5%) and it was named allele 4 (Table 7.2). The nucleotide differences found 
in D13 cause five amino acid substitutions compared to the AmpC of 3208 (Figure 7.1). Moreover, 
the ampC sequence of three other strains, D15, D45 and D108, from the SG6 group were 
determined and all were found to contain the allele 4 (Table 7.2). As expected, SG6 strains all 
included the same ISAba1 variant, which contains a unique SNP compared to the AYE/D36 variant. 
 
Table 7.2: Nucleotide differences in ampC allelic variants  
 
Strain GC Allele AYE a A85b G7 D13 WM99c  
AYE 1 1 0 22 27 29 37 
A85b 1 5  0 31 19 33 
G7 1 3   0 41 48 
D13 1 4    0 39 
WM99c c 2 2a     0 
 
a representative for allele 1. 
b in Tn6168. 
c WM99c is a GC2  isolate.  
 
G7 also contained a distinct ampC allele that had not been seen before (last search 
28/10/2013). This sequence, which differed from allele 1 by 27 bp, was named allele 5 (GenBank 
accession no.  KC118541) (Table 7.2).  Compared to AmpC-1, the AmpC in G7 contained six 
amino acid substitutions (Figure 7.1). However, these differences could not explain the relatively 
low, 32 mg/L, MIC of ceftazidime observed in this strain, because none of the substitutions were in 
the domains known to be crucial for ß-lactamase activity, such as the ! loop, helix H-2, or helix-
H10 (195) (Figure 7.1). Although allele 5 and 4 shared some of the differences relative to allele 1 
they differed from one another by 41 bp (Table 7.2). This suggested that both G7 and the SG6 
strains have acquired an ISAba1-activated ampC from a distantly related A. baumannii strain. 
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3208 (1)    MRFKKISCLLLSPLFIFSTSIYAGNTPKDQEIKKLVDQNFKPLLEKYDVPGMAVGVIQNN 60  
D36  (1a)   ------------------------------------------------------------  
D13  (4)    ------------------------------------------------------------  
G7   (5)    -------------------------------------------------------I----  
 
                                                      SVSK  Helix H-2 
3208        KKYEMYYGLQSVQDKKAVNRSTIFELGSVSKLFTATAGGYAKNKGKISFDDTPGKYWKEL 120  
D36         ------------------------------------------------------------  
D13         -------------------S--------------------------------------V-  
G7          -------------------S-------------------------------K--------  
 
                                                                   YSN 
3208        KNTPIDQVNLLQLATYTSGNLALQFPDEVQTDQQVLTFFKDWQPKNPIGEYRQYSNPSIG 180  
D36         ------------------------------------------------------------  
D13         ------------------------------------------K-----------------  
G7          ------------------------------------------------------------  
 
                                                                        Ω- 
3208        LFGKVVALSMNKPFDQVLEKTIFPALGLKHSYVNVPKTQMQNYAFGYNQENQPIRVNPGP 240  
D36         ------------------------------------------------------------  
D13         ------------------------------------------------------------  
G7          -------------------E----------------------------------------  
            - Loop 
3208        LDAPAYGVKSTLPDMLSFIHANLNPQKYPADIQRAINETHQGFYQVNTMYQALGWEEFSY 300 
D36         ------------------------------------------------------------  
D13         ------------------------------------------------------------  
G7          ------------------------------------------------------------  
 
                   Helix-H10                     KTG   
3208        PATLQTLLDSNSEQIVMKPNKVTAISKEPSVKMYHKTGSTNGFGTYVVFIPKENIGLVML 360 
D36         ----------------------------------------T-------------------  
D13         ----------------------------------------T-------------------  
G7          ----------------------------------------------I-------------  
 
3208        TNKRIPNEERIKAAYAVLDAIKK  383  
D36         -----------------------  
D13         ------------------N----  
G7          ------------------S----  
Figure 7.1: Alignment of the AmpC variants identified in the GC1 collection. Identical amino acids are indicated by 
dashes and amino acid substitutions are colored. The typical ß-lactamase domains (SVSK, YSN, and KTG) are bold. 
Helices H-2 and H-10 and ! loop are underlined with their name indicated above. The strains names are indicated on 
the left and the numbers in bracket represent the ampC alleles. 
 
 
7.4 The size of the ampC patch 
When draft genomes became available in 2012 (in collaboration with Prof. Gordon Dougan; 
WelcomeTrust Sanger Institute and Kathryn Holt; University of Melbourne) it was possible to 
explore the extent of the substituted ampC region, in D13 and G7. The two contigs that contain the 
folE-ISAba1-ampC sequence were recovered, assembled using the manually determined sequence 
and compared to the ampC region of 3208 that includes the standard GC1 ampC sequence in a 
single 325 kb contig (Figure 7.2a) and has the same sequence as AYE and AB307-0294. A pairwise 
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alignment of ~15-20 kb on either side of ampC to the GC1 sequence from 3208 was inspected to 
find the length of the diverged sequence, defined as the span between the first and last base 
differences.  
In G7 a ~31.8 kb region, which differs from the corresponding region in 3208 by 2.4% (24 
bp/ kb) was found (Figure 7.2). 
 
 
Figure 7.2: Schematic representation of the substituted ampC region in G7 and D13.  (a) represents the contig that 
contains ampC in 3208 and the 2 contigs, one blue one black, that include the same region in G7 and D13. Contig 
numbers and sizes are below. (b) shows the extent of the region surrounding ampC in G7 and D13. The thin horizontal 
line on top is the scale and the thick horizontal lines below indicate the extent of ~25 kb surrounding ampC on either 
side in G7 and D13. The segments of the thick lines coloured black represent sequences identical to 3208 and red shows 
the diverged sequences. The green arrow indicates the position of ISAba1. (c) indicates the extent of the substituted 
region and position of ISAba1. 
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For D13 the length of the diverged sequence surrounding the ampC gene was only 2,412 bp, 
which differed from the corresponding region in 3208 by 2.3% (23 bp/ kb).  The diverged region  
in D13 was estimated as the segment between the T, 80 bp before the ISAba1 insertion point, and   
the G located 17 bp before the ampC stop codon (the bases indicated white on red in Appendix III, 
Figure III-2). This segment was identical in all SG6 strains confirming a common origin. 
These findings indicate that G7 and D13 have incorporated a divergent chromosomal segment 
that contained an activated ampC gene. This was likely diverged from another A. baumannii strain 
and introduced by homologous recombination.  
 
7.5 Source of the ampC patch 
In order to find the source of sequence incorporated in D13 and G7, a few genomes of non-
GC1 non-GC2 strains available in the Hall Lab were screened (Section 7.6). The GenBank non-
redundant and WGS databases were also explored. A possible source for the ampC allele in G7 was 
not found in the Hall lab collection or in GenBank. 
However, strain D4 from Sydney was found to contain an ampC allele only 2 bp different to 
that found in D13 (Table 7.3). This allele was named allele 4a. D13 included C and T at positions 
1,022 and 1,068 while D4 contained A and C and T at these positions and the aa at position 341 T 
in D13 and N in D4, which caused by the nucleotide substitution at position 1022. D4 is a non-GC1 
non-GC2 strain belonging to ST25 (Institut Pasteur) and does not include ISAba1 before the start of 
the ampC. Because the ampC sequence in D4 contained allele 4a, the 2,412 bp substituted ampC 
sequence from D13 was compared to the corresponding region in D4 and no additional differences 
were found.  
The WGS database was explored to find strains with allele 4, and five strains (Table 7.3) 
that all belonged to ST25 and contained ampC allele 4a were found. Two strains, AB5256 and 
Naval-18, included a copy of ISAba1 next to ampC, which could be the source for the substituted 
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region in D13. This could indicate that the SG6 strains have gained a 2,412 bp DNA segment 
containing ISAba1-ampC from an ST25 strains such as Naval-18 and AB5256 that include this 
configuration.  
In Chapter 3, it was shown that SG6 strains have picked up a 19 kb sequence including the 
csuE region from another A. baumannii. In order to examine whether ST25 strains are also the 
source of the diverged csuE sequence in SG6 strains, this region was also compared to the 
corresponding region in ST25 strains and was found to differ from it by 2% indicating that SG6 
strains have acquired their csuE from another source. 
 
Table 7.3: Properties of the strains containing variants of the ampC allele 4. 
 
Strain Origin Year ampC 
allele 
ISAba1
-ampC  
 
MLST; Institut Pasteur GenBank 
accession no. ST (cpn60-fusA-gltA, 
pyrG-recA-rplB-rpoB) 
D13 Sydney 2008 4 + 1  (1-1-1-1-5-1-1) HM590877 
D4 Sydney 2006 4a a  - 25 (3-3-2-4-7-2-4) - 
AB_2008-15-69 USA 2008 4a - 25 (3-3-2-4-7-2-4) AMHN01000000 
AB5256 USA 2009 4a + 25 (3-3-2-4-7-2-4) AHAI01000000 
UMB003 USA 2008 4ab - 25 (3-3-2-4-7-2-4) AEPM01000000 
OIFC143 USA 2003 4a - 25 (3-3-2-4-7-2-4) AFDL01000000 
Naval-18 USA 2006 4a + 25 (3-3-2-4-7-2-4) AFDA02000000 
 
a differs from allele 4 by 2 bp. 
b 1 bp of the ampC sequence is missing (possibly a sequencing error). 
 
 
The distribution of the mobile element ISAba1 as the major driver of resistance to the 3rd 
generation cephalosporins was investigated using Southern hybridization and examination of the 
draft genomes. It was shown in Chapter 3 that ISAba1 is distributed in GC1 strains as most of the 
strains contain multiple copies of this IS. However, the ISAba1 profile of the SG6 group was 
variable  (Figure 3.4b and Figure 7.3a) and only 1 band was shared.  
In order to confirm that the band shared in all strains belongs to the ISAba1 next to ampC, the 
membrane in Figure 7.3 was stripped and re-hybridized with an ampC probe (Figure 7.3 b).  The 
ampC probe hybridized to the shared ~ 9 kb EcoRI band. (Figure 7.3 b).  
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      (a)                                                                     (b) 
 
Figure 7.3: Southern Hybridization using ISAba1 and ampC probes.  The first lane on the left is DIG-labelled 
DNA ladder with the sizes of the fragments indicated next to them. The strain names are indicated on the top. (a) 
represents ISAba1 profiles of SG6 strains using and (b) shows hybridizing the same membrane using ampC probe. 
The arrows at the right of both figures indicate the EcoRI fragments that contain ISAba1-ampC the band and 
hybridized with ampC probe.  
 
This was confirmed by identifying the location of all ISAba1 copies in the draft genome of 
the SG6 strains (Appendix III; Table III-3). The locations of ISAba1 are shown in Figure 7.4 and 
which ISAba1 are in each strain is in Table 7.4. Hence, the ISAba1 between the folE and ampC 
genes was the first ISAba1 that incorporated into the genome of the SG6 strains and then expanded 
into new chromosomal locations.  
Figure 7.4: ISAba1 copies identified in SG6 isolates. P1, the red arrow, indicates the first position of ISAba1 located 
upstream of ampC. The blue arrows show the unique ISAba1 positions identified only in 1 isolate and the rest, black 
arrows, are the ISAba1 positions found in more than one isolate (see Table 7.4). D108 is not shown in Figure 7.3 as it 
was received in 2011 and examined in a separate experiment. 
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Table 7.4: ISAba1 positions identified in SG6 strains. 
 
Isolate Date ISAba1 positions 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 a 15 a 
D15 16/5/2009 + + + - - - - - - - - - - - - 
D14 30/5/2009 + - - + + - - - - - - - - - - 
D13 03/6/2009 + - - + + + - - - - - - - - - 
D18 18/6/2009 + - - + + - + - - - - - - - - 
D20 04/7/2009 + - - + + - + + - - - - - - - 
D45 2010 + - - + + - + - + - - - - - - 
D48 2010 + - - + + - + - - + - - - - - 
D108 2011 + - - - - - - - - - + + + + + 
 
a P14 and P15 belong to Tn2006, which is present on a plasmid. 
 
7.6 ISAba1 target specificity  
Examination of the boundary of ISAba1 and ampC revealed that 9 bp separate the IS from 
ampC in AYE, D36, D78 and D81, which contained variants of ampC allele 1. ISAba1 was also 9 
bp upstream of ampC in G7 and in D13, which contained a distinct ampC sequences.  
The ampC genes of the GC2 strains A91 and RBH44, which determined here, and differed only 
by a single base (data not shown), also were found to be 9 bp away from ISAba1 (Figure 7.5; Table 
7.5).  
The boundary of ISAba1 and ampC was therefore analyzed in the strains from different clonal 
types. D46 isolated in 2010 in Sydney, and RBH2, isolated in 1999 in Brisbane, each contained a 
distinct ampC allele and ISAba1 was again appropriately oriented and 9 bp away from the ampC start 
codon (Table 7.5).  
                                                                  !ISAba1                              9 bp         ampC" 
AYE      TTATCTATTTTTGTCGTGTACAGAGGAGCTAATCATGCGATTTAAAAAAATTTCTTGTC 
D13      ----------------------------------------------------------- 
RAN      ----------------------------------------------------------- 
D46      ----------------------------------------------------------- 
CGAB09   --------------------------------------A-------------------- 
G7       ------------A---------------------------------------------- 
RBH44    ------------A---------------------------------------------- 
RBH2     ------------A---------------------------------------------- 
Figure 7.5: DNA sequence alignment of the boundaries at the ISAba1 insertion sites upstream of different ampC 
sequence variants. Dashed lines indicate identical sequences. The ampC sequences are shown white on black and 
ISAba1 is shown black on dark grey. The nine bases separating ISAba1 and ampC are shown bold black. 
Nucleotide differences of ISAba1 and ampC are also shown with a different colour. RBH44, which contains allele 
2, is shown as a representative of the strains containing variants of the allele 2 as their sequence is identical over 
the span shown in this figure. 
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To further examine the possibility that ISAba1 can target this position, the location of ISAba1 
relative to ampC in other sequences available in the GenBank non-redundant DNA database was 
examined. 15 strains were found to contain ISAba1-ampC, 12 of which were GC2 and contained 
variants of the allele 2 (Table 7.5) and in all of them ISAba1 was found 9 bp away from the ampC 
gene (Figure 7.5).   
 
 
Table 7.5: Properties of ISAba1-ampC containing strains. 
 
Strain Origin GC Allele ISAba1 
position a 
Accession no. 
AYE b France 1 1 9 CU459141 
G7 Melbourne 1 5 9 KC118541 
D13 Sydney 1 4 9 HM590877 
RBH44 Brisbane 2 2 c 9 This study 
A91  Sydney 2 2a d 9 JN968483 
MDR-ZJ06 China 2 2a e 9 CP001937 
RAN South Africa nk f 10 g 9 AY325306 
D46 Sydney - 6 9 KF030679 
RBH2 Brisbane - 7 9 KF030678 
 
a the numbers indicate the number of bases between ISAba1 and ampC. 
b representative for allele 1. 
c EF653401 and EU835512 were also found to include allele 2 and the IS 9bp away from the start of the ampC. 
d 2a differs from allele 2 by 1 bp at position 1024. ISAba1 was also found 9 bp away from the ampC allele differed from 
allele 2a by 1-2 bp in JF265068, AY228469, AJ009979, JF265067 and AY758396. 
e CP002522, CP003856 and CP001921 are also completed GC2 genomes and include an ISAba1 9 bp away from an 
ampC differed from allele 2 by 1-2 bp. 
f not known 
g allele 10 is a unique sequence and differs from the other alleles by ~3%.  
 
 
 
Two additional cases of ISAba1 associated with distinct ampC alleles were found in the strains 
CGAB09 and RAN (accession numbers EU604835 and AY325306). In both of them, the IS was again in 
the same orientation and separated from the ATG of ampC by 9 bp. Hence, in all the strains from 
different clonal types that contain ISAba1 preceding ampC, the IS was found 9 bp upstream of 
ampC (Table 7.5). So far, ISAba1 is seen 7 bp upstream of ampC only in Tn6168 (Chapter 6). The 
fact that ISAba1 was found in the same position and orientation relative to eight different ampC alleles 
can be explained by ISAba1 repeatedly inserting at exactly the same position. 
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7.7 Discussion  
The work presented in this Chapter examined the variability of the ampC gene in GC1 A. 
baumannii. Ceftazidime and cefotaxime sensitive strains all contained the same, standard GC1 
ampC, allele 1. Two different ampC sequences were also found in two resistant isolates, indicating 
that the ampC gene and the ISAba1 have been acquired from another Acinetobacter strain. The 
extent of the diverged sequence was determined to be 31.8 kb in one of the strains, though it was 
not possible to find a potential source for this diverged sequence. The SG6 strains also contained a 
distinct ampC allele in a 2.4 kb diverged segment that appeared to have been picked up from a 
different clonal complex, ST25. The ISAba1 copy located before the start of the ampC gene was the 
first ISAba1 to enter into the SG6 genome.  
These findings add to the finding in Chapter 6 that ACICU (GC2) has incorporated a 9 kb 
segment of chromosome, including ISAba125-ampC, from the chromosome of a GC1 isolate. 
Hence, homologous recombination incorporating an activated ampC gene into the genomes of 
cephalosporin susceptible isolates represents a new mechanism by which A. baumannii strains can 
become resistant.  
In addition, ISAba1 was repeatedly found 9 bp away from ATG of ampC, and if ISAba1 has 
independently inserted into the same position in each of the different backgrounds this would indicate 
some site specificity for ISAba1. This could contribute to the importance of this mechanism of 
resistance to third generation cephalosporins.  
The ISAba1 which was acquired along with ampC subsequently expanded into new spots in 
the chromosomes of individual isolates. This movement was rapid, as most of the SG6 strains had 
been recovered over a relatively short period in 2009.  
In summary, both direct insertion of ISAba1 upstream of ampC and horizontal transfer of a 
chromosomal segment containing ISAba1-ampC have contributed to the generation of 
cephalosporin resistance in Australian GC1 isolates. 
 
CHAPTER EIGHT                                                                The tobramycin and gentamicin plasmid pRAY 
 
 178 
 
 
 
 
 
 
 
 
 
Chapter 8  
 
  
The tobramycin and gentamicin resistance 
plasmid pRAY in Acinetobacter 
 
 
CHAPTER EIGHT                                                                The tobramycin and gentamicin plasmid pRAY 
 
 179 
8.1 Introduction  
Among many aminoglycoside resistance genes only a few confer resistance to tobramycin and 
among these, aadB is one of the most often encountered genes (213). Resistance to gentamicin, 
kanamycin and tobramycin at the same time is usually indicative of the presence of the aadB gene 
(31, 188, 213). Gentamicin and kanamycin resistance can be accounted for by the presence of other 
aminoglycoside resistance genes e.g. aacC1 and aphA1, which confer resistance to gentamicin and 
kanamycin respectively (213). Therefore, tobramycin resistance, together with gentamicin and 
kanamycin, is a useful indicator for the presence of the aadB gene. 
The aadB gene encodes an aminoglycoside adenyltransferase (AAD(2")) which inactivates the 
aminoglycosides antibiotics gentamicin, kanamycin and tobramycin by adenylylating the 2"-
hydroxyl group (98, 213, 239). The aadB gene is part of a 591 bp gene cassette and has usually 
been found associated with class 1 integrons (31, 188). However, in 1997 an aadB gene cassette 
was found in a secondary location on a plasmid, named pRAY, from an isolate of Acinetobacter 
(204, 205). This strain, SUN, was isolated from a patient in a hospital in Cape Town but the species 
was not determined (204, 205).  
pRAY is 6076 bp (GenBank accession no. AF091755) and was predicted to include 10 open 
reading frames (including aadB) ranging in size from 240 to 1095 bp (Figure 8.1). However, no 
potential replication initiation protein was found (204). Only one of the open reading frames could 
be identified and it was an mbeA gene encoding a protein related to mobilization proteins (Figure 
8.1) (60, 204, 205). A putative origin of transfer, oriT, was identified based on homology to the bom 
region of pCN3 and related ColE1 plasmids (204). It is located upstream of orf 3 (mbeA) and was 
named bom (Figure 8.1) (204). In addition, pRAY is not stably maintained in E. coli, suggesting it 
is an Acinetobacter specific plasmid (204). 
Most known gene cassettes, including aadB, do not include a promoter (188). Segal and Elisha 
identified the transcription initiation site of the aadB gene in Acinetobacter calcoaceticus and E. 
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coli (204). In A. calcoaceticus this site was (the red A in Figure 8.2) located 277 bp upstream of the 
aadB start codon (Figure 8.2), and the hexamer, TATTCA, upstream of this site shows some 
similarity to the consensus -10 sequence (TATAAT) recognized by sigma 70 (204).  
Figure 8.1: Map of pRAY from GenBank accession number AF003958 and the PCR for identifying the aadB in the 
context of pRAY. The positions of PCR primers are represented by lines joining pairs of primers, with primer names 
adjacent to them. Arrows within the circle represent the ORFs. The location of the HindIII (H) and BamHI (B) sites are 
shown outside the circle representing the plasmid and the numbers inside indicate the nucleotide position in kb. Red 
indicates aadB gene cassette, blue represent oriT and green shows orf 3 which was previously identified as mobilization 
protein (MbeA).  
 
 
However, no sequence with homology to the consensus -35 hexamer (TTGACA) was 
identified near this potential -10 hexamer (204). The transcription initiation site in E. coli was 126 
bp upstream of the aadB start codon (Figure 8.2) near the -35 and -10 promoter signals (204). 
                                                      -10 
TACTTCATCT AAAAGGGGGA AGAATCAATA CCGCAACCTT ATTCATTCTC -280 
-277 
CTATCCAAAA TATCCAAATA CAAGCTGCTA AATGGTCTTA AAAAAATTTA -230 
 
TATTGAGGAA CAAAGTAAAG TAAAAATACT TAGCACTTTC AAACTCCTTG -180  
                     -35                      -10    
AAGAAATAAA GAACCTAGTT GACACTAACA CCGCATTCAA ACAGAATAAT -130  
 -126 
GGTGCTCTGC CCCATCCAAT CGAAAGGTTG GATAGTTAAG ACAATCACTG -80 
 
GGAGCTCACT ATTGGATGTA ACAATTCAAT TAATAGTCTA ATTACTGACA -30  
                                M       
TTCTGGGAGG GCTTACTATG TTAGGCCGCA TGGACACAAC GCAGGTCGCA 21 
 
Figure 8.2: Nucleotide sequence of the region upstream of the aadB gene (Bold black bases indicate the beginning of 
the gene). Transcription initiation sites in A. calcoaceticus (A) and E. coli (G) are the red bases with their position 
relative to the ATG of aadB indicated above. The -35 and -10 hexamers are bold and coloured green. The vertical arrow 
represents the first base of the aadB gene cassette. The numbers at the right are relative to the ATG of the aadB gene. 
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Recently, a PCR (Figure 8.1) was developed to detect the aadB gene in the location it occupies 
in pRAY (152). Using this PCR, it was shown that aadB is in the context of pRAY in 18 GC2 A. 
baumannii isolates from four Australian hospitals that were resistant to gentamicin, kanamycin and 
tobramycin, but did not contain a class 1 integron (152). The aadB cassette was found in the same 
context in A. baumannii A297 (RUH875), the GC1 reference strain isolated in 1984 in the 
Netherlands (153). pRAY has recently been reported to be in A. baumannii AB058, a GC1 isolate 
from the USA, but only parts of the pRAY sequence can be found in the draft genome (GenBank 
accession number ADHA00000000) (1). Hence, in these GC1 and GC2 strains the presence of 
pRAY accounts for tobramycin resistance. 
The aim of the work in this chapter was to investigate the molecular basis of gentamicin, 
kanamycin and tobramycin resistance in GC1 strains, and in strains from different clonal types as 
well as identifying the gene(s) and their context.  
 
8.2 Gentamicin and tobramycin resistant strains 
The GC1 collection was examined to find tobramycin resistant strains (see chapter 3). In 
addition to A297 (RUH875) that had already been shown to carry aadB in the context of pRAY 
(153) only one other strain, D36, isolated in 2008, was tobramycin resistant (Table 8.1). Amongst 
the non-GC1, non-GC2 isolates, six strains (Table 8.1) were found to be tobramycin resistant and 
one of them, J9, was representative of a group of strains that had caused an outbreak between 1996-
1999 at Westmead hospital in Sydney (hospital J) (240). All but one of the six non-clonal isolates, 
PCH49, were identified as A. baumannii based on the presence of the chromosomal oxa-Ab gene 
(Table 8.1). Also, an MLST type could not be assigned to PCH49, as the gdhB gene could not be 
amplified.  
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The sequence of the oxa-Ab gene designated allele 1 in Table 8.1 was consistent with the 
assignment of RUH875 (A297) and D36 to GC1 and allele 2 in C2 is found in other GC2 strains 
(152). A297 (78) and D36 shared six of the seven Oxford scheme MLST alleles (Table 8.1). 
 
Table 8.1: Characteristics of gentamicin and tobramycin resistant Acinetobacter isolates. 
 
Isolates Clone Year Hospital a City oxa-Ab b MLST c 
RUH875 d 1 1984 LUMC Dordrecht 1 (69) ST109 (10-12-4-11-4-9-5) 
D36 1 2008 RNSH Sydney 1 (69) ST247 (10-12-4-11-4-58-5) 
C2 2 2007 CRGH Sydney 2 (66) ST92   (1-3-3-2-2-7-3)  
D46 - 2010 RNSH Sydney 3 (64) ST110 (1-15-2-28-1-52-32) 
D4 - 2006 RNSH Sydney 3 (64) ST364 (1-15-2-28-1-40-32) 
RBH2 - 1999 RBWH Brisbane 4 (88) ST125 (1-52-59-12-1-18-44) 
RCH51 - nk e RCH Brisbane 5 (70) ST253 (1-52-29-28-18-24-7) 
J9 - 1999 WM Sydney 6 (new)  ST- - - (*-44-58-1-*-*-*) f 
PCH49 - nk  PCH Brisbane - ST- - - (11-27-*-21-16-22-15) g 
 
a LUMC (Leiden University Medical Centre), RNSH (Royal North Shore Hospital), CRGH (Concord Repatriation 
General Hospital), RBWN (Royal Brisbane and  Woman's Hospital), WVH (Woden Valley Hospital), RCH (Royal 
Children's Hospital) and PCH (Prince Charles Hospital), WM (Westmead Hospital). 
b oxa-Ab alleles  have been named arbitrarily. 1 predicts OXA-69, 2 (OXA-66), 3 (OXA-64), 4 (OXA-88), 5 (OXA-70) 
and 6 predicts a unique allele that it’s protein differs from OXA-91 by 2 aa (9 bp at DNA level). 
c Oxford MLST scheme which uses -gltA, gyrB, gdhB, recA, cpn60, gpi and rpoD housekeeping genes. 
d A297(GC1 reference strain). 
e not known. 
f gltA, , cpn60, gpi and rpoD primers didn’t produce any product for J9. 
g  gdhB could not be amplifies. 
 
The non-clonal isolates were from different places and ST types. Amongst them isolates D4 
and D46 shared the same oxa-Ab allelic variant and had a related ST type, however they carry 
different aminoglycoside resistance genes (discussed in section 8.2.1). Isolate J9 had a unique oxa-
Ab allelic variant and differed from its closest match in GenBank by 9 bp. RBH2 and RCH51 also 
had a different ST type and oxa-Ab gene (allele 4) (Table 8.1).  
 
8.2.1 Do tobramycin resistant strains carry aadB in pRAY? 
 
To examine whether aadB was present in the gentamicin, kanamycin and tobramycin resistant 
GC1 isolates as well as in non-GC1 non-GC2 isolates, a PCR assay using primers amplifying 524 
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bp of an internal segment of the aadB gene was performed (152). The strain C2, which had already 
been shown to carry aadB in pRAY (152) was used as a control in all PCR experiments. 
This PCR assay revealed that all the isolates contained the internal fragment of the aadB gene, 
which indicates the presence of this gene and accounts for their resistance to tobramycin, 
gentamicin and kanamycin.  
To test if aadB was in pRAY another PCR assay was performed using primers RH561-RH562 
(Table 8.3; Figure 8.3). The primers for this PCR had already been designed based on the available 
sequence of pRAY (GenBank accession no. AF091755) and amplify from regions external to the -
aadB gene (Figure 8.3) (152). The presence of this 1kb fragment indicates that pRAY, or at least a 
fragment of pRAY that contains the aadB gene cassette, is present in the isolates that generate 
positive result.  All but one of the isolates, D4, generated the predicted product for the PCR 
amplifying the aadB in pRAY, indicating that this plasmid, or at least a fragment of it that contains 
aadB gene is present in these isolates.  
 
Table 8.2: The presence of aadB in the context of pRAY 
 
Isolates Year Inhibition zones (mm) a aadB aadB in 
pRAY Tm Gm Km Nm Ne Ak 
A297 b 1984 4 3 0 9 9 8 + + 
D36 2008 4 4 0 5 9 8 + + 
C2 2007 4 3 4 8 8 8 + + 
D46 2010 1 0 0 3 6 1.5 + + 
D4 2006 4 3 0 4 7 7 + - c 
RBH2  1999 1 0 0 2 2.5 0 + + 
RCH51 NK d 2 2 2 2.5 9 8 + + 
J9 1999 3 3 4 9 9 6 + + 
PCH49  nk 3 1 3 8 9 8.5 + + 
 
a  annular radius; Tm: tobramycin, Gm: gentamicin, Km: kanamycin, Nm: neomycin, Ne, Netilmicin, Ak: amikacin. 
b RUH875 (GC1 reference strain). 
c D4 has aadB in class 1 integron. 
d not known 
 
 
To examine whether a complete copy of pRAY is present and also to simplify detection of 
pRAY a PCR strategy was devised. The available sequence from Acinetobacter strain SUN 
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(GenBank Accession number AF003958; Figure 8.3) was used to design two overlapping PCRs 
(RH561 with RH1359 generates a 3314 bp product and RH1360 with RH1361 generates a 3279 bp 
product) to amplify the complete pRAY plasmid (Table 8.3).  
Figure 8.3: Map of pRAY (GenBank accession number AF003958) and overlapping PCRs designed for identifying 
pRAY. The positions of PCR primers are represented by lines joining pairs of primers, with primer names adjacent to 
them. The red arrow within the circle represents the aadB gene. The location of the HindIII (H) and BamHI (B) sites are 
shown inside the circle representing the plasmid and numbers inside indicate the nucleotide position in kb. The thick red 
segment of the circle indicates the aadB gene cassette.  
 
 
Table 8.3: Primers used for characterization of pRAY.  
 
PCR Primer  Primer sequence (5'– 3') Size 
(bp) 
Reference 
aadB RH377-R 
RH212-R 
GCATATCGCGACCTGAAAGC 
GACACAACGCAGGTCACATTGAT 
524 (152) 
(152) 
aadB in 
pRAY 
RH561 
RH562 
GGGAAGAATCAATACCGCAA 
AATTTCACCCCAAACAATCG 
999 (152) 
(152) 
PCR1 RH561 
RH1359 
GGGAAGAATCAATACCGCAA 
ATTCAAAACAACGCCCAGAC 
3314 (152) 
This study 
PCR2 RH1360 
RH1361 
GACGAGACCAAGCGAGAAAA 
GCCCTCCCAGAATGTCAGTA 
3279 This study 
This study 
 
These PCRs were then used to demonstrate the presence of a complete copy of pRAY in the 
strains examined. For all but one strain, D4, these PCRs generated products of the predicted size. 
The PCR products were digested with HindIII and yielded fragments of the predicted sizes (1407, 
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910, 525, 396 and 76 bp for PCR1 and 1697, 1545 and 37 bp for PCR2) (Figure 8.4). This indicates 
the presence of pRAY in the strains. 
 Figure 8.4: PCR product restriction profiles of pRAY1 and pRAY2 PCRs for C2, D36 and A297 (RUH875). 
Restriction fragments were generated by HindIII restriction digestion and separated on a 1% agarose gel.  In lanes 2 and 
10, undigested PCR products of pRAY1 and pRAY2 PCRs are loaded. On both sides, the sizes of restriction fragments 
are shown and the names of the strains are indicated above. 
 
Plasmid DNA was extracted from all isolates (Table 8.1) and digested with BamHI, which 
linearizes pRAY yielding a 6 kb band (Figure 8.5). Digestion with HindIII generated the expected 
fragments of 2,808, 1851, 910, 396, 76 and 37 bp suggesting that pRAY is present in all the strains 
tested. The restriction profiles of the strains also showed that all the strains examined contain at 
least one additional plasmid, which were not shared by the other strains.  
Figure 8.5: Plasmid restriction profiles. Restriction fragments generated by digestion of plasmid DNA with BamHI and 
HindIII and separated on an agarose gel are shown. Sizes of markers are shown on the right. On the right, HindIII 
fragments derived from pRAY are indicated by arrows and on the left; the black arrow represents the 6 kb band derived 
from BamHI linearization of pRAY.  The names of the isolate are indicated above. 
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8.3 Characterization of pRAY 
To examine if the pRAY sequences in Australian isolates are the same as the available pRAY 
sequence, the pRAY sequence of D36 (GC1) and C2 (GC2) were determined by sequencing the two 
overlapping PCRs. The sequences are deposited in GenBank under accession numbers JQ904627 for 
D36 and JF343536 for C2.  
8.3.1 pRAY* 
Sequencing revealed that the plasmid recovered from D36 was 6,078 bp long and contained 
the aadB gene cassette. However, when these sequences were compared to the available sequence 
for pRAY (GenBank accession number AF003958), a total of 14 additions or deletions of 1-6 bases 
were revealed. As nine of the differences alter the reading frame within one of the predicted orf in 
pRAY shown in Figure 8.6 (a), these differences may represent errors in the original pRAY 
sequence (Figure 8.6; Table 8.4). The plasmid recovered from D36 was designated pRAY*. The 
sequence was re annotated and the reading frames found in it are shown on Figure 8.6 (b). It was 
not possible to examine whether the differences were due to a sequencing error since the strain A. 
baumannii SUN was not accessible.  
Figure 8.6: Maps of pRAY (GenBank accession number AF003958) and pRAY* (GenBank accession number 
JQ904627). Arrows within the circle represent the ORFs. The location of the HindIII (H) and BamHI (B) sites are 
shown outside the circle representing the plasmid and numbers inside indicate the nucleotide position in kb. Red 
indicates the aadB gene cassette and green shows orf 3 in (a), which was previously indicated as mobilization protein 
(mbeA) and mobC and mobA in (b).   
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Table 8.4: Open reading frames found in pRAY and pRAY* 
 
Plasmid/ 
Length (bp) 
Gene/ orf Positions Size 
(bp) 
pRAY aadB 648..1181 533 
/6076 orf2 5948..6076-1..399 527 
 mbeA 3932..4549 617 
 orf4 3658..3966 308 
 orf5 2736..3830 1094 
 orf6 3224..3490 266 
 orf7 2804..3220 416 
 orf8 2083..2625 542 
 orf9 1649..1888 239 
 orf10 1398..1697 299 
pRAY* aadB 649..1182 533 
/6078 orf 1 5950..6078-1..558 686 
 orf2 1341..1889 548 
 orf3 2142..2687 545 
 orf4 2804..3220 416 
 orf5 3224..3835 611 
 mobA 2736..4550 1814 
 mobC 4540..4947 407 
8.3.2 pRAY* has mobC and mobA 
pRAY* included eight reading frames, including aadB, whilst pRAY contained 10.  The 
mobA predicted a 604 aa MobA protein, which was 146 aa longer than MbeA seen in pRAY (orf3 
in Figure 8.6 (a)). The N-terminal portion of MobA was 43% identical to the equivalent part of the 
mobilization protein, Mbe, from ColE1 consistent with the placement in the ColE1 superfamily 
(MOBHEN family) of MobA proteins. A further reading frame, mobC (Figure 8.6 (b)), was found. 
The 3’-end of this open reading frame overlaps mobA by 11 bp, and predicted a 135 aa protein 
homologous to MobC proteins in the GenBank protein database. The region previously identified as 
the putative origin of transfer identified previously as bom, here re-named oriT, is located upstream 
of mobC (Figure 8.6). Though two additional orfs overlap the mobA gene and three further orfs 
were found elsewhere, none had homologues in the GenBank protein database, and no potential 
replication initiation protein could be found. Hence, the exact region required for plasmid 
replication could not be established. 
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8.4 Properties of pRAY* 
8.4.1 Transformation of pRAY* 
In order to further study pRAY in A. baumannii electro-transformation was carried out using 
E. coli DH5", A. baumannii ATCC19606, A. baumannii B1 (GC2 strain) and A. baumannii D108 
(GC1 strain), which are susceptible to tobramycin, gentamicin and kanamycin, as recipients. 
Plasmid DNA from D36 (GC1) was used to transform E. coli and A. baumannii cells and 
transformants were selected on LA medium supplemented with kanamycin. No transformant was 
recovered when E. coli DH5" was used as the recipient indicating that pRAY does not replicate in 
E. coli and is a specific plasmid for the Acinetobacter genus. This result is in agreement with the 
findings of Segal and Elisha, in which they failed to isolate pRAY-containing E. coli transformants 
(205). Gentamicin, kanamycin and tobramycin resistant transformants of A. baumannii 
(ATCC19606, B1 and D108) were obtained (Figure 8.7) and transformation frequency was 
calculated at 1.5-2 # 107 transformants /$g plasmid DNA.  
Figure 8.7: HindIII plasmid restriction profiles of A. baumannii ATCC19606 (lane1), A. baumannii ATCC19606 
transformant that contains pRAY (lane 2) and A. baumannii D36 that contains pRAY*. The arrows at the left of the 
picture indicate the positions of pRAY* bands in D36 and ATCC19606/ pRAY*. The numbers indicate the sizes of 
fragments in kb. 
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The presence of pRAY in transformants was confirmed using the overlapping PCR 
amplifying the complete pRAY as well as isolation of plasmid DNA (Figure 8.7). Even though D36 
contained at least two plasmids, HindIII restriction profiles of isolated plasmid DNA of 
transformants (ATCC19606) showed that transformants had incorporated only pRAY* (Figure 8.7). 
 
8.4.2  Replication region in pRAY* 
 In order to confine the region likely to contain sequences necessary for replication, a HindIII 
restriction digest of pRAY*, isolated from D36, was ligated and was transformed into ATCC19606. 
Transformants were then selected on LA plates containing 20$g/ml kanamycin. PCR using the 
primers RH1370, 5’-CGTTATCGGATTTACTGCTTTAC-3’, and RH1377, 5’- 
CGTCAGCCCAATTACAGGTT-3’, which includes the all HindII restriction sites of pRAY*, 
(Figure 8.10 a) followed by HindIII digestion of PCR products were used to screen the 
transformants. It was found that 19 transformants, of 22 tested, generated a ~ 900 bp product whilst 
four transformants produced larger bands (Figure 8.8; transformants number 7, 14, and 20). This 
suggested that the transformants that produced ~900 bp products, given the positions of the primers 
used (Figure 8.10), contain only the 2.8 kb fragment of pRAY* and the others include additional 
HindIII fragments. 
 
 
Figure 8.8:  PCR screening of transformants containing different fragments of pRAY*. 
 
In order to confirm the number of fragments in the transformants that generated ~ 900 bp 
product three of them were digested with HindIII and all generated two bands of 521 bp and 387 bp  
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Figure 8.9:  HindIII digestion of the PCR product generated by RH1370 and RH1377, of the transformants that 
contained pRMH972. 
 
(Figure 8.9) consistent with only the 2.8 kb fragment of pRAY* being present. The 2.8 kb HindIII 
fragment was named pRMH972. pRMH972 contains orf 1, the aadB gene cassette and the 3’-end of 
orf 2 (Figure 8.10 b). 
 
Figure 8.10:  Linearized map of pRAY (a) and pRMH972 (b). The thick central lines indicate extent of plasmids, 
which have been opened at BamHI site. The letter “H” in both plasmids indicates HindIII restriction sites and the 
arrows below the central line represent open reading frames with their named indicated bellow. The green arrows in 
(a) indicate mobilization genes. In (b) only aadB and orf 1 are present and the 5’-end of orf 2 has been removed. The 
5’-end of orf 1 can be seen at the right below the central line.  
 
To confirm the PCR results, five transformants that appeared to contain only pRMH972 were 
selected and plasmid DNA was extracted followed by HindIII digestion (Figure 8.11). All of the 5 
transformants tested were found to contain only pRMH972 in addition to their indigenous plasmids 
(the 2.8 kb band in the red box; Figure 8.11). These findings confine the regions that provide the 
necessary signals for plasmid replication to sequence retained pRMH972 since it replicates 
independently and renders ATCC19606 kanamycin resistant. 
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Figure 8.11: HindIII plasmid restriction profiles of A. baumannii ATCC19606, ATCC19606 transformants that contain 
only pRMH972 and ATCC19606 that contains pRAY*.The arrows on the right of the picture indicate the positions of 
pRAY* bands in ATCC19606 that contains pRAY* and the numbers on the left represent the kb sizes of ladder. 
ATCC19606 transformants contain only one additional band, pRMH972, which is shown in the red box, compared to 
the ATCC19606 that contains pRAY*. 
 
 
8.5 pRAY variants in the Acinetobacter collection 
8.5.1 pRAY*-V1, a new variant of pRAY* 
To test whether GC2 strains have the same pRAY sequence, the sequence from the strain C2 
was determined and designated pRAY*-v1. The sequence of pRAY*-v1 from A. baumannii C2 
differed from pRAY* by 66 single base differences 65 of which were clustered between bp 3,344 
and 4,702 covering the C-terminal end of the mobC gene and the N-terminal end of the mobA gene 
(Figure 8.12). The differences generate 19 amino acid (aa) substitutions in total four of which in the 
135 aa MobC protein and 15 substitutions in the 604 aa of MobA.  
 
Figure 8.12:  Linearized map of pRAY*-v1. The thick central line indicates extent of plasmid, which has been opened 
at BamHI site. The blue segment of the central line indicates the diverged sequence in pRAY*-v1 compared to pRAY* 
and black segments represent identical sequences in both plasmids. 
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8.5.2 pRAY variants in non clonal strains 
To examine if other strains from different clones contain either pRAY*, pRAY*-v1 or 
possibly another variant, two non-clonal strains, RCH51, PCH49 and A297 (GC1 reference strain) 
were sequenced manually using the products of the two overlapping pRAY PCRs. Sequencing 
revealed that pRAY* is in A297 (RUH875), and PCH49 contained pRAY*-v1. The sequence in 
RCH51 differed from pRAY*-v1 by only a single base change (Table 8.5). This indicates that at 
least two variants of pRAY have been circulating in Australian A. baumannii strains of different 
clonal types. 
 
Table 8.5: pRAY* variants in Acinetobacter collection. 
 
Isolates GC Origin Year Phenotype a pRAY 
variant 
A297 (RUH875) 1 Netherlands 1984 GmKmTm pRAY* 
D36 1 Sydney 2008 GmKmTm pRAY* 
C2 2 Sydney 2007 GmKmTm pRAY*-v1 
PCH49 - Brisbane nk GmKmTm pRAY*-v1 
RCH51 - Brisbane nk GmKmTm pRAY*-v1 b 
 
a Gm, gentamicin; Km, kanamycin; Tm, tobramycin. 
b differs from pRAY*-v1 by 1 bp; C-5183" A. 
 
 
8.5.3 Variants of pRAY* in GC2 strains 
Plasmid DNA was also extracted from other pRAY-containing GC2 A. baumannii isolates 
from the collection as described previously (152). Isolates A72, A87, C15, C18, D8, D37, E1, E16, 
F38 and F18 were selected to represent the various hospitals of origin and a wide time span, and in 
all cases the digests  (Figure 8.13) revealed the presence of pRAY confirming the previous 
assignment by the PCR showing the presence of aadB in the pRAY context. 
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Figure 8.13: Plasmid restriction profiles. Restriction fragments generated by digestion of plasmid DNA with HindIII 
and separated on an agarose gel are shown. Sizes of 1 kb ladder fragments are shown on the left. On the right, fragments 
derived from pRAY are indicated by arrows and bands derived from p1 or p2 are labelled. The names of the isolates are 
indicated above.  
 
 
8.5.4 Additional plasmids in pRAY containing strains 
Linearizing with BamHI revealed that all isolates contained additional plasmids of different 
sizes. Isolates A72, A87, C15, C18, D8, D37, E1, E16, F38 and F18 (Table 8.6), which were from 
different Australian hospitals, contained an additional plasmid of either 9.5 kb or 12 kb, designated 
p1 and p2 (Table 8.6). Isolates C15 and C18 also contained a further additional plasmid(s). After 
digestion with HindIII, the fragments derived from pRAY were visible (marked with arrows in 
Figure 8.13) together with an approximately 7 kb fragment shared by p1 and p2 and a second 
fragment of 2.5 kb from p1 or 5 kb from p2. The 12 kb p1 plasmid was found in isolates from 
hospitals A and D in Sydney and F in Brisbane, and the 9.5 kb plasmid was in isolates from 
hospitals C in Sydney and E in Canberra. These similarities may indicate connections between the 
two sets of hospitals. The two GC1 strains had additional plasmids but they were not related to one 
another. Also, all the non-clonal strains, RBH2, RCH51, PCH49 and D46 had unrelated additional 
plasmids. 
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Table 8.6: Distribution of plasmids in aadB positive GC2 strains from Australian hospitals. 
 
Isolate Year City pRAY Other plasmids a 
C2 2006-7 Sydney + p1 
C15 2006-7 Sydney + p1, p3, p4 
C18 2002 Sydney + p1, p3 
A87 2004 Sydney + p2 
A72 2001 Sydney + p2 
D8 2006-7 Sydney + p2 
D37 2008 Sydney + p2 
E1 2006 Canberra + p1 
E16 2009 Canberra + p1 
F38 2000 Brisbane + p2 
F18 2002 Brisbane + p2 
 
a Estimated sizes are: p1, 9.5kb and p2, 12kb. 
 
 
 
8.5.5 pRAY variants from the genomes 
Draft genomes of all the remaining gentamicin, tobramycin and kanamycin resistance isolates, 
available in the Hall Lab collection, were explored using the sequence of pRAY* and pRAY*-v1 as 
query to determine the variant of pRAY in the entire collection. Searching the genome sequencing 
data revealed that the pRAY sequence was in a single contig for individual isolates. These contigs 
contained ~ 20 bp overlaps at both ends, which indicate that these contigs may be circular. The 
sequences confirmed the sequence of pRAY* from D36 and pRAY*-v1 from C2, which had been 
determined manually. Interestingly all the GC2 isolates from different Australian hospitals 
contained pRAY*-v1 though they were isolated from five different Australian hospitals between 
2000-2009 (Table 8.7).  The fact that RBH2, from Brisbane in 1999, contained pRAY*-v1 the same 
as the GC2 strains suggests a connection between these strains. D46, a non-GC1 non-GC2 strain, 
contained pRAY* as found in the GC1 strains, D36 and A297 (Table 8.7). 
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Table 8.7: pRAY* variants identified from genome data. 
 
 Isolates GC Origin Year Phenotype a pRAY variant 
D36 1 Sydney 2008 GmKmTm pRAY* 
C2 2 Sydney 2007 GmKmTm pRAY*-v1 
C3 2 Sydney 2007 GmKmTm pRAY*-v1 
C4 2 Sydney 2007 GmKmTm pRAY*-v1 
C5 2 Sydney 2007 GmKmTm pRAY*-v1 
C8 2 Sydney 2007 GmKmTm pRAY*-v1 
C15 2 Sydney 2006 GmKmTm pRAY*-v1 
C18 2 Sydney 2002 GmKmTm pRAY*-v1 
D8 2 Sydney 2006 GmKmTm pRAY*-v1 
D9 2 Sydney 2006 GmKmTm pRAY*-v1 
D12 2 Sydney 2007 GmKmTm pRAY*-v1 
D37 2 Sydney 2008 GmKmTm pRAY*-v1 
A72 2 Sydney 2001 GmKmTm pRAY*-v1 
A87 2 Sydney 2004 GmKmTm pRAY*-v1 
RBH1 2 Brisbane 2002 GmKmTm pRAY*-v1 
RBH18 2 Brisbane 2002 GmKmTm pRAY*-v1 
RBH38 2 Brisbane 2000 GmKmTm pRAY*-v1 
RBH45 2 Brisbane 2002 GmKmTm pRAY*-v1 
E1 2 Canberra 2006 GmKmTm pRAY*-v1 
E16 2 Canberra 2009 GmKmTm pRAY*-v1 
RBH2 - Brisbane 1999 GmKmTm pRAY*-v1 
D46 - Sydney 2010 GmKmTm pRAY* b 
J9 - Sydney 1999 GmKmTm pRAY* c 
 
a Gm, gentamicin; Km, kanamycin; Tm, tobramycin. 
b pRAY* in D46 differs from that of D36 by 1 bp; T-6192"A, which changes a single amino acid Y"N.  
c differs from pRAY* by 1 bp; C-2693" T. 
 
 
 
8.5.6  Global distribution of pRAY  
In addition to the strains available in the Hall Lab collection and the strains previously found 
in GenBank (non-redundant sequence database), the WGS database was also explored to find 
strains that contain pRAY* or pRAY*-v1. Six distantly related A. baumannii strains (Table 8.8) as 
well as one Acinetobacter pittii, strain D499, were found to contain pRAY* sequence with only 1-2 
bp differences (Table 8.8). Surprisingly, no pRAY*-v1 was found in the WGS database. This 
indicates the widespread distribution of pRAY* in A. baumannii strains from different clonal types. 
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Table 8.8: Properties of the pRAY* containing strains found in the whole genome shotgun database. 
 
Isolate Country Year Global 
clone 
pRAY 
variant 
MLST a accession number 
IP O 
A. baumannii        
AB_908-13 USA 2007 1 pRAY* ST1 ST207 AMHW01000000 
OIFC180 USA 2003 2 pRAY* b ST2 ST459 AMDQ01000000 
6013150 USA 2007 - pRAY* ST81 ST247 ACYQ02000000 
AB_909-01-7 USA 2007 - pRAY* c ST242 ST356 AMHY01000000 
OIFC065 USA 2003 - pRAY* b ST136 ST195 AMFV01000000 
Naval-18 USA 2002 - pRAY* b ST25 ST*d AFDA02000000 
A. pittii        
D499 China - - pRAY* b ST* d ST* d AGFH01000000 
A. ursingii 
DSM 16037 
 
Czech 
Republic 
  
- 
 
Precursor  
 
ST* d 
 
ST* d 
 
AIEA01000000 
 
a IP: Institut Pasteur; O: Oxford Scheme.  
b differs from pRAY* by 1 bp; T-6192"A. 
c differs from pRAY* by 2 bp; C-795" G and C-807" A. 
d MLST could not be determined as some of the alleles were not defined in the MLST database. 
 
8.5.7 Potential precursor of pRAY  
One Acinetobacter strain, Acinetobacter ursingii DSM 16037 (GenBank accession number 
AIEA01000000), was found to contain a 5858 bp plasmid related to pRAY*. However, 
examination of the sequence at the aadB gene cassette insertion point revealed that this plasmid 
lacks the aadB gene cassette (Figure 8.14).   
 
Precursor GGGAGGGCTTACTATG --------------------------------------------TTAGGAAACACTGCTA 
          ||||||||||||||||                         |||||||||||||||| 
pRAY*     GGGAGGGCTTACTATGTTAGGCCGCATG…TTAACTCAGGTGTTAGGAAACACTGCTA  
                                   aadB gene cassette 
Figure 8.14:  Pairwise alignment of the aadB gene cassette insertion point in pRAY* in D36 and a plasmid found in A. 
ursingii DSM 16037. Bases white on black represent 12 bp of the beginning and the end of the aadB gene cassette. The 
start of the aadB is shown bold grey on black.  
 
 
The plasmid sequence found in A. ursingii DSM 16037 was different from pRAY* by 120 
single base change (~ 2%) and 20 bp addition or deletions, which were clustered between bp 693 
and 4816 (4124 bp) covering the entire mobC, mobA and orf3 (blue segment in Figure 8.15). The 
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deletions and additions of bases include a 12 bp insertion at position 5202 rendering orf 1 two aa 
longer, a 3 bp insertion at position 494 that adds one aa to MobC and five single base insertions and 
deletions with no effect on the reading frames. Compared to pRAY*, the plasmid in A. ursingii 
DSM 16037 includes an additional HindIII restriction site at position 3362, which is located in the 
middle of mobA (Figure 8.15). Difference in the size of the diverged sequence in this plasmid as 
well as the pattern of the base changes compared to the pRAY*-v1 indicate that this plasmid and 
pRAY*-v1 have acquired the mobilization segment from two different but related sources. 
Moreover, this sequence lacked the aadB gene cassette and contained a 357 bp duplication located 
47 bp downstream of the aadB gene cassette insertion point (Figure 8.15).  This sequence is 
presumably a cryptic plasmid, which could indicate the probability of the presence of similar 
precursors which have then given rise to pRAY* and pRAY*-v1 by acquisition of the aadB gene 
cassette.  
Together, this is an interesting finding that could reinforce that pRAY* and its variants are 
part of a very big family of transmissible plasmids, which have undergone many DNA sequence 
exchange events. 
Figure 8.15:  Linearized map of the plasmid related to pRAY* found in A. ursingii DSM 16037. The blue segment of 
the central line represents the extent of the diverged sequence compared to pRAY*; black represents the identical 
sequence and red and green show the 357 bp duplication. The vertical arrow indicates the insertion point of the aadB 
gene cassette in pRAY*. The letter “H” indicates HindIII restriction sites and the “H*” indicates the additional 
HindIII site compared to pRAY*. Arrows below the central line represent open reading frames with their named 
indicated bellow.  
 
 
In addition, DNA segments closely related (79-91 % identity) to the mobilization segment and 
containing mobC and mobA genes and oriT of pRAY* were found in the draft genomes of 7 
Acinetobacter strains (Table 8.9). This suggests that pRAY may belong to a bigger family of 
plasmids circulating in the Acinetobacter genus.  
1 H 2 H 3H H 4 H 5 H 6
mobA
mobCorf 5orf 4orf 3orf 2orf 1 orf 1
B H*
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Table 8.9: Characteristics of strains containing mobilization region of pRAY*. 
 
Strains Identitya accession number 
A. baumannii 4190 79 AEPA01000000 
A. baumannii 3909 79 AEOZ01000000 
A. baumannii AB900 79 ABXK01000000 
A. calcoaceticus XM1570 87 AMXH01000000 
A. johnsonii TG19625 83 AMJE01000000 
A. johnsonii TG19605 83 AMJD01000000 
A. johnsonii SH046 91 ACPL01000000 
A. bereziniae LMG 1003 83 AIEI01000000 
A. pittii TG6411 79 AMJI01000000 
A. radioresistens SK82 83 ACVR01000000 
Acinetobacter sp. TG19627 83 AMJM01000000 
Acinetobacter sp. P8-3-8 83 AFIE01000000 
 
a DNA sequence identity. 
 
8.6 Discussion 
The work presented in this chapter aimed to investigate the basis of tobramycin resistance in 
Acinetobacter strains. The results indicated that tobramycin resistance in the strains examined was 
accounted for by the presence of the aadB gene cassette. It was also shown that, except for one 
strain, in all the strains from different clonal types examined the aadB gene cassette was located on 
variants of a 6 kb plasmid, which were then called pRAY* and pRAY*-v1. 
Sequencing of pRAY* and pRAY*-v1 revealed nine frameshifts, possibly representing errors 
in the available pRAY sequence, which change the length of all the reading frames, except aadB 
and orf 7, in the original pRAY sequence. In addition, a new open reading frame was found in 
pRAY*, which predicted a 135 aa protein homologous to MobC proteins in the GenBank protein 
database. Analysis of the protein sequences of mobA and mobC showed that they belong to the 
MOBHEN family of ColE1superfamily (60). A recent study has also been shown that in ColE1, 
mbeC interacts with mbeA and they form a binary complex that enhances the binding of mbeA to 
ssDNA at nic site (245). Therefore, they have concluded that MbeC is acting as an accessory 
protein to MbeA corresponding to its role as the relaxase for ColE1 mobilization (245). Finding 
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mobC and full length mobA revealed the proteins needed for the mobilization machinery of pRAY* 
and pRAY*-v1.  
Transmissible plasmids can be classified based on their mobilization machinery as being 
conjugative (self-transmissible) or mobilizable (60).  Mobilizable plasmids are transmissible only in 
the presence of additional conjugative functions because they carry the mobilization region (mob 
genes) encoding specific relaxosome components and the origin of transfer (97), but lack the 
functions required for mating pair formation (60, 226). Mobilization properties of transmissible 
plasmids especially amino acid sequence similarity of the plasmid’s relaxases, has been used as one 
of the first criteria for classification of these plasmids (60, 226). RSF1010, ColE1, CloDF13 and 
pMV158 are the main plasmid superfamilies according to the amino acid sequence similarity of the 
relaxases. In the classification of small plasmids based on mobilization proteins, the product of 
mbeA is identified as belonging to the MOBHEN family of ColE1superfamily(60).  
Generating pRMH972, which only includes the 2.8 kb HindIII fragment of pRAY* together 
with transformation experiments indicated that pRMH972 can replicate independently. It therefore 
contains the region providing the necessary signals for its replication. Nonetheless, more 
experimental work is needed to determine the exact sequences required for replication. 
pRAY* is responsible for tobramycin resistance in A. baumannii from different clonal 
complexes as well as in other Acinetobacter spp. strains. Finding the pRAY* sequence or closely 
related plasmids in the strains from geographically unrelated areas indicated that these plasmids are 
globally distributed. They have now been detected in Acinetobacter isolates recovered in South 
Africa, Australia, Europe and the USA. Finding the precursor of pRAY* is an interesting finding 
that highlights the significance of cryptic plasmids as vehicle for carrying antibiotic resistance 
determinants. In addition, identifying related sequences belonging to the mobilization segment of 
pRAY* indicates that these plasmids are part of a bigger family. In addition, the fact that no 
pRAY*-v1 was found in the database could indicate that pRAY*-v1 is restricted to Australia and 
could be characteristic of Australian isolates. 
 
CHAPTER EIGHT                                                                The tobramycin and gentamicin plasmid pRAY 
 
 200 
In summary, this work indicates that pRAY* has been circulating in Acinetobacter population 
globally and has a crucial role for conferring the gentamicin, tobramycin and kanamycin resistance 
phenotype observed in the isolates from different clonal complexes.  
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 9.1 Overview  
The work described in this thesis examined the cause of antibiotic resistance in a diverse 
collection of 26 Australian GC1 isolates. To provide a historical context, one of the oldest GC1 
isolates in available collections, isolated in 1982 in the UK, was also examined.  
Four distinct mechanisms were identified:  
First, antibiotic resistance genes were present in AbaR-type islands in the chromosomal 
comM gene of most isolates, but they contained different variants of AbaR islands. IS26-mediated 
deletion was the main way new variants were created. Homologous recombination between the two 
Tn6018 copies also led to loss of the entire MARR. A deletion identified in the 5'-CS separated two 
main lineages of AbaR islands derived from AbaR0 and AbaR3  
Second, in D36, AbaR4 that has a structure distinct from that of an AbaR0/AbaR3 type 
islands, was inserted in the comM gene. Potential ancestors of D36 that belonged to the same MLST 
type as D36 and included an intact comM gene were found. Thus, D36 represents a third lineage 
that has arisen from a susceptible ancestor by incorporating AbaR4.  
Third, some resistance genes were carried by plasmids. Plasmids accounted for tobramycin 
and gentamicin resistance in D36 and for carbapenem resistance in four isolates. A conjugative 
plasmid that contained AbaR4 carrying the oxa23 carbapenem resistance gene was in two unrelated 
isolates from different hospitals, and the oxa58 carbapenem resistance gene in two related isolates is 
likely to be carried in another plasmid. A 6 kb plasmid included the aadB gene conferring 
tobramycin resistance.  
Fourth, resistance to third generation cephalosporins was due to activation of the 
chromosomal ampC gene by ISAba1. In some cases, the activated ampC gene was in a class I 
transposon. In other cases, the original ampC gene had been replaced by ISAba1-ampC derived 
from a different strain. In an isolate from Greece by cephalosporin resistance was due to ISAba125 
upstream of ampC. 
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9.2 AbaR genomic islands  
Only four isolates contained AbaR3, which was the same as AbaR3 in AB0057 (2). The 
island in the isolate WM98 differed from AbaR3 in that it contains an additional orfP in the cassette 
array and also includes an intact 5'-CS. This configuration was named AbaR0 and proposed to be 
the original insertion. It was initially suggested that AbaR1 might be the original insertion(2). 
However, as more sequences and maps became available, it emerged that AbaR3 was likely to be 
the ancestral island (183, 184) as none of the variants characterized at the time contained the large 
additional segment found in AbaR1 (1, 2, 112, 113, 183, 184). The AbaR0 structure with a 
complete 5'-CS is likely to pre-date the lineage that includes the deletion, making it the ancestor of 
AbaR3.  
Several AbaR variants were found in this study, some of which had not been seen before. 
These various AbaR configurations have arisen from either AbaR0 or AbaR3, largely due to distinct 
IS26-mediated deletions removing segments of MARR (AbaR8, AbaR23 and AbaR24) and even 
extending into the chromosome as in AbaR26 (Table 9.1). AbaR5, AbaR6, AbaR7, AbaR9 and 
AbaR12-AbaR19, have also been described in members of GC1 from different countries, all of 
which were created by a distinct IS26-mediated deletion (1, 2, 112, 113, 183, 184, 224) (Table 9.1). 
However, one SG6 isolate had lost the entire MARR of AbaR8 via homologous recombination 
between the two Tn6018 copies. The same configuration was also seen in the European isolate 
NIPS470 (112) (Table 9.1). Homologous recombination between the two sul1 copies, removing the 
segment between these two genes, also gave rise to AbaR10 (1). Hence, it appears that IS26-
mediated deletion is mainly responsible for creating variants of the AbaR while homologous 
recombination between the only duplicated elements, Tn6018 and sul1, can also occur leading to 
the loss of the segment between these elements. Properties of AbaR0/AbaR3-type variants seen so 
far are summarized in Table 9.1. 
 
 Table 9.1: GI with a Tn6019 backbone (AbaR0-type).  
a L (245) and R(right) indicate the direction of the deletions.  
b (+) indicates that 108 bp of the 5'-CS is missing and (–) shows the absence of the deletion; na indicates not applicable and nk indicates not known. 
c P and Q indicate orfP and orfQ respectively.      
d ACICU belongs to GC2. 
e the deletion extends into the chromosome.  
f the sequence of AbaR5 was completed in this study by sequencing 15 kb of the Tn6019 backbone. 
g homologous recombination between 3'-CS.  
h homologous recombination between Tn6018. 
i the presence of  the 5'-CS deletion was tested in this study on these isolates supplied by  S. Bnsse, Institut Pasteur.  
j published as TnAbaR23.  
k IS26 has caused deletions on either sides removing 532 bp from 5'-end of catA1 and 46 bp from 5'-end of aacC1 respectively.  
AbaR Isolate Source Year Origin of 
deletion a 
Size 
bp 
intI1! b Cassettes c Other antibiotic resistance genes Accession 
number 
References 
AbaR0 WM98 Australia 1998 - - - aacC1-P-P-Q-aadA1 sul1, tetA(A),  catA1, blaTEM, aphA1b KF483599 This study 
AbaR1 AYE France 2001 IS26-1/ L 2,039 - aacC1-P-P-Q-aadA1 
dfrA1-orfC 
veb1-aadB-arr2-
cmlA5-oxa10-aadA1  
strA,  strB  cmlA9, tetA(G), aacA,  
dfrA10, tetA(A), catA1, aphA1b,  sul1  
CU459141 (58) 
AbaR2  ACICU d Italy 2005 aphA1b e 52196 - aacA4-orfO-oxa20 sul1, !aphA1b CP000863 (93) 
AbaR3 AB0057 US 2004 - - + aacC1-P-Q-aadA1 sul1, tetA(A),  catA1, blaTEM, aphA1b CP001182 (2) 
AbaR5 3208 Australia 1997 IS26-1/ L 7,326 - aacC1-P-P-Q-aadA1 sul1, tetA(A), aphA1b FJ172370 f (183) 
AbaR6 D2 Australia 2006 IS26-2/ L 36,245 - aacC1-P-P-Q-aadA1 sul1, aphA1b GQ406245 (184) 
AbaR7 A92 Australia 2005 IS26-2/ L 43,430 - aacC1-P-Q-aadA1 sul1, aphA1b GQ406246 (184) 
AbaR8 D13 Australia 2009 IS26-2/ L 17,852 + aacC1-P-Q-aadA1 sul1, aphA1b HM590877 This study 
AbaR9 AB056 US 2004 IS26-3/ L 23,721 + aacC1-P-Q-aadA1 sul1 ADGZ00000000 (1) 
AbaR10 AB058 US 2003 sul1g 31,859 na none sul1 ADHA00000000 (1) 
AbaR11 NIPH470 Czech 1997 Tn6018 h 40,552 na none None JF262167 (112) 
AbaR12 LUH6013 Italy 1997 IS26-2/ L  24,808 + i aacC1-P-P-Q-aadA1 sul1, aphA1b JF262168 (112) 
AbaR13 LUH6015 Italy 1998 IS26-1/ L 1,8123 + i aacC1-P-Q-aadA1 sul1, aphA1b  JF262169 (112) 
AbaR14 LUH5881 Spain 1998 IS26-2/ L 41,444 -  i aacA4 sul1, aphA1b  JF262170 (112) 
AbaR15 LUH6125 Poland 1998 IS26-3/ L 8,165 -  i aacC1-P-P-Q-aadA1 sul1, tetA(A),  catA1  JF262171 (112) 
AbaR16 LUH7140 UK 2000 IS26-2/ L 22,025 nk aacC1-P-Q-aadA1 sul1, aphA1b  JF262172 (112) 
AbaR17 LUH8592 Bulgaria 2001 IS26-2/ L 5,437 nk aacC1-P-Q-aadA1 sul1, tetA(A),  catA1, aphA1b  JF262173 (112) 
AbaR18 NIPH2713 Czech 2005 IS26-2/ L 10,692 nk aacC1-P-Q-aadA1 sul1, tetA(A),  ! catA1, aphA1b  JF262174 (112) 
AbaR19 NIPH2554 Czech 2005 IS26-3/ L 31,552 nk aacC1-P-P-Q-aadA1 sul1  JF262175 (112) 
AbaR21 A297/RUH875 Netherlands 1984 - - - dfrA5 sul1, tetA(A),  catA1, blaTEM, aphA1b JN121384 (153) 
AbaR23 D81 Australia 2010 IS26-3/ L 12,174 + aacC1-P-Q-aacC1 sul1, tetA(A),  catA1 JN409449 This study 
AbaR24 A1 UK 1982 IS26-3/ L 10,876 - aacC1-P-P-Q-aacC1 sul1, tetA(A),  catA1 JN968482 This study 
AbaR26 D30 Australia 2008 IS26-2/ L e 49,942 - aacC1-P-P-Q-aadA1 sul1, aphA1b KC665626 This study 
AbaR27j A424 Croatia - IS26-3/ L k 
IS26-3/ R 
12,944  
1,809 
na "aacC1 -P-Q-aadA1 sul1, tetA(A),  "catA1  JN676148 (109) 
204 
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The deletion in the 5'-CS of the class 1 integron in AbaR3, AbaR8 and AbaR23, could 
separate two lineages that are derived from AbaR0 and AbaR3. The phylogenetic tree based on the 
distribution of SNPs in the core genome that was provided by Kathryn E. Holt (personal 
communication, K. E. Holt; University of Melbourne) included two main branches and these 
correspond to the islands with and without the 5'-CS deletion.  
 
Figure 9.1: Schematic representation of the evolutionary path of the AbaR islands in the GC1 isolates. Blue arrows 
indicate that IS26 mediated deletion has given rise to the new AbaR variant and orange arrows show homologous 
recombination between Tn6018 copies. 
 
D36 differed from all other Australian MAR GC1 isolates because it did not contain an island 
of the AbaR0 or AbaR3-type in the comM gene. In D36, AbaR4 is located in the place in the comM 
gene where AbaR0/AbaR3-type islands are usually found and D36 clearly represents a distinct GC1 
lineage that has emerged by acquiring AbaR4. Potential direct ancestors of D36 which belonged to 
the same ST type as D36 and had an intact comM gene were found in the WGS database (strains 
6013113, GenBank accession no. ACYR02000002 and 6013150, GenBank accession no. 
ACYQ02000000).  
 
9.3 Resistance genes carried on plasmids 
Carbapenem resistance in two isolates was due to the oxa23 gene in AbaR4 carried on an 86 
kb conjugative plasmid. These two strains, D108 and A85 belonged to different ST types differing 
in two MLST alleles, gpi and gyrB. They were not from the same hospital and had been isolated in 
No island
AbaR4 AbaR0 AbaR3
AbaR8 AbaR23
Tn6019::Tn6018
AbaR6AbaR7
AbaR26AbaR5
AbaR24
5'-CS deletion
AbaR21
CHAPTER NINE                                                                                                         General discussion 
 206 
different years, A85 in 2003 and D108 in 2011. Previously, a 130 kb conjugative plasmid carrying 
oxa23, in Tn2006, (143) and a further conjugative plasmid with an aci6 replicase gene carrying 
oxa23 (17) have been shown to contribute to carbapenem resistance in A. baumannii. However, this 
is the first time that AbaR4 has been found on a plasmid and this suggests a role for plasmids in 
circulating AbaR4 and the oxa23 gene. Analysis of the contigs containing the oxa58 carbapenem 
resistance gene in two other carbapenem resistant isolates, D78 and D81, suggested that this gene is 
also carried in a plasmid. However, this was not pursued further.  
Only one GC1 isolate, D36, was tobramycin resistant and this was was due to the presence of 
the aadB gene carried on variant of a 6kb plasmid, pRAY*. The same plasmid was found in some 
non-GC1 isolates. The aadB gene is part of a gene cassette that is usually found associated with 
class 1 integrons (31, 188) but pRAY includes the aadB gene cassette at a secondary site (205). 
pRAY was originally found in South Africa in 1997 (205), and subsequently in 2010 in USA in a 
GC1 isolate AB058 (GenBank accession no. ADHA01000000) (1). The GC1 reference strain 
A297/RUH875 recovered in the Netherlands in 1984 also contains pRAY* (153). Hence, the fact 
that pRAY* or its variants are found in geographically unrelated areas indicates that these plasmids 
are globally distributed and play an important role in tobramycin resistance in A baumannii.  
 
 9.4 Cephalosporin resistance   
ISAba1 was found preceding the ampC gene in all Australian cephalosporin resistant GC1 
isolates and this is consistent with the findings of previous studies (1, 2, 40, 84, 195, 206, 208). 
However, this study reported for the first time the association of ampC with a transposon, Tn6168. 
Tn6168, which contained an ISAba1 activated ampC gene was found in three Australian ST126 
(Oxford Scheme) isolates, recovered between 2002-3, in the same position as in the genomes of 
GC1 strains AB0057 isolated in 2004 from a US military hospital (GenBank accession no. 
CP001182) (2) and Canada BC-5 isolated in 2007 in a nosocomial spread of war-related MAR 
isolates (GenBank accession no. AFDN01000002). These strains were all from different places and 
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times. Tn6168 was also found in a non-GC1 non-GC2 strain from Sydney where it was in a new 
location, indicating both horizontal gene transfer and transposition can occur.  
The SG6 group and the single isolate G7 included ampC sequences distinct from the standard 
GC1 sequence that did not include an IS upstream of ampC. This indicates that the ampC gene has 
been acquired from another strain in at least two occasions. In G7, the extent of the diverged 
sequence was 31 kb, but it could not be traced to a sequenced source. The SG6 isolates had acquired 
a 2.4 kb segment of DNA including ISAba1-ampC from a distantly related strain, which belongs to 
a different ST. Together, these data indicate for the first time that resistance to 3rd generation 
cephalosporins can arise via horizontal transfer of a chromosomal segment followed by 
homologous recombination introducing ISAba1-ampC into the recipient chromosome. It has 
previously been shown that incorporation of an ampC gene derived from an A. baumannii strain 
with an ISOur1 upstream into the genome of Oligella urethralis leads to cephalosporin resistance 
(135) but such a an exchange has not been seen in A. baumannii.  
An interesting aspect of this work is the finding that, ISAba1 was at a specific position before 
the start of ampC in each of the distantly related A. baumannii. The target specificity of ISAba1 
remains to be properly explained but it appears to have played a crucial role in resistance to 3rd 
generation cephalosporins in A. baumannii.  
A single GC1 isolate from Greece was also studied, and in this isolate cephalosporin 
resistance was due to the presence of ISAba125 before the ampC gene. However, based on an 
examination of the sequence, ISAba125 does not appear to provide a promoter to activate the ampC 
gene. This raises the possibility that ISAba125 enhances the expression of ampC by making the 
ampC transcripts more stable and/or disrupting the additional regulatory features. However, this 
was not investigated here and needs to be further examined. In the GC2 strain ACICU (GenBank 
accession no. CP000863), the transfer of 9.6 kb of the chromosome, including ISAba125-ampC, 
from a GC1 isolate has given rise to cephalosporin resistance.  
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Overall, these findings indicate that homologous recombination should be considered as one 
way of acquiring cephalosporin resistance. 
 
9.5 Structure of AbaR islands as epidemiological markers 
The structure of the AbaR0/AbaR3-type islands served to group the isolates as isolates with 
the same island shared other properties such as resistance profile, MLST or ISAba1 profile. For 
instance, all the isolates with AbaR8 belonged to the SG6 group and shared a csuE region, which 
was distinct from that in the other GC1 isolates. The isolates that contained AbaR6 all shared the 
same antibiotic resistance and ISAba1 profiles indicating that they are closely related and progenies 
of a common ancestor. These groups represent outbreaks. A further example is the two isolates that 
contained AbaR23 as both belonged to the same ST type, which was an SLV of the ST109/231 that 
is the most common ST types amongst MAR GC1 isolates. Hence, carrying the same variant of 
AbaR0/AbaR3-type islands can be the indication of isolates being closely related and can be used as 
marker to identify outbreak strains, or inter-hospital transfer events. The two isolates that carried 
AbaR7, A92 and A83 recovered in 2002 and 2005, in this study belonged to ST109/ST231. Two 
MAR GC1 strains isolated between 2007-2011 in Korea have been shown to also carry AbaR7 and 
belong to ST109/ST231(224). Thus, given that AbaR variants are usually created via random IS26-
mediated deletions indicates that these strains are related.  
  
9.5.1 Outbreaks caused by isolates carrying AbaR6 and AbaR8 
Using the structure of the AbaR islands together with additional features, two outbreak strains 
were identified in the collection. The outbreak isolates comprised 6 strains carrying AbaR6 and 8 
SG6 strains. Seven SG6 strains carried AbaR8 and a single strain from 2011 contained a deletion 
derivative of AbaR8. These strains had repeatedly caused infections between 2006-2011 in the ward 
7D of the RNSH at Sydney and RRC, which is related to 7D by including shared patient 
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populations. The fact that the strains carrying AbaR6 caused infections between 2006-2010 and 
SG6 strains between 2009-2011 indicates that SG6 strains have replaced the first group. Moreover, 
given that 7D and RRC are spinal injury units might also indicate that these patients have a 
propensity to develop infections caused by these MAR isolates.  
 
9.6 Variation in the Australian GC1 collection 
The Australian GC1 collection consists of diverse isolates and the causes of the divergence 
observed could be seen at genomic level by a range of events such as insertion/ deletion and 
recombination at different chromosomal locations. The majority of the isolates, including the 14 
outbreak strains and 6 others, belonged to ST109/ST231 and the remaining 6 isolates were all gpi 
and/or gyrB variants of ST109/ST231. It has recently been shown that the gpi gene is located in the 
capsule cluster (105) and that this locus has been substituted repeatedly in isolates belonging to 
global clones (2, 105, 198, 219). Given the close proximity of gyrB and gpi (Figure 1.11), it is 
possible that both genes can be affected by a single event and this reflected in a previous study that 
showed gpi and gyrB are the most variable alleles of the Oxford MLST scheme in a set of European 
isolates (78).  
Evidence for diversity in other parts of the genome was also obtained. The SG6s, had picked 
the csuE region from another A. baumannii strain, and some of the Australian GC1 isolates 
contained different ampC sequences. ISAba1 also plays a role in generating diversity (84). 
Australian GC1 contain different number of ISAba1 in their genomes and in one case, the SG6 
group, even closely related strains include a different number of ISAba1 at different chromosomal 
locations. Hence, it appears that all of these variations described have led to the separation of the 
members of GC1 into many different sub-lineages.  
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9.7 Final remarks 
Overall, this study revealed the complexity of antibiotic resistance mechanisms in GC1 
isolates involving genomic islands, plasmids, transposons, integrons and insertion sequences. This 
information will provide a better understanding of the evolution of resistance regions in GC1, which 
leads to the emergence of MAR strains. IS26-mediated deletion and homologous recombination 
were the driving forces for the evolution of the main antibiotic resistance regions in the AbaR 
genomic islands, but ISAba1 was important elsewhere.  
Moreover, using combinations of different molecular typing methods was found to be 
extremely useful analysing the relationship between isolates and to find groups of closely related 
isolates. Amongst the typing methods, MLST was useful to compare the isolates with the ones 
recovered in other countries in order to depict a global distribution of isolates belong to different 
sequence types. However, whole genome sequences reveal the entire genetic repertoire and make 
the comparisons possible at finest level. 
The data presented in this study will provide a basis for further investigations about the role of 
insertion sequences in driving the expression of antibiotic resistance genes, and the role of 
recombination events in antibiotic resistance and increasing diversity in GC1.  
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 Appendix I                                                                                         A1-2   
Table I-1: Antibiotic resistance profiles of the isolates from Royal North Shore Hospital. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Ap, ampicillin; SA, ampicillin/sulbactam Cx, cefotaxime; Cz, ceftazidime; TI, timentin (ticarcillin clavulanic acid); IP, imipenem; ME, meropenem; Sm, streptomycin; Sp, 
spectinomycin; Su, sulphonamides; Tc, tetracycline; Tp, trimethoprim; Cm, chloramphenicol; Fl, florfenicol;  Km, kanamycin; Nm, neomycin; Gm, gentamicin; Ne, netilmicin; 
Ak, amikacin; Tm, tobramycin; Cip, ciprofloxacin; Nx, nalidixic acid; Ri, rifampicin. 
Strain Year      Annular radius of zone of inhibition a 
Ap SA Cx Cz TI IP ME Sm Sp Su Tc Tp Cm Fl Km Nm Gm Ne Ak Tm Cip Nx Ri 
3208 1997 1 10 6 7 5 10 9 3 0 0 1 0 0 0 0 2 1 5 6 6 0 0 6 
D2 2006 2 
3.5 
10 4 
6 
5 
6.5 
8 12 
11.5 
10 
9 
3 
3.5 
0 
0 
0 
6 
4 
5 
2 
3 
0 
2 
0 
2 
0 
0 
3 
3 
1 
3 
5 
7 
6 
8 
6 
8 
0 
0 
0 
0 
7 
D3 2006 3 11 6 4 9 11 10 3 0 0 4 3 0 0 0 2 1 5 5 5 0 0 7 
D6 2006 2 11 4 4 8 12 11 3 0 0 4.5 2 0 0 0 2 1 5 7 6 0 0 6 
D7 2006 2 10 4 5 8 11 10 3 0 0 4 2 0 0 0 2 1 5 6 5 0 0 7 
D27 2008 2 
2 
10 4 
4 
5 
5 
7 11.5 
11 
10 
10 
2 
2 
0 
0 
0 
0 
3.5 
4 
4 
4 
0 
0 
0 
0 
0 
0 
2 
1 
1 
1 
7 
8 
7 
7 
8 
9 
0 
0 
0 
0 
6.5 
D62 2010 11 
7.5 
12 12 
10 
12 
12 
8 15 
14 
11 
11 
9 
5.5 
0 
0 
3 
2 
7 
6 
9 
4 
0 
2 
0 
0 
0 
0 
5 
4.5 
4 
4 
10 
8 
10 
9 
9 
8 
0 
0 
0 
0 
6 
D30 2008 2 
1 
11 4 
4 
5 
5 
7 12.5 
12 
10 
11 
2 
3 
0 
0 
0 
0 
4.5 
5 
2 
2 
0 
0 
0 
0 
0 
0 
2 
2 
1 
1 
6 
8 
6 
7 
5 
5 
0 
0 
0 
0 
6 
D36 2008 0 
0 
9 0 
0 
2 
1 
0 3.5 
4 
3 
3 
0 
0 
5 
5 
0 
0 
4.5 
3.5 
0 
1 
0 
1 
0 
0 
0 
0 
5 
4 
4 
4 
9 
9 
8 
8 
4 
4 
0 
0 
0 
0 
8 
D13  2009 0 8 0 1 6 9 8 4 0 0 3.5 5 0.5 0 0 3 1.5 6 7 6.5 0 0 7 
D14  2009 0 7 0 1 7 10 9 3.5 0 0 4.5 4 0.5 0 0 3 2 7 7 7 0 0 6.5 
D15  2009 0 7.5 0 1 7 9 8 2 0 0 3.5 3 0 0 0 1.5 0 5 7 7 0 0 8 
D18  2009 0 7 0 1 5 9 8 3 0 0 4 4 0 0 0 2.5 2 6.5 6.5 7 0 0 7 
D20  2009 0 8 0 1 6 10 8 3 0 0 4.5 5 1 0 0 2 2 6.5 6.5 6 0 0 7 
D45  2010 0 
0 
7 0 
0 
0 
1 
5 8.5 
8 
8 
7.5 
4.5 
4 
0 
0 
0 
0 
3.5 
4 
6 
5 
0.5 
1 
0.5 
1 
0 
0 
3.5 
4 
2 
3 
6 
12 
7 
7 
7 
7 
0.5 
0 
0.5 
0 
6 
D48  2010 0 
0 
8 0 
0 
0 
1 
6 10 
10 
9.5 
9 
4 
4 
0 
0 
0 
0 
3 
3 
6 
5 
0 
1 
0 
1 
0 
0 
3 
3 
2 
3 
7 
7 
7 
7 
7.5 
7 
0 
0 
0 
0 
7 
D108 2011 0 
0 
5 0 
0 
1 
1 
0 4 
4 
3 
3 
4.5 
4.5 
0 
0 
13 
13 
4 
4 
4.5 
4.5 
0.5 
0.5 
0 
0 
7 
8 
6.5 
7 
6 
6 
6 
6 
6.5 
7 
6 
6 
0 
0 
0 
0 
2.5 
D78 2010 0 
0 
3 0 
0 
3 
1.5 
0 3.5 
4 
3.5 
4.5 
4 
0 
0 
0 
0 
0 
0 
0 
3 
3.5 
0 
0 
0 
1 
0 
0 
2 
1.5 
2 
2 
6 
6 
0.5 
0.5 
6.5 
6.5 
0 
0 
0 
0 
7 
D81 2010 0 
0 
3.5 0 
0.5 
3 
3.5 
0 3 
3 
3 
4 
4.5 
4.5 
0.5 
0.5 
0 
0 
0 
0 
3 
3.5 
0 
0 
0 
1 
0 
1 
2 
2 
2 
1.5 
6 
7 
0.5 
1 
6.5 
7 
0 
0 
0 
1 
7.5 
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Table I-2: Antibiotic resistance profiles of the isolates from Australian hospitals. 
 
a S, Sydney; M, Melbourne; B, Brisbane; A, Adelaide. 
b Ap, ampicillin; SA, ampicillin/sulbactam Cx, cefotaxime; Cz, ceftazidime; TI, timentin (ticarcillin clavulanic acid); IP, imipenem; ME, meropenem; Sm, streptomycin; Sp, 
spectinomycin; Su, sulphonamides; Tc, tetracycline; Tp, trimethoprim; Cm, chloramphenicol; Fl, florfenicol;  Km, kanamycin; Nm, neomycin; Gm, gentamicin; Ne, netilmicin; Ak, 
amikacin; Tm, tobramycin; Cip, ciprofloxacin; Nx, nalidixic acid; Ri, rifampicin. 
 
 
 
 
 
 
 
 
 
 
 
 
Strain Year Source 
a   
    Annular radius of zone of inhibition b 
Ap SA Cx Cz TI IP ME Sm Sp Su Tc Tp Cm Fl Km Nm Gm Ne Ak Tm Cip Nx Ri 
A92 2005 S 2 11 4 5 8 12 10 3 0 0 4 1 0 0.5 0 2 1 5 6 6 0 0 7 
A83 2002 S 3 
3 
10 5 
5 
5.5 
6 
7 12 
12 
10 
11 
4.5 
4 
0 
0 
0 
0 
4.5 
5.5 
1 
1 
1 
1 
1 
1 
0 
0 
3 
3.5 
2 
0 
6.5 
7 
7 
7 
7 
7 
0 
0 
0 
0 
5 
G7 2002 M 0 
0 
2 0 
0 
4.5 
4.5 
3.5 9 
9 
8 
7.5 
4 
4 
0 
0 
0 
0 
0 
0 
4 
4.5 
0 
0 
1 
0 
0 
0 
2 
2 
2 
2 
7 
8 
2 
2 
7 
7 
8 
8 
6 
6.5 
6 
WM98 1998 S 0 
0 
3 3 
4 
5 
5 
3 9 
10 
8 
9 
5 
5 
0 
0 
0 
0 
1 
1 
4 
3.5 
0 
0 
0 
0 
0 
0 
4 
4 
2.5 
2.5 
7 
7 
7 
7 
7 
6.5 
0 
0 
0 
0 
6 
RBH3 2002 B 0 
0 
3 0 
0 
0 
0 
3.5 11 
11 
10 
9.5 
3.5 
3.5 
0 
0 
0 
0 
0 
0 
3 
3 
0 
0 
0 
0 
0 
0 
3 
3 
1 
1 
6 
6 
6.5 
6.5 
7 
6 
0 
0 
0 
0 
7 
A85 2003 S 0 
0 
2.5 0 0 0 4 
3.5 
3 
3 
3.5 
4 
0 
0 
0 
0 
0 
0 
0 
0 
0.5 
1 
1 
1 
0 
0.5 
3 
3.5 
2 
2 
6 
6.5 
7 
7 
7 
7 
0 
0 
0 
0 
8 
6772166 2002 A 0 
0 
3 0 
0 
0 
0 
3.5 10 
10.5 
10 
11 
5 
5 
0 
0.5 
0 
0 
0 
0 
1 
1.5 
0 
0 
0 
0 
0 
0 
4 
3.5 
2 
2 
7 
7 
8 
8 
8 
7.5 
0 
0 
0 
0 
7 
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Table I-3: Antibiotic resistance profiles of the European isolates used as control. 
 
 
a. AB0057, A1, A297, A388 and ACICU are isolated in the US, UK, the Netherlands, Greece and Italy respectively.  
b Ap, ampicillin; SA, ampicillin/sulbactam Cx, cefotaxime; Cz, ceftazidime; TI, timentin (ticarcillin clavulanic acid); IP, imipenem; ME, meropenem; Sm, streptomycin; Sp, 
spectinomycin; Su, sulphonamides; Tc, tetracycline; Tp, trimethoprim; Cm, chloramphenicol; Fl, florfenicol;  Km, kanamycin; Nm, neomycin; Gm, gentamicin; Ne, netilmicin; Ak, 
amikacin; Tm, tobramycin; Cip, ciprofloxacin; Nx, nalidixic acid; Ri, rifampicin.
c GC2. 
Strain a Year     Annular radius of zone of inhibition b 
Ap SA Cx Cz TI IP ME Sm Sp Su Tc Tp Cl Fl Km Nm Gm Ne Ak Tm Cip Nx Ri 
AB0057 2004 0 1.5 0 0 0 2.5 2 4 0 0 0 3 0 1 0 3 1.5 6 7 7 0 0 7 
  0  0 0 8 3 2.5 3.5 0 0 0 2 0 1 0 3 2 6 0.5 6.5 0 0  
A1 1982 3.5 
2 
11 4.5 
3 
6 
3 
5 13 
12.5 
11 
10 
3.5 
3 
0 
0 
0 
0 
0 
0 
1 
0 
0 
0 
0 
1 
7 
5 
6 
4 
1.5 
1 
6 
6 
6.5 
9 
7 
4 
6.5 
5 
4.5 
4 
6.5 
A297 1984 0 
0 
3.5 5 
4 
5.5 
3 
1 14 
14 
11 
10.5 
2 
0 
6 
3 
0 
0 
1 
1 
0 
0 
1 
0 
1 
1 
0 
0 
5 
4 
4 
3 
9 
7 
8 
9 
4 
3 
7 
9 
5 
4 
8 
A388 2001 0 
0 
3.5 0 
0 
0 
0 
0 5 
4.5 
5 
5 
5 
6 
1 
1 
0 
0 
1 
1 
1 
2 
1 
0 
2 
2 
0 
0 
2 
2 
4 
4 
0 
0 
5 
6 
4 
4 
7 
8 
5 
5 
8 
ACICUc 2002 0 3.5 0 0  4 4 6 2 0 2.5 0 0 0 0 4 5.5 0.5 3 4 0 0 6 
  0  0 0 0 4 4 6 2 0 2 0 0 0 0 4 5 0.5 3 3.5 0 0  
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Table II-1: Primer pairs used for detection of integrons and antibiotic resistance genes. 
 
Location Name Sequence 5' - 3' Product  
size (bp) 
Annealing 
temperature °C 
GenBank 
accession no. 
Reference1 
Class 1 integrons      
intI1 HS463a CTGGATTTCGATCACGGCACG 473 60 U12338 (221) 
 HS464 ACATGCGTGTAAATCATCGTCG   U12338 (221) 
5'-CS L1 GGCATCCAAGCAGCAAGC variable 57 U12338 (121) 
3'-CS R1 AAGCAGACTTGACCTGAT   U12338 (121) 
 
Sulphonamide resistance genes 
    
sul1 HS549 ACTAAGCTTGCCCCTTCCGC 1,103 65 U12338 (221) 
 HS550 CTAGGCATGATCTAACCCTCG   U12338 (221) 
sul2 sulII-F GGCAGATGTGATCGACCTCG 405 60 M28829 (120) 
 sulII-R ATGCCGGGATCAAGGACAAG   M28829 (120) 
sul3 sul3-F GAGCAAGATTTTTGGAATCG 790 51 AJ459418 (170) 
 sul3-R AACTAACCTAGGGCTTTGGA   AJ459418 (170) 
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Table II -2: Primer pairs used for detection of resistance genes. 
 
Location Name Sequence 5' - 3' Product  
size (bp) 
Annealing  
temperature °C 
Genbank  
accession no. 
Reference1 
Aminoglycoside resistance genes     
aadA1 RH522 GTGGATGGCGGCCTGAAGCCA 517 60 X12870 Hall Lab 
 RH531 GGCAGCGACATCCTTCGGCGC   X12870 Hall Lab 
strA strA-F CTTGGTGATAACGGCAATTC 548 53 M95402 (63) 
 strA-R CCAATCGCAGATAGAAGGC   M95402 (63) 
strB strB-F ATCGTCAAGGGATTGAAACC 509 53 M95402 (63) 
 strB-R GGATCGTAGAACATATTGGC   M95402 (63) 
aphA1 aphAI-F AAACGTCTTGCTCGAGGC 460 56 AY123253 (59) 
 aphAI-R CAAACCGTTATTCATTCGTGA   AY123253 (59) 
aadB RH212-R GCATATCGCGACCTGAAAGC 524 60 AY123253 Hall Lab  
 RH377-R GACACAACGCAGGTCACATTGAT   AY123253 Hall Lab  
aacA4 RH532 GTTAGGCATCACAAAGTACAGC 518 60 AF479774 Hall Lab  
 RH533 CATCTGGGGTGGTTACGGTACC   AF479774 Hall Lab  
aacC1 RH935 GCAGTCGCCCTAAAACAAAG 455 60 U12338 Hall Lab  
 RH936 CCCGTATGCCCAACTTTGTA   U12338 Hall Lab  
Tetracycline resistance gene     
tetA(A) tetA-F GCTACATCCTGCTTGCCTTC 210 55 X61367 (150) 
 tetA-R CATAGATCGCCGTGAAGAGG   X61367 (150) 
Chloramphenicol resistance gene     
catA1 RH513 GTACTGTTGTAATTCATTAAGCAT 595 60 AY123253 Hall Lab  
 RH514 TCCCAATGGCATCGTAAAGAACA   AY123253 Hall Lab  
Beta-lactamase resistance gene     
blaTEM temSFW GTATGGATCCTCAACATTTCCGTG 860 59 V00613 (45) 
 temSRV ACCAATGCTTAATCAGTGAGGCA   V00613 (45) 
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Table II -3: Primer pairs used for detection of class D carbapenemase resistance genes. 
 
Location Name Sequence 5' - 3' Product  
size (bp) 
Annealing 
temp (°C) 
GenBank 
accession no. 
Reference 
oxa-Ab a oxa-Ab-F 
oxa-Ab-R 
TAATGCTTTGATCGGCCTTG 
TGGATTGCACTTCATCTTGG 
535 60 AY859527 
AY859527 
(253) 
(253) 
oxa23 oxa23F-like GATCGGATTGGAGAACCAGA 501 60 AF201828 (253) 
 oxa23R-like ATTTCTGACCGCATTTCCAT   AF201828 (253) 
oxa24 oxa24F-like 
oxa24R-like 
GGTTAGTTGGCCCCCTTAAA 
AGTTGAGCGAAAAGGGGATT 
246 60 AJ239129 
AJ239129 
(253) 
(253) 
oxa58 oxa58F-like 
oxa58R-like 
AAGTATTGGGGCTTGTGCTG 
CCCCTCTGCGCTCTACATAC 
599 60 EF138631 
EF138631 
(253) 
(253) 
oxa-Ab b OXA-69A CTAATAATTGATCTACTCAAG 975 57 AY859527 (82) 
 OXA-69B CCAGTGGATGGATGGATAGATTATC   AY859527 (82) 
 
a  This primer set of oxa-Ab belongs to the multiplex set and amplifies an internal fragment of the gene. 
b  These primers amplify the entire oxa-Ab gene. 
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Table II -4: Primer pairs used for detection of insertion sequences (IS). 
 
Location Name Sequence 5' - 3' Product  
size (bp) 
Annealing 
Temperature ºC 
GenBank 
accession no. 
Reference 
IS26 IS26F ACCTTTGATGGTGGCGTAAG 617 60 AY123253 Hall Lab  
 RH601 GATGGAGCTGCACATGAACC   AY123253 Hall Lab  
IS1 RH517 GTGTTTTATGTTCAGATAATGCC 493 60 AY123253 Hall Lab  
 RH518 GCCGGGCAACCGCCCGCATTATG   AY123253 Hall Lab  
IS6100 IS6100-Rv2 AATGGTGGTTGAGCATGCC 356 60 U12338 (123) 
 DB-T1 TGCCACGCTCAATACCGAC   U12338 (22) 
ISAba1 ISAba1A 
ISAba1B 
GTGCTTTGCGCTCATCATGC 
CATGTAAACCAATGCTCACC 
435 56 AY758396 
AY758396 
(41) 
(41) 
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Table II-5: Primer pairs used for mapping AbaR3. 
 
PCR Primer Sequence 5'- 3' Length 
(bp) 
Annealing 
temp (ºC) 
GenBank 
accession no. 
Reference1 
1 RH768 GAATCGCTGGTGATGATGGC 3,041 60 CT025832 (183) 
 RH901 GCGGCTCTATCCCTAGTTCC   CP001182 (183) 
2 RH903 GGGCAAGGTGAAGAAGATCA 1,935 60 CP001182 (183) 
 RH904 GTCTGATAGCTGGCGTCACA   CP001182 (183) 
3 RH922 CGAAGAAGAAGGGCATGAAG 1,494 60 CP001182 (183) 
 RH923 CATCAATGCCAACGGTGAAC   CP001182 (183) 
4 RH902 AAGTGGATCGAGCATTACCG 1,179 60 CP001182 (183) 
 sul1-R TTTACAGGAAGGCCAACGGT   AF261825 (120) 
5 sul1-F GTGACGGTGTTCGGCATTCT 2,719 60 AF261825 (120) 
 IS6100-Rv2 AATGGTGGTTGAGCATGCC   AF261825 (123) 
6 DB-T1 TGCCACGCTCAATACCGAC 1,436 60 AF261825 (22) 
 RH521 CATATCGTGCGCGACTACCTG   U12338 Hall Lab 
7 sul1-F GTGACGGTGTTCGGCATTCT 3,799 60 AF261825 (120) 
 RH521 CATATCGTGCGCGACTACCTG   U12338 Hall Lab 
8 RH658 GACAGGACAAACARGCCGGTC 1,841 60 U12338 Hall Lab 
 RH672 GTGTGCCGTCCAAGATCATG   U12338 Hall Lab 
9 RH361 GATGCCTTCGTACTTGG 1,590 54 U12338 Hall Lab 
 RH448 CGGTGTTGGAACCCTATCG   Z00027 (124) 
10 RH655 GTCGCCTTGGTCARCTTCTG 1,163 55 U12338 Hall Lab 
 RH657 CGGAAAATAAAGYACGCTAAG   U12338 Hall Lab 
11 RH383 CTTCGTGAAATCAGCCCAG 2,536 60 Z00027 (124) 
 tetA-R CATAGATCGCCGTGAAGAGG   X61367 (150) 
12 RH1001 GGTTCACTCGAACGACGTCA 3,371 60 X00006 (186) 
 RH762 CATCGGAGGATGAGGTCGTG   X61367 Hall Lab 
13 RH761 GAACACGACCATCAGCGGCTGC 3,865 62 X61367 Hall Lab 
 RH514 TCCCAATGGCATCGTAAAGAACA   AY123253 (183) 
 
a References are for primer.
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Table II-5: continued 
 
PCR Primer Sequence 5' - 3' Length 
(bp) 
Annealing 
temperature (ºC) 
GenBank 
accession no. 
Reference a 
14 RH513 GTACTGTTGTAATTCATTAAGCAT 2,586 60 AY123253 (183) 
 RH356 CACTGGCACAGATATGG   V00613 Hall Lab 
15 RH405 CAGCGTTTTGTTGATGC 3,592 60 V00613 Hall Lab 
 RH410 AGCGTTTCTGGGTGAGC   V00613 Hall Lab 
16 RH605 TTTCGTGTCGCCCTTATTCC 2,651 60 AJ851089 Hall Lab 
 RH759 GCCAGCTCATTTACCTTGCCGA   CT025832 (183) 
17 IS26-F ACCTTTGATGGTGGCGTAAG 1,631 60 AY123253 Hall Lab  
 RH759 GCCAGCTCATTTACCTTGCCGA   CT025832 (183) 
18 RH780 GCACGTTATTACTTGATGAGA 1,773 60 CT025832 (183) 
 RH781 TCACCAGACCCAGAGCACCGA   CT025832 (183) 
19 RH758 TGCAGTGGCTGAGCCATTTG 3,204 60 CT025832 (183) 
 RH880 CAACGGGAAACGTCTTGCTC   AF024666 (59) 
20 RH881 CAACGGGAAACGTCTTGCTC 1.994 60 AF024666 Hall Lab 
 intI-RV GGGCATGGTGGCTGAAGG   U12338 Hall Lab 
21 RH881 CAAACCGTTATTCATTCGTGA 3,619 60 AF093572 (59) 
 RH936 CCCGTATGCCCAACTTTGTA   CT025832 Hall Lab 
22 L1 GGCATCCAAGCAGCAAGC 3,080b 57 AF261825 (199) 
 R1 AAGCAGACTTGACCTGAT   U12338 (121) 
23 RH522 GTGGATGGCGGCCTGAAGCCA 3,198 60 X12870 (183) 
 RH783 GATGAAGCGCACCCATCCGGCC   CT025832 (183) 
24 RH763 CATGTTCACCGACGAGGAT 1,639 60 CT025832 (183) 
 RH764 CAACCATTATTGGCGCATTTTTG   CT025832 (183) 
25 RH766 TCCTGCGTCAAAATCTGCTGTG 1,435 60 CT025832 (183) 
 RH767 CCTCCCGATGTTTGGATATG   CT025832 (183) 
 
a References are for primer. 
b Size is variable depending on the number of orfs present; 2.5 kb when 1 orfP is present and 3 kb when two orfP is present.
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Table II -6: Primer pairs used to identify deleted segment of AbaR variants. 
 
PCR Primer Sequence 5'-3' Length 
(bp) 
AbaR6 RH912 
RH880 
GGGGGAGAGTATGAATAGCACTT 
CAACGGGAAACGTCTTGCTC 
4,018 
AbaR7 RH791 
RH880 
TGCTGCAATGAGCTGAAAGT 
CAACGGGAAACGTCTTGCTC 
3,366 
AbaR8 RH655 
RH880 
GTCGCCTTGGTCARCTTCTG 
CAACGGGAAACGTCTTGCTC 
2,500 
AbaR23 RH513 
IntI1-RV 
GTACTGTTGTAATTCATTAAGCAT 
GGGCATGGTGGCTGAAGGACC 
2,767 
AbaR24 RH513 
IntI1-RV 
GTACTGTTGTAATTCATTAAGCAT 
GGGCATGGTGGCTGAAGGACC 
4,065 
Tn6019::Tn6018 RH793 CCCAAGAGAGCTGATTTTGC 6,130 
  GGGCGAAAATTATTGTTCTTA  
 
 
 
Table II-7: Primer pairs used for mapping the Tn6019 backbone of AbaR-types. 
 
PCR Primer Sequence 5' - 3' Length (bp) Reference 
PCR1-b RH791 TGCTGCAATGAGCTGAAAGT 3,120 (184) 
 RH909 GCGATTCAAAATATCGGTCAA  (184) 
PCR2-b RH910 GCGATAGTGAACGGATTGAGA 3,607 (184) 
 RH911 GCGATTCAAAATATCGGTCAA  (184) 
PCR3-b RH912 GGGGGAGAGTATGAATAGCACTT 3,945 (184) 
 RH800 GATCGTAACCTCACGCTATGG  (184) 
PCR4-b RH799 GCCACAAAGACACGCTAACT 4,350 (184) 
 RH767 CCTCCCGATGTTTGGATATG  (184) 
PCR5-b RH772 GCAGCCATAGGAATGACTTTTA 3,949 (184) 
 RH913 GCCTCTCATTGAGGTTGAGG  (184) 
PCR6-b RH768 
RH771 
GAATCGCTGGTGATGATGGC 
TGTAAAATCTGGTGGTCGTAC 
3,100 (184) 
(184) 
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Table II -8: Primer pairs used to detect AbaR junctions and AbaR features.  
  
Region  Primer a Sequence 5' - 3' Length 
(bp) 
comM   RH791 TGCTGCAATGAGCTGAAAGT 982 
  RH913 GCCTCTCATTGAGGTTGAGG  
comM-AbaR  J1 RH927 CAACCCTGTCTTTGCATTTG 846 
  RH792 TTCGAGCTTGAAAACTGCAC   
AbaR-comM  J2 RH916 CCCAAATACTGCCATGTTGA 796 
  RH928 GCCAGCAAGCTCAGCATAA  
uspA-Tn6018L  J3 RH793 CCCAAGAGAGCTGATTTTGC 1,620 
  RH767 CCTCCCGATGTTTGGATATG  
Tn6018R-uspA  J4 RH770 CGATGCCCTAGAGAGAGTGCGC 1,615 
  RH771 TGTAAAATCTGGTGGTCGTAC  
Tn6018L LJ J5 RH770 CGATGCCCTAGAGAGAGTGCGC 1,526 
  RH901 GCGGCTCTATCCCTAGTTCC  
Tn6018R RJ J6 RH766 TCCTGCGTCAAAATCTGCTGTG 1,435 
  RH767 CCTCCCGATGTTTGGATATG  
arsB  RH799 GCCACAAAGACACGCTAACT 984 
  RH800 GATCGTAACCTCACGCTATGG  
uspA  RH919 TGTCAAAAATTATTGCATGT 632 
  RH793 CCCAAGAGAGCTGATTTTGC  
top  RH903 GGGCAAGGTGAAGAAGATCA 1,935 
  RH904 GTCTGATAGCTGGCGTCACA  
Tn6018 (cadA-tnpA)  RH768 GAATCGCTGGTGATGATGGC 1,630 
  RH769 GGTCTGAGACTTCGTGAGCGC  
 
a primers are from reference (184). 
 
 
Table II-9: Primer pairs used identifying Tn1. 
 
Primer Sequence 5'-3' Amplicon length (bp) Reference 
tem-R TGAGCGGATACATATTTGAA 1,018 Hall Lab 
RH356 CACTGGCACAGATATGG  (9) 
RH404 GTATTTGCGGTTCGGTCC 1,163 (9) 
RH354 CTCGCTGAAGGATCTGG  (9) 
RH402 CACCTCAGCACGAATCG 1,068 (9) 
RH344 GCCGATATGCCCGTTG  (9) 
RH401 CAGTGCCAGTTTGTTCC 1,542 (9) 
RH410 AGCGTTTCTGGGTGAGC  (9) 
RH605 TTTCGTGTCGCCCTTATTCC 845 (9) 
tem-SRV ACCAATGCTTAATCAGTGAGGCA  Hall Lab 
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Table II-10: PCRs designed for characterization of pRAY in the A. baumannii collection 
 
PCR Primer names Primer sequence (5'– 3') Amplicon 
size (bp) 
Reference 
aadB RH377-R 
RH212-R 
GCATATCGCGACCTGAAAGC 
GACACAACGCAGGTCACATTGAT 
524 Hall Lab 
Hall Lab 
aadB in 
pRAY 
RH561 
RH562 
GGGAAGAATCAATACCGCAA 
AATTTCACCCCAAACAATCG 
999 (152) 
(152) 
pRAY1a RH561 
RH1359 
GGGAAGAATCAATACCGCAA 
ATTCAAAACAACGCCCAGAC 
3,315 (152) 
This Study 
pRAY2 a RH1360 
RH1361 
GACGAGACCAAGCGAGAAAA 
GCCCTCCCAGAATGTCAGTA 
3,276 This Study 
This Study 
 
a annealing temperature was 62°C for PCRs pRAY1 and pRAY2. 
 
 
 
 
 
 
 
 
 
 
Table II-11: Primer pairs used for characterization of ampC regions in A. baumannii 
 
PCR /Region Primer Sequence 5'-3' Amplicon length (bp) Reference 
ampC pw51 
pw52 
CGGGCAATACACCAAAAGAC 
CCTTAATGCGCTCTTCATTTGG 
1,050 (134) 
(134) 
ampC a  RH1357 
RH1358 
TCACCGATTGGGTTTTTAGG 
TGGCTGTGGGTGTTATTCAA 
355 This study 
This study 
ISAba1b ISAba1A 
ISAba1B 
GTGCTTTGCGCTCATCATGC 
CATGTAAACCAATGCTCACC 
435 (41) 
(41) 
ISAba1-ampC pw52 
ISAba1B 
CCTTAATGCGCTCTTCATTTGG 
CATGTAAACCAATGCTCACC 
1,700 (134) 
(41) 
folE-ampC-orf RH581 
RH582 
TGATGATGCGTGGTGTAGGT 
GAGCTGCCATATTGGGAAGA 
1,667c This study 
This study 
ampC d RH1382 
RH1383 
GCCGTAAATCGCAGTACCAT 
ACCAGGCGTATCGTCAAAAG 
114 This study 
This study 
16SrRNA d RH1384 
RH1385 
GGAGAAAGCAGGGGATCTTC 
ATCCTCTCAGACCCGCTACA 
114 This study 
This study 
 
a RH1357 and RH1358 were used to make ampC probe. 
b The primers were used to make ISAba1 probe.  
c RH581 and RH582 generate 2853 and 2753bp PCR product when ISAba1 or ISAba125 are upstream of ampC 
respectively.  
d These primers were designed for Real-Time PCR experiments.  
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Table II-12: Primer pairs used identifying global clones. 
 
PCR  Primer Sequence 5'-3' Amplicon length (bp) Reference 
Group 1  
ompAF306 
ompAR660 
 
GATGGCGTAAATCGTGGTA 
CAACTTTAGCGATTTCTGG 
 
355 
 
(235) 
(235) 
 csuEF 
csuER 
CTTTAGCAAACATGACCTACC 
TACACCCGGGTTAATCGT 
702 (235) 
(235) 
 OXA66F89 
OXA66R647 
GCGCTTCAAAATCTGATGTA 
GCGTATATTTTGTTTCCATTC 
559 (235) 
(235) 
Group 2     
 ompAF378 
ompAR660 
GACCTTTCTTATCACAACGA 
CAACTTTAGCGATTTCTGG 
343 (235) 
(235) 
 csuEF 
csuER 
GGCGAACATGACCTATTT 
CTTCATGGCTCGTTGGTT 
580 (235) 
(235) 
 OXA69F169 
OXA69R330 
CATCAAGGTCAAACTCAA 
TAGCCTTTTTTCCCCATC 
162 (235) 
(235) 
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III-1 Promoters found upstream of the ampC gene 
Previous studies have identified the promoter upstream of the transcription start site 
experimentally (the bold G with an asterisk above Figure III-1) as TTAGAA (-35) and TTATTT (-
10), separated by 16 bp (208). However the same authors identified a different start point (the bold 
T with an asterisk above in Figure 6.19, when ISAba1 was located next to the oxa23 gene (207). 
Examination of the ISAba1 sequence revealed an alternative outwardly facing -35 and -10 promoter 
consensus (Figure 6.19) in ISAba1, which seems stronger than the ones previously proposed 
(Figure 6.19). The -10 sequence identified here, is an extended -10 (TGnCATTAT), which would 
increase the promoter’s strength even further (11, 27). This promoter overlaps with the promoter 
identified previously (Figure 6.18) (208). 
 
(a)                                                                                                                          !    -35 
TCGACCAATTCTATAAAATATAACAATTAAATTAGGTGATTTTTGTTATAAAAGTAGGCA  
 
       -10                      M 
TCTTTCTTTTTAAATAATTTATGAGCTAATCATGCGATTTAAAAAAATTTCTTGTCTACT  
                                                                                                                    " 
(b)                   65 
         M       T   -35                   -10       *  * 
AGATGTGTCATAGTATTCGTCGTTAGAAAACAATTATTATGACATTATTTCAATGAGTTA  
 
         13 
         A            RBS          M                 
TCTATTTTTGTCGTGTACAGAGGAGCTAATCATGCGATTTAAAAAAATTTCTTGTCTACT  
                                                                                                                                   " 
Figure III-1: The nucleotide sequence of the 5'-end of ampC and its position relative to the ISAba1. (a) indicates the 
original sequence adjacent to the 5' of the ampC gene. The black and orange arrows indicate the insertion points of 
ISAba1 and ISAba125 respectively  (b) represents the sequence at 5'-end of ampC when ISAba1 is present. In (b): The 
transcription start points determined experimentally in references (207, 208) are bold with an asterisk above. The 
outward-facing promoter of ISAba1, -35 (17) -10 and extended -10 (TGN), are white on black. The ampC sequences are 
bold and the “M” above stands for Methionine. The ribosome binding sequence, RBS, is underlined. The vertical arrow 
indicates the first base of ISAba1 and its adjacent italic letters indicate the sequences belong to the chromosome. The 
letters coloured green indicate the positions -13 and -65 relative to the first base of ISAba1 in the orientation present 
upstream of ampC and the letters above indicate the sequence variants observed. The letters coloured blue represent the 
start of the transposase and the “M” above indicates the Methionine.  
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3208   AAGCTGTTGCAGAAGTCACTGATGCTCGCGGTGTCGCTGTAGTTATCGATTCAGCACATA  
D13    ---------------------A---------------------T----------------  
D4     ---------------------G---------------------C----------------  
 
3208   TGTGTATGATGATGCGTGGTGTAGGTAAACAAGAATCTACCACTCGTACAGTTTCATTTG  
D13    -------------------------------------------C----------------  
D4     -------------------------------------------C----------------  
 
3208   TCGGAGATTTTAAAACCGATAAAGAAGCGCGCCGTGAATTCTTAAGTGCAGTACCAGAAA  
D13    ----------------------------G-------------------------------  
D4     ----------------------------A-------------------------------  
            folE stop codon 
3208   GCTACTAATATAGTTTTTACTGCCTAAATAAAAGCCCGACAATGTTGGGCTTTTTTTATA  
D13    ----------------------C--------A----------------------------  
D4     ----------------------T--------G---------------------------- 
 
                                                                   ! 
3208   GCTGAACGCGATAAACTTCGA-CCAATTCTATAAAATATAACAATTAAATTAGGTGATTT  
D13    -------------------A-T--------------C-----------------------  
D4     -------------------G-T--------------C-----------------------  
                                                                                       ISAba1 insertion point in D13 
                                                                                                               !                          ampC # 
3208   TTGTTATAAAAGTAGGCATCTTTCTTTTTAAATAATTTATGAGCTAATCATGCGATTTAA  
D13    ------------------------------------------------------------  
D4     ------------------------------------------------------------  
  
3208   AAAAATTTCTTGTCTACTTTTATCCCCGCTTTTTATTTTTAGTACCTCAATTTATGCGGG  
D13    ------------------------------------------------------------  
D4     ------------------------------------------------------------  
 
3208   CAATACACCAAAAGACCAAGAAATTAAAAAACTGGTAGATCAAAACTTTAAACCGTTATT  
D13    ------C--------------------------------------T--------A-----  
D4     ------C--------------------------------------T--------A-----  
 
3208   AGAAAAATATGATGTGCCAGGTATGGCTGTGGGTGTTATTCAAAATAATAAAAAGTATGA  
D13    ------------------G-----------------------------------------  
D4     ------------------G-----------------------------------------  
 
3208   AATGTATTATGGTCTTCAATCTGTTCAAGATAAAAAAGCCGTAAATCGCAGTACCATTTT  
D13    ----------------------------------------------A-------T-----  
D4     ----------------------------------------------A-------T-----  
 
3208   TGAGCTAGGTTCTGTCAGTAAATTATTTACCGCGACAGCAGGTGGATATGCAAAAAATAA  
D13    ------------------------------------------------------------  
D4     ------------------------------------------------------------  
 
3208   AGGAAAAATCTCTTTTGACGATACGCCTGGTAAATATTGGAAAGAACTAAAAAACACACC  
D13    --------------------------------------------TG--------T-----  
D4     --------------------------------------------TG--------T-----  
 
3208   GATTGACCAAGTTAACTTACTTCAACTCGCGACGTATACAAGTGGTAACCTTGCCTTGCA  
D13    ------------------------------------------------------------  
D4     ------------------------------------------------------------  
 
3208   GTTTCCAGATGAAGTACAAACAGACCAACAAGTTTTAACTTTTTTCAAAGACTGGCAACC  
D13    -------------------------------------------------------A----  
D4     -------------------------------------------------------A----  
 
3208   TAAAAACCCAATCGGTGAATACAGACAATATTCAAATCCAAGTATTGGCCTATTTGGAAA  
D13    ------------------------------------------------------------  
D4     ------------------------------------------------------------  
 
3208   GGTTGTGGCTTTGTCTATGAATAAACCTTTCGACCAAGTCTTAGAAAAAACAATTTTTCC  
D13    ------A-----------------------------------------------------  
D4     ------A----------------------------------------------------- 
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3208   GGCCCTTGGCTTAAAACATAGCTATGTAAATGTACCTAAGACCCAGATGCAAAACTATGC  
D13    ---------------------------------------------A--------------  
D4     ---------------------------------------------A--------------  
 
3208   ATTTGGTTATAACCAAGAAAATCAGCCGATTCGAGTTAACCCCGGCCCACTCGATGCCCC  
D13    T-----C--------------------------------------T--------------  
D4     T-----C--------------------------------------T--------------  
 
3208   TGCATATGGCGTCAAATCGACACTACCCGACATGTTGAGTTTTATTCATGCCAACCTTAA  
D13    A-----C-----------C--CT----G--T--------------------------C--  
D4     A-----C-----------C--CT----G--T--------------------------C--  
 
3208   CCCACAGAAATATCCGGCTGATATTCAACGGGCAATTAATGAAACACATCAAGGGTTCTA  
D13    ------------------A-----------------------------------------  
D4     ------------------A-----------------------------------------  
 
3208   TCAAGTAAATACCATGTATCAGGCACTCGGTTGGGAAGAGTTTTCTTATCCGGCAACGTT  
D13    ------------------------------------------------------------  
D4     ------------------------------------------------------------  
 
3208   ACAAACTTTATTAGACAGTAATTCAGAACAGATTGTGATGAAACCTAATAAAGTGACTGC  
D13    ------------------------------------------------------------  
D4     ------------------------------------------------------------  
 
3208   TATTTCAAAGGAACCTTCAGTTAAGATGTACCATAAAACTGGCTCAACCAACGGTTTCGG  
D13    --------------------------------------------------C---------  
D4     --------------------------------------------------A---------  
 
3208   AACATATGTAGTGTTTATTCCTAAAGAAAATATTGGCTTAGTCATGTTAACCAATAAACG  
D13    ---------G--C-----------------------T-----------------------  
D4     ---------G--C-----------------------C-----------------------  
 
                                                                                                                        !         ampC stop codon 
3208   TATTCCAAATGAAGAGCGCATTAAGGCAGCTTATGCTGTGCTGGATGCAATAAAGAAATA  
D13    -------------------------------------------A----------------  
D4     -------------------------------------------A----------------  
 
3208   ACCGTTTTAGCCAAAAACAAAAAGAGAAATGGATAATCCCATTTCTCTTTTTTATGCACT  
D13    ------------------------------------------------------------  
D4     ------------------------------------------------------------  
       
                                  orf stop codon 
3208   TATTCTTTAAAAGAACCAAACATATCCTAAGCTTGATTTCATCCAATCTAGATGATTTTG  
D13    ------------------------------------------------------------  
D4     ------------------------------------------------------------  
 
3208   TTTTTCATAATCCCAATTAAAGCGAATGGCATTATTACTATTAATGGCATATTGCCACTG  
D13    ------------------------------------------------------------  
D4     ------------------------------------------------------------  
 
3208   TGTATTTAGCCGTAAGTTCCATTGGTTTTGGTCTTCCCAATATGGCAGCTCAACTTGTAC  
D13    ------------------------------------------------------------  
D4     ------------------------------------------------------------  
 
3208   CACAGTGTTAAATTTTTCAAACCACTGATTCATACATCCTAATGTCGGCCCTACTCCCAC  
D13    ------------------------------------------------------------  
D4     ------------------------------------------------------------         
 
3208   ACGCCAGCCTTTATCTAAATTTGAACCCGCTTGGACATAAGTTTGTACCTGCCCATAGCA  
D13    ------------------------------------------------------------  
D4     ------------------------------------------------------------
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3208   AATATGTTTGCGCGCATAATCTGCAAGACTGTAACCAACCTGAGCATTAAAACTCGCGAC  
D13    -------------G----------------------------------------------  
D4     -------------T---------------------------------------------- 
 
3208   GCCATGCTGCTTTTCATCACTATAAACACCGTCATGAACCGCTTCCTGACGCCAGCCTAA  
D13    ------------------------------------------------------------  
D4     ------------------------------------------------------------  
 
3208   GTTAAATCCCCAAGTCAGCGGAGTTTTAAATGGTTGAATCGGGTTATAAGAGTTCACTTC  
D13    ------------------------------------------------------------  
D4     ------------------------------------------------------------  
 
3208   TAACAGATCAAGACGTTCTAGTTTTAAATGATCATCTCGCCACTGTGCATTACCATTTAA  
D13    -------------CG---------------------------------------------  
D4     -------------TA---------------------------------------------  
 
 
Figure III-2: Alignment of the 3208, D13 and D4 sequences in the ampC region. Dashes indicate identical bases 
and base variations are highlighted. Start and stop codons are also shown. The vertical arrows shown yellow on 
black indicate the span estimated as the DNA segment incorporated. 
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Table III-1: ISAba1 positions in SG6 strains.  
Strain ISAba1 
bands a 
ISAba1 
blast hits 
Copies of 
ISAba1 
EcoRI fragment 
size (bp)/ position  
Contig number/Size (bp) Associated gene(s)/ orf(s) b 
D15 2 7 3 9,056    / P1 38(305359)-28(62370) folE/ ampC 
    8,876   / P2 19(20973)-20(175738)  orf (Peptidase C13 family protein ) ! 
    20,414 / P3 86(196304)-12(348002) ferrichrome-iron receptor / sugar kinase, ribokinase family 
D14 3 8 3 9,056    / P1 109(306615)-53(72726)  folE/ ampC 
    12,870  / P4 15(111544)-43(267538) diguanylate cyclase (GGDEF) domain protein ! 
    29,229  / P5 196(4778)-101(73351)  NhaP-type Na+\H+ and K+\H+ antiporter  ! 
D13 4 10 4 9,056    / P1 250(307029)-117(72726)  folE/ ampC 
    12,870  / P4 15(111544)-44(267521) diguanylate cyclase (GGDEF) domain protein ! 
    29,229  / P5 181(5173)-77(93245)  NhaP-type Na+\H+ and K+\H+ antiporter  ! 
    5,760    / P6 17(215230)-118(227075) MaoC-like protein/ 3-ketoacyl-ACP reductasec 
D18 4 9 4 9,056    / P1 118(302096)-117(72726)  folE/ ampC 
    12,870  / P4 12(111544)-17(40956)  diguanylate cyclase (GGDEF) domain protein ! 
    29,229  / P5 183(5168)-62(93224) NhaP-type Na+\H+ and K+\H+ antiporter !   
    2,501    / P7 17(40956)- 31(226653)  aldehyde dehydrogenase/ shikimate kinase 
D20 5 11 5 9,056    / P1 231(307009)-125(72469)  folE/ ampC 
    12,870  / P4 14(111544)-25(40955) diguanylate cyclase (GGDEF) domain protein ! 
    29,229  / P5 189(5173)-80(93263)  NhaP-type Na+\H+ and K+\H+ antiporter ! 
    2,501    / P7 25(40955)-48(226652)  aldehyde dehydrogenase/ shikimate kinase 
    74,66    / P8 68(118085)-61(78435)  diguanylate cyclase (GGDEF) domain protein !   
D45 4 11 5 9,056    / P1  295(307034)-151(72724)  folE/ ampC 
    12,870  / P4  25(111604)-51(40954)  diguanylate cyclase (GGDEF) domain protein ! 
    29,229  / P5 252(5105)-86(93241)  NhaP-type Na+\H+ and K+\H+ antiporter ! 
    2,501    / P7 51(40952)-47(226650)  aldehyde dehydrogenase/ shikimate kinase 
    29,797  / P9 116(86628)-115(267967) orf ! 
D48 5 11 5 9,056    / P1  162(307030)/ 77(72692)  folE/ ampC 
    12,870  / P4 16(111544)-19(40956) diguanylate cyclase (GGDEF) domain protein ! 
    29,229 / P5 147(5173)-73(93244)  NhaP-type Na+\H+ and K+\H+ antiporter ! 
    2,501   / P7 19(40956)-40(226653)  aldehyde dehydrogenase/ shikimate kinase 
    13,964 / P10 20(1330)-189(15847)  BNR/Asp-box repeat family protein ! 
D108 4 13 6c 9,056   / P1 36(307005)-20(72740) folE/ ampC 
    19,591 / P11 201(739915)-31(427998)  cAMP receptor-like protein / OsmC-like protein 
    19,158 / P12 2(25684)-136(520278) HTH-type transcriptional regulator ! 
    6,949  /  P13 48(17927)-23(66612) orf / orf 
a Southern hybridization.  
b ! indicates the interruption of the gene or orf; Left gene name/ Right gene name indicates that ISAba1 is inserted between the two genes or orfs; gene names are based on AB0057.  
c D108 contains 6 ISAba1 copies two of, which present on a plasmid, which generate a 2,1144 bp EcoRI fragment (P14: contigs 10 & 27; P15: contigs 27 & 104).  
